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Sepsis, defined as a life-threatening organ dysfunction triggered by infection, carries a high
mortality. Recent improvements in outcome high-income settings have been driven by
prompt antimicrobial therapy and fluid resuscitation but mortality remains disproportion-
ately high in low-resource settings like the nations of sub-Saharan Africa (sSA). Sepsis
therapy here often consists of empiric, prolonged courses of broad-spectrum antimicrobials,
especially third generation cephalosporins like ceftriaxone, which may be driving the rise of
ceftriaxone-resistant extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-
E). However the aetiology of sepsis in sSA is far from clear, and in this thesis I hypothesise
that it may be possible to improve outcomes in sepsis whilst reducing selection pressure for
ESBL-E, with novel, targeted, antimicrobial strategies tailored to the pathogens that are
truly causing sepsis here.
To that end, I present findings from a clinical cohort study of sepsis in Blantyre, Malawi,
with two aims: first, a description of the presentation and outcomes of sepsis in Blantyre,
with a focus on aetiology and an analysis of the determinants of mortality; and secondly, a
description of the gut mucosal carriage of ESBL-E in sepsis survivors (as well as antibiotic
unexposed inpatient and community controls) as they pass through the hospital to identify
determinants of carriage. An expanded package of diagnostic tests was used to define
sepsis aetiology, and serial stool sampling with selective culture for ESBL-E used to define
ESBL-E carriage. I use whole-genome sequencing of cultured ESBL E. coli to track bacteria
and mobile genetic elements within participants over time, and continuous time Markov
models to provide insight into the drivers of carriage.
I find that the majority of participants with sepsis are young, and HIV-infected. Dissem-
inated tuberculosis (TB) dominates as a cause of sepsis, and there is an association of
receipt of antituberculous chemotherapy with survival that suggests an expanded role for
TB therapy in these very unwell patients may be beneficial. Sepsis mortality seems to
have improved compared to historic cohorts, but post 28-day mortality in HIV-infected
individuals is significant.
At baseline gut mucosal ESBL-E carriage is common, with cultured ESBL-E present in
the stool of 49% of participants with sepsis on the day of admission. There is further
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rapid increase in colonisation prevalence following admission and antibacterial exposure.
Associations of baseline colonisation - household crowding and unprotected water sources
- suggest both within-household and environmental routes of transmission are important.
Genomic analysis suggest unrestricted mixing of ESBL E. coli at multiple spatial levels and
rapid turnover within the individual, perhaps suggestive of frequent re-exposure. By using
the genetic environment of ESBL genes as a proxy for mobile genetic elements (which are
difficult to assemble from short read sequencing) I show that, within individuals, the E.
coli strain-mobile genetic element combination is conserved over time whereas the strain or
mobile genetic element alone is not; this suggests that the unit of transmission of ESBL
gene to study participants is the bacterium, rather than mobile genetic element.
Longitudinal modelling provides further insight into ESBL-E carriage dynamics: hospitali-
sation and antibacterial exposure act synergistically to bring about rapid and prolonged
carriage driven, in part, by a significant post-antibiotic effect. This effect means that
antibacterials act to prolong carriage long after antibacterial exposure stops. In terms of
ESBL-E carriage, short courses of antibacterials have a similar effect to longer courses,
such that the data generated in this study do not support my hypothesis and it may not
be possible to reduce ESBL-E carriage by truncating courses of ceftriaxone. Nevertheless,
the post-antibiotic effect deserves further scrutiny to understand the mechanism and as a
potential therapeutic target. In addition, the modelling approach suggests cotrimoxazole
preventative therapy (CPT) may be a significant driver of long-term ESBL-E carriage, and
I suggest that a more nuanced approach to its deployment may be necessary in an era of
increasing Gram-negative resistance.
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The syndrome of sepsis has been described since antiquity; from Hippocrates to Galen and
Semmelweis, the potentially serious systemic consequences of a localised infection have long
been recognized. The word sepsis arises from the Greek σηψιζ meaning decomposition
and was described by Hippocrates as a dangerous putrefaction in the body[1]. Modern
definitions of sepsis conceptualise it as a syndrome of life threatening organ dysfunction due
to a dysregulated host response to infection[2], but despite increased understanding of its
pathogenesis[3], mortality from sepsis remains high. Progress has been made in improving
sepsis mortality in high income settings[4,5], through timely application of basic care[6,7]:
early appropriate antimicrobials, aggressive fluid resuscitation and organ support largely in
a critical care environment. Limited data from low resource settings including sub-Saharan
Africa (sSA) suggest that mortality remains high[8], and increasing evidence suggests that
exporting high-income setting sepsis protocols to sSA has the potential to do harm[9,10].
Data to guide sepsis management protocols for sSA are urgently needed.
Data on sepsis aetiology from sSA to guide antimicrobial strategies are lacking; currently,
in Blantyre Malawi, for example, empirical management of sepsis is the norm and patients
often receive prolonged empiric courses of broad spectrum antimicrobials – largely ceftriax-
one, a third-generation cephalosporin antibiotic. Limited data suggest that tuberculosis,
arboviruses and bacterial zoonoses may be important causes of severe febrile illness in
sSA[11–14], pathogens which largely go untreated by ceftriaxone. On a population level
invasive Escherichia coli and Klebsiella pneumoniae bacteria are showing an alarming in-
crease in ceftriaxone resistance since the drug was introduced in Malawi in 2005[15,16]. The
majority of these resistant bacteria are so-called extended-spectrum β-lactamase producers
(ESBL-producers) and are often untreatable with locally available antimicrobials. Novel
antimicrobial strategies are needed to safely preserve ceftriaxone - often a first and last line
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antibiotic in Malawi - for those who need it.
It is the hypothesis of this thesis, then, that sepsis in Malawi is caused by a wide variety
of infections that are currently unrecognised and untreated, and that this is contributing
to high sepsis mortality. Conversely, prolonged ceftriaxone exposure in sepsis survivors is
causing acquisition and carriage of resistant bacteria (principally ESBL Enterobacteriaceae,
henceforth ESBL-E) and their transportation into the community. I ask the question as to
whether novel antimicrobial strategies in sSA can not only improve outcomes in sepsis, but
can minimise pressure for antimicrobial resistance (AMR) by altering the way in which we
use antibacterials in these very sick patients. Before addressing this question I will review,
in this chapter, the definitions, epidemiology, aetiology and management of sepsis, with a
focus on aetiology and antimicrobial treatment followed by the epidemiology and drivers of
ESBL-E carriage, both with a focus on sSA.
1.2 Sepsis in sub-Saharan Africa
1.2.1 Search strategy
A review of the literature was undertaken to identify prospective cohort, case control studies
or randomised controlled trials (RCTs) of sepsis in sub-Saharan Africa with the search
terms shown in the appendix to this chapter. Pubmed and Scopus were searched, yielding
5460 unique studies on 17 July 2018. Inclusion criteria were any prospective cohort, RCT
or case-control studies of sepsis in sSA (defined as taking place in the countries listed in
search terms panel) recruiting patients using sepsis 1,2 or 3 definitions. Abstract review
was undertaken resulting in inclusion of 91 studies for full text review. Eleven publications
providing data on eight prospective cohorts[17–24] and three intervention studies (two
RCTs[25,26] and one before-after intervention[27]) were identified. These data inform
the following review, alongside non-systematically searched studies examining sepsis in
high-resource settings.
In order to put sepsis aetiology data in context, systematic searches of the Pubmed and
Scopus databases for leptospirosis, brucellosis, Q fever, rickettsioses, arboviruses (dengue,
or chikungunya) and histoplasmosis prevalence in unselected sepsis or fever cohorts in sSA
were undertaken. Because a recent systematic review[12] has examined these pathogens
up to 2013 (see “sepsis aetiology” below), the date of these searches were restricted the
2014 to the present. Any studies examining disease prevalence in cohorts of febrile adults
or children were included; outbreaks were excluded. Studies where the inclusion criteria
were not clear (including those with, for example, “suspected leptospirosis” with no further
details) were excluded. Finally, systematic searches of Pneumocystis jiroveci pneumonia
(PCP) were made using the search terms below; because a recent systematic review has
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examined the role of PCP up to 2015, the date on this search was restricted to 2015
or later. Table 1.1 shows the search terms, number of of hits and number of included
studies after full text review: nine studies provided data on Leptospirosis[28–36], seven on
Brucellosis[37–43], seven on Q-fever[35,39,44–47] , six on Rickettsioses[35,44,48–51], eighteen
on Dengue[29,31,35,36,44,50,52–63], thirteen on Chikingunya[31,36,50,53,56,58,60–66], three
on Zika [59–61], two on Histoplasmosis[67,68] and none on PCP. Details of the included
studies are provided below.
Table 1.1: Search terms for fever studies
Organism Search n abstracts n included
Leprospirosis Leptospir AND 187 9
Brucellosis Brucell AND 123 7
Q-fever ((Q fever) OR (coxiella)) AND 315 7
Rickettsioses (Ricketts OR typhus OR (spotted
fever)) AND
375 6





Histoplasmosis Histoplasm AND 72 2





All searches included the sSA country list in addition to the disease-specific terms above.
1.2.2 Statistical methods
Largely, narrative review of identified sepsis cohorts was undertaken, but meta analysis was
used to summarise outcomes. 28 or 30-day sepsis mortality were extracted from identified
studies or, if 28- or 30-day data were not available, in-hospital mortality was used. For
interventional studies, in order to reflect the “usual-care” mortality, only the usual care
arms were included. Pooled mortality estimates were then generated using a random effect
meta-analysis of proportions with a generalised linear mixed model (GLMM, the so called
binomial-normal model) using the meta package v.4.9.5[69] in R v3.6.0. Exact binomial
95% confidence intervals for all proportions were used throughout.
1.2.3 Defining sepsis
Sepsis is a heterogeneous syndrome, with no diagnostic gold standard. In 1991 the first
modern sepsis diagnostic criteria were defined in a consensus conference of key opinion
makers[70] (Table 1.8, chapter appendix). Sepsis was defined as the presence of the systemic
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inflammatory response syndrome (SIRS) plus infection, with a gradient of severity increasing
through severe sepsis (sepsis plus organ dysfunction) to septic shock. These definitions were
widely adopted as entry points into clinical trials, but ongoing concerns that SIRS was both
insensitive and non-specific for the diagnosis of sepsis led to an expansion of the diagnostic
criteria in 2001[71] again by expert consensus. Despite these revised guidelines the SIRS
criteria largely continued to be preferred both as the entry point to clinical trials of sepsis
and in clinical practice until the development of the current sepsis-3 definitions in 2016[2].
The sepsis-3 definitions redefined sepsis as “life threatening organ dysfunction triggered
by infection”, a definition that rendered the sepsis-2 severe sepsis category obsolete. In
contrast to the previous diagnostic criteria that had relied largely on expert opinion, the
sepsis-3 criteria attempted to use a probabilistic approach to defining sepsis, by mandating
that sepsis should be associated with excess mortality. The sequential organ dysfunction
score (SOFA, Table 1.9, chapter appendix), an organ-dysfunction score already in use
in high income settings, and shown to be associated with mortality[72] was selected to
operationalise the definition of sepsis. An acute change in SOFA of 2 or more points defines
sepsis under sepsis-3.
Mindful that the SOFA score requires a large number of variables and is difficult to apply
at the bedside, the consensus guideline group suggest the use of a simpler score, quick
SOFA to identify patients who may have sepsis. Any two of: altered mental status, SBP <
100mmHg or respiratory rate > 22 breaths min−1 defines a positive qSOFA score. qSOFA
does not define sepsis; rather, under sepsis-3 patients with a qSOFA score of 2 or more are
at increased risk of poor outcomes and should be screened for sepsis using a full SOFA
score. The qSOFA was derived by identifying factors associated with mortality in large
datasets of patients with infection from the United States and validated in further US and
German datasets; in these datasets it showed good discriminant ability to predict mortality,
equivalent to full SOFA score outside the intensive therapy unit (ITU)[73].
Finally, sepsis-3 defines septic shock as persistent hypotension requiring vasopressors to
maintain mean arterial blood pressure (MAP) above 65mmHg and serum lactate greater
than 2mmol L−1. This definition was arrived at by a combination of consensus and
systematic review to identify potential defining variables and validation in large datasets
from the United States, where it was found to be strongly associated with mortality[74].
1.2.4 Applicability of sepsis-3 definitions in sub-Saharan Africa
Application of the sepsis-3 definitions, both in terms of clinical use and as inclusion criteria
for research studies in sub-Saharan African low resource settings, is problematic. Several
of the domains of SOFA require the results of blood tests, which may not be available.
In Blantyre, and elsewhere in sSA, intensive organ support with inotropes or mechanical
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ventilation (invasive or non-invasive) may not be available[75] or be difficult to access[76],
yet use of these treatment modalities form components of the SOFA score. Both lactate
measurement and inotropic support may be unavailable in some settings and yet these
define septic shock. Five studies have validated the qSOFA score in sub-Saharan African
settings[22,77–80] and found variable discriminant ability for mortality but it is not clear
how this score should be deployed in this setting; no studies have been undertaken to link
qSOFA score to clinical action, and it is not intended to define sepsis under sepsis-3. The
optimal sepsis definitions (both clinical and for research) for sSA are therefore not clear.
1.2.5 Sepsis epidemiology in sub-Sahara Africa
1.2.5.1 Incidence
The changing case definition of sepsis over time hampers estimation of incidence even
in high-income settings, furthermore sepsis is not included in global burden of disease
estimates. Different methods of defining sepsis from disease registries can result in very
different estimates[81], but a recent systematic review and meta-analysis of 27 studies from 9
high income countries found a recent population incidence rate of 437/100,000 person-years
(95% CI 334-571) for sepsis and 270 (95% CI 176 – 412) for severe sepsis with an increasing
incidence over time from 1979 to 2015[4]. Crudely extrapolating these estimates to the
worldwide population would result in 20.7 million sepsis and 10.7 million severe sepsis cases
a year, largely in low resource settings. However, no data are available from low or middle
income settings and these estimates must be treated with caution.
1.2.5.2 Risk factors: the sepsis population in sub-Saharan Africa
In high-income settings, risk factors for sepsis have been identified, though once again
changing definitions as well as a lack of large scale community based studies make it
difficult to draw definitive conclusions. However, chronic diseases (including HIV) and
immunosuppressive agents have been associated with increased sepsis incidence, as well as
older age[82,83]. In the United States, male sex and black ethnicity (vs white) and poverty
are associated with increased sepsis incidence and severity[84].
Though equivalent studies aiming to identify risk factors for sepsis in adults in sSA are
lacking, it is clear from the available data that HIV-infection is the dominant risk factor
there. Summary patient demographics from the 10 identified sepsis studies are shown in
Table 1.2; of 2788 included patients with available HIV status, 69% (1809/2788) were HIV
infected, and often with advanced disease; of 1278 HIV-infected patients from 5 studies with
available CD4 count the median CD4 count ranges from 52-168 cells/µL. In keeping with
the epidemiology of the HIV epidemic in Africa, these patients are young, with average ages
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(variably reported as mean or median) ranging from 30-39 across the studies. These studies
recruited an equal proportion of males and females (1444/2812 males, 51%), suggesting
that sex is not a risk factor.
These data contrast sharply with the sepsis population in high income settings, from
whom the majority of sepsis data have been generated, and who are older and mostly HIV
uninfected[7,82,85]. The need for data from sSA to guide sepsis treatment protocols, rather

















Table 1.2: Characteristics of patients recruited to sSA sepsis studies
Study Type Year Country Inc. criteria n Male Age HIV infected Median CD4
Jacob 2009 Cohort 2006 Uganda Severe sepsis 382 156/382 (41%) 34.8 (11.2) 320/382 (85%) 52 (16-131)
Jacob 2012a Before-after 2006 Uganda Severe sepsis 245 95/245 (39%) 34 (28-41) 207/245 (86%) 43 (11-178)
2008-09 426 207/426 (49%) 34 (27-40) 362/426 (85%) 63 (15-178)
Waitt 2015 Cohort 2008-09 Malawi Sepsis 213 87/213 (41%) 30 (25-39) 161/213 (76%) NR
Ssekitoleko 2011 (1)b Cohort 2009 Uganda Sepsis 96b 193/418b (46%) 35.1 (12.0) 331/418b (83%) NR
Ssekitoleko 2011 (2) Cohort 2009 Uganda Sepsis 150 94/150 (63%) 35 (13) 96/150 (64%) NR
Chimese 2012 Cohort 2010 Zambia Sepsis 161 79/161 (49%) 39 (15.6) 110/138 (80%) NR
Andrews 2014 RCT 2012 Zambia Severe sepsis 112 58/109 (53%) 35 (1.4) 88/109 (81%) NR
Auma 2013 Cohort 2012 Uganda Sepsis 216 106/216 (49%) 32 (27-43) 122/216 (56%) NR
Andrews 2017 RCT 2012-13 Zambia Severe sepsis 209 117/209 (56%) 36.7 (12.4) 187/209 (89.5%) 66 (21-143)
Huson 2014 Cohort 2012-13 Gabon Sepsis 384 142/382 (37%) 34 (25-46) 77/384 (20%) 168 (61-438)
Amir 2016 Cohort 2014-15 Uganda Severe sepsis 218 110/218 (50%) 35 (26-50) 125/218 (57%) 78 (20-202)
Note:
RCT = randomised controlled trial. All studies use a modified sepsis-2 definition of sepsis or severe sepsis. Age is given as median (IQR) or mean
(SD). Units of CD4 count are cells/microlitre.
a Jacob 2012 includes two cohorts of patients – results shown for both separately.
b Ssekitoleko 2011 (1) includes some participants also included in Jacob 2009; the n here (n=96) includes only participants not included in Jacob 2009
but the proportion of male and HIV-infected participants includes all patients including those from Jacob 2009 (n= 418) as they are not disaggregated
in the publication.
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1.2.5.3 Outcomes
Summary 28/30 day mortality outcomes for sepsis and severe sepsis in sSA from the identified
studies are presented in Figure 1.1. It is clear that there is significant heterogeneity in
outcomes of sepsis and severe sepsis in sSA, likely reflecting diverse patient and pathogen
populations and variation in availability of available resources. This heterogeneity means
that summary estimates should be interpreted with extreme caution but severe sepsis (49%
[95% CI 39-58]), as expected, seems to carry a higher mortality hazard than sepsis (23%
[95% CI 12-38]). Data of outcomes beyond 30 days are absent.
How does this compare to high income settings? A recent meta-analysis of population level
estimates in high income settings found that a pooled sepsis 30-day mortality estimate
of 17% (95% CI 11-26%)[4], though even older cohort studies as well as the more recent
large sepsis-3 derivation cohorts have found considerably lower mortalities for sepsis (as
defined by sepsis-2) ranging from 4-7%[73,86,87]. Most recent (largely post-2005) estimates
of 30-day mortality from severe sepsis range from from 18-29%[4,5,81,85,88]. It seems likely
therefore, that both sepsis and severe sepsis 30-day mortality is considerably higher in sSA
than in high-income settings.
In the longer term, sepsis mortality continues to rise after the usual sepsis-study primary
end point of 28 or 30 days, though data from sSA are absent. A systematic review in 2010
of long term sepsis mortality identified 26 studies (with none from low-resource settings)
that reported long term sepsis mortality; 1 year mortality ranged from 22-72%, increasing
to 45-75% at greater than 3 years[89]. Both short and long term morbidity is formidable
also, though, once again, data from low income settings including sSA are absent[90–94]
and health-related quality of life in sepsis survivors in high-income settings have been found
to be persistently below population norms[89]. Long term sepsis outcomes in sSA are
unknown.
1.2.6 Sepsis aetiology in sub-Saharan Africa
The 11 identified prospective sepsis studies in sSA carried out various combinations of
diagnostic testing for malaria (either microscopy or rapid diagnostic test) and aerobic and
mycobacterial blood culture; a summary is shown in Table 1.3 and 1.4. The commonest
bloodstream infection (BSI) in all studies where mycobacterial blood cultures were carried
out was tuberculosis – present in a higher proportion than of all BSI isolates from aerobic
culture combined - though it is important to note that mycobacterial blood cultures in most
studies were carried out in HIV infected people and bacteraemic tuberculosis was almost
exclusively HIV-associated. With the exception of one study, malaria was less common than
BSI, highlighting the importance of non-malarial fever in sSA as malaria control efforts
reduce the burden of malaria.
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Figure 1.1: Pooled sepsis (A, top) and severe sepsis (B, bottom) inpatient mortality in sSA
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Table 1.3: Aetiology of sepsis in sSA
Study BSI MTB BSI Malaria
Jacob 2009 48/382 (13%) 156/382 (22%) 34.8 (15%)
Jacob 2012 83/671 (12%) 104/576 (18%) 83/671 (12%)
Waitt 2015 33/213 (15%) ND 26/213 (12%)
Ssekitoleko 2011 (1) ND ND ND
Ssekitoleko 2011 (2) 39/150 (26%) ND 7/150 (5%)
Chimese 2012 27/161 (17%) ND ND
Andrews 2014 26/109 (24%) 32/81 (40%) 2/109 (2%)
Auma 2013 41/216 (19%) ND 9/216 (4%)
Andrews 2017 29/209 (14%) 43/187 (23%) 3/47 (6%)
Huson 2014 39/384 (10%) NR 130/384 (33%)
Amir 2016 ND ND ND
TOTAL 365/2493 (15%) 234/1093 (21%) 311/2139 (15%)











Excluded are coagulase-negative Staphylo-
cocci, alpha-haemolytic Streptococci other
than Pneumococcus, Bacillus spp. and
Micrococci as likely contaminants.
1.2.6.1 Tuberculosis
Beyond the studies of sepsis described above, there is ample evidence that disseminated
tuberculosis is a significant cause of hospitalisation and death in people living with HIV in
sSA, but optimum management in the context of critical illness is less clear. Mycobacterial
blood culture is a difficult diagnostic tool to use in clinical practice - it requires laboratory
infrastructure and usually takes many weeks to become positive - but when carried out
hospitalised adults in sSA the prevalence of Mycobacterium tuberculosis bloodstream infec-
tion (MTB BSI) is between 2.5-23%, and almost universally restricted to participants with
HIV[14,95–108]. The recent STAMP study in Malawi and South Africa found a mortality
benefit in some prespecified subgroups of a strategy of screening all HIV-infected inpatients
for TB using urinary lipoarabinomannan[109]. Autopsy studies have persistently found
evidence of TB in a significant proportion of HIV-infected people who die in hospital - 43% in
one meta analysis - which is often missed ante mortem, and is very often disseminated[110].
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Both of these findings strongly suggest a high burden of undiagnosed disseminated TB
in HIV-infected inpatients. The WHO, recognising this, has published guidelines on the
management of smear negative tuberculosis in the seriously unwell[111] which suggest a
trial of broad-spectrum antimicrobials for 3-5 days and prompt initiation of TB therapy if
there is no response. Though based on expert opinion, these guidelines have been shown to
improve outcomes in South Africa[112]. It is unknown whether delaying TB therapy in this
way is associated with higher mortality in the critically unwell, analogously to antibacterial
delay in sepsis in high income settings.
1.2.6.2 Bacterial zoonoses, rickettsioses and arboviruses
There are several reasons to suspect that aetiologic agents other than bacterial BSI and
tuberculosis may be significant in sSA, though data in sepsis are sparse. Studies of febrile
illness in sSA have implicated rickettsioses, arboviruses and bacterial zoonoses as causes of
fever, accounting for a third of fever in hospitalised adults in one study in Tanzania[14].
Historically, however, data on these pathogens have been lacking. A 2015 systematic review
of fever aetiology in LMIC (considering studies from 1980-2013) found that small numbers
of patients had been systematically screened for these pathogens: in sSA 40/453 (8.8%) of
adults with fever fulfilled diagnostic criteria for Leptospirosis, 16/453 (3.5%) for Brucellosis,
36/450 (8.0%) for spotted fever group Rickettsiosis, 24/482 (5%) for Q-fever and 55/700
(7.9%) for Chikingunya[12].
Increasing interest in non-malarial fever, however, has meant that data are accumulating
from different settings in sSA, post-2013, as identified by the systematic review of the
literature performed for this thesis. Details of the studies identified from this review are
shown in Table 1.10 in the chapter appendix. These data highlight, firstly, the heterogeneity
in diagnostics which are used for these pathogens – a combination of serology, PCR and
antigen testing (often not using gold-standard case definitions), and secondly, the spatial
and temporal heterogeneity across the continent.
These studies also demonstrate an increase, post-2013, in the use of molecular tests,
particularly multiplex PCR assays (TaqMan array cards or PCR macroarrays) to detect
multiple pathogens in fever aetiology studies. Despite the attractiveness of these assays – the
ability to detect tens of pathogens in one assay on one body fluid sample – many infections
will have only transiently detectable pathogen genetic material in blood and as such may
have limited sensitivity. The post-2013 fever aetiology data strongly suggest paired sera
will maximise the diagnostic yield of bacterial zoonoses and rickettsioses: for example, in
studies of leptospirosis using PCR only 23/2533 (0.9%) of samples were positive versus
75/1464 (5.1%) in studies using paired sera; for Q-fever 9/3811 (0.2%) of samples were
positive in PCR only studies versus 25/370 (6.8%) for paired sera studies; for brucellosis
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PCR only studies 15/1005 (1.5%) of samples were positive versus 39/562 (6.9%) for paired
sera studies; and for rickettsioses 55/1932 (2.8%) of samples were positive for PCR studies
vs paired sera 63/364 (17%). Some care must be taken with this conclusion: there are no
studies that aim to directly compare paired sera and PCR assays for diagnosis of febrile
illness, so the possibility of confounding remains.
Available data therefore suggest that bacterial zoonoses, rickettsioses and arboviruses are
significant causes of febrile illness in sSA. Their role is sepsis however is unknown. Only two
studies have directly addressed the question of sepsis aetiology beyond BSI, malaria and
TB: the first[11] performed PCR for 43 pathogens (using a TaqMan array card) including
viruses (including dengue, chikungunya, and causes of viral haemorrhagic fever), bacteria
(including S. pneumoniae, E. coli, Salmonella spp., S. aureus as well as Coxiella burnetti,
Rickettsia spp., Brucella spp. and Leptospira spp.), Mycobacterial (including M. tuberculosis
(MTB) and M. avium complex), fungal (Cryptococcus and Histoplasma spp.) and parasitic
(including malaria) on a convenience sample of 336 stored plasma samples from a Ugandan
sepsis study. In keeping with the original study, MTB was frequently identified as was
pneumococcus and malaria. Cytomegalovirus (CMV) was detected in 139/336 (41%) of
patients, and was found to be independently associated with death, a finding which has
been seen in sepsis studies in high-income settings[113] and may be related to the immune
paresis of sepsis and CMV viraemia rather than disease. This study had no pathologic
specimens and could not address this question. Dengue was detected in 17/336 (5%) of
patients; Rickettsia spp. in 6/336 (2%), Leptospira spp. in 2/366 (0.6%) and Coxiella
burnetti and Brucella spp. in 1/336 (0.3%) each. The true burden of disease of these
pathogens may be higher, given the potential for increased diagnostic yield from serological
assays.
The second study[13] is a retrospective analysis of a fever aetiology cohort from Tanzania,
in which paired serology for bacterial zoonoses and Rickettsioses was carried out, as well as
arboviral PCR. Of 423 enrolled adults, 25 were retrospectively classified as having septic
shock, 37 severe respiratory distress without shock and 109 severe pneumonia by WHO
Integrated Management of Adolescent and Adult Illness (IMAI) District Clinician Manual
criteria[114]. These patients would likely fulfil sepsis criteria under sepsis-2 or 3 guidelines,
and were found to have a variety of diagnoses, though not all patients had all diagnostic
tests: chikungunya (6/154 [3%]),leptospirosis (5/82 [6%]), Q-fever (7/83 [8%]) and spotted
fever group rickettsioses (6/83 [7%]).
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1.2.6.3 HIV opportunistic infections: PCP, histoplasmosis and cryptococcal
disease
The burden of HIV opportunistic infections in sepsis in sSA (including Pneumocystis
jiroveci pneumonia [PCP], cryptococcal disease and including here histoplasmosis as an
opportunistic infection) is unclear. Beyond blood culture identification of Cryptococcus
neoformans (present in 20/365 of positive blood cultures in the sepsis studies identified in
this review) none of these pathogens have been systematically sought in sepsis cohorts in
sSA, and their role as causative agents of sepsis is far from clear. Cryptococcal disease most
commonly manifests as cryptococcal meningitis, is common in HIV infection and is thought
to account globally for 15% of AIDS-related deaths[115]. No study has attempted to define
the burden of PCP in sepsis in sSA, though a 2016 systematic review[116] addressed the
prevalence and attributable mortality of PCP generally, finding the pooled prevalence of
PCP in HIV-infected inpatients (n = 2593, 23 studies) to be 22% (95% CI 17 – 27%) in
random effect meta-analysis. Data examining the role of Histoplasmosis as a cause of fever
or sepsis in sSA are sparse. A 2015 systematic review[12] identified only one study up to
2013 which Histoplasma urine antigen testing in 628 febrile adults and children in Tanzania
finding 9/628 (1%) probable cases, 6/9 of whom were HIV infected. Since then one study
in Uganda found 0/151 HIV-infected patients with suspected meningitis[67] had detectable
IgM to Histoplasma capsulatum and and no Histoplasma antigen was detected in serum
(n = 57), urine (n = 37) or CSF (n=63); a study in Cameroon[68] used histopathologic
examination and culture to diagnose histoplasmosis in 7/56 (13%) of HIV infected patients
with CD4 < 200 cellsµL−1 and chronic cough with histoplasmosis like skin manifestations.
1.2.7 Sepsis management
The cornerstone of sepsis management is rapid administration of appropriate antimicrobial
therapy, source control of any infectious focus and normalisation of tissue perfusion using
intravenous fluids and, if necessary, inotropes, with other organ support as necessary (e.g. in-
tubation and mechanical ventilation and renal replacement therapy). Several international
guidelines for sepsis care are available; this section will examine these and specific guidance
for sepsis in adults in sSA followed by a review of the evidence to inform these guidelines.
The surviving sepsis campaign has published four editions of comprehensive guidance on
the management of sepsis in adults, which are endorsed by all the major critical care
organisation in high income settings and form the basis of most sepsis care in high income
settings; selected major recommendations of the latest guidance[117] are shown in Table
1.5 below.
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Administer 30ml/kg of intravenous crystalloid solution,
within 3hr of diagnosis of sepsis
Strong Low
Use frequent reassessment to guide further fluid BPS BPS
Use dynamic variables to assess fluid responsiveness
(e.g. cardiac output)
Weak Low
Use vasopressors in patients who remain hypotensive
despite adequate fluid resuscitation; target a MAP of
65mmHg
Strong Moderate
Use noradrenaline as first-line vasopressor Strong Moderate
Measure lactate and use lactate normalisation to guide
resuscitation in patients with elevated lactate
Weak Low
Antimicrobials




Use hydrocortisone 200mg IV per day if adequate fluid




BPS = best practice statement
Mindful that guidelines aimed at high-income settings may be impossible to implement in
low-resource settings (including large areas of sSA) the Global Intensive Care Working Group
of the European Society of Intensive Care Medicine (ESICM) published recommendations
for sepsis management in resource-limited settings in 2012[118], endorsed by a number
of national and international sepsis organisations, and supplements in 2016-17 covering
general supportive care[119], infection management[120], management of severe malaria and
severe dengue[118] and haemodynamic assessment and support[121] in sepsis in low-resource
settings. The major recommendations of this guidance are consolidated in Table 1.6 below.
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Use capillary refill time, skin mottling scores or skin
temperature gradients to assess adequacy of tissue
perfusion.
Weak Ungraded
Use passive leg raise (PLR) to guide fluid resuscitation
in sepsis or septic shock
Weak High
Use crystalloid for fluid resuscitation Strong Moderate
Give 30ml/kg of fluid over the first 3hr following sepsis
diagnosis, to start within 30mins of recognition
Strong High
Larger volumes of fluid may be needed if the patient
remains fluid responsive and still shows signs of tissue
hypoperfusion
Strong Low
Be extremely cautious in settings with no or limited
access to vasopressors and mechanical ventilation and
consider stopping fluid if respiratory distress or lung
crepitations develop
Strong High
Use noradrenaline as first line vasopressor Strong Moderate
Target a MAP of > 65mmHg Strong Moderate
Antimicrobials
Appropriate antibiotics should be given within the first
hour following septic shock
Strong Low




Use hydrocortisone 200mg IV per day if adequate fluid




MAP = Mean arterial blood pressure
The World Health Organisation (WHO) in 2011 published the integrated management
of adolescent and adult illness (IMAI) guidance[114], which includes guidance on the
management of septic shock and is aimed at district-level clinicians in resource limited
settings rather than critical care clinicians. This suggests defining shock as SBP < 90mmHg
or pulse > 110/minute and suggest that, once shock is identified, oxygen should be given, a 1
litre bolus of fluid should be given immediately and pulse, SBP and signs of perfusion (urine
output, mental status) should be rechecked. If shock persists, another litre should be given;
if shock persists after the second litre then help should be sought. Antimicrobials should
be administered: the choice of agent should depend on local epidemiology and guidelines,
with antimalarials if indicated. No evidence base is referenced for these recommendations.
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1.2.7.1 Early goal directed therapy
In 2001 a pivotal single centre study in the United States of 263 patients with severe sepsis
or septic shock[122] found that protocolised aggressive early resuscitation (called Early
Goal Directed Therapy, EGDT) significantly reduced mortality from 46.5% to 30.5% (p =
0.009). EGDT called for early central venous catheterisation and protocolised resuscitation
to central venous pressure (CVP), MAP and central venous oxygen saturation (ScvO2)
targets, and was widely adopted. However three large multicentre randomised controlled
trials of EGDT – ProCESS in the United States[123], ARISE in Australasia[124] and
ProMISe[125] in the United Kingdom, reporting in 2014 and 2015 failed to show any
difference in outcomes between the EGDT and usual-care arms. A pre-planned individual
level meta-analysis of the 3723 patients included in these trials confirmed similar 90 day
mortality in both arms (24.9% for EGDT vs 25.4% for usual care, aOR 0.97 [95% CI
0.82-1.14]) with no benefit found in pre-planned subgroup analysis for patients with worse
shock or in hospitals with lower propensity for vasopressors or fluid administration[85]. It
is likely therefore that the tenets of EGDT that improve outcomes (early antimicrobials
and aggressive fluid resuscitation) have been absorbed into usual care in the fifteen years
since the original EGDT study, as evidenced by the reduction is sepsis mortality over this
time period, and so the specific package of protocolised care and EGDT targets does not in
itself improve outcomes. Unanswered questions now remain regarding the most effective use
of the individual components of EGDT (fluids, vasopressors etc.). A number of attempts
have been made to develop protocolised sepsis care packages in the style of EGDT for sSA;
these are described below in relation to the individual components of sepsis care.
1.2.7.2 Evidence to guide antimicrobial therapy in sSA
There is evidence from high income settings that delay in appropriate antimicrobial admin-
istration is associated with worse outcomes in sepsis. The first study to investigate this
relationship, published in 2006, found a very strong relationship between time to appropriate
antimicrobial administration from onset of hypotension and mortality with an absolute
increase in mortality of 7.6% for each hour delay over the first six hours[126]. Subsequent
data have been more nuanced: a 2015 meta-analysis addressing this question identified
11 studies of 16,178 patients and found no relationship between antimicrobial delay and
mortality[127], though many of the included studies are open to confounding by indication
(sicker patients are given antimicrobials more quickly), timed antimicrobial administration
to non-physiological events (e.g. arrival to hospital or time of blood culture draw rather
than onset of hypotension) and did not assess the appropriateness of antimicrobial therapy,
all of which could mask a relationship. Appropriate antimicrobial therapy has certainly
been shown to be associated with improved survival: a 2010 meta-analysis quantified the
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pooled adjusted odds ratio to be 1.6 (95% CI 1.4-1.9) from 26 studies for appropriate
versus inappropriate antimicrobial therapy[128]. A recent large retrospective study of 49,331
patients in New York hospitals[7] confirmed the relationship between antimicrobial delay
and mortality with an adjusted odds ratio of in-hospital death of 1.04 per hour delay (95%
CI, 1.03 – 1.06), and rapid antimicrobial administration forms a key recommendation of
current sepsis guidelines.
Data from sSA are lacking, however; neither of the meta analyses above (including between
them 37 studies) included any data from sSA, but three of the sepsis studies identified in this
systematic review attempt to address the question. The first[17], in an observational study
of 382 adults with severe sepsis in Uganda found no association between administration of
antibiotics within 1 hour and mortality (OR 0.9 [95% CI 0.6-1.6]) but a total of 42 antibiotic
regimens were used and there was a high proportion (22%) of bacteraemic tuberculosis;
no assessment of appropriateness of antimicrobials was undertaken and it is possible that
inappropriate antimicrobials could mask any association between time of administration
and mortality, if one existed.
The second[27], interventional, study in the same centres in Uganda used a before-after design
with 661 patients to implement a clinical-officer delivered fluid resuscitation protocol (see
below) and administration of antimicrobials. 426 patients were included in the intervention
with 245 in the usual care group. The protocol resulted in more rapid administration
of antibiotics (67% administered within 1hr versus 30%, p < 0.001) and less (though
still very prevalent) inappropriate antimicrobial administration (81% versus 95%, p <
0.001). Antimicrobial administration was associated with a reduced hazard of death in a
multivariable Cox proportional hazards model, but the comparator group used was patients
who received no antimicrobials and the hazard ratio for rapid administration (< 1hr HR
0.44 [95% CI 0.21 – 0.89]) was not significantly different from delayed administration (>
6hr HR 0.39 [95% CI 0.19 – 0.81]). This type of study design is very prone to bias due to
confounding as sepsis management changes over time, especially as the “before” arm was
recruited two years before the “after” arm, so results from this study should be interpreted
with caution.
A third observational study in a Ugandan teaching hospital[129] provides data on the effect
of rapidity of administration of antimicrobials; this study enrolled 218 patients; 89% of them
received any antibiotics within 6 hours, with a median time to antibiotic administration of
30mins. Antibiotic administration within 6hr (versus not) was not significantly associated
with in hospital mortality in univariate analysis (OR 1.5 95% CI 0.6 – 3.8) though the
confidence intervals are wide and could incorporate a clinically significant effect. Again, no
assessment of appropriateness of antimicrobials was made.
Only one study provides limited evidence that appropriate antimicrobial therapy improves
outcomes in infection in sSA[130]: a combined retrospective-prospective analysis of 104
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patients with typhoid perforation (defined by clinical and operative findings rather than
culture) from a single Tanzanian teaching hospital found that adequate antimicrobial
exposure (defined as at least 3 days of antimicrobial active against S. Typhi prior to hospital
admission) was associated with improved in-hospital survival in multivariable analysis (aOR
2.9 [95% CI 2.1-4.5]), however it is doubtful that this very specific complication of typhoid
fever is generalizable.
1.2.7.3 Intravenous fluid therapy in sub-Saharan Africa
The evidence base for rapid fluid administration – and the surviving sepsis recommendation
of 30ml/kg within 3hrs following diagnosis - is less secure than for rapid antimicrobial
administration. As with antimicrobial administration, adoption of guidelines in response
to the EGDT study has meant that disentangling the independent effect of fluid adminis-
tration is difficult. The data are contradictory. Several large retrospective observational
analyses have found no impact on rapidity of fluid bolus administration following sepsis
diagnosis[7,131]. Indeed, fluid clearly has the potential for harm; positive fluid balance for
patients with sepsis in the ITU has been persistently linked with worse outcomes[7,132,133].
Other studies, in contrast, have found that more rapid initiation of IV fluid is beneficial
[134,135]. It may be that heterogeneity in response to fluids plays a role in these conflicting
findings; a retrospective multicentre cohort analysis of 3686 patients[136] found that 64%
were “fluid responders” – that is, they had a sustained blood pressure response to initial
fluid resuscitation without need for vasopressors, and mortality was 15% greater (95% CI
10-18%) in fluid nonresponders.
In sSA, in some ways, the picture is clearer: there is increasing evidence that liberal
intravenous fluid administration to septic patients causes harm. The landmark FEAST
trial[10] randomised 3141 children with severe febrile illness in Kenya, Uganda and Tanzania
to receive either albumin bolus or 0.9% saline bolus or usual care and found an increased
risk of death by 48 hours in both bolus groups (RR 1.45 [95% CI 1.13-1.86] for any
bolus compared to no bolus). In a secondary analysis[137] this was thought to be due to
cardiovascular collapse rather than pulmonary oedema; the mechanism of this is unclear.
Only three controlled studies have addressed the question of optimal intravenous fluid
resuscitation for septic adults in sSA. One before-after intervention study in septic shock
patients carried out in Uganda and described above[27], found a mortality benefit of > 1L
fluid over the first 6hr compared to < 1L in multivariable Cox proportional hazard model
(HR 0.54 [95% CI 0.35-0.82] 1.0 – 2.5 L vs < 1.0L) but was hampered by a before-after
design. Two randomised controlled trials of protocolised early sepsis care in adults have been
carried out at a single centre in Zambia assessing the effect of a protocol that administers
up to 4L of fluid over 6hrs. The first[25] recruited patients with severe sepsis with organ
dysfunction criteria including respiratory rate > 40/min and was stopped early as it was felt
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that participants with baseline respiratory compromise might be at risk of harm; 7/10 (80%)
of this subgroup died in the usual care group, compared to 8/8 (100%) in the intervention
group (p = 0.09). The second[9] was unequivocally harmful, with more participants dying
by 28 days in the intervention group (48% vs 33%, p = 0.03). The reasons are not clear.
More respiratory compromise (defined as increase in respiratory rate by 5 breaths/min or
reduction in oxygen saturation of 3% or more) occurred in the intervention group (35% vs
22%, p =0.03) but persisted beyond 6 hours in similar numbers in both groups (17% vs
15%, p = 0.63).
1.3 ESBL-E in sub-Saharan Africa
I here discuss the definition and global epidemiology of ESBL-E, with systematic review
and meta analysis of the prevalence of ESBL-E colonisation and invasive infection.
1.3.1 Introduction: definition and classification of ESBL-E
β-lactamases are enzymes that hydrolyse the active β-lactam ring in β-lactam antimicrobials.
Two classification schemes are usually used for β-lactamases: the molecular (or structural)
classification of Ambler[138], or the Bush-Jacoby-Medeiros functional classification[139]
(Table 1.7). Molecular classification is straightforward and depends on protein homology;
class A, C and D enzymes are serine β-lactamases and class B are metallo-β-lactamases,
named for the composition of their active site. The functional classification is complex and
clusters enzymes into four groups, with a number of subgroups, based on substrates and the
effect of β-lactamase inhibitors and EDTA: class 1 (corresponding to Ambler class C) are
cephalosporinases that are not inhibited by clavulanic acid, and includes the AmpC enzymes
of the Enterobacteriaceae; class 2 enzymes are β-lactamases that are largely inhibited by
clavulanic acid and belong to Ambler class A or C; and class 3 are the metallo-β-lactamases
corresponding to Ambler class B. Class 4 enzymes are penicillinases which are not inhibited
by clavulanic acid, though are of limited significance and not included in Table 1.7.
The vast majority of clinically relevant ESBLs belong to Ambler class A, functional class 2be.
For the purpose of this thesis, therefore, I define ESBL as enzymes which confer resistance
via hydrolysis to penicillins, cephalosporins of the first, second or third generation (excluding
cephamycins), aztreonam, but not carbapenems, and are inhibited by β-lactamase inhibitors
such as clavulanic acid[140]; this corresponds to the Bush-Jacoby group 2be and makes
clear that I draw a distinction between ESBL and AmpC enzymes, which would be grouped
with the Bush-Jacoby group 1. When referring to ESBL genes I will refer to them is the
standard way using bla and a subscript to indicate the gene as for example blaCTX−M−15;
when referring to the enzyme, I will refer to them as, for example CTX-M-15.
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1 C Cephalosporins No No cephalosporins >
benpen, hydrolyzes
cephamycins
E. coli AmpC, P99,
ACT-1, CMY-2,
FOX-1, MIR-1




















Yes No oxyimino-beta lactams TEM-3, SHV-2,
CTX-M-15, PER-1,
VEB-1
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TEM-50

























Yes No Inhibited by clavulanic
acid but not aztreonam
CepA
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B (B3) L1, CAU-1, GOB-1,
FEZ-1




BLI = Beta-lactamase inhibitor
1.3.2 Global molecular epidemiology of ESBL-E: an overview
The history of the global spread of ESBL-E is complex and an enormous number of unique
ESBL amino acid sequences have been described; at the time of writing the NCBI beta-
lactamase directory contains 1557 named β-lactamase genes, many of them ESBL. However,
there are 3 families of enzymes which cause the majority of infections in humans: TEM,
SHV, and CTX-M. They will be briefly described here in turn in the context of their
putative origins and global dissemination in the latter half of the 20th century. A diverse
range of other ESBL enzymes have been described, but are largely of less clinical significance
than those described above, and are beyond the scope of this review: most notably the
OXA type, which in contrast to TEM, SHV, and CTX-M, are of the molecular class D and
functional class 2d, and are characterised by a high rate of hydrolysis of cloxacillin[141];
like TEM and SHV, OXA β-lactamases are not always extended-spectrum.
1.3.2.1 1980s-1990s: First identification of ESBL in nosocomial pathogens
β-lactamases form an integral part of the natural armamentarium of many genera of
bacteria – particularly Gram negatives, including Enterobacteriaceae - and predate the
antibiotic era; penicillinases were identified in E. coli, for example, prior to the widespread
introduction of penicillin for treatment of human disease[142]. These β-lactamases are often
chromosomally located; the first plasmid-mediated narrow-spectrum β-lactamase, TEM-1
-named for the patient, Temoneira, from whose blood it was first isolated – was found in
Athens in the 1960s[143]. It rapidly disseminated globally and is thought to be responsible
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for a high proportion of ampicillin resistance in E. coli[141]. This worldwide spread
spurred the development and use of β-lactamase resistant extended-spectrum cephalosporin
antimicrobials, which found wide use in the 1980s. Perhaps inevitably, an enzyme conferring
resistance to extended-spectrum oxyimino-cephalosporins was subsequently identified in a
German clinical Klebsiella ozaenae isolate in 1983, encoded for on a pBP60 plasmid and
enzymes of this sort were named ESBLs[144,145].
This first ESBL enzyme was found to be similar to an existing plasmid-encoded narrow
spectrum beta lactamase, SHV-1, which had been described in the 1970s in E. coli, and
was thought to itself be descended from a chromosomally encoded K. pnemoniae narrow
spectrum beta lactamase which was liberated onto a plasmid[146]. The point mutations in
SHV-1 conferred the ESBL phenotype, and this enzyme was named SHV-2. This pattern -
mutation of a narrow spectrum β-lactamase to produce an ESBL phenotype - also occurred
in TEM, and the first ESBL TEM was described in France in 1989[147] and named TEM-3.
Many TEM and SHV variants were subsequently described[148]. However, in this early
stage of the epidemic, ESBL enzymes were largely nosocomial, and often associated with
Klebsiella spp.[149].
1.3.2.2 1990s-2010s: Emergence and globalisation of CTX-M
From the late 1990s onwards, there were profound changes in the global epidemiology of
ESBL-E, on three fronts, all intricately interrelated, and occurring simultaneously: first,
the rapid emergence and globalisation of the successful CTX-M ESBL enzyme family[150],
aided by mobile genetic elements; second, E. coli joining Klebsiella spp. as a major ESBL
host[151], and the emergence of so-called high risk bacterial clones; and third, the spread of
ESBL-E into the community[152]. CTX-M-1 was first identified and named in Germany in
1989[153], the name derived from “active on cefotaxime first isolated in Munich.” Many
variants were subsequently identified, largely in E. coli and K. pneumoniae, from isolates
all over the world[154]. The blaCTX−M genes are clustered by homology into 5 groups
(blaCTX−M groups 1,2,8,9 and 25) and each group is thought to have descended from a
chromosomal beta lactamase from Kluyvera spp.[150]
A year-on-year rise in incidence of invasive ESBL-E infection was seen in most high-
income settings (Figure 1.2) throughout the 2000s and 2010s, the majority of which
were CTX-M producers, though with varying proportions of different CTX-M enzymes in
different locations[151,155]. Risk factors for ESBL-E infection in high income settings have
persistently been shown to be hospital or long-term care facility exposure, antimicrobial
exposure and chronic health conditions though it was recognised in the 2000s that a large
proportion of patients with invasive ESBL-E lack any of these risk factors[152], suggesting
acquisition in the community. Colonisation prior to infection is thought to be the norm;
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E. coli K. pneumoniae




























Figure 1.2: Prevalence of third generation cephalosporin resistance in representative
high income (EU, USA) and middle income (China, Mexico, India) areas in inva-
sive E. coli (left panel) and K. pneumoniae (right panel) isolates. Data for EU are
from ECDC surveillance atlas (https://ecdc.europa.eu/en/antimicrobial-resistance/surveillance-
and-disease-data/data-ecdc) and for other countries are from CCDEP resistance map
(https://resistancemap.cddep.org/AntibioticResistance.php) both accessed 28 December 2018. 3GC
= third generation cephalosporin. Note that these data are 3GC-resistant isolates rather than
confirmed ESBL-producers, but would be expected to be ESBL-producers in the vast majority of
cases.
prior colonisation is a significant risk factor for infection and indeed when sought ESBL-E
are found in the stool of healthy community members worldwide[156].
Though less comprehensive, data from middle income countries suggests that prevalence of
ESBL producers amongst invasive E. coli and K. pneumoniae can be very high (Figure
1.2) and in countries such as India invasive E. coli and K. pneumoniae that are sensitive
to third-generation cephalosporins are in the minority. The reasons for this are not clear
but country and regional level associations (which are open to ecologic bias) have been
shown with antimicrobial consumption[157,158] and economic status; GDP per capita has
been found to correlate inversely at a country level with third-generation cephalosporin
resistance rates[159]. Data from sSA have historically been lacking and are systematically
reviewed below.
1.3.2.3 Epidemiology of gut mucosal carriage of ESBL-E: the first step to-
wards invasive infection
Invasive infections with Enterobacteriaceae are thought to usually result from infection
from an individual’s own gut microbiota, irrespective of resistance pattern[160], and whole
genome sequencing has confirmed that invasive isolates are often closely related to prior gut
54 CHAPTER 1. INTRODUCTION
carriage isolates[161]. Strategies to minimise carriage are therefore potentially attractive
as interventions to reduce invasive infection and a number of studies have attempted to
understand the dynamics of gut mucosal ESBL-E carriage in health and disease. A brief
overview of ESBL-E community carriage is presented here, and ESBL-E carriage in sSA
specifically is systematically reviewed below.
ESBL-E community carriage in Spanish outpatients[162] and healthy children in Poland[163]
was first described in 2001. Since that time carriage by healthy community members has
been found worldwide in all populations[156,164], though there are heterogeneities between
and within countries which mirror the prevalence of invasive ESBL-E prevalence amongst
E. coli and K. pneumoniae. In Europe, for example, community prevalence of ESBL-E
carriage was estimated be 7.3% in the UK in 2014 in a large community study[165], 4.5%
in the Netherlands in 2012[166] and 4.7% in Sweden in 2012/13[167] and 3.7% in Spain in
2003[168], significantly lower than community carriage prevalence of 50.9% seen in China
in 2009[169] or 33.8% in India in 2011-2013[170].
Risk factors for colonisation have been identified in many studies and antimicrobial ex-
posure[171,172] and healthcare facility exposure[170,173] (including long term care fa-
cilities[174]) are consistently identified as such. Colonisation of a household member
has also been identified as a risk factor[175,176], suggesting significant within-household
spread. Antacid use has been associated with ESBL-E colonisation[171] as has expo-
sure to farming[166]. In low prevalence areas, travel to high prevalence areas is a risk
factor[165,167,171,172,177].
The majority of studies of ESBL-E carriage are cross sectional and only a handful have
attempted to characterise longitudinal carriage of ESBL-E with a longitudinal sampling
approach. Estimates of carriage duration vary, partly because of the difficulty in inferring
them from interval-censored rectal swab or stool data, but it is clear that some patients
remain colonised for many months. Following a Swedish ESBL-E outbreak, 12% of patients
still carried ESBL-E at the final sampling visit, a median 58 months after the outbreak[178].
French and German studies found a median duration of carriage of 4.3[179] and 12.5[180]
months respectively following hospitalisation or outbreak. More transient carriage following
international travel seems to be the norm with a median of 30 days in a large Dutch
study[181]; the reasons for this are not clear.
The largest longitudinal community study of ESBL-E carriage took place in the Nether-
lands which recruited 76 ESBL-E colonised and 249 uncolonised community members and
carried out longitudinal stool sampling at 5 time points over 8 months. 25/76 (33%) of
initially-colonised participants remained persistently colonised after a median 242 days.
Antimicrobial exposure in the past 6 months, proton-pump inhibitor use, colonisation with
E. coli phylogroup B2 or D and presence of blaCTX−M−27 or blaCTX−M−14 was associated
with persistent carriage, suggesting both host and bacterial factors may be important
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determinants of carriage duration. K. pneumoniae colonisation seemed to be less common
in the persistent carriage group[177,182]. This study also found significant heterogeneity of
E.coli sequence type in longitudinal samples of persistent carriers but that ESBL genes and
often detectable plasmid replicons remained unchanged, suggesting a significant role for
mobile genetic elements.
1.3.2.4 Molecular mechanisms underlying success of CTX-M: mobile genetic
elements and high-risk clones
The remarkable success of CTX-M has led to efforts to understand the molecular mechanisms
by which this enzyme spread so rapidly. The system is complex, and poorly understood,
but should be considered at multiple levels including that of the organism; the plasmid; the
transposon, which may contain integrons or insertion sequences and, at the lowest level the
ESBL gene. These will briefly be reviewed here.
The initial mobilisation event of blaCTX−M from Kluyvera spp. is thought to have been
mediated by capture of transposable insertion sequences; the insertion sequence ISEcp1
has been experimentally demonstrated to mobilise the blaCTX−M precursor from Kluyvera
ascorbata[183] and ISEcp1 is most consistently associated with blaCTX−M genes. However,
IS26, ISCR1 and IS10 have also persistently been described upstream from blaCTX−M genes,
suggesting multiple mobilisation events[155]. blaCTX−M genes cluster by homology into
groups and there is an association between particular blaCTX−M gene clusters and particular
insertion sequences, consistent with a hypothesis of multiple mobilisation events[184]. These
insertion sequences provide two roles: they encode a transposase enabling gene mobilisation
but act as a strong promotor of blaCTX−M , without which phenotypic cephalosporin
resistance is absent or reduced[185].
After mobilisation from the Kluyvera genome, the blaCTX−M genes were integrated onto
a plasmid backbone, a process which is likely ongoing as a substantial number of diverse
blaCTX−M carrying plasmids have been described: there is, however, an association between
blaCTX−M genotype and plasmid incompatibility group. The successful blaCTX−M−15 gene
is very strongly associated with the narrow host-range IncF plasmid group, for example,
which are restricted to Enterobacteriaceae[185,186]. Identical blaCTX−M containing plas-
mids have been found across diverse geographical regions and have been termed “epidemic
plasmids”[155] though the mechanism of persistence of these plasmids within a bacterial
population remains unclear.
In addition to frequently co-occurring blaCTX−M genes, transposable elements and plasmids,
some clonal groups of E. coli and K. pneumoniae are both globally successful and associated
with particular blaCTX−M genes and plasmids. These successful sequence types (STs)
are known as “high risk clones.” The archetypal example is E. coli ST131 which is often
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associated with an IncFII plasmid containing blaCTX−M−15[187]. First described in 2008,
E. coli ST131 is thought to be responsible for around 80% of extra-intestinal ESBL E. coli
infection[188]. Population genomics studies have demonstrated that a particular clade,
ST131 clade C, is globally dominant and have shown a sequential acquisition of virulence
determinants followed by mobile genetic elements conferring fluoroquinolone and ESBL
resistance[189,190]. These events may have contributed to the global success of ST131, but
the precise mechanism of its apparent fitness advantage remains unknown.
1.3.3 Epidemiology of ESBL-E in sub-Saharan Africa
In order to clearly define the epidemiology of ESBL-E in sSA I performed a systematic
review and meta analysis, which is presented here.
1.3.3.1 Search strategy
A systematic review of the literature was undertaken to answer the following questions:
firstly, what is the prevalence of ESBL-E amongst invasive isolates of Klebsiella pneumoniae
and Escherichia coli infecting humans in sub-Saharan Africa? Secondly, what is the
prevalence of gut mucosal carriage of ESBL-E amongst humans in sSA, and what risk
factors for carriage have been identified? To this end a search of PubMed and Scopus was
carried out using the search terms given in the chapter appendix.
Inclusion criteria were any study that took place in sSA and allowed the calculation of a
prevalence of ESBL-producers in K. pneumoniae or E. coli amongst invasive human isolates,
or prevalence of human gut mucosal carriage of ESBL-E. Studies were excluded if no
ESBL-E confirmatory testing was performed using phenotypic (double disc or combination
disc or E-test) or molecular (PCR or whole genome sequencing) methods. Invasive isolates
were defined to be any blood or CSF sample or other usually sterile fluid, or urine or wound
swabs with clinical suspicion of infection.
1.3.3.2 Statistical analysis
Data were extracted from the identified studies: prevalence of ESBL-E in K. pneumoniae
or E. coli amongst invasive human isolates, or prevalence of human gut mucosal carriage of
ESBL-E. Proportions were plotted in forest plots with exact binomial confidence intervals,
and stratified by location of isolation in the case of carriage isolates (community, outpatient,
on hospital admission, or inpatient). Summary estimates were calculated using random-
effect meta analysis with generalised linear mixed models (GLMMs) assuming binomially
distributed prevalences and normally distributed random effects - the normal-binomial
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model - using the R packages meta[69] v4.9.5 and lme4 v1.1.21[191]. Heterogeneity was
explored by meta-regression, particularly regressing proportion of ESBL producing E. coli
and K. pnemoniae against year of isolation. This was achieved by adding year as a fixed
effect covariate and assessing explanatory power of a model including the parameter to
one without using likelihood ratio testing and considering p < 0.05 to be statistically
significantly better fit. Predicted population prevalences were generated from the fitted
models and plotted with 95% confidence intervals generated from 1000 bootstrap re-samples.
Where available, data on the identified ESBL enzymes were also extracted and plotted as
simple proportions.
1.3.3.3 Results
On 8th December 2018 the search identified 2975 unique studies; after abstract review 192
underwent full-text review, resulting in the inclusion of 86 studies, 54[192–244] providing
data on invasive infection and 32 [245–277] on carriage. Details of these studies are given
below and in the chapter appendix.
1.3.3.4 Invasive ESBL-E infection
Table 1.11 in the chapter appendix shows the 54 included studies in this analysis, which
provide data on 6067 E. coli and 2974 K. pneumoniae isolates. All studies were cross
sectional in design. Of the 54, 18/54 were laboratory based (i.e. a survey of all samples
received in the laboratory); 17/54 were truly invasive in that they included predominantly
blood culture; a combination of urine, CSF, and wound swabs were included in the remaining
studies. 36/54 studies provided data on adults and children; 6/54 on adults only; and 12/54
on children only. The majority of studies (42/54) include both community and nosocomial
acquired infection. Of the remainder, 3/54 provided data on nosocomial infection only.
Figure 1.3A shows a map of available data by country; data are available from across the
continent though Nigeria (8 studies) and Tanzania (7 studies) are over represented and
many countries provide no data.
The proportion of ESBL producers amongst invasive E. coli and K. pneumoniae in sSA
is heterogeneous but many studies show an extremely high prevalence (Figures 1.3B and
1.3C), comparable to that seen in the Indian subcontinent and other high-prevalence areas
and highlighting the scale of the public health problem posed by ESBL-E in sSA. Meta
regression shows clear temporal trends of an increase over time: addition of time as a
fixed-effect covariate to the random effects model gives improved fit on likelihood ratio
testing of nested models (p < 0.001 for both E. coli and K. pneumoniae). Though data are
sparse pre-2000, those data that are available suggest that ESBL producing E. coli and K.
pneumoniae were identified in West Africa even in the 1990s: a retrospective laboratory
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Figure 1.3: Invasive ESBL-E in sSA. A: Available studies by country. B and C: meta regression of
proportion of invasive E. coli and K. pneumoniae respectively as a function of time. In both cases
time is statistically significantly associated with proportion of ESBL (p < 0.001 on likelihood ratio
testing of nested models). 95% CI generated from 1000 bootstrap replicates.
based study in Yaounde, Cameroon on isolates from a variety of clinical samples from
1995-1998 found that 13/91 E coli. and 12/64 K. pneumoniae were ESBL producers, with
the blaSHV−12 gene predominant[236]; in Dakar, Senegal, 6/97 K. pneumoniae isolates
from community acquired urinary tract infections in 1999-2000 were found to be ESBL
producers[239].
Some of the heterogeneity in prevalence does however seem to be explained by sample
type; a clearer picture appears when the analysis is restricted to the 16 studies including
predominantly blood culture (Figure 1.4)[196,198–203,205,208,209,211,213,218,221,235,244].
In this analysis it seems clear that the worldwide epidemiology of ESBL-E was mirrored
in sSA; ESBL initially spread amongst invasive K. pneumoniae post 2000 (particularly
post 2005) before becoming established in E. coli after 2010. In 2014, the latest available
data, the pooled population prevalence of ESBL from binomal-normal random effects meta
analysis was 61% [95% CI 40-80%] amongst E. coli and 86% [95% CI 73-92%] amongst K.
pneumoniae bloodstream infection isolates, suggesting endemicity of ESBL amongst these
pathogens in sSA, and comparable to the highest prevalence areas in the world.
ESBL genes were characterised in 10 studies by whole genome sequencing[244] (n=1) or by
PCR[197,200,201,203,210,218,219,235,238] (n=9) for 821 E. coli and 791 K. pneumoniae
isolates (Figure 1.5). blaCTX−M were the most commonly occurring ESBL genes, and



























Figure 1.4: Meta regression of proportion of ESBL producing E. coli and K. pneumoniae amongst
invasive isolate in sSA from studies carrying out blood culture, as a function of time. Includes 1242
K. pneumoniae and 489 E. coli isolates. 95% CI generated from 1000 bootstrap replicates from
fitted models. In both cases time is statistically significantly associated with proportion of ESBL (p
< 0.001 on likelihood ratio testing of nested models).
the majority of these were blaCTX−M−15 in both organisms. blaOXA, blaTEM and blaSHV
genes were also commonly found but were often not further characterised, presenting
some problems of interpretation, as these enzymes can be narrow or broad-spectrum beta-
lactamases. Certainly, blaSHV−1 and blaTEM−1 encode narrow spectrum beta lactamase
enzymes, which were commonly identified in these studies, though only a handful of isolates
had characterisation of blaSHV genes beyond identification of the blaSHV group. All the
identified blaOXA genes were narrow spectrum beta lactamases (blaOXA−1 or blaOXA−30).
These data suggest that the genomic landscape of invasive ESBL-E in sSA is dominated by
blaCTX−M , and blaCTX−M−15 in particular, mirroring that seen worldwide.
Though no data were identified from Malawi that fulfilled the inclusion criteria of the
systematic review, there are three studies that suggest the epidemiology of invasive ESBL-E
in Malawi is similar to that described above. A study from Blantyre in 2004-2005 found that
ESBL-E were unusual in blood stream infection (BSI) isolates: of 1191 Enterobacteriaeciae
BSI, only 8 unique isolates showed an ESBL phenotype (K. pneumoniae 4/8, K. oxytoca,
1/8, Enterobacter cloacae 2/8 and E. coli 1/8) though no denominators are provided to allow
calculation of prevalence. In terms of ESBL enzymes, CTX-M-15 (n = 1) was described,
though in the minority: SHV-11 (n = 1), SHV-12 (n = 3), SHV-27 (n = 1) and TEM-63
(n = 2) were the other enzymes identified[278]. Longitudinal blood culture surveillance in
Blantyre suggests that after 2005 – which coincided with the introduction of ceftriaxone
in government hospitals – the prevalence of ceftriaxone resistance rapidly increased, to
90.5% in K. pneumoniae and 30.3% in E. coli BSI isolates by 2016[15], though this study
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Figure 1.5: Distribution of beta-lactamase enzymes in invasive ESBL producing E. coli (n= 821)
and K. pneumoniae (n = 791) from 10 studies. Invasive is here defined as those recovered from
sterile sites or from urine or wound swabs with clinical suspicion of infection.
did not carry out confirmatory ESBL testing. Finally, two retrospective whole-genome
sequencing study which selected 94 diverse (largely invasive) clinical E. coli and 72 K.
pneumoniae isolates from Blantyre from 1996-2014 found that 21/94 E. coli isolates carried
an ESBL gene, with CTX-M predominating (20/21)[279] and 31/60 K. pneumoniae had an
ESBL phenotype again with blaCTX−M−15predominant (39% [28/72] of identified ESBL
genes)[280].
1.3.3.5 Gut mucosal carriage of ESBL-E in sub-Saharan Africa
Table 1.12 in the chapter appendix shows the 32 identified studies that provide data on gut
mucosal carriage in different populations in sSA. The populations recruited to the studies
are heterogeneous but include community members, hospitalised patients, outpatients,
orphanage residents, hospital workers and food handlers in schools. Adults and children
are included. Data on 10,232 individuals from 19 countries are available in total, and are
plotted in Figure 1.6. The earliest samples were collected from staff and children in a Malian
orphanage in 2003, when 72% (49/68) of participants were found to be colonised with
ESBL-E[271]. There is significant heterogeneity in prevalence, some of which is explained
by the study population (Figure 1.6); inpatients tend to have a higher ESBL-E carriage
prevalence than community members. Outpatients have similar carriage prevalence to
community members but inpatients even on hospital admission seem to have a higher
carriage prevalence than community members.
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Heterogeneity: I2 = 74%, τ2 = 0.0663, p < 0.01
Heterogeneity: I2 = 95%, τ2 = 0.3084, p < 0.01
Heterogeneity: I2 = 97%, τ2 = 0.9421, p < 0.01


































































































































































































Figure 1.6: ESBL-E gut mucosal carriage in sSA. A: included studies by country; B: forest plot
of ESBL-E carriage prevalence stratified by population. Pooled random effect summary estimates
shown.
Significant heterogeneity in prevalence persists across all groups meaning that summary
estimates should be interpreted with caution; community carriage if ESBL-E ranges from
5% in adults in The Gambia in 2015[275] to 59% in children in the Central African Republic
in 2013[250], but a summary estimate from a random effect meta analysis is that 18% (95%
CI 12-28%) of community members in sSA are colonised with ESBL-E, significantly higher
than the prevalence in high-income settings.
Hospitalisation is clearly a driver of ESBL-E colonisation in the included studies - hospitalised
cohorts have persistently higher prevalence of ESBL-E carriage – and prior antimicrobial
exposure is consistently identified as a risk factor for carriage[252,259,275]. Consistent
with a putative faecal-oral transmission route, boiling water and using a borehole as a
source of water were identified as protective factors in studies in Rwanda[274] and Togo[277]
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respectively. Data to elucidate the role of within-household transmission are sparse, though
one study in Rwanda found that a colonised family member was independently associated
with ESBL-E carriage on admission to hospital[277]. Lower socioeconomic status was found
to both be protective against ESBL-E colonisation in the Central African Republic[250]
and be associated with ESBL-E colonisation in Madagascar[266]; this relationship is likely
to be complex and mediated by, for example, local availability and cost of antimicrobials.
The role of HIV is not clear: in children in Dar-es-salaam, Tanzania, ESBL-E carriage was
much more common amongst HIV infected children[255], and in Harare Zimbabwe, receipt
of ART for less than a year was associated with carriage[249]. This relationship is very
open to confounding and many studies have not found an association between ESBL-E
carriage and HIV infection[252,259,265,273,275,277].
Data on ESBL enzymes present in carriage isolates are available for 996 E. coli and 607 K.
pneumoniae from 8 studies (Figure 1.7), showing a similar picture to invasive isolates; the
landscape is dominated by CTX-M-15. One study used whole-genome sequencing [272], the
remainder used a variety of PCR techniques[248,260–262,265,267,273].
Only 4 studies are longitudinal cohorts which could provide insight into temporal trends
and determinants of carriage[267,269,273,277]; all of these studies were health facility based
and ascertained ESBL status on admission and discharge. Significant increases in ESBL-E
carriage were seen in all studies: from 50% to 65% in Rwanda; from 30% to 95% in Niger;
from 21% to 57% in Madagascar; and from 23% to 36% in Tanzania. No studies followed
patients into the community, thus carriage duration of ESBL-E in sSA remains unknown
and no interventional studies identified aiming to reduce ESBL-E carriage were identified.















































Figure 1.7: Distribution of beta-lactamase genes in carriage ESBL producing E. coli (n= 996) and
K. pneumoniae (n = 607) from 9 studies. Carriage isolates are here defined as those isolated from
stool or rectal swabs.
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1.4 Conclusions
The aetiology of sepsis in sSA is poorly defined, hence optimal antimicrobial strategies are
unknown; disseminated TB is likely to play a significant role, but data to guide tuberculosis
therapy strategies in the critically unwell are lacking. The role of bacterial zoonoses,
arboviruses and HIV opportunistic infections are not well defined, but may be significant.
Diagnostic uncertainty and paucity of microbiologic support across sSA may be creating a
permissive environment for the widespread broad spectrum antimicrobial use, often third-
generation cephalosporins. It is likely that dose, duration and indication are frequently
inappropriate, and thus could contribute both to increased mortality and to spread of
ESBL-E.
Certainly, ESBL-E are endemic in sSA and are a problem of serious public health concern;
sSA has rates of ESBL-E in invasive disease that are comparable to the highest in the
world and ESBL-E gut mucosal carriage in healthy populations across the continent is
common. Whilst it is clear that health care facilities are strongly associated with ESBL-E
acquisition, a deeper understanding of the determinants and sources of acquisition, and
carriage duration is lacking. In order to understand the role of health facilities in driving
the ESBL-E pandemic, a high quality longitudinal ESBL-E carriage data from both healthy
and sick (health facility exposed) populations are required.
I propose that optimising the management of severe febrile illness can tackle two problems:
reduce over prescription of broad spectrum antimicrobials and improve outcomes in critically
unwell patients. This may seem counter-intuitive: why target the very unwell with an
antimicrobial stewardship intervention? However I hypothesise that the “step-up” way
in which we approach antimicrobial therapy in the immunosuppressed in resource limited
settings is flawed, is driving the twin problems of poor sepsis outcomes and AMR, and
may represent a low hanging fruit to tackle both problems. In a setting where so much
management is empiric, current management begins with broad spectrum antibacterials and
adds in further therapies - TB therapy, PCP therapy, or antifungals - based on non-response.
This is the management that is codified in the WHO guidance for treating critically unwell
TB suspects, but I suggest that it results in prolonged antibacterial exposure and delay
in definitive treatment. We can imagine an alternate therapy, whereby we start broad,
and rapidly narrow the spectrum of therapy based on the results of investigations. But
such a strategy requires data; what are the causes of sepsis in sSA that we should target?
How should we rationalise therapy? What are the determinants of AMR acquisition in
sepsis survivors and how can we mitigate against acquisition? It is the aim of this thesis
to provide data to inform novel antimicrobial strategies for sepsis in Malawi and similar
high-HIV high-TB prevalence settings throughout sSA.
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1.4.1 Specific aims
The specific aims of this thesis are:
1. To describe the presentation, aetiology, outcome, and determinants of mortality from
sepsis in adults presenting to Queen Elizabeth Central Hospital, Blantyre Malawi;
2. To describe the acquisition and carriage of ESBL-E in sepsis survivors, with an
analysis of determinants of carriage.
1.5 Thesis overview
This thesis is based around a clinical study of sepsis in Blantyre, Malawi, which is described
in Chapter 2. Chapter 3 presents data on the clinical presentation, aetiology and outcomes
of sepsis in Blantyre, Malawi, with extended exploratory modelling of outcome in Chapter
4. Chapter 5 follows sepsis survivors out of the hospital and presents longitudinal stool
sampling data to quantify ESBL-E carriage. Antibiotic-unexposed hospital controls and
community members provide comparator cohorts to the antibacterial-exposed sepsis cohorts.
To track bacteria and AMR-containing mobile genetic elements within study participants, I
have used whole-genome sequencing (WGS) of cultured isolates. Chapter 6 presents the
WGS data to give an overview of the genomic landscape of ESBL E. coli in Blantyre, whilst
Chapter 7 outlines my attempts to use whole genome sequencing as a high-resolution typing
tool to track AMR. Chapter 8 develops and fits longitudinal Markov models to understand
the determinants of ESBL-E carriage in study participants, and brings in the genomic




1.6.1 Search terms for sepsis literature review
Sepsis and ((Angola or Benin or Botswana or Burkina Faso or Burundi or Cameroon or
Cape Verde or Central African Republic or Chad or Comoros or Republic of the Congo or
Congo Brazzaville or Democratic republic of the Congo or Cote d’Ivoire or Djibouti or
Equatorial Guinea or Eritrea or Ethiopia or Gabon or The Gambia or Ghana or Guinea
or Guinea-Bissau or Kenya or Lesotho or Liberia or Madagascar or Malawi or Mali or
Mauritania or Mauritius or Mozambique or Namibia or Niger or Nigeria or Reunion or
Rwanda or Sao Tome and Principe or Senegal or Seychelles or Sierra Leone or Somalia
or South Africa or Sudan or Swaziland or Eswatini or Tanzania or Togo or Uganda or
Western Sahara or Zambia or Zimbabwe) or Africa).
1.6.2 Search terms for ESBL literature review
(((ESBL) or Extended-spectrum beta-lactamase)) and (((Angola or Benin or Botswana
or Burkina Faso or Burundi or Cameroon or Cape Verde or Central African Republic or
Chad or Comoros or Republic of the Congo or Congo Brazzaville or Democratic republic
of the Congo or Cote d’Ivoire or Djibouti or Equatorial Guinea or Eritrea or Ethiopia or
Gabon or The Gambia or Ghana or Guinea or Guinea-Bissau or Kenya or Lesotho or
Liberia or Madagascar or Malawi or Mali or Mauritania or Mauritius or Mozambique
or Namibia or Niger or Nigeria or Reunion or Rwanda or Sao Tome and Principe or
Senegal or Seychelles or Sierra Leone or Somalia or South Africa or Sudan or Swaziland
or Eswatini or Tanzania or Togo or Uganda or Western Sahara or Zambia or Zimbabwe)
or Africa)).
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Table 1.8: Sepsis diagnostic criteria
Definition Diagnosis Criteria
Sepsis-1 (1991) SIRS Two or more of:
Temperature > 38°C or < 36°C, Heart rate > 90 /min,
Respiratory rate > 20 /min or PaCO2 < 32mmHg (4.3
kPa), White blood cell count > 12 x 10-9 /Lor < 4 x 10-9
/L or > 10% immature forms
Sepsis SIRS plus proven or suspected infection
Severe Sepsis Sepsis plus acute organ dysfunction
Septic shock Sepsis with persistent hypotension after fluid resuscitation
Sepsis-2 (2001) Sepsis Infection documented or suspected and some of the
following
General variables: temperature > 38°C or < 36°C, heart
rate > 90 min-1 or > SD above normal for age,
tachypnoea, altered mental status, significant oedema or
positive fluid balance (> 20ml/kg over 24hrs),
hyperglycaemia > 7.7mmol /L
Inflammatory variables: white blood cell count > 12 x
10-9 /L or < 4 x 10-9 /L or > 10% immature forms,
plasma C-reactive protein > SD above normal, plasma
procalcitonin > 2 SD above normal
Haemodynamic variables: arterial hypotension (SBP < 90
mmHg or MAP < 70 mmHg or SBP decrease > 40mmHg
in adults or 2SD below normal range, SvO2 > 70%,
Cardiac index > 3.5
Severe sepsis Sepsis plus organ dysfunction
Organ dysfunction variables: arterial hypoxaemia (PaO2 /
FiO2 ) < 300, acute oliguria (urine output < 0.5 ml kg-1
hr -1 for at least 2 hours), creatinine increase > 0.5mg/
dL, coagulation abnormalities (INR > 1.5 or aPTT >
60s), ileus, thrombocytopenia (platelet count < 100,000
/mL, hyperbilirubinaemia (plasma bilirubin > 4mg /dL or
70 mmol /L
Septic shock Sepsis plus hypotension
SBP < 90mmHg or MAP < 60mmHg or reduction in
SBP of 40mmHg from baseline despite adequate volume
resuscitation
Sepsis-3 (2016) Sepsis Infection plus life threatening organ dysfunction defined
by an acute change in SOFA score of 2 or more
Septic shock Persisting hypotension requiring vasopressors to maintain
MAP 65mmHg AND serum lactate below 2mmol /L
Note:
SIRS = Systemic Inflammatory Response Syndrome, SD = Standard deviation, SBP = Systolic
blood pressure, MAP = Mean arterial blood pressure
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Table 1.9: Sequential organ failure assessment (SOFA) score
Score
System 0 1 2 3 4
Respiratory
Pao2 / FiO2 mmHg
(kPa)
















































< 1.2 (110) 1.2 – 1.9 (110
-170)
2.0 – 3.4 (171
– 299)





< 500 < 200
Note:
PaO2 = Arterial partial pressure of oxygen, FiO2 = Inspired fraction of oxygen, MAP = mean arterial
blood pressure, CNS = Central nervous system. All doses of inotropes are micrograms/kg/min
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Table 1.10: Selected causes of fever in sSA since 2013







































































































































































Table 1.10: Selected causes of fever in sSA since 2013 (continued)
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Table 1.10: Selected causes of fever in sSA since 2013 (continued)










































































































































Table 1.10: Selected causes of fever in sSA since 2013 (continued)
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Table 1.10: Selected causes of fever in sSA since 2013 (continued)


























































































































































Table 1.10: Selected causes of fever in sSA since 2013 (continued)
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Table 1.10: Selected causes of fever in sSA since 2013 (continued)

































































































































RS = Rickettsia spp., RF = R. felis, SFG/TG/STG = spotted fever/ typhus/scrub typhus group
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Table 1.11: included studies providing an estimate of proportion of ESBL producers in invasive E.
coli and K. pneumoniae isolates in sSA.
Year First author Country Population Sample E. coli K.
pneumoniae
2018 Guiral Mozambique A C IP Blood urine 13/151 (9%) ND
2018 Karppinen Angola C IP OP Wound swab 8/15 (53%) 10/13 (77%)
2018 Kpoda Burkina Faso A C IP OP Various 117/296
(40%)
48/109 (44%)
2018 Onanuga Nigeria A OP Urine 4/18 (22%) 30/45 (67%)
2018 Seni Nigeria A C IP OP Various 41/60 (68%) ND
2018 Zeynudin Ethiopia NA IP OP Various 13/13 (100%) 30/31 (97%)
2017 Ampaire Uganda A C IP OP Various 18/146 (12%) 10/68 (15%)
2017 Andrew Uganda A C IP OP Various 33/44 (75%) 33/36 (92%)
2017 Archary South Africa C IP Various 2/11 (18%) 13/19 (68%)
2017 Henson Kenya A C IP OP Blood ND 101/198
(51%)
2017 Ibrahim Nigeria A C IP OP Urine wound
swab
68/140 (49%) 76/108 (70%)
2017 Kassam Tanzania A C IP OP Wound swab 6/14 (43%) 8/11 (73%)
2017 Legese Ethiopia C IP Blood urine 5/6 (83%) 16/19 (84%)
2017 Manyahi Tanzania A C IP OP Urine 15/110 (14%) 9/27 (33%)
2017 Sangare Mali A C IP Blood 20/31 (65%) 20/26 (77%)
2017 Vasaikar South Africa A C IP OP Various ND 117/169
(69%)
2016 Abera Ethiopia A C IP OP Blood urine 71/122 (58%) 34/49 (69%)
2016 Agyekum Ghana A C IP OP Blood urine 30/58 (52%) 33/43 (77%)
2016 Breurec Senegal C IP Blood CSF ND 33/41 (80%)
2016 Buys South Africa C IP Blood ND 339/410
(83%)
2016 Eibach Ghana A C IP Blood 5/50 (10%) 34/41 (83%)
2016 Kabwe Zambia C IP Blood 5/5 (100%) 71/74 (96%)
2016 Leski Sierra Leone A C OP Urine 0/13 (0%) 9/15 (60%)
2016 Mohammed Nigeria A C IP OP Various 41/172 (24%) 59/178 (33%)
2016 Naas Madagascar C IP OP Blood 0/7 (0%) 11/14 (79%)
2016 Ndir Senegal C IP Blood 7/12 (58%) 33/40 (82%)
2016 Ouedraogo Burkina Faso A C IP OP Various 121/202
(60%)
46/70 (66%)
2016 Sangare Mali A C IP Blood 8/11 (73%) 10/14 (71%)
2016 Seni Tanzania A IP Pertitoneal
fluid
7/19 (37%) 5/10 (50%)
2015 Dramowski South Africa C IP OP Blood 14/97 (14%) 119/154
(77%)
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Table 1.11: included studies providing an estimate of proportion of ESBL producers in invasive E.
coli and K. pneumoniae isolates in sSA. (continued)





A C IP OP Blood 9/54 (17%) 10/21 (48%)
2015 Kateregga Uganda A C IP OP Various 36/64 (56%) 24/33 (73%)
2015 Opintan Ghana A C IP OP Various 81/440 (18%) ND




A C IP Wound swab 33/47 (70%) 10/19 (53%)




A C IP OP Urine 57/376 (15%) ND
2014 Scherbaum Gabon A IP Various 5/14 (36%) 3/6 (50%)
2014 Yusuf Nigeria A IP OP Various 47/278 (17%) 19/128 (15%)
2013 Alabi Gabon A C IP OP Various ND 43/85 (51%)
2013 Ibrahim Sudan A C IP OP Various 70/232 (30%) ND
2013 Obeng-
Nkrumah
Ghana A C IP OP Various 55/126 (44%) 59/96 (61%)
2013 Raji Nigeria A C IP OP Various 21/43 (49%) 12/32 (38%)
2013 van der
Meeren
Mozambique C IP Urine 9/14 (64%) 15/17 (88%)
2011 Idowu Nigeria A IP Wound swab 6/15 (40%) ND




A C OP Urine 29/357 (8%) 17/57 (30%)
2009 Mshana Tanzania A C IP OP Various 31/127 (24%) 58/91 (64%)
2007 Sire Senegal A C IP OP Urine 38/1010 (4%) ND
2005 Blomberg Tanzania C IP OP Blood 9/36 (25%) 9/48 (19%)
2005 Gangoue
Pieboji
Cameroon A C IP Various 13/91 (14%) 12/64 (19%)
2005 Ndugulile Tanzania A IP Various 4/13 (31%) 2/2 (100%)
2004 Dromigny Senegal A C OP Urine 2/233 (1%) 1/34 (3%)
2002 Dromigny Senegal A C OP Urine 1/386 (0%) 6/97 (6%)
Note:












Country Study Type Inclusion Age group Median
age
n
Ruppe 2009 NR Senegal Cross sec. Children in village selected for
remoteness
Children 6.9yr* 20
Tande 2009 2003 Mali Cross sec. Orphanage children Children NR 38
Orphanage staff Adults NR 30
Andriatahina 2010 2008 Madagascar Cohort Inpatients Children 38.3m 244
Herindrainy 2011 2009 Madagascar Cross sec. Health centre attendees Adults NR 306
Health centre attendees Children NR 147
Woerther 2011 2007-08 Niger Cohort Children with SAM, inpatients Children 16.3m* 55
Albrechtova 2012 2009 Kenya Cross sec. Community members Adults NR 23
Isendahl 2012 2010 Guinea-
Bissau
Cross sec. Children att. hospital w/ fever or
tachycardia
Children NR 408
Lonchel 2012 2009 Cameroon Cross sec. Students in the community Adults 24.7yr* 150
Outpatients Adults 36.9yr* 208
Lonchel 2013 2009 Cameroon Cross sec. Inpatients Adults 46.8yr* 121
Magoue 2013 2010 Cameroon Cross sec. Hospital workers and their families Adults NR 87
Inpatients Adults NR 208
Relatives and carers of inpatients Adults NR 63
Outpatients Adults NR 232
Schaumburg 2013 2010-11 Gabon Cross sec. Hospital inpatients Children NR 200




Chereau 2015 2013-14 Madagascar Cross sec. Pregnant women in the community Adults 26yr* 356
Desta 2016 2012 Ethiopia Cross sec. Inpatients Adults 35yr 154























Country Study Type Inclusion Age group Median
age
n
Inpatients Neonate 9d 19
Djuikoue 2016 2011-12 Cameroon Cross sec. Outpatient women with susp. UTI Adults NR 86
Farra 2016 2013 CAR Cross sec. Healthy community controls from
diarrhoea study
Children 10.5m 134
Kurz 2016 2014 Rwanda Cohort Inpatients and one main caregiver both 29yr 753
Mshana 2016 2014 Tanzania Cross sec. Community members both 10yr 334




Tellevik 2016 2010-11 Tanzania Cross sec. <2yr attending health centre for
vaccine
Children NR 250
Inpatients Children NR 353
Magwenzi 2017 2015 Zimbabwe Cohort Inpatient within 24hr of admission Children 1.0yr 164
Moremi 2017 2015 Tanzania Cross sec. Street children Children 14.2yr* 107
Wilmore 2017 2014-15 Zimbabwe Cross sec. Outpatient, HIV infected, stable
on ART
Children 11yr 175
Chirindze 2018 2016 Mozambique Cross sec. Students in the community Adults NR 275
Founou 2018 2017 South Africa Cohort On hospital admission Adults NR 43
Herindrainy 2018 2015-16 Madagascar Cross sec. Pregnant women at delivery
(home/facility)
Adults 26yr* 275
Katakweba 2018 2011-13 Tanzania Cross sec. Community members Adults NR 70
Marando 2018 2016 Tanzania Cross sec. Neonates with sepsis Neonate 6d 304
Moremi 2018 2014-15 Tanzania Cohort On hospital admission Adults NR 930
Nikema 2018 2015-16 Togo Cross sec. <5yr with febrile gastroenteritis Children NR 81












Country Study Type Inclusion Age group Median
age
n
Stanley 2018 2017 Uganda Cross sec. Participants who reared animals,
attending health facility with a




NR = Not reported, CAR = Central African Republic.
* Mean not median




This chapter gives an overview of the clinical study which underpins this thesis, and the
laboratory procedures used in analysis. Computational and statistical procedures are largely
detailed in the relevant chapters as are further specific details, where necessary.
2.2 Study site
2.2.1 Malawi
Malawi is a country of 17.5 million people in South-Eastern Africa[281]. It is one of the
poorest countries in the world: it is a low income country under the World Bank classification,
with a 2017 Gross National Income (GNI) per capita of $320 in US dollars[282], and was
ranked 171st of 189 countries in 2017 by the human development index (HDI), a composite
statistic of life expectancy, education and income per capita indicators[283]. In 2010, 71%
of the population was estimated to survive on less than $1.90 per day. Life expectancy
at birth in 2017 was 63 years, and though significant progress is being made, neonatal
and under-5 mortality remains high at 23 and 55 per 1000 live births, respectively. The
population is largely rural (83% in 2017), with a young population (44% under the age of 15,
2017) and high fertility rate[282]. Malaria is endemic, and there is an ongoing generalised
HIV epidemic: adult HIV prevalence (age 15-49) was estimated to be 9.6% in 2017, though
falling from a peak of 16.6% in 1999[284]. HIV antiretroviral therapy (ART) national scale
up began in 2004 and in 2017 71% of eligible adults and children were estimated to be
receiving ART[284]. It is classed by the WHO as a high-TB/high-HIV burden country,
with an estimated TB incidence rate of 131 (95% CI 70-210) cases per 100,000 population
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Blantyre
Lilongwe
Figure 2.1: Malawi, showing administrative boundaries (North, Central, and South regions),
Lilongwe, the capital city and Blantyre, the study location. Source: openstreetmap.org, used under
Creative Commons Attribution ShareAlike 2.0 licence CC-BY-SA
per year[285].
It has a subtropical climate, with three main seasons: a warm wet season from November to
April, a cooler dry winter period from May to August and a hot dry period from September
to October. Blantyre city, the location of the study in this thesis, is the second city of
Malawi with a population of 585,000. It is located in Blantyre district, population 995,000
in 2018[281], in the Shire highlands at an altitude of 1000m (Figure 2.1).
2.2.2 Queen Elizabeth Central Hospital
Queen Elizabeth Central Hospital (QECH), located in Blantyre city, is the tertiary referral
hospital for the Southern Region of Malawi. It has 1300 beds but often operates above
capacity, and is the only site providing free inpatient healthcare to the adult population
of Blantyre district. Since 2011 it has had a dedicated emergency department for adults,
the Adult Emergency and Trauma Centre (AETC), staffed 24 hours a day. Since 2015
(and for the whole of the study period), attendees to the AETC must be referred from a
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primary health clinic. Adults attending the AETC are triaged by a nurse and then reviewed
by a doctor or clinical officer; if admission under a speciality team (including medicine)
is deemed appropriate then a patient will be reviewed by an intern or registrar from the
admitting speciality and usually by a consultant within 24 hours. There is a 6-bed AETC
resuscitation area in which oxygen concentrators, cardiac monitors and a defibrillator are
available; none of these items are available in the rest of the AETC.
There are two dedicated single-sex medical wards, each of approximately 60 beds, and
one mixed-sex TB ward. Male and female high-dependency units (HDUs), each with
a capacity of six beds, have oxygen concentrators (or, if available, oxygen cylinders) to
deliver supplemental oxygen. The medical wards are staffed by two or three trained nurses
and a variable number of nursing students. Basic nursing care is usually provided by a
patients relative or friend, called a ‘guardian.’ Patients on the medical wards are reviewed
twice-weekly by a consultant physician and then variably at other times by junior doctors,
clinical officers or medical students depending on the availability of staff. Malawi national
treatment guidelines suggest ceftriaxone for the treatment of sepsis requiring hospitalisation.
2.2.3 Participating Laboratories
2.2.3.1 Malawi-Liverpool-Wellcome Clinical Research Programme
The Malawi-Liverpool Wellcome Trust Clinical Research Programme (MLW) was established
in 1995 and since them has been active in researching priority health issues in Malawi. It is
an affiliate of the Malawi College of Medicine, and is based in the grounds of QECH in
Blantyre. It runs an on-site microbiology laboratory which has provided an aerobic blood
culture service to QECH since 1998, and also provides cerebrospinal fluid (CSF) microscopy
and culture. Bacterial culture is carried out as per British Society of Antimicrobial
Chemotherapy (BSAC) guidelines[286] and the laboratory adheres to UK NEQAS external
quality control. It is core funded by the Wellcome Trust. MLW operates the Malawi College
of Medicine Tuberculosis Laboratory where sputum GeneXpert testing and mycobacterial
blood culture were undertaken.
2.2.3.2 Wellcome Trust Sanger Institute
The Wellcome Sanger Institute (WSI) is a research institute based in Hinxton, UK, which
was established in 1993, and undertakes research in all aspects of genomics including
bacterial genomics as part of the parasite and microbes programme. It has one of the
largest DNA sequencing facilities in the world as well as exceptional high performance
computing cluster capacity. It is funded by the Wellcome Trust.
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2.3 Clinical Study
The DASSIM (Developing an Antimicrobial Strategy for Sepsis in Malawi) study was an
observational cohort study, recruiting from the AETC at QECH with two broad aims:
firstly, to describe the presentation, aetiology and determinants of outcome in sepsis in
Malawi; and secondly to determinants of carriage of ESBL-E in sepsis survivors.
2.3.1 Objectives
The study was open for recruitment between 19 February 2017 and 2 October 2018; there
were three arms:
1. Adults with sepsis attending AETC, recruited as early as possible in their attendance
to QECH following triage.
2. Antibiotic unexposed adults attending AETC with no plan for antimicrobial adminis-
tration.
3. Antibiotic-unexposed community members.
Arm 1 (sepsis) participants were recruited in order to clearly define the aetiology of sepsis;
arm 2 to clearly define the relative effects of antimicrobial exposure versus hospital admission
in ESBL-E acquisition and carriage; and arm 3 to define baseline flux of ESBL-E.
2.3.2 Recruitment criteria
Detailed inclusion and exclusion criteria for each arm are given shown in Table 2.1. For
logistic reasons, recruitment occurred 7am - 5pm Monday to Friday.
Exclusion criteria were the same for all arms of the study: Participants were not eligible
for enrolment if and of the following were true:
• They were unable to give informed consent and no guardian was available to provide
proxy consent.
• They spoke neither English nor Chichewa.
• They lived > 30km from Blantyre city.
The antibiotic-unexposed inpatients and community members were matched on age (+/-
5yr) and sex to sepsis survivors (defined as patients surviving to 28 days). In addition
community members were matched on location to sepsis survivors; putative households for
recruitment were identified by random walk from the houses of surviving sepsis participants,
with initial direction established by spinning a bottle on the floor.
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Table 2.1: Study inclusion criteria
Study Arm Inclusion Criteria
Arm 1 - Sepsis Adults (16 years or over) attending AETC
AND
Axillary temperature > 37.5C or history of fever within
72 hours
AND
Life threatening organ dysfunction defined by any one of:
Oxygen saturations < 90 percent on air, respiratory rate
> 30 breaths/minute, systolic blood pressure < 90mmHg,
glasgow coma scale < 15
Arm 2 - Inpatient Adults (16 years or over) attending AETC
AND
No suspicion of infection or plan for antimicrobial
administraton
AND
No antimicrobial therapy within last 4 weeks
Arm 3 - Community Adults (16 years or over)
AND
No antimicrobial therapy within last 4 weeks
Note:
AETC = Adult Emergency and Trauma Centre
2.3.3 Study Visits and Patient Sampling
2.3.3.1 Enrolment assessment
An overview of the study visit schedule is shown in Figure 2.2. At enrolment, following
informed written consent, a baseline questionnaire administered to the patient (or the
guardian if the participant was obtunded) to capture background demographic and clinical
data, a Chichewa-language EQ-5D-3L heath related quality of life questionnaire completed,
and sample collection undertaken (see below). For hospitalised patients, enrolment aimed
to be as soon after triage as possible. Data on therapies administered were captured by the
study team including the time of administration of antimicrobial therapy and volumes of
intravenous fluid administered, the latter visually confirmed by the study team member.
Vital signs were measured by trained study nurses. All blood pressure measurements
were made non-invasively with an automated cuff (Omron M2, Omron, Japan), oxygen
saturations measured with a dedicated study pulse oximeter (Contec CM50, Contec Medical
Systems, China), and temperature measured in the axilla with a digital thermometer
(Omron FWH000, Omron, Japan).
All treatment decisions were at the discretion of the participant’s attending healthcare
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worker.
2.3.3.2 Subsequent visits
Hospitalised participants were reviewed daily Monday to Friday following admission whilst
on the wards to capture details of therapies administered. The visit schedule for the study
is shown in Figure 2.2. Arm 1 (sepsis) and 2 (hospital inpatients) were reviewed by a
study team member 7 and 28 days following enrolment, and at 3 and 6 months; community
members were reviewed at 28 days and 6 months. At each visit, details of any antimicrobials
or other therapies received and any health care facility contact were collected, and the
Chichewa language EQ-5D-3L was repeated. Samples were collected as below.
These study visits occurred preferentially at QECH, but at the patient’s home if it was
difficult for them to attend the hospital. If patients missed a scheduled visit, then attempts
were made to contact them by telephone. If these attempts were unsuccessful then attempts
to visit them at home were undertaken by a member of the study team.
2.3.3.3 Blood, urine, and stool, sputum and CSF collection
Blood was collected from arm 1 (sepsis) participants only on enrolment (Figure 2.2) and at
the 4-week visit. At baseline, blood was collected aseptically directly into collection tubes
with a vacutainer device with the following order of draw and volumes: one BacT/Alert
(BioMerieux, France) aerobic blood culture bottle (7-10ml), one BD BACTEC Myco/F
Lytic mycobacterial culture bottle (3-5ml) (Beckton Dickinson, United States), one serum
(10ml) and two EDTA (4ml, both Grenier Bio-One, Austria) samples. Finger prick for
capillary blood was used for point of care diagnostics as described below. At the 4-week
visit, 10mls of convalescent serum was collected. At baseline, urine was collected from
all arm 1 (sepsis) participants into a sterile polypropylene universal container (Alpha
Laboratories, UK) either by the participant themselves (if this was possible) or with the
aid of a disposable bedpan.
At the enrolment visit and all other visits for all arms of the study stool was collected into a
sterile polypropylene universal container (Alpha Laboratories, UK) with aseptic technique.
If it was not possible for a patient to provide stool then a rectal swab was taken using
a sterile rayon-tipped swab (Technical Service Consultants Ltd, UK) inserted into 2-3cm
into the rectum, rotated for approximately 10 seconds and placed into Amies gel media for
transport to the laboratory.
The decision to collect sputum for Xpert testing for tuberculosis or to perform lumbar
puncture (LP) rested with the participant’s attending healthcare worker. Lumbar puncture,
where done, was carried out by QECH AETC or medicine department doctors or clinical
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Figure 2.2: Overview of patient sampling schedule.FBC = Full blood count, U&E = Urea and
elctrolytes, mRDT = Malaria rapid diagnostic test, uLAM = Urinary LAM, FASH USS = Focussed
assessment for HIV-associated tubercusosis ultrasound scan
officers and 7-10ml of cerebrospinal fluid (CSF) was aseptically collected. Sputum samples
were collected in sterile polypropylene universal container and transported to the Malawi
College of Medicine (CoM) tuberculosis laboratory. Myco/F lytic bottles for mycobacterial
blood culture were also transported to the CoM tuberculosis laboratory; all other samples
were transported to the MLW laboratories in the first instance.
2.3.4 Outcomes and sample size calculations
The two co-primary outcomes for the study are:
1. 28-day mortality.
2. Acquisition of ESBL-E detected in stool by aerobic culture at 28 days.
Two power calculations were undertaken: to inform the size of the sepsis cohort, and one
for the non-sepsis participants. The sepsis component was powered to detect clinically
relevant risk factors for death; we made the a priori assumption that a risk ratio of 2 or
more is clinically relevant in this setting and patient population. The initial calculation
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suggested 250 patients with severe sepsis with 50% mortality (as seen in previous studies in
Malawi) would have 80% power to detect risk factors for death with prevalence of 20-50%
that confer a risk ratio (RR) of 1.5-3; therefore, a RR of 2 is likely to be detected. Logistic
considerations resulted in a reduction of a feasible sample size to 225; repeating a power
calculation with this number of participants suggested 80% power to detect risk factors
conferring a RR of 2 with 25-50% prevalence, assuming 50% mortality.
For the second co-primary outcome, assuming 30% of participants with sepsis and hence
antimicrobial exposure acquire ESBL-E by 28 days, and that 50% of them die by day 28,
125 antibiotic unexposed hospitalised participants would give 80% power to detect a 50%
relative difference in acquisition. Logistic considerations resulted in the target sample size
being reduced to 100 participants; revised power calculation suggested that the 80% power
to detect a 50% relative difference was maintained.
In order to define the baseline flux of ESBL-E organisms and ESBL genes, one community
member for each antibiotic unexposed hospitalised participant, giving a target sample size
of 100.
2.4 Diagnostic Laboratory Procedures
Results of all laboratory diagnostic procedures were fed back to participant’s attending
healthcare worker in real time. If any investigation result became available after the
participant was discharged (e.g. Mycobacteraemia was identified) then they were contacted
and called back to the hospital to be reviewed by me, and referred for care to the relevant
QECH department.
2.4.1 Point of care diagnostics
Point of care tests were carried out on capillary blood for capillary lactate (Lactate Pro 2,
Arkray, Japan), for P. falciparum HRP-2 antigen (Paracheck Pf, Orchid Biomedical, India)
and, if HIV status was unknown, to test for HIV antibodies using Determine HIV 1/2 kit
(Abbott Diagnostic Division) and Unigold HIV 1/2 kit (Trinity Biotech Inc.) following
Malawian national guidelines[287].
2.4.2 Laboratory diagnostics
2.4.2.1 Haematology and biochemistry
Automated full blood counts (Beckman Coulter HmX Haematology Analyser, Beckman
Coulter, USA) were undertaken in the MLW laboratories on EDTA whole-blood samples,
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as were CD4 cell counts (Becton Dickinson FACSCount, Becton Dickinson, USA) for
HIV-infected participants. Serum samples were allowed to settle upright for 30-60 minutes
and then centrifuged (at 1300 g for 10 min). Biochemistry testing for urea and electrolytes
(Beckman Coulter AU480 Chemistry Analyser, Beckman Coulter, USA) was undertaken
immediately and a maximum of three 1.8ml aliquots of serum stored at -80°C for subsequent
analysis.
2.4.2.2 Aerobic blood and CSF culture
Blood in aerobic culture bottles was incubated in an automated system (BacT/Alert
BioMerieux) and any bottles that flagged as positive were further processed by Gram’s
stain and subculture with any pathogens identified to genus level (all) and species level in
the case of Enterobacteriaceae using the API system (Biomerieux, France) and standard
techniques[288]. Anaerobic culture was not available. Coagulase-negative Staphylococci,
Bacillus spp., diptheroids and alpha-haemolytic Streptococci other than S. pneumoniae
were considered as contaminants. Antimicrobial sensitivity testing was undertaken using
the disc diffusion method following BSAC guidelines.
CSF, where available, was cultured onto blood, chocolate and Sabouraud agar and then
identification of any growth undertaken as above.
2.4.2.3 Mycobacterial blood culture
Blood in Myco/F Lytic bottles was cultured at 37°C in and inspected daily for the
first 14 days with a handheld UV Wood’s lamp, and once every two days thereafter.
Contents of the bottles were centrifuged (3000xg for 20 minutes) within 48hr of detection of
fluorescence, examined by ZN and Gram stain to exclude contamination, then inoculated
into mycobacterial growth indicator tubes (MGIT, Becton Dickinson Diagnostic Systems,
United States) for up to 6 weeks. Isolates were classified asM. tuberculosis or nontuberculous
Mycobacteria by microscopic cording and MPT-64 lateral flow assays (TAUNS Laboratories,
Japan).
After 8 weeks of culture of Myco/F Lytic bottles if no fluorescence was seen, then centrifu-
gation and microscopy was carried out. If no organisms were seen, the culture was reported
as “no growth.”
2.4.2.4 Sputum Xpert
Sputum Xpert testing (Cepheid, United States) was carried out as per the manufacturers
instructions: sputum specimens were mixed with sample reagent and incubated at room
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temperature for 15 minutes. The liquefied specimen was then loaded into the Xpert
MTB/RIF test cartridge for processing.
2.4.2.5 Urinary LAM
Urinary LAM testing was carried out on all available urine samples from HIV-infected
participants, using the Alere Determine TB LAM Ag lateral flow assay (Alere, United
States) following the manufacturer’s instructions. Frozen urine samples were used: they
were allowed to come to room temperature and then briefly centrifuged to remove debris.
60 microlitres of urine was applied to the sample pad and the result read after 25 minutes
by comparing to the provided reference scale card. If a line was visible in the patient
window of the test and darker than the lightest positive line on the reference card then it
was considered positive. If a line was visible but lighter than the lightest positive line on
the reference card, or if no line was visible, then it was considered negative. If no line was
visible in the control window of the test then the test was considered invalid, and repeated.
The results were read independently by two readers, who were unaware of the other reader’s
finding. A tie-break read by a third reader who was unaware of the findings of the other
two readers was undertaken in the even of disagreement.
2.4.2.6 Selective stool culture for ESBL-E
Stool and rectal swabs received in the laboratory were stored at 4°C pending processing,
before being plated onto commercially available ESBL selective media (CHROMagar ESBL
media, CHROMagar, France) and cultured aerobically at 37°C overnight. Rectal swabs
were streaked directly onto the plate, or a cotton tipped applicator used for solid stool.
CHROMagar is also chromagenic: E. coli colonies are pink, Klebsiella spp., Enterobacter
spp. and Citrobacter spp. blue and other species white (Figure 2.4). Blue or white colonies
were speciated using the API 20E system (Biomerieux, France). Morphologically distinct
colonies were confirmed to be ESBL producers using combination disc methods: the putative
ESBL producer was cultured overnight on ISO-sensitest agar with discs of cefotaxime and
ceftazidime (30 micrograms) with and without clavulanic acid (10 micrograms), and ESBL
production confirmed if there was a difference of at least 5mm between discs with and
without clavulanic acid (Figure 2.5). For organisms likely to carry a chromosomal AmpC and
hence be capable of hydrolysing cefotaxime and ceftazadime, ( Enterobacter spp., Citrobacter
freundii, Morganella morganii, Providencia stuartii, Serratia spp., Hafnia alvei) cefipime
(30 micrograms), an AmpC-stable cephalosporin was used with and without clavulanic acid
(10 micrograms). Antimicrobial sensitivity testing to meropenem, amikacin, gentamicin,
co-trimoxazole, chloramphenicol and ciprofloxacin following BSAC guidelines[286] was
undertaken for a subset of confirmed ESBL-producers.
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Figure 2.3: A Appearance of urinary LAM tests. B: Urinary LAM reference card. Any line in the
patient window darker than the lightest positive line in the reference card is considered positive.
Any line lighter than this was classed as negative. Reproduced from [289] .
Figure 2.4: Representative example of chromogenic agar appearance showing typical pink colony
appearance of E. coli and blue colony appearance of Klebsiella, Citrobacter and Enterobacter spp.
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Figure 2.5: Example of combination disc ESBL confirmatory testing. In this example cefpodoxime
discs with and without clavulanic acid (a β-lactamase inhibitor) are used. The small zone of
inhibitaion around cefpodoxime (CPD) indicates resistance to cefpodoxime; the larger zone (> 5mm
larger) around the combination cefpodoxime and clavulanic acid disc (CD) confirms this isolate as
an ESBL-producer. Reproduced from [290].
2.4.3 Case definitions
Bloodstream infection is defined as any pathogenic organism isolated from at least one
aerobic blood culture. Coagulase-negative Staphylococci, Bacillus spp., diptheroids and
alpha-haemolytic Streptococci other than S. pneumoniae were considered as contaminants.
Malaria was defined as a positive malaria rapid test. Meningitis was defined as either a
positive CSF culture for a pathogenic organism - excluding the same contaminants as for
bloodstream infection - or a positive cryptococcal antigen test on CSF. Tuberculosis was
defined as any of positive sputum Xpert, positive urinary LAM at any grade, or positive
mycobacterial blood culture.
2.5 Molecular methods
One of each morphologically distinct colony from ESBL-E selective culture was taken forward
for DNA extraction and whole genome sequencing. DNA was extracted from overnight
nutrient broth culture using the Qiagen DNA mini kit (Qiagen, Germany) following the
manufacturers instructions. Extracted DNA was shipped to the Wellcome Sanger Institute
where it underwent library preparation according to the Illumina protocol and paired-end
150bp sequencing on Illumina HiSeq X10 by the WSI DNA pipelines team. Details of the
bioinformatic analyses undertaken are given in the relevant chapters.
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2.6 Statistical Analysis
Details of analysis methods are given in the relevant chapters. All analyses were undertaken
using R v3.6.0 and any Bayesian modelling using Markov Chain Monte Carlo (MCMC)
methods using Stan v2.18 via the rstan interface with R. This thesis was written using
the bookdown package in R and the code to generate it as well as all analysis scripts are
available at https://github.com/joelewis101/thesis. Unless otherwise states, all boxplots
show median and IQR as boxes, 1.5 times IQR as whiskers and outliers (any points outside
the whiskers) as points.
2.7 Study Team
I am the principal investigator of the study, and led a study team which consisted of:
Emma Smith, a medical doctor who managed the running of the study from March 2017 -
May 2017; study nurses Lucy Keyala, Grace Mwaminawa and Tusekile Phiri who recruited
patients, collected samples and completed follow up visits; field workers Witness Mtambo
and Gladys Namacha who recruited patients, collected samples and completed follow up
visits; and laboratory technicians Madalitso Mphasa and Rachel Banda who processed
laboratory specimens, did stool culture and DNA extractions, and the uLAM testing. The
MLW core laboratory staff undertook haematology and biochemistry testing and blood and
CSF culture, and the Malawi CoM tuberculosis laboratory staff carried out tuberculosis
culture and Xpert testing. Lumbani Makhaza was the data officer in the MLW data team
who built and designed and built the study database and electronic and paper data capture
forms.
2.8 Data Collection and Storage
Data was captured electronically using Open Data Kit software[291] (ODK) and struc-
tured TeleForm paper forms (OpenText, Waterloo, Canada). Electronic ODK forms were
loaded onto Asos ZenTouch tablets running Android using the ODK Collect Android
app. Completed forms were pushed daily to the dedicated secure study SQL (structured
query language) database built and administered by the MLW data team. Teleform forms
were checked by me, batched and scanned by the MLW data team, and variable values
automatically extracted by the TeleForm system; validation was undertaken by the MLW
data team and data queries generated for missing or invalid values. Queries were resolved
either by manually reconciling with the forms or by discussion with the clinical team.
Once the data passed validation it was pushed to the SQL database. Completed paper
TeleForm records were stored securely in the MLW data department. All data on the
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study database is stored securely with access restricted to the study PI and the study data
officer and head of the MLW data team. Other paper records including consent forms were
stored in a locked cabinet with access restricted to members of the study team. Results
of laboratory investigations in the MLW laboratory were stored in the MLW PreLink
laboratory information management system (LIMS), anonymised and linked only to the
participant unique study ID number. For analysis, anonymised data were extracted from
the study SQL and LIMS databases as comma delimited files.
2.9 Ethical Approval, Consent and Participant Remunera-
tion
The study protocol was granted ethical approval by the Malawi College of Medicine Research
Ethics Committee (COMREC), protocol number P.11/16/2063 and the Liverpool School of
Tropical Medicine (LSTM) Research Ethics Committee, protocol number 16-062. LSTM
acted as the study sponsor. All study team member were trained in NIHR Good Clinical
Practice (GCP).
All participants in the study provided informed, written consent, as follows: if a patient
lacked capacity to provide informed consent themselves then informed consent was sought
from the patient’s representative, usually their guardian. Patients with no representative
and lacking capacity to provide informed consent were not recruited. Initially, eligible
patients (or their representative) were approached by a member of the study team and
the study was explained to them including study procedures, risks and benefits, financial
and confidentiality considerations and how to obtain more information. Written patient
information leaflets were provided in English and Chichewa. If the patient/representative
was willing to enter the study then they were asked to sign and date two copies of the
consent form, and provided with a copy of the form to keep. If either the patient or
representative was unable to read then the consent form was read to them by the study
team, and witnessed by an additional staff member who was not part of the study team.
If the patient (or their representative) agreed to enter the study, then the witness signed
and dated the form. Any patient who was enrolled to the study after consent from a
representative and who then regained the capacity for informed consent was subsequently
approached independently for informed consent. A patient could withdraw at any time
without giving a reason.
Hospitalised patients were not financially compensated for their time and/or transport
costs, but all other participants were, following standard MLW guidelines: 500MWK
(approximately USD$0.7 at February 2019 exchange rates) was provided to participants
if they were visited at home and 2000MWK (approximately USD$2.8 at February 2019
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exchange rates) or their reported transport costs (whichever was higher) for participants
who attended QECH for study purposes.
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Chapter 3
A clinical and microbiological
description of sepsis in Blantyre,
Malawi
3.1 Chapter overview
In this chapter, I present a clinical and microbiological description of sepsis in Blantyre,
Malawi. As expected, participants are young relative to high income settings and there
is a high prevalence of HIV-infection. 28-day case-fatality is 18% (95% CI 13-26%) but
continues to rise throughout the study period to 31% (95% CI 25-38%) by 180 days and is
higher in the HIV-infected in a time-to event analysis, seemingly driven by late (> 2 week)
deaths. Participants had been unwell for some time (median 7 days) prior to presentation.
Microbiological testing identified an aetiological agent for 51% of the cohort: Mycobacterium
tuberculosis is the commonest cause identified, in 34% of all participants, usually manifesting
as disseminated mycobacterial disease diagnosed by urinary lipoarabinomannan testing.
Bloodstream infection was next most prevalent (11%), followed by malaria caused by
Plasmodium falciparum (9%). I use logistic regression to identify determinants of 28-day
mortality. Time to antibacterial therapy and volume of intravenous fluid administered show
no significant association with mortality; however, receipt of antituberculous showed an
independent association with survival to 28 days (aOR 0.17 for death [95% CI 0.03-0.74]).
The logistic regression models used to provide these estimates of effect size had some
problems, which could result in biased estimates: some predictors perfectly predicted
outcome (i.e. separation occurred) and so were excluded from the model, and the number
of predictors included meant that the model is likely overparametrised.
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3.2 Introduction and chapter aims
The aetiology of sepsis of sepsis in sSA is poorly described (reviewed in Chapter 1), and
the appropriateness of the blind introduction of sepsis treatment principles and protocols
from high-income settings to sSA is coming under increasing scrutiny. A focus on reducing
door-to-antimicrobial time and rapid administration of intravenous fluid is likely effective
at reducing sepsis mortality in high-income settings[6,7], but data on the utility of this
strategy in sSA are limited, and it is possible that other patient or treatment factors may
be stronger determinants of outcome in sSA. The aims of this chapter are twofold:
1. To describe the demographics, mode of presentation, aetiology, management, and
outcomes of sepsis in Blantyre with to 180 days in terms of mortality and morbidity
as health related quality of life.
2. To identify independent associations of mortality - particularly modifiable treatment-
related factors - with a view to informing sepsis treatment protocols for sSA.
3.3 Methods
The clinical and laboratory methods of the clinical study are described in Chapter 2,
Methods; a further overview of chapter aims and description of the statistical analysis used
is given here.
For the first aim - description of sepsis in Blantyre - patient demographics, health seeking
behaviour, symptoms and admission physiology are described as medians and interquartile
ranges for continuous variables or proportions for categorical variables. Difference in
medians or difference in proportions with bootstrapped or binomial 95% confidence intervals,
respectively, were used to assess for difference between groups. For bootstrapped differences
in medians 1000 replicates were used and confidence intervals constructed using the percentile
bootstrap. Aetiology is presented as simple proportions with exact binomial 95% confidence
intervals, stratified by HIV status and co-infections visualised as Venn diagrams and UpSet
plots using eulerr [292] and UpSetR[293] packages, respectively, in R. Mortality is presented
as simple proportions at 28, 90 and 180 days with exact binomial confidence intervals, and
Kaplan-Meier estimates of the survival function generated using the survival package in
R[294]. Both of these estimates are presented aggregated and stratified by HIV status, with
difference in proportions with 95% binomial confidence intervals used to test the hypothesis
that point mortality estimates differ between HIV-infected and uninfected participants,
and log-rank test used to test the hypothesis that HIV-infected and uninfected survival
functions differ.
Morbidity was assessed as health related quality of life (HRQoL) using the EQ-5D-3L
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questionnaire, which assesses HRQoL across five domains (anxiety, pain, self care, usual
activities, walking) with participants describing their problems across the domains on a 3
point ordinal scale: no problems, moderate or extreme. The level of disability is selected
by the participant by choosing from the statements: “I have no problems”, “I have some
problems” or “I have extreme problems” for each domain. So-called tariff sets are used to
convert these scores to an overall utility score, which compares the health state compared
to perfect heath: a utility score of one represents perfect health and zero represents death,
but scores of below zero (states worse than death) are possible. Tariff sets are country
specific, and no Malawian tariff sets are available, so a Zimbabwean tariff set was used[295].
The eq5d package in R was used to convert health states into utility scores. HRQoL was
measured at baseline, and the 1,4,12 and 24 week visits, and is presented as proportion of
participants reporting at least moderate impairment in each domain (with exact binomial
confidence intervals) at each time point, as well as boxplots of utility score. Utility scores
of participants with sepsis were compared to community controls using difference in means
and 95% confidence intervals between the groups.
Univariable associations of 28-day mortality were assessed by 1) calculating differences in
medians or proportions between participants who died and survived, with 95% confidence
intervals constructed from the Chi-square distribution for proportions or percentile bootstrap
as above and 2) from univariable logistic regression models considering each variable alone
as a predictor. Variables were selected for these comparisons that a priori may be expected
to be associated with mortality: host variable (age, sex, HIV status, CD4 cell count,
ART status, haemoglobin), severity variables (admission vital signs, inability to stand on
admission, white cell count (WCC), platelet count, serum creatinine, urea, and bicarbonate,
capillary lactate), diagnosis, or treatment variables (receipt of any antibacterial, any
antifungal, any antituberculous drug or any antimalarial all as binary variables, time to
receipt of each as a continuous variable, and volume of intravenous fluid received in the first 6
hours of admission as a continuous variable). To address confounding, multivariable logistic
regression models were constructed, using all these variables except CD4 cell count, ART
status and time-to-antibacterials (as these variables were not available for all participants).
Otherwise the full set of a priori variables were used as predictors and 28-day mortality as
the outcome, and fitted using the glm command in R v3.6.0. All statistical analysis were
carried out in R v3.6.0.
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3.4 Results
3.4.1 Study population
225 participants were recruited in 20 months between 19th February 2017 and 2nd October
2018 (Figure 3.1). Participants were recruited soon after arrival in hospital (median 1.5
hours [IQR 0.8-2.6] after first attendance). In total, 4 participants (2%) were lost to follow
up over the 180-day study period; 5 participants (2%) withdrew; and 7 participants (3%)
transferred out of the study area before 180 days. Four of the five participants who withdrew
gave a reason for their wish to withdraw, all that they no longer wished the inconvenience
of being involved in the study. 15/225 (7%) participants had their final study visit before
180 days, and so were not included in the 180-day outcome analysis.
3.4.2 Baseline characteristics
Table 3.1 shows the baseline characteristics of the recruited participants. Subjects tended
to be young (median [IQR] age 36 [28-44]). The majority were HIV-infected (67% [143/213]
of those with known HIV status), of whom 117 (82%) were on ART, almost exclusively the
Malawian first-line regimen of efavirenz, lamivudine and tenofovir. The majority (88/117
[75%]) had been taking ART for more than three months; the distribution of reported time
on ART is shown in Figure 3.2.
Almost all (221/225 [98%] of participants) experienced subjective fever (Figure 3.3). Partic-
ipants had been unwell for some time, a median (IQR) of 7 (3-14) days; 32/225 (14%) of
participants had been unwell for more than 4 weeks. 18/225 (8%) of participants had been
admitted to hospital within the last 4 weeks. Over half (123/225 [55%]) of participants had
sought care for their current illness (Table 3.2), most commonly at a government health
centre (101/123 [82%]), a median (IQR) of 2 (1-6) days previously.
Prehospital antimicrobial use was common: 60/225 (27%) of all participants had received
an antimicrobial for their current illness: 7/60 (12%) of all prehospital antimicrobials were
antimalarials, the remainder antibacterial, most commonly co-trimoxazole or ciprofloxacin.
Prehospital intravenous or intramuscular antimicrobials were administered in 16/60 (27%)
participants receiving antimicrobials: ceftriaxone (n=6), benzylpenicillin (n=4), gentamicin
(n=3) and artesunate (n=3).
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Figure 3.1: Study recruitment and follow up.
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Table 3.1: Participant characteristics
Variable Value
Demographics
Age (years) 36 (28-44)
Male sex 114/225 (51% [44-57%])
HIV/TB status
HIV Reactive 143/225 (64% [57-70%])
HIV Non Reactive 70/225 (31% [25-38%])
HIV Unknown 12/225 (5% [3-9%])
Ever treated for TB 37/225 (16% [12-22%])
Of those, current TB treatment 10/37 (27% [14-44%])
ART status*
Current ART 117/143 (82% [75-88%])
Months on ART 29 (4-73)
ART regimen: EFV/3TC/TDF 110/117 (94% [88-98%])
ART regimen: other 7/117 (6% [2-12%])
Current CPT† 98/141 (70% [61-77%])
Tobacco/alcohol use
Never tobacco 196/225 (87% [82-91%])
Ex tobacco 17/225 (8% [4-12%])
Current tobacco 12/225 (5% [3-9%])
Current alcohol 51/225 (23% [17-29%])
Employment
Unemployed 82/225 (36% [30-43%])
Currently employed 65/225 (29% [23-35%])
Self-employed 56/225 (25% [19-31%])
Student 21/225 (9% [6-14%])
Retired 1/225 (0% [0-2%])
Animals at home?
Any animal 71/225 (32% [26-38%])
Poultry 46/71 (65% [53-76%])
Dogs 18/71 (25% [16-37%])
Goats 12/71 (17% [9-28%])
Dogs 18/71 (25% [16-37%])
Other 11/71 (15% [8-26%])
Note:
ART = Antiretroviral therapy, CPT = Co-trimoxazole
preventative therapy, EFV: Efavirenz, 3TC: Lamivudine,
TDF: Tenofovir. Numeric values are median (IQR)) or
proportions with exact binomial 95% confidence intervals
unless otherwise stated.
* ART status includes HIV reactive only as denominator
† Missing CPT data for two participants.
3.4.3 Admission physiology and laboratory investigations
Admission vital signs and laboratory investigations are shown in Table 3.3. Shock, defined
as systolic blood pressure below 90mmHg, was more common than hypoxia, defined as
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Figure 3.3: Symptoms of recruited participants. A: Row and column clustered heatmap of participant
symptoms. Each row represents a patient. Red = presence, blue = absence. B: Frequency of
occurence of symptoms
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Table 3.2: Prehospital healthcare seeking and antimicrobial exposure
Variable Value
Pre-hospital healthcare seeking
Sought care prior to attendance at hospital 123/225 (55% [48-61%])
At health centre 101/123 (82% [74-88%])
At hospital 16/123 (13% [8-20%])
At private doctor 8/123 (7% [3-12%])
Somewhere else 1/123 (1% [0-4%])
Days prior to today that participant sought care 2 (1-6)
Prehospital antimicrobial exposure
Received any antimicrobial prior to attendance at hospital 60/225 (27% [21-33%])
Co-trimoxazole 12/60 (20% [11-32%])
Ciprofloxacin 10/60 (17% [8-29%])
Amoxicillin 9/60 (15% [7-27%])
Ceftriaxone 6/60 (10% [4-21%])
Metronidazole 5/60 (8% [3-18%])
Benzylpenicillin 4/60 (7% [2-16%])
Artesunate 3/60 (5% [1-14%])
Gentamicin 3/60 (5% [1-14%])
Erythromycin 2/60 (3% [0-12%])
LA 2/60 (3% [0-12%])
SP 2/60 (3% [0-12%])
Azithromycin 1/60 (2% [0-9%])
Flucloxacillin 1/60 (2% [0-9%])
Days prior to today that antimicrobials started 2 (1-5)
Method of transport to hospital
Minibus 78/225 (35% [28-41%])
Taxi 65/225 (29% [23-35%])
Private car/truck 42/225 (19% [14-24%])
Ambulance 37/225 (16% [12-22%])
Other 2/225 (1% [0-3%])
Walk 1/225 (0% [0-2%])
Cost (MWK) of transport to hospital 1000 (275-3000)
Note:
LA = Lumefantrine-artemether, SP = Sulfamethoxazole-pyrimethamine, MWK =
Malawian Kwacha. Numeric values are median (IQR)) or proportions with exact
binomial 95% confidence intervals unless otherwise stated.
defined as Glasgow coma scale (GCS) below 15 was rarer (9% [21/225]); 28% (63/225) of
participants were unable to stand on admission.
Despite high ART coverage (117/143 [82%]) among HIV-infected participants for a median
of 29 months, the median (IQR) CD4 count was low at 98 (31-236) cells µL-1. 108/141
(70%) of participants had a CD4 count below 200 cells µL-1. CD4 count was similar in
participants who had started ART more than 6 months ago as compared to less than three
months ago (median [IQR] 99 [27-260] vs 93 [39-137] cells µL-1 respectively). 42/83 (51%)
of participants who had been taking ART for more than 6 months had a CD4 count of
less than 100 cells µL-1, which fulfils the WHO definition of immunological failure of HIV
treatment.
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Table 3.3: Admission physiology, haematology and biochemistry
Variable Value
Admission physiology
Temperature (°C) 38.5 (37.9-39.0)
Heart rate (min-1)) 121 (102-132)
Systolic BP (mmHg) 99 (85-119)
Diastolic BP (mmHg) 66 (56-76)
MAP (mmHg) 76 (65-89)
Respiratory rate (min-1) 34 (32-38)
Oxygen saturation (%) 96 (94-98)
GCS 15 204/225 (91% [86-94%])
GCS 11-14 16/225 (7% [4-11%])
GCS < 11 5/225 (2% [1-5%])
Unable to stand 63/225 (28% [22-34%])
Admission CD4 count
CD4 count* (µL-1) 98 (31-236)
Admission haematology
Haemoglobin (x109 g dL-1) 10.8 (8.2-13.2)
White cell count (x109 L-1) 6.5 (4.4-11.4)
Neutrophil count (x109 L-1) 4.0 (2.1-7.5)
Platelet count count (x109 L-1) 218 (146-297)
Admission biochemistry
Sodium (mmol L-1) 134 (130-137)
Potassium (mmol L-1) 4.0 (3.6-4.4)
Bicarbonate (mmol L-1) 19 (17-22)
Chloride (mmol L-1) 101 (97-104)
Urea (mmol L-1) 4.8 (3.5-8.0)
Creatinine (mmol L-1) 76 (59-103)
Lactate (mmol L-1) 3.4 (2.3-5.2)
Note:
GCS = Glasgow coma scale, BP = Blood pressure, MAP
= Mean arterial blood pressure. Numeric values are
median (IQR)) or proportions with exact binomial 95%
confidence intervals unless otherwise stated.
* CD4 count includes only HIV-infected participants; 2
values were missing.
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3.4.4 Aetiology
In total, 51% (114/225) of the 225 participants had at least one infectious agent identified
(Table 3.4), most commonly disseminated mycobacterial infection (76/225 [34%]) followed by
culture confirmed bacterial or fungal bloodstream infection (24/225 [11%]) and Plasmodium
falciparum malaria (21/225 [9%]). Table 3.5 shows the availability of test and proportion
of positive tests across the cohort, stratified by HIV status. 2/225 patients (1%) had a
missing aerobic blood culture; the remaining 223 patients had a total of 259 blood cultures
performed. 15/259 (6%) blood cultures grew at least one contaminant, but 26 blood
cultures from 24 patients were positive for a total of 28 pathogenic bacteria (Figure 3.6):
Salmonella enterica Serovar Typhi was the most commonly isolated bacterial pathogen.
Of note 8/9 participants from whom S. Typhi was isolated were HIV noninfected, with
one untested. Of the 18 Gram-negative bacteria isolated, 3/18 (17%) were cefpodoxime
resistant on AST via disc diffusion testing, and likely ESBL producers: one K. pneumoniae
and one E. coli (both from the same blood culture and same patient) and one Acinetobacter
baumannii. Both Staphyloccus aureus isolates were oxacillin sensitive. The one Streptococcus
pneumoniae cultured was penicillin intermediate on AST. There was no significant difference
in proportion with positive blood culture in those who self reported receipt of prehospital
antibacterials versus those who did not (7/52 [13%] BSI in those reporting prehospital
antibacterials vs 17/154 [11%] not, difference 2% [95% CI -9-14%]).
Lumbar puncture and CSF culture was carried out in 44 participants: 5/44 (11%) of
samples grew a containment and no pathogenic bacteria were recovered from any sample.
4/44 (9%) had a detectable cryptococcal antigen (CRAG) in CSF. Malaria testing was
missing for 6/225 (3%) of participants, but of the remainder, a positive malaria test was
more likely in the HIV-uninfected (12/69 [17%] vs 6/138 [4%], difference 13% [95% CI
2-24%]). Positive aerobic blood culture showed no statistically significant association with
HIV, nor did positive CSF testing, though in the latter case numbers were small and all
positive tests (all positive CRAG) were in fact in the HIV-infected (Table 3.5).
Testing for TB, with the exception of sputum Xpert testing, was restricted to HIV-infected
participants. Sputum Xpert was carried out in 44/225 (20%) of participants, and was more
commonly carried out in the HIV-infected: 35/143 [24%] of HIV-infected participants had
sputum testing performed vs 8/70 (11%) of HIV uninfected (difference 13% [95% CI 2-24%]).
53 sputum samples were sent in total from the 44 patients, and 8/44 (18%) diagnoses of
TB made, all except one in HIV-infected participants. One sample identified a rifampicin
resistance gene, but the participant died before the result was available and so was not
started on MDR-TB treatment; the remainder of infections were rifampicin-sensitive.
155 participants were eligible for urinary lipoarabinomannan (uLAM) and mycobacterial
blood culture testing, being either HIV-infected (n=143) or of unknown HIV status (n=12).
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Table 3.4: Number of diagnoses
Diagnosis Proportion of participants
Tuberculosis 76/225 (34% [28-40%])
Bloodstream infection 24/225 (11% [7-15%])
Malaria 21/225 (9% [6-14%])
Meningitis 4/225 (2% [0-4%])
No diagnosis 111/225 (49% [43-56%])
Urine was available for 145/155 (94%) of those eligible, and 74/145 (51%) of samples were
positive for uLAM. 150/155 (97%) of eligible participants had blood samples collected
and cultured for mycobacteria. 12/150 (8%) grew contaminants and are excluded from
the denominators in Table 3.5; of the remainder 8/138 (6%) grew mycobacteria, all M.
tuberculosis.
Figures 3.4 and 3.5 show the overlap of positive tests form the different diagnostic modalities.
Of the 114 patients with at least one positive diagnostic test, 90/114 (79%) had only one
positive diagnostic test. The exceptions to this were mycobacterial blood culture and
sputum Xpert: patients who had TB diagnosed by these tests tended to also have a positive
uLAM. 2/4 (50%) of patients with positive CSF testing (all of whom had detectable CRAG)
had also grew Cryptococcus neoformans in aerobic blood culture. 111/225 (49%) of patients




















Table 3.5: Diagnostic tests performed and results, stratified by HIV status.
HIV status
type Reactive Non reactive Unknown
Number of participants 143 70 12
TB diagnostics
Urinary LAM 70/136 (51% [43-60%]) - 4/9 (44% [14-79%])
Sputum Xpert 7/35 (20% [8-37%]) 1/8 (12% [0-53%]) 0/1 (0% [0-98%])
TB blood culture 7/128 (5% [2-11%]) - 1/10 (10% [0-45%])
Other diagnostics
Aerobic blood culture 13/141 (9% [5-15%]) 9/70 (13% [6-23%]) 2/12 (17% [2-48%])
CSF culture or CRAG 4/31 (13% [4-30%]) 0/12 (0% [0-26%]) 0/1 (0% [0-98%])
Malaria RDT 6/138 (4% [2-9%]) 12/69 (17% [9-28%]) 3/12 (25% [5-57%])
Total with diagnosis 86/143 (60% [52-68%]) 21/70 (30% [20-42%]) 7/12 (58% [28-85%])
Note:
LAM = Lipoarabinomannan, CSF = Cerebrospinal fluid, CRAG = Cryptococcal antigen, RDT =










Figure 3.4: Venn diagram showing overlap of positive diagnostic tests; culture of blood and CSF
shown in red, malaria in green and TB diagnostics in blue. The CSF variable in includes either a
positive culture for a pathogenic bacteria or positive cryptococcal antigen, BSI a positive aerobic
culture of pathogenic bacteria from blood and MTB BSI culture of M. tuberculosis from blood. BSI:
Bloodstream infection, CSF: Cerebrospinal fluid, mRDT: Malaria rapid diagnostic test, MTB BSI:
Mycobacterium tuberculosis bloodstream infection, uLAM: urinary lipoarabinomannan.
3.4.5 Treatment
At least one antimicrobial drug was received by 214/225 (95%) of the cohort during their
admission (Table 3.6), most commonly an antibacterial (207/225 [92%]), but also a signifi-
cant minority received antituberculous chemotherapy (63/225 [28%]). Of those receiving
antituberculous therapy, 10/63 (16%) were taking the medication prior to admission, and
the remainder were initiated on therapy during admission. The first antibacterial agent
administered was most often ceftriaxone, (181/207 [87%]) but ciprofloxacin (9%), amoxicillin
(3%) and metronidazole (1%) were also used. Median door to antimicrobial time was 5.3
hours (IQR 3.7-10.8) for antibacterials and 4.5 hours (IQR 3.1-21.7) for antimalarials but
longer for antifungals at 47.7 hours (IQR 27.9-73.9) and longer still for antitubercular
therapy at 120.9 hours (IQR 63.7-171.0). Cumulative incidence curves for administration
of the different antimicrobial classes are shown in Figure 3.7A-D.
Of all participants, 85% (192/225) received any intravenous fluid in the first 6 hours of
enrolment to the study; of these, most received 0.9% saline (160/192 [83%] of those receiving
fluid) but 5% dextrose (91/192 [57%]) were also used; Ringer’s lactate (6/192 [6%]) and
blood (2/192 [1%]) were rarely administered. Of the 192 patients who were administered
any fluid, a median of 1.5L (IQR 1.0-2.0L) was administered over the 6hr study period;
fluid administration as a function of time is shown in Figure 3.7E.


































Figure 3.5: UpSet plot of overlap of positive diagnostic tests, showing that for the majority of
participants, one test alone is positive. Red colour indicates HIV-infected; black is a composite of
HIV-negative and unknown. The CSF variable in includes either a positive culture for a pathogenic
bacteria or positive cryptococcal antigen, BSI a positive aerobic culture of pathogenic bacteria
from blood and MTB BSI culture of M. tuberculosis from blood. BSI: Bloodstream infection, CSF:
Cerebrospinal fluid, CRAG: Cryptococcal antigen, mRDT: Malaria rapid diagnostic test, MTB BSI:


















Figure 3.6: Pathogenic isolates recovered from aerobic blood culture. 26 blood cultures in 24




































































Figure 3.7: Timing of antimicrobial and fluid administration. A-D: Cumulative incidence of
administration of antibacterial (A), antitubercular (B), antifungal (C) and antimalarial (D) agents
as a function of time since arrival at hospital in hours. E: Total volumne of administered intavenous
fluid as a function of time since enrollment to study in hours. Boxplots show median, quartiles box
and 1.5 times interquartile range as whiskers. Points are jittered around the hour at which they
were measured to show distribution.
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Table 3.6: Door-to-antimicrobial times.
Antimicrobial class No. participants Median [IQR] time (hours)
Antibacterial 207/225 (92% [88-95%]) 5.3 (3.7-10.8)
Antitubercular 63/225 (28% [22-34%])* 120.9 (63.7-171.0)
Antifungal 26/225 (12% [8-16%]) 47.7 (27.9-73.9)
Antimalarial 12/225 (5% [3-9%]) 4.5 (3.1-21.7)
* 10/63 participants who received antitubercular agents during admis-
sion were taking them prior to admission; they are excluded from the
calculation of median door-to-antimicrobial time for this class.
3.4.6 Outcome
Median hospital stay was 4 (IQR 1-9) days. Case fatality rate (CFR) was 18% (95% CI
13-23%) at 28 days, 24% (95% CI 18-30%) at 90 days and 31% (95% CI 25-38) at 180
days, and higher in HIV-infected participants at each time point (Table 3.7), though not
statistically significant: HIV-infected vs noninfected 19% vs 13% at 28 days (difference
6% [95% CI -6-13%] ), 27% vs 17% at 90 days (difference 10% [95% CI -4-22%]) and 36%
vs 21% at 180 days (difference 15% [95% CI 0-30%]). The primary planned Kaplan-meier
estimation of the survival function (Figure 3.8) showed a precipitous decline in survivorship
to around day 30 and CFR declined thereafter, to the end of the study period. Stratifying
the analysis by HIV status revealed that early deaths (within the first 1-2 weeks) occur
at similar rates in the two groups before the curves diverge; log-rank test suggested a
significant difference in survival function between the two groups (p = 0.03). In view of the
fact that a number of the HIV-infected participants were likely to be failing ART, only two
were recorded as switching to second line therapy during the study period, though details
of any interventions (e.g. ART adherence counselling) or HIV viral load testing carried out
as part of routine care were not captured.
Health related quality of life measures, as assessed by EQ-5D-3L, are shown in Figure 3.9 for
participants with sepsis and the community cohort as a comparator. Acutely, participants
with sepsis reported were significantly disabled, reporting at least moderate impairment
across all domains in the majority of cases, and over 90% of participants reporting at least
moderate impairment in activities of daily living and experiencing at least moderate pain or
discomfort. However, recovery following treatment in survivors was rapid. The mean EQ-5Q
utility score (a measure of the weight compared to a health state compared to 1, perfect
health) of healthy community controls was 0.910 (SD 0.102) at enrolment, significantly
higher than participants with sepsis at enrolment (utility score 0.496 (SD 0.251), difference
in means versus community enrolment 0.414 [95% CI 0.364-0.463]), but comparable to
participants with sepsis at their 12 week assessment (0.913 (SD 0.147), difference in means




























































Figure 3.8: Kaplan-Meier survival curves of all included participants (A) and stratified by HIV
status (B). Crosses indicate censoring. p value from log-rank test comparing survival of HIV-infected
to HIV-noninfected participants shown (p = 0.03).
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Figure 3.9: Health-related quality of life following sepsis admission, compared to community controls,
showing a return to usual quality of life by 12 weeks following admission. A: proportion of participants
across each of the five domains of the EQ-5D questionnaire who report at least moderate impariment.
B: EQ-5D utility score derived using the Zimbabwean tariff set. The utility score is interpreted as
the weight attached to a health state compared to perfect health, which is assigned a value of 1.
By 12 weeks there is no statistically significant difference between sepsis and baseline community
participant utility scores (difference in means 0.003 [95% CI -0.039-0.045]).
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Table 3.7: Day 28, 90 and 180 mortality stratified by HIV status
HIV+ HIV- HIV Unknown Total
n Mortality n Mortality n Mortality n Mortality
Day 28 143 19% (13-26%) 67 13% (6-24%) 12 25% (5-57%) 222 18% (13-23%)
Day 90 139 27% (19-35%) 64 17% (9-29%) 12 25% (5-57%) 215 24% (18-30%)
Day 180 125 36% (28-45%) 58 21% (11-33%) 11 27% (6-61%) 194 31% (25-38%)
Note:
n in this table indicates the number of patients with known vital status, contributing data at
the given time point (i.e. not lost to follow up, withdrawn, or transferred out).
3.4.7 Determinants of mortality
Bivariable associations of mortality are shown in Table 3.8 with variables grouped into
putative host, severity, diagnosis and treatment variables. Variables associated with
immunosuppression - CD4 count and haemoglobin - were associated with death in unadjusted
analysis, as were well recognised markers of disease severity: shock, hypoxia, reduced
conscious level, hyperlactataemia, and inability to ambulate, as were reduced venous
bicarbonate and increased venous urea. A diagnosis of malaria was strongly associated with
survival (0/21 died), as was receipt of antimalarials. Conversely, a diagnosis of meningitis
was associated with mortality (Table 3.8) though numbers were small (n = 4) and confidence
intervals of differences between groups crossed zero. Receipt of antibacterials, or antifungals
showed no association with mortality, though almost all participants received antibacterials
and only a minority antifungals, so moderate effect sizes would be unlikely to be detected.
However, receipt of antituberculous chemotherapy therapy was associated with survival:
8% (4/53) of participants receiving TB therapy died compared to 21% (35/169) who did
not receive it (difference 13% [95% CI 3-30%]).
All of these associations are likely to be affected by confounding, so I constructed logistic
regression models to attempt to produce unbiased effect estimates (Table 3.9. There were
some difficulties with these models. Separation occurred when malaria and meningitis
diagnoses and receipt of antimalarials were included - they perfectly predicted outcome, so
parameter estimates become unstable - and so they were excluded from the model. Receipt
of TB therapy remained strongly associated with survival (aOR 0.17 [95% CI 0.03-0.74]) as
did higher haemoglobin (aOR 0.69 [95% CI 0.52-0.86] per 1g dL−1 increase) and higher
oxygen saturation (aOR 0.67 [95% CI 0.47-0.96] per 5% increase). Perhaps surprisingly,
an increased respiratory rate was associated with survival (aOR 0.35 (0.14-0.81) per 10
breaths min−1 increase; less surprisingly, inability to stand on admission strongly predicted







Table 3.8: Bivariate associations with death by 28 days
Variable Died Survived Difference
Host Variables
Age (years) 36.4 (31.5-46.0) 35.9 (27.4-42.9) -0.5 (-7.9 to 3.3)
Male sex 19/39 (49%) 93/183 (51%) 2% (-17 to 21%)
HIV Infected* 27/36 (75%) 116/174 (67%) -8% (-26 to 9%)
Taking ART† 21/27 (78%) 96/116 (83%) 5% (-14 to 24%)
CD4 count† (µL-1) 28.5 (9.5-124.5) 103.0 (43.5-251.0) 74.5 (1.5 to 108.5)
Haemoglobin (x109 g dL-1) 9.1 (6.0-10.4) 11.0 (8.6-13.4) 1.9 (0.8 to 4.0)
Severity Variables
Temperature (°C) 38.1 (37.7-38.8) 38.5 (38.0-39.0) 0.4 (0.0 to 0.7)
Heart rate (min-1)) 123.0 (104.5-138.5) 120.0 (102.0-131.0) -3.0 (-13.0 to 6.0)
Systolic BP (mmHg) 89.0 (75.0-103.0) 99.0 (86.5-118.5) 10.0 (1.0 to 20.0)
Diastolic BP (mmHg) 58.0 (49.5-70.5) 67.0 (57.0-75.5) 9.0 (2.0 to 16.0)
Mean arterial BP (mmHg) 68.3 (59.7-80.7) 78.7 (67.0-89.2) 10.3 (3.7 to 17.3)
Respiratory rate (min-1)) 34.0 (32.0-36.5) 34.0 (32.0-38.0) 0.0 (-2.0 to 2.0)
Oxygen saturation (%) 95.0 (89.5-97.0) 97.0 (95.0-98.0) 2.0 (0.0 to 3.0)
GCS 15.0 (15.0-15.0) 15.0 (15.0-15.0) 0.0 (0.0 to 0.0)
Unable to stand 27/39 (69%) 36/183 (20%) -50% (-67 to -32%)
Lactate (mmol L-1) 4.9 (3.0-10.6) 3.2 (2.1-4.5) -1.7 (-6.3 to -0.1)
White cell count (x109 L-1) 5.9 (3.5-11.0) 6.9 (4.5-11.5) 1.0 (-1.4 to 2.8)
Platelet count (x109 L-1) 181.5 (86.8-300.8) 223.0 (148.0-296.5) 41.5 (-30.0 to 72.0)
Bicarbonate (mmol L-1) 17.0 (14.0-21.0) 20.0 (17.0-22.0) 3.0 (0.0 to 4.5)
Urea (mmol L-1) 7.8 (4.5-14.3) 4.5 (3.2-7.0) -3.3 (-8.7 to -1.2)
Creatinine (mmol L-1) 90.0 (60.0-185.0) 73.0 (59.0-96.0) -17.0 (-48.0 to 7.0)
Diagnosis
BSI 3/39 (8%) 20/183 (11%) 3% (-8 to 14%)
TB 15/39 (38%) 61/183 (33%) -5% (-23 to 13%)
Malaria 0/39 (0%) 21/183 (11%) 11% (5 to 18%)
Meningitis 3/39 (8%) 1/183 (1%) -7% (-17 to 3%)
No diagnosis 21/39 (54%) 88/183 (48%) -6% (-25 to 13%)
Treatment Received
Antibacterials 37/39 (95%) 167/183 (91%) -4% (-13 to 6%)
Time to Antibacterials (hr) 4.7 (3.8-8.8) 5.3 (3.6-10.8) 0.6 (-1.0 to 1.7)
Antifungals 7/39 (18%) 19/183 (10%) -8% (-22 to 7%)




















Table 3.8: Bivariate associations with death by 28 days (continued)
Variable Died Survived Difference
Antimalarials 0/39 (0%) 12/183 (7%) 7% (1 to 12%)
Time to Antimalarials (hr) - 4.5 (3.1-21.7) -
Antimycobacterials 4/39 (10%) 49/183 (27%) 17% (3 to 30%)
Time to Antimycobacterials (hr) 107.3 (23.6-138.7) 99.0 (37.0-169.4) -8.3 (-110.0 to 104.8)
IV fluid (L) 1.4 (1.0-2.0) 1.3 (0.6-2.0) -0.1 (-0.6 to 0.2)
Note:
BP = Blood pressure, GCS = Glasgow coma scale. Numeric variables are presented as median
(IQR) and categorical variables as proportions. Difference column shows difference in medians
or difference in proportions with 95% confidence intervals. Variables shown in bold are those for
which the 95% confidence intervals do not cross 0.
* Participants with HIV status unknown not included in this row
† Includes only HIV-infected participants
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Table 3.9: Unadjusted and adjusted odds ratios of death by 28 days
Univariable models Multivariable model
Variable OR (95% CI) aOR (95% CI)
Host Variables
Age (per 5 years increase) 1.09 (0.94-1.26) 0.99 (0.76-1.27)
Male sex (vs female) 0.92 (0.46-1.84) 1.04 (0.31-3.55)
HIV Infected (vs uninfected) 1.50 (0.68-3.57) 0.31 (0.05-1.71)
HIV Unknown (vs uninfected) 2.15 (0.42-8.93) 0.22 (0.01-3.25)
Haemoglobin (per g dL-1 increase) 0.81 (0.72-0.90) 0.69 (0.52-0.86)
Severity Variables
Temperature ( per °C increase) 0.61 (0.42-0.86) 0.65 (0.33-1.26)
Heart rate (per 10 min-1) increase) 1.02 (0.87-1.20) 1.10 (0.83-1.48)
Mean arterial BP (per 10 mmHg increase) 0.77 (0.62-0.95) 1.11 (0.70-1.69)
Respiratory rate (per 10 min-1) increase) 0.75 (0.45-1.23) 0.35 (0.14-0.81)
Oxygen saturation (per 5% increase) 0.72 (0.58-0.88) 0.67 (0.47-0.96)
GCS (per 1 unit increase) 0.82 (0.65-1.01) 0.83 (0.58-1.20)
Unable to stand 9.19 (4.34-20.51) 14.55 (3.81-69.78)
Lactate (per 1 mmol L-1 increase) 1.27 (1.15-1.41) 1.06 (0.88-1.29)
White cell count (per 1x109 L-1 increase) 0.98 (0.91-1.03) 0.97 (0.86-1.07)
Platelet count (per 100x109 L-1 increase) 0.93 (0.72-1.15) 1.11 (0.77-1.55)
Bicarbonate (per 1 mmol L-1 increase) 0.89 (0.82-0.96) 0.93 (0.80-1.08)
Urea (per 1 mmol L-1 increase) 1.12 (1.06-1.19) 1.05 (0.90-1.22)
Creatinine (per 10 mmol L-1 increase) 1.04 (1.01-1.08) 1.00 (0.95-1.08)
Diagnosis
BSI (vs no BSI) 0.68 (0.15-2.12) 0.15 (0.02-1.01)
TB (vs no TB) 1.25 (0.60-2.53) 0.94 (0.24-3.57)
Malaria (vs no malaria) - -
Meningitis (vs no meningitis) 15.17 (1.88-311.38) -
Treatment Received
Received any antibacterial (vs none) 1.77 (0.48-11.52) -
Received any antifungal (vs none) 1.89 (0.69-4.70) 2.12 (0.40-11.07)
Received any antimalarial (vs none) - -
Received any antimycobacterial (vs none) 0.31 (0.09-0.83) 0.17 (0.03-0.74)
IV fluid received (per L increase) 1.00 (1.00-1.00) 1.00 (1.00-1.00)
Note:
BP = Blood pressure, GCS = Glasgow coma scale, BSI = Bloodstream infection, TB =
tuberculosis. Separation occurred for those variables for which no parameter estimates
are given, and they were excluded from the multivariable model. All odds ratios are
for an increase in the variables shown. Variables for which the 95% confidence intervals
of odds ratios do not cross 1 are shown in bold.
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3.5 Discussion
3.5.1 Demographics and outcome: significant longer-term mortality
In this chapter, I have presented a clinical and microbiologic description of sepsis in adults
in Blantyre, Malawi. Inkeeping with sepsis cohorts elsewhere, the participants are young,
with high prevalence of HIV infection. The proportion of HIV-infected participants (67% of
those with known HIV status) is comparable to a study of Sepsis-2 defined sepsis which
recruited in QECH in 2008/9 (75%) but lower than sSA sepsis studies with the highest
prevalence of HIV-infected participants Uganda in 2006[17] (85%) and 2009[27] (86%) and
Zambia in 2012-13[9] (90%). Notably, the proportion of participants receiving HIV therapy
(82%) is high compared to other sepsis studies in sSA: higher than the 08/09 Malawian
study (44%), Uganda (12-24%) and Zambia (51%), which likely reflects both the success of
the Malawian ART programme as well as the impressive increases in ART coverage across
the continent. Despite this ostensibly high coverage, it is likely that presentation with sepsis
is a manifestation of ART failure for many participants as evidenced by the low CD4 cell
counts despite ART. In the significant minority of participants who recently initiated ART -
25% of those on ART started it less than three months before presentation - it seems likely
that immune reconstitution inflammatory syndrome (IRIS) is playing a significant role.
Participants had been unwell for some time: a median 7 days. Published data on length of
current illness in sepsis is both high and low-resource settings is lacking, but what data
there are from elsewhere in sSA suggest that this is not unusual[9,25,129,296]. Barriers to
accessing care were not addressed in this study and so the reasons for delaying hospital
attendance (including the role of patient and healthcare factors) are not clear; 55% of
participants had sought care for their current illness prior to presentation at the hospital,
usually at the health centre. Optimum triage and other management of critically unwell
patients at the health centre in a resource limited setting is not clear, and is likely to differ
from hospital management. This could represent a fruitful area for future research.
The 28-day mortality of the cohort was 18% at 28 days, comparable to the pooled Sepsis-2
sepsis mortality from the systematic review and meta analysis presented in Chapter 1
(23% 95% CI [12-38%]) though considerably lower than the pooled Sepsis-2 severe sepsis
mortality (49% 95% CI [39-58]). This is perhaps surprising as the inclusion criteria of this
study include organ dysfunction criteria that are more similar to Sepsis-2 severe sepsis
definitions than the Sepsis-2 sepsis definitions that are based on the systemic inflammatory
response syndrome (SIRS), and would perhaps be expected to result in a higher mortality.
In particular, the previous Malawian sepsis study (in the same hospital) from 2008/09
used a SIRS based definition of sepsis and found a mortality of 22%, with a severe sepsis
mortality (defined using either 2 SIRS criteria and SBP < 90mmHg or any two of SBP <
90mmHg, capillary refill time > 2s, oxygen saturations < 90% or thrombocytopaenia) of
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50%[18]. There are several possible explanations for this. First, there is likely an effect of
differing inclusion criteria: this study includes a respiratory rate criterion for recruitment,
which has been shown elsewhere in sSA in large pooled datasets to be associated with
mortality[297], a finding which was not replicated here. Second, sepsis mortality at our
centre may be improving, either through improved management, or by population level
changes resulting in improved health such as widespread ART coverage or reducing malaria
incidence. Certainly, improving sepsis mortality in high-income settings is a trend that
has been seen since the pivotal early goal directed therapy trial in 2001[5,85,122]. Third,
participants in this study received reasonably intensive monitoring over the first 6 hours of
their hospital attendance, which may have contributed to improved processes of care and
hence improved outcomes. There is no way to address these hypotheses with the available
data.
Participants continued to die post 28-days, to the end of the study period; this was most
apparent in HIV-infected participants in whom there was a near-doubling of mortality from
19% at 28 days to 36% at 180 days. To my knowledge, this is the first data on post-30
day outcomes in sepsis in sSA, and demonstrates that longer term mortality following an
admission with sepsis is a significant problem. The causes of late (post 28-day) death
are unknown from this study. Given the advanced HIV of many of the participants, and
the high prevalence of TB, opportunistic infection seems likely. Despite the suspicion of
ART failure at baseline, switching to second line ART was unusual in participants who
survived to discharge. This is perhaps not entirely surprising, as WHO and Malawian
treatment guidelines mandate two elevated HIV viral load tests at least three months apart
in the context of good adherence to diagnose ART failure and before switching to second
line therapy, which may not have occurred during the six-month study period. Details of
any HIV viral load testing performed as part of standard care (as well as any adherence
counselling received) were also not captured in this study, so the proportion of true virologic
ART failure are unknown. Nevertheless it is tempting to speculate that rapid adherence
interventions or ART switching could improve post discharge outcomes in sepsis in Malawi.
This could be an area of future research (Chapter 9), and is of increasing relevance as more
people are exposed to first-line ART thanks to the success of global ART roll out.
In contrast to significant medium- to long-term mortality, health-related quality of life
(HRQoL, as measured by EQ-5D-3L) seems to return to baseline by 12 weeks following sepsis
admission, in contrast to high income settings where longer term morbidity is significant[89].
This may represent different patient populations with differing levels of physiologic reserve
and capacity for recovery from critical illness, as the patient population in this study is
significantly younger than a high-income setting sepsis population. It may also reflect the
lack of resources available in LMIC: patients who would survive, but with disability, in a
high-resource setting may die in a low-resource one. Nevertheless, the rapid return to a
comparable HRQoL to healthy community controls following sepsis admission could make
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improvement of sepsis outcome a cost-effective condition. Once again, to my knowledge,
this HRQoL is the first available such data from sepsis in sSA, and can inform health
economics analyses in sepsis here: the EQ-5D-3L utility scores can be used to calculate
DALYs (disability-adjusted life years) in such an analysis.
3.5.2 Aetiology: TB dominates as a cause of sepsis
The aetiology of sepsis in this cohort is dominated by TB, with 34% of participants having
at least one positive diagnostic test for TB. The majority of these were positive for urinary
LAM. The prevalence of culture-confirmed MTB BSI was lower than expected; in previous
studies of Sepsis-2 defined severe sepsis in Uganda[17,27] and Zambia[9,25] it was 28-40%
in HIV-infected participants. In Malawi in the pre-ART era[99] the prevalence of MTB
BSI in febrile adults at QECH was 14% (21/173), and 9% (9/104) in 2011 in the same
centre in HIV-infected adults admitted with fever and chronic cough[106]. The 6% (8/138)
I find here in HIV-infected participants therefore seems low. This could be due to technical
(e.g. bottle under or over filling with blood) or laboratory factors, though the latter seems
unlikely as the testing was carried out at the same laboratory and with the same SOP as
the 2011 study by Feasey et al[106]. This could also be a true finding: given the association
of MTB BSI with mortality the lower than expected mortality of this cohort could go
hand-in-hand with a lower than expected MTB BSI prevalence, for example, or the high
ART prevalence (despite the suspicion of common ART failure) could have an effect on the
prevalence of MTB BSI.
Other identified causes of sepsis are as might be expected. Salmonella Typhi was the
commonest blood stream infection isolate, reflecting the ongoing Typhoid epidemic in
Blantyre which began in 2011[298], and seemed to be associated with HIV-uninfected
participants, as has been previously described[299].
3.5.3 Determinants of mortality
Several expected markers of disease severity were associated with 28-day mortality, as have
previously been described[7,18,27]. Unexpectedly, tachypnoea was associated with survival.
The reasons for this are not clear. It could be that participants better able to mount an
inflammatory response (and hence an increased respiratory rate) are more likely to survive,
or that the effect is driven by low respiratory rates in the very unwell. It could also be
explained by bias: elevated respiratory rate was an inclusion criterion for the study, as were
shock, reduced conscious level and hypoxia. If unmeasured factors associated with mortality
were also associated with these other inclusion criteria then this could cause an apparent
mortality benefit to tachypnoea: a collider bias, in the language of causal inference.
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A diagnosis of malaria was strongly associated with survival to 28 days. In Malawi - a
malaria endemic country - most adults will have some level of immunity[300], which may
explain this finding, but it is possible that the rapid diagnosis and treatment facilitated
by the availability of malaria rapid diagnostic tests also contributes. Meningitis - all
cryptococcal - strongly predicted death by 28 days, reflecting the well-described high
mortality of this condition[301].
There was no signal of an association between time to antibacterials or volume of IV fluid
administered and survival to 28 days. In high-resource settings, rapid administration of
antimicrobials has been shown to be associated with improved survival in sepsis[6,7,126],
and all sepsis guidelines stress the importance of rapid administration of antimicrobials[302].
This is based purely on observational evidence and no RCT has ever been (or will be,
given the ethical issues) carried out; these studies are all open to confounding and require
adjustment for disease severity. In this study, no significant effect of time-to-antibacterials
was seen, though it is important not to interpret this lack of detected effect as lack of effect.
The largest study to address this question, in a high income setting (New York, USA) found
an adjusted odds ratio of 1.04 (95% CI 1.02-1.05) for death per hour delay of antibiotics,
and included 49,331 participants[7], so lack of demonstration of effect here could be due to
underpowering. I also have not, in this chapter, attempted to provide an estimate of the
effect of time-to-antibacterials on mortality that is adjusted for confounding. Confounding
could easily mask any apparent effect (i.e. sick patients given antibacterials quicker). I
present an attempt to address this using modelling in the next chapter.
However it is important to be cognisant of the differences of this cohort to sepsis cohorts
in high-income settings: presentation here was subacute, participants were often unwell
for many days, and pathogens such as S. Typhi and TB would perhaps not be expected
to cause such fulminant illness as the Gram-negative pathogens that often cause sepsis in
high-income settings. In this context, rapidity of antimicrobial administration may not
be such a critical determinant of survival. Further, most participants simply did not have
sepsis caused by a pathogen that would be responsive to broad-spectrum antibacterials.
There was no detected benefit or harm associated with volume of intravenous fluid ad-
ministered. How to safely administer intravenous fluid in sSA is unclear after RCTs in
children[10] and adults[9] have shown harm to be associated with aggressive fluid resuscita-
tion. Participants in this study received a comparable volume of fluid to the usual care
arm of the Zambian RCT in adults[9], given that the trial was recruiting participants with
shock: median 2.0L (IQR 1.0-2.5L) by 6 hours versus 1.5L (1.0 - 2.0L) in this study. The
intervention arm of the RCT received 3.5L (2.7-4.0L). It may be that participants in this
study did not receive enough fluid to be harmful; that there was insufficient variation in
fluid exposure to detect an effect on mortality, that the current study is underpowered
(particularly with the lower than expected mortality); that only a subset of the participants
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in this study (i.e. those with shock) would benefit from fluid; or that the Zambian study
population differs in some way and so response to fluid was different.
Perhaps the most striking finding is the strong association of receipt of TB therapy with
survival. Care must be taken in interpreting this as cause and effect, because of the risks of
confounding, and especially considering the limitations of the modelling undertaken in this
chapter (see limitations). A protective effect of TB therapy in sepsis is plausible, however,
from prior studies: autopsy studies show that TB is under diagnosed in HIV-infected
patients who die in hospital[110]. The STAMP trial[109] found a mortality benefit in some
a priori subgroups of a strategy of screen-and-treat with urinary LAM for all HIV-infected
inpatients, suggesting a significant burden of undiagnosed TB, and prior sepsis cohorts
in sSA have found TB as a common cause of sepsis. A retrospective study of 149 HIV
infected adults with sepsis in Uganda[303], 55 of whom received anti-TB therapy, found an
association between receipt of TB therapy and survival in Sepsis-2 severe sepsis (hazard
ratio 0.32 95% CI 0.13-0.80 from Cox proportional hazard model) but not Sepsis-2 sepsis
(hazard ratio 1.24 95% CI 0.53-2.90), but is hampered by its retrospective design.
What, then, is the role of TB therapy in sepsis in sSA? RCTs of empirical TB treatment
have not previously been successful. The REMEMBER trial recruited outpatients with
CD4 cell count below 50 cells µL−1 and randomised them to isoniazid preventative therapy
or full TB therapy, and found no mortality benefit[304]. STASIS found no difference in
mortality between a strategy of Xpert and urine LAM screening versus empiric TB therapy
in outpatients with CD4 count below 100 cellsµL−1[305] and TB Fast Track found no
mortality benefit in empiric therapy for outpatients with CD4 cell count below 150 µL−1 if
they were randomised to an algorithm that started TB therapy if they were assessed as high
risk for TB using a combination of diagnostic tests (including urinary LAM) and clinical
features (including BMI and haemoglobin)[306]. However all of these studies recruited
ambulatory outpatients; it may be that inpatients have more disseminated TB, or a higher
baseline risk of mortality. Empiric TB therapy for sepsis in a high-HIV/TB burden setting
is a strategy that has never been assessed in an RCT.
The WHO provides guidance on empiric TB therapy in inpatients, however[111]: “Hospi-
talised HIV-infected patients in high TB burden settings with cough and so-called”danger
signs" (fever > 39°C, inability to stand, respiratory rate above 30 min−1, heart rate above
120 min−1) should receive broad spectrum antimicrobials for 3-5 days, and, if there is no
improvement, consider empiric TB therapy". This strategy was largely based on expert
opinion, but has been shown to improve survival compared to usual care in a before-after
study in South Africa[112]. Whether a 3-5 day delay will worsen outcomes in critically
unwell patients with TB is unknown. There was no apparent relationship seen in this
study between time to antitubercular therapy and death, but numbers were small (n=
53), and TB therapy administration was reasonably rapid, with a median of 120.6 hours
3.5. DISCUSSION 123
from admission to administration of TB therapy; 56% (35/53) of participants received TB
therapy in less than 5 days.
In this context, the finding of a putative survival benefit for TB treatment in participants
with sepsis is worth exploring further. Is it possible to produce unbiased estimates of the
association of TB therapy with mortality, given the problems with the modelling approach
presented in this chapter? Is it possible to move beyond association and assess the causal
effect of TB therapy on mortality? Is any benefit confined to particular subgroups, especially
groups that can be easily identified in low resource settings, to guide future sepsis treatment
protocols? I take up these questions in the following chapter.
3.5.4 Limitations
There are limitations to this study. There is no community control group, so it is not
possible to say whether the positive malaria rapid tests in this study represent incidental
parasitaemia or disease. Malaria films could perhaps inform this question by quantifying
parasitaemeia, but were not done. Only one aerobic blood culture and mycobacterial blood
culture were done, and both tests are known to have suboptimal sensitivity with only a
single culture[307,308]. No anaerobic culture was possible. HIV viral load testing was not
done due to resource limitations.
There are several flaws with the logistic regression models used in this chapter that mean
the parameter estimates from them may be biased. Separation was a significant challenge.
This is a phenomenon where some predictor variable levels perfectly predict outcome,
meaning that parameter value estimates become unstable. In this case, this occurred with
malaria and meningitis, so these two predictor variables - both of which were very strongly
associated with the outcome variable - were excluded from the model. If other variables
were associated with these excluded variables then this could give biased estimates thanks to
confounding. In addition, the model is very likely over-parametrised - around ten outcomes
for each predictor variable are needed to avoid this[309] meaning that the out-of-sample
predictive ability of this model would likely be poor, and would restrict the generalisability
of findings. There is a risk that the model is fitting to noise rather than identifying the true
data-generating process. Choosing which variables to include in the model, however, is not
an easy task, and strategies such as stepwise variable inclusion have been shown to produce
biased parameter estimates[309]. It may also be that some of the predictor variables are
collinear - tachycardia and increased respiratory rate are associated with shock, for example,
which can inflate the apparent standard errors of parameter estimates. Finally, it is likely
that the mortality hazard of some variables included in the model is mediated by other
variables (e.g. HIV mortality hazard may be disease mortality), and so interpretation of
the parameters is difficult without an explicit causal framework[310].
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3.6 Conclusions and further work
In conclusion, this chapter presents an in-depth clinical and microbiologic assessment of
sepsis in Blantyre, Malawi, and finds that sepsis here is in some ways a subacute illness,
with the dominant cause being tuberculosis. Nevertheless, long-term mortality is significant,
and empiric TB therapy seemingly has a strong protective effect. Given the likelihood of
confounding, arising partially from difficulties in the logistic regression modelling strategy I
have used, this latter conclusion should remain speculative. In the next chapter, I extend
the modelling presented here to attempt to address the problems I have identified.
Notwithstanding the next chapter of this thesis, some further work is planned.
• 49% of the cohort still have no diagnosis, and further testing for leptospirosis, rick-
ettsioses and arboviruses in the first instance, using acute and convalescent sera is
underway.
• The reason for the low prevalence of TB BSI in combination with a high prevalence of
urine LAM positivity is unknown, and running Xpert ultra on stored blood samples
may help to understand if there were technical problems with the mycobacterial blood
cultures.
• Fluid administration in sepsis in sSA is clearly complex, and longitudinal modelling
of response to fluid over the first six hours of hospital admission in this cohort is
planned.
Chapter 4
Modelling to identify determinants
of sepsis mortality
4.1 Chapter overview
In this chapter I develop the mortality models from Chapter 3 to address difficulties arising
from the problems of separation, overparametrisation, collinearity and missing data. I use
Bayesian logistic regression following multiple imputation of missing data and dimensionality
reduction using factor analysis of mixed data (FAMD), to show that, broadly, inferences
from the original models are sound: well recognised markers of severity were associated
with death. In terms of treatment determinants of outcome, the association of receipt of TB
therapy with survival persisted across all models. In contrast to high-income settings, there
was no clear association between more rapid administration of antibacterials or volume
of intravenous fluid administered and survival, though in both cases the 95% credible
intervals of effect size incorporated a clinically significant effect. A subgroup analysis using
a propensity-score approach suggested that the association of TB therapy with survival was
strongest in immunosuppressed and/or anaemic participants, though numbers were small
and confidence intervals wide. The role of early administration of TB therapy in septic
adults in Malawi is unknown, though the analyses here suggest a potentially significant
impact, and, I suggest, contribute to the equipoise necessary for clinical trials.
4.2 Introduction and chapter aims
In Chapter 3, I used classical epidemiological approaches to identify associations with
mortality in sepsis in Malawi, however there were some problems with the approaches used,
both technical and conceptual. The technical issues are: that the model may include too
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many parameters and be overfit; that a complete-case analysis was undertaken which can
introduce bias; that included variables may be collinear which can contribute to increased
variance in parameter estimates; and, perhaps most importantly, some parameters perfectly
predicted outcome and so were excluded from the model. Conceptually, I argue that it is
difficult to interpret parameters without first making explicit the causal model for data
generation. I will cover each of these points below, before describing the techniques I used
to address them.
First, the model may be overfit. Adding covariates to a model may reduce bias in parameter
estimates but will increase variance (the so called bias-variance trade off[311]) which may
make interpretation difficult. More parameters in a model results in a better fit to the data,
but an overfit model may end up fitting to noise, rather than identifying the true data-
generating process, and so would have biased inferences and poor out of sample prediction.
Rules of thumb based on ~ 10 outcomes per included predictor have been suggested[309],
but the process of selecting variables to include is difficult with no consensus as to how
it should be achieved. Common approaches include stepwise inclusion strategies, where
variables are sequentially added or removed based on some criteria of model fit or statistical
significance, but these can introduce significant bias. This is because the statistics used to
test the parameters (and generate confidence intervals around effect sizes) are based on an
assumption that a single hypothesis is being tested, an assumption which is violated by the
stepwise model building process. It can be shown that standard errors are too small, that
p-values are biased towards zero and parameter estimates biased away from zero[309].
How, then, to select variables to include in the models presented here? A priori selection
of variables for theoretical reasons is likely ideal, but this becomes difficult when there are
a large number of potentially important predictors, as variance in parameter estimates may
be increased. Dimensionality reduction techniques (such as principal components analysis)
or shrinkage methods (lasso or ridge regression) have been suggested as alternative predictor
variable selection techniques[309,311,312]. I use a dimensionality reduction technique called
factor analysis of mixed data[313] (FAMD) and compare out-of sample prediction (using
cross validation) of models built using this technique to the original model - see methods,
below.
A further problem in modelling mortality in studies of sick inpatients is collinearity, where
some predictor variables can be predicted with high accuracy by other predictor variables.
For example, shocked patients are likely to have elevated lactate, low blood pressure,
low bicarbonate, and high heart rate and so uncertainty in parameter estimates becomes
very large (or the parameters are unidentifiable) when these are all entered a regression
model together[314]. An advantage of principal-components type dimensionality reduction
(including FAMD) is that they can solve this problem by generation new coordinate systems
that are constrained to be orthogonal. Missing data bias too can be significant; I address
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this by using multiple imputation by chained equations where new values for each missing
data point are generated by models based on all other data[315].
The final technical modelling challenge to overcome is the phenomenon of separation, where
some covariates perfectly predict outcome[314]. In the maximum likelihood framework
(the method usually used to fit logistic regression models) the parameter estimates for
such covariates are non identifiable (essentially infinite), and hence the covariates are often
excluded from the model, even though they are often very strong predictors of outcome. I
use Bayesian logistic regression with weakly informative priors to overcome this problem. In
the Bayesian modelling framework, probabilities encode our belief about parameter values,
rather than encoding a long-term expectation of parameter estimates following multiple
samples from a population, as in the frequentist framework. Probability distribution of
parameters are generated from a combination of the data and a prior probability distribution,
quantifying our belief about the parameter values prior to seeing the data. To overcome the
problem of separation, Gelman et al [316] suggest using our belief that very large or very
small parameter estimates (e.g. an odds ratio of 100) are unusual, which is encoded as a
prior with a student’s t distribution with 3 degrees of freedom, centre zero and scale 2.5. In
the broadest sense, this is a distribution not dissimilar to a normal distribution, but with
longer tails: we think that the parameters will be close to 0, but allow a chance they may
be larger. In effect, this pulls the infinite parameter estimates from the data closer to 0.
Even if the parameters of the regression can be correctly specified, however, correct
interpretation of predictor effects is often difficult or impossible without a clear hypothesised
causal structure. For example, consider a hypothesised causal structure of death in sepsis in
Figure 4.1, which I express as a directed acyclic graph (DAG); nodes represent collections
of variables which theoretically specify host status (age, sex, immune status including
HIV status and CD4 cell count), infection type (e.g. causative pathogen, site), disease
severity (e.g physiological variables quantifying shock, hypoxia etc.), therapies administered,
and outcome. Arrows (called edges in the DAG framework) show causality: host status
influences infection (e.g. TB is more common in HIV) and severity (patients with advanced
HIV may have more severe infection), for example, and therapies administered is likely to be
influenced by disease severity (perhaps sicker patients receive antimicrobials more quickly),
host status (clinicians are likely to administer different therapies to HIV-infected patients),
and infection type. A standard analysis of sepsis would construct a predictive multivariable
model for death by including factors which the analyst felt likely to be associated with
mortality, which would usually include HIV status, CD4 cell count, physiologic variables
(such as presence of shock) and infection variables (e.g. presence of bloodstream infection
[BSI]). The effects of the predictor variables are often then interpreted as the independent
effect of the included predictors, after controlling for all others; however, this may not be
the case.
128 CHAPTER 4. SEPSIS OUTCOME MODELS
For example, severity is at least in part a mediator of the effect of HIV on outcome, so the
interpretation of the coefficient of HIV in such a model is the residual effect of HIV once
disease severity is accounted for. It is likely that there are direct effects of host and infection
factors on outcome (dotted edges in Figure 4.1), not least because measured variables in a
study are unlikely to wholly quantify disease severity, but if not then controlling for disease
severity will completely remove the effect of HIV status on mortality, which may not be
the analysts intention, or interpretation of parameters. This has been called the “Table
2 fallacy”[310]. It is important therefore to clearly define the effect that is being sought
from an analysis (e.g. the effect of HIV status on mortality) and to ascertain which factors
need to be controlled for based on this. It may be that a number of different models are
necessary to estimate parameters of interest, if more than one parameter is of interest.
The causal inference framework provides tools to do this using DAGs[317], and the dagitty
package in R[318] automates this framework so, when provided with a DAG, it can output
the variables that must be conditioned upon to estimate the causal effect of an exposure
on an outcome. In this chapter, therefore, I am clear that the aim of the analysis is to
provide an estimate of the effect of treatments administered on mortality; the class of
antimicrobial administered (antibacterial, antifungal, antimycobacterial or antimalarial)
as well as the time-to-antimicrobial for different classes, and the volumes of intravenous
fluid administered. This will inform the overarching aim of the thesis - to develop novel
antimicrobial strategies for sepsis in sSA to improve outcomes.
4.3 Methods
Assuming the causal model in Figure 4.1, an estimation of the effect of administered
treatment will require correcting for (or conditioning on) host, infection, and severity
variables (assuming a direct effect of infection and host on outcome, as seems likely) i.e. all
the variables that were included in the logistic regression model in Chapter 3. To solve
the problem of nonidentifiability of the models including malaria and meningitis status, I
refit the models in a Bayesian framework with weakly informative priors. All continuous
variables were scaled to have mean 0 and standard deviation 1, and a student’s t distribution
centred on 0 with three degrees of freedom and a scale of 2.5 was used as the prior for
all parameters, following Gelman et al[316]. The model was fit using the brms package
in R[319], which acts as a front end to the Stan probabilistic programming language[320].
Four Markov-chain Monte-Carlo (MCMC) chains each with 1000 iterations and a burn-in
of 500 iterations were used with default brms settings. Convergence was assessed using
traceplots and assessing for autocorrelation using the Gelman-Rubin diagnostic (R̂) with








Figure 4.1: Hypothesised causal structre of death in sepsis. Host factors (e.g. age, sex, immune status)
influence the type of infection; disseminated TB is more common in HIV, for example. Severity
(variables quantifying e.g. shock or respiratory failure) is influenced by infection type and host
factors. Therapy encodes which antimicrobials were administered and rapidity of administration of
antimicrobials, and is influenced by disease severity (sicker patients may be given different therapies),
host factors (HIV status may influence treatment) and the infection type (for example, malaria
rapid diagnostic tests influenceing rapidity of malaria treatment). Dotted edges from host and
infection to outcome are because it is not clear a priori whether the effect of infection and host
factors are entirely mediated by disease severity: in fact, even if this were the case in a theoretical
sense, the available severity variables are unlikley to completely account for the causative effect of
infection type on mortality and so conditioning on all available severity variables is likely to leave
some residual causative effect of infection type. See text for further discussion.
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To correct for missing-data bias, missing data were imputed using multiple imputation of
chained equations using default settings in the mice package in R[321], with each missing
variable predicted by all other missing variables n the model, to produce 5 imputed datasets.
Models were fit using brms and then pooled parameter values calculated by taking medians
and 95% confidence intervals of pooled posterior parameter estimates from all imputed
datasets. The parameter estimates from complete-case analysis and multiple imputation
are both presented.
One of the concerns of this model is that it is overfit - that is, there are so many parameters
that it will fit to noise in the data rather than to the true data-generating process. To
assess whether this was the case, I performed dimensionality reduction to collapse the
predictor variables into a smaller number of variables, refit models using these variables,
and then compared all models predictive ability using leave-one out cross validation. The
dimensionality reduction technique that I used was factor analysis of mixed data (FAMD)
from the FactoMineR package in R[313]. This technique uses principal component analysis
(PCA) for continuous variables and multiple correspondence analysis (MCA) to generate a
new orthogonal coordinate system which maximises explained variance in each FAMD axis.
FAMD axis one therefore explains the most variance in the dataset, followed by FAMD axes
2 and 3, and so on. As well as reducing the dimensionality of the dataset, this technique
has the advantage of ensuring an orthogonal coordinate system to tackle the problem of
collinearity. The raw covariate values were used to generate these new coordinate system.
Because the exposures of interest are the therapies administered to the participants in
the study, treatment variables (receipt of antibacterials, antifungals, antimalarials, an-
timycobacterials, and IV fluid) were left untransformed. These variables and a number
of transformed FAMD variables (ranging from 1 to 5) were used as predictors in new
models to predict death by 28 days. The out of sample predictive ability of the models was
assessed by performing leave-one-out cross validation using the loo package in R[322]. This
estimates the out-of sample predictive ability of the model by estimating a quantity called
the expected log predictive density (ELPD) essentially the logarithm of the likelihood for
a new, unseen dataset conditional on the current data. This quantity is estimated using
leave-one-out cross validation to produce and estimate of the ELPD, hereafter referred
to as ELPDloo. The standard error of ELPDloo for a model is also calculated and so
two models can be compared by comparing the ELPDloo difference and standard error;
if the difference is greater than twice the standard error (i.e. a 95% confidence interval,
assuming normality) we can be confident that one model would be expected to have greater
out-of-sample predictive ability than the other[322].
The relationship between time-to-antimicrobials and mortality was assessed, initially in
bivariate associations using nonparametric locally estimated scatterplot smoothing (LOESS)
regression which performs a rolling linear regression[323] and estimates the probability of
4.4. RESULTS 131
death by 28 days as a function of the predictor variables. Only for antibacterials were there
sufficient data to construct regression models which used time to antibacterial therapy as a
predictor for death by 28 days, alongside the other treatment variables and the first three
FAMD dimensions. In view of possible nonlinear relationship between time to therapy and
death apparent in the bivariate plots both linear and second-order polynomial models were
fit. Coefficient estimates are presented, but because interpretation of polynomial coefficients
is challenging, predicted probability plots with 95% credible intervals with the levels of
the other covariates set to their mean values were plotted, using all the posterior draws to
generate the median prediction and 95% credible intervals.
Finally, to attempt to correct for confounding using a different method, a propensity-score
matching approach was used to produce an unbiased estimate of the effect of receipt of
TB therapy on 28-day mortality. Variables that had been identified as being associated
with mortality from the models described above, along with variables that were associated
with receipt of TB therapy apparent on bivariable analysis were included in a (maximum-
likelihood fit) logistic regression model to generate a propensity score. Because HIV-
uninfected participants did not have a CD4 count measured, a new dichotomous variable
was used which was coded as 1 for HIV-infected participants with a CD4 count below 100
cells µL−1 and 0 for everyone else. The variables used to generate the propensity score
were therefore: haemoglobin, HIV status, CD4 count, respiratory rate, oxygen saturations,
inability to stand, diagnosis of BSI, diagnosis of TB, diagnosis of meningitis, diagnosis of
malaria, bicarbonate, and heart rate. Participants were then matched 1:1 on this propensity
score without calliper restriction using the MatchIt package in R[324] and the distribution
of covariates in this new cohort examined using kernal density plots. Effect of TB therapy
on mortality was then expressed as risk ratios, and subgroup analysis carried out to explore
whether there was any effect modification of the apparent effect of TB therapy in advanced
immunosuppression (defined as CD4 cell count below 100 µL−1), or anaemia (defined as
haemoglobin below 8g dL−1) or confirmed TB.
4.4 Results
Bayesian logistic regression with weakly informative priors succeeding in fitting the models
from Chapter 3, where a maximum likelihood approach had failed; the inferences - particu-
larly concerning the apparent association between TB therapy and survival - were largely
unchanged, including after multiple imputation of missing data (Table 4.1). Because of
concerns about overfitting, dimensionality reduction with FAMD was carried out; the first
four FAMD dimensions explained 42% of the variance in the dataset, a not inconsiderable
amount for 21 predictor variables. The composition of FAMD dimensions one, two, three
and four are shown in Figure 4.2. FAMD dimensions 1 (explaining 14% of the total variance
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of the dataset) was composed primarily of variables that were associated with shock (urea,
lactate, low MAP and bicarbonate, and creatinine) and HIV-associated immunosuppres-
sion (HIV status and haemoglobin); FAMD dimension 2 was similar but included organ
dysfunction criteria that were orthogonal to FAMD 1: low oxygen saturation and platelet
count, and male sex. FAMD 3 was composed of absence of malaria, low GCS, high white
cell count and inability to stand; FAMD 4 with young age, fever, and tachycardia.
Table 4.1: Unadjusted and adjusted odds ratios of death by 28 days in sepsis from Bayesian logistic




Age (per 5 years increase) 0.92 (0.66-1.25) 0.87 (0.65-1.14)
Male sex (vs female) 0.91 (0.22-3.51) 0.67 (0.18-2.36)
HIV Infected (vs uninfected) 0.21 (0.03-1.22) 0.32 (0.06-1.59)
Haemoglobin (per g dL-1) 0.71 (0.54-0.91) 0.69 (0.52-0.90)
Severity Variables
Temperature ( per °C) 0.72 (0.30-1.73) 0.56 (0.26-1.18)
Heart rate (per 10 min-1) 1.20 (0.87-1.72) 1.14 (0.85-1.57)
Mean arterial BP (per 10 mmHg) 1.20 (0.73-1.93) 1.14 (0.70-1.80)
Respiratory rate (per 10 min-1) 0.25 (0.08-0.66) 0.38 (0.16-0.88)
Oxygen saturation (per 5%) 0.73 (0.48-1.11) 0.67 (0.45-0.99)
GCS (per 1 unit) 0.76 (0.50-1.12) 0.75 (0.51-1.10)
Unable to stand 13.79 (2.88-74.50) 13.64 (3.35-64.82)
Lactate (per 1 mmol L-1) 1.12 (0.91-1.39) 1.13 (0.92-1.41)
White cell count (per 1x109 L-1) 0.96 (0.84-1.07) 0.94 (0.83-1.05)
Platelet count (per 100x109 L-1) 1.13 (0.70-1.78) 0.94 (0.60-1.43)
Bicarbonate (per 1 mmol L-1) 0.97 (0.81-1.17) 0.95 (0.81-1.11)
Urea (per 1 mmol L-1) 1.20 (1.00-1.45) 1.17 (1.00-1.37)
Creatinine (per 10 mmol L-1) 0.99 (0.92-1.08) 0.99 (0.93-1.08)
Diagnosis
BSI (vs no BSI) 0.04 (0.00-0.48) 0.04 (0.00-0.40)
TB (vs no TB) 1.12 (0.25-5.00) 0.72 (0.18-2.69)
Malaria (vs no malaria) 0.01 (0.00-2.27) 0.00 (0.00-0.41)
Meningitis (vs no meningitis) 68.53 (1.29-27384.82) 37.00 (1.03-6237.92)
Treatment Received
Received antibacterial (vs none) 8.38 (0.20-6631.38) 1.46 (0.10-30.00)
Received antifungal (vs none) 1.39 (0.23-8.60) 1.19 (0.24-5.65)
Received antimalarial (vs none) 0.03 (0.00-8.68) 0.08 (0.00-13.22)
Received antimycobacterial (vs none) 0.11 (0.02-0.58) 0.12 (0.02-0.56)
IV fluid (per L) 0.82 (0.29-2.21) 0.79 (0.31-1.98)
Note:
CCA = Complete case analysis, BP = Blood pressure, GCS = Glasgow coma scale,
BSI = Bloodstream infection, TB = tuberculosis. All odds ratios are for as increase in
the variables shown.
Graphically, FAMD dimensions one (and perhaps two) appeared to show an association
with mortality (Figure 4.3), which was confirmed on logistic regression modelling. The first
5 FAMD dimensions were used to fit models predictive of death by 28 days, along with
untransformed treatment variables; the primary interest here was to see if the apparent

































































































































































































































































Figure 4.2: Composition of FAMD variables 1-4. FAMD uses both principal coordinate analysis
(PCA) and multiple correspondence analysis (MCA) to generate new orthognal coordinates. A and
e show projections of the original variables into the new PCA space to show, for example, that a
higher haemoglobin is associated with smaller (more negative) values of FAMD dimension 1. B and
F show the positions of the categorical variable values in MCA coordinate space. C-D and G-H
show the composition of the FAMD dimensions 1-4 in terms of the untransformed variables. Cr =
serum creatinine, CO2 = serum bicarbnate, gcs = Glasgow coma scale, Hb = haemoglobin, HR
= heart rate, Malaria = diagnosis of malaria, MAP = mean arterial blood pressure, Meningitis =
diagnosis of meningitis, Plt = platelet count, ptsex = sex, RR = respiratory rate, SpO2 = capilliary
oxygen saturation, temp = temperature, TB = diagnosis of TB, WCC = white cell count.
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Figure 4.3: Individuals plotted in FAMD space projected onto FAMD dimensions 1 and 2 (A) or 3
and 4 (B) with patients who died by 28 days coloured red. There is an apparent correlation between
higher values of FAMD dimensions 1 and perhaps 2 with death (more red points in the upper right
quadrant)
was to provide estimates of association of FAMD dimensions with death. Five models were
fit using one, two, three, four or five FAMD dimensions; parameter estimates from these
models are shown in Figure 4.4A, along with the parameter estimates form the original
model using all, untransformed, parameters. Parameter estimates from treatment variables
were largely unchanged across all models, though uncertainty was markedly increased in the
original models. Nevertheless, inferences were largely unchanged: we can be confident only
that the odds ratio of the effect of TB treatment is different to zero. FAMD dimensions one
was strongly associated with mortality; FAMD dimensions two and three less so. FAMD
dimensions 4 and 5 showed no convincing association; in fact, FAMD dimension 4 seemed,
if anything, protective, though 95% credible intervals of odds ratios crossed 1.
The out-of-sample predictive ability of the models was assessed using the expected log
predictive density (ELPD) estimate form leave one out cross validation. In absolute terms,
all FAMD models greater ELPD than the original model but any differences were small
compared to the standard error of the ELPD estimate. We can not be confident that any
model has different out of sample predictive accuracy and therefore can be as confident in
the parameter estimates form the original (untransformed) model as any other.
4.4.1 Exploring time-to antibacterials and IV fluid as determinants of
mortality
Exploration of bivariate associations of mortality with time to antimicrobials and volume of
intravenous fluid received are shown in Figure 4.5, where LOESS moving linear regression
provides a nonparametric estimate of probability of death by 28 days as a function of
treatment variables. Time to antimalarial therapy is not shown in this plot as no patient
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Figure 4.4: Modelling the effect of reciept of different treatments following dimensionality reduction
with factor analysis of mixed data (FAMD). A (Top) shows parameter estimates for treatment
variables only from the original imputed model using all raw covariate values. Models 1-5 use
the first 1,2,3,4 or 5 transformed dimensions from FAMD. Parameter estimates and inferences are
essentially unchanged, though there is less uncertainty generally in the estimates from the FAMD
models. This would be expected as fewer parameters with less collinearity, are used. B (bottom)
shows the estimated ELPD (expected log predictive denisty) from leave-one out cross validation from
all the models, along with the standard error of the estimate. This is a measure of out of sample
predictive accuracy: bigger (less negative) is better. One of the concerns of the original model is
that it is overfit and so would have poor ELPD. In absolute terms this is true but the magnitude of
the difference is much less than the standard error, meaning that out of sample prediction for all
the models is broadly similar, giving confidence in the original model inferences.
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apparent effect on 28 day mortality (Figure 4.5A). It might be expected that any effect
would be most apparent in participants with shock: stratifying the analysis by shock
(defined as mean arterial blood pressure below 75mmHg, Figure 4.5B) once again showed
no apparent relationship. Neither time to antimycobacterial or antifungal therapy showed
any apparent association though confidence intervals are wide (Figures 4.5C and D).
There was no apparent relationship between time to antibacterials and 28 day mortality
up to around 40 hours, when there was a suggestion of an increased probability of death
(Figure 4.5E). To explore this further, I used a logistic regression analysis, including only
patients who received antibacterials (n = 207) using both linear models, fitted in a Bayesian
framework as before (and following imputation of missing data), and, in view of a possible
nonlinear effect, second order polynomial models. Model three from the analysis above
was used (incorporating the first three FAMD dimensions), as the best fitting model. The
estimates of the coefficients of the linear model is shown in Table 4.2 and the predicted
probability of death by 28 days shown in Figure 4.5. In both cases it is not possible to fully
rule in or out an effect of antibacterial delay. The 95% credible interval of the adjusted
odds ratio for death per hour of antibacterial delay from the linear model crossed one
(aOR 1.01 95% [CrI 0.98-1.04]) though incorporated a clinically relevant effect size, and the
uncertainty in predictions from the polynomial of a late nonlinear effect of antibacterial
delay are so wide that it is not possible to draw any conclusions.
Table 4.2: Adjusted odds ratio of death by 28 days per hour delay in antibacterials
Variable aOR (95% CrI)
Time to antibacterials (per hour) 1.01 (0.98-1.04)
IV fluid (per L) 0.65 (0.36-1.16)
Received antimalarial (vs none) 0.02 (0.00-1.37)
Received antifungal (vs none) 1.03 (0.28-3.49)





The variables famd1,2 and 3 are the three trans-
formed dimensions following dimensionality reduc-
tion using factor analysis of mixed data that account
for the most variability in the dataset.
4.4.2 Propensity score matching and subgroup analysis
Finally, I used propensity score matching, a different method to attempt to generate
unbiased estimates of the effect of receipt of TB therapy on mortality. First I examined
bivariate associations of receipt of TB therapy (Table 4.3 in the chapter appendix). Patients
who received TB therapy were almost all HIV-infected (88% [46/52] vs 60% [95/161],
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Figure 4.5: Associations of IV fliud volume and time-to-antimicrobials with death by 28 days. A-E
show nonparametric regression (LOESS) of outcome (with death coded as 1 for died and 0 for
survived) against various covariates; the regression line can be interpreted as the probability of
death by 28 days and can be used to assess for a bivariate relationship and also the nature of
any relationship (i.e. linear versus nonlinear). A: IV fluid (L), B: IV fluid stratified by presence
or absence of shock (defined as MAP < 75mmHg), C: Time to antimycobacterials, D: Time to
antifungals E: Time to antibacterials, with a possible late, nonlinear relationship. F: Models of
time-to-antimicrobials as a predictor of mortality considering time-to-antibacterials to have a linear
or second order polynomial effect. In both cases the uncertainty in the effect is such that there is no
convincing relationship. Overall, there is no convincing relationship between any of these variables
and death by 28 days.
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cells µL-1, between group difference 63 [15-142] cells µL-1) and haemoglobin (median 9.7 vs
11.1 g dL-1, between group difference 1.4 [95% CI 0.5-29] g dL-1), with higher heart rate
(median 125 vs 120 min-1 difference 5 (1-13) -1) and lower bicarbonate (18 vs 20 mmol L-1
difference 2 (0-3) mmol -1) though most of these associations would be expected to pull an
estimate of the mortality effect of TB therapy towards the null, rather than inflate an effect
size. More patients with a positive diagnostic test for TB received TB therapy, as might be
expected (53% [28/53] of those receiving TB therapy had a positive diagnostic test for TB,
versus 28% [48/172] not receiving therapy, difference 25% (95% CI 9-41%)), though almost
all the TB treatment was empiric, as the treating clinicians did not have access to urinary
LAM results (which were batch processed on frozen urines) or mycobacterial blood culture
results (which take up to 6 weeks to become positive).
Factors associated with receipt of TB therapy on univariate analysis (HIV status, CD4
count, haemoglobin, diagnosis of TB, heart rate, and bicarbonate) and factors associated
with mortality from the models presented above (haemoglobin, respiratory rate, oxygen
saturation, inability to stand, bloodstream infection and diagnosis of malaria) were used
as predictors in a logistic regression to predict receipt of TB therapy. Predictions from
this model were used to generate a propensity score for each participant, and then each
participant who received TB therapy was matched with one participant who did not to
generate a new cohort, with better matching of covariates (Figure 4.7). The propensity-
score adjusted risk ratio of survival to 28 days in this cohort upon receipt of TB therapy
was 1.22 (95% CI 1.03-1.46), similar to the unadjusted estimate (Figure 4.6). Mortality
benefit seemed higher in the immunosuppressed and anaemic in absolute terms, though
with significant uncertainty in the estimates (Figure 4.6): RR 1.59 (95% CI 1.02-2.50) in
those with haemoglobin below 8g dL−1 compared to 1.09 (95% CI 0.92-1.30) above 8g dL−1;
1.42 (95% CI 1.04-1.93) in those with a CD4 cell count below 100 cells µL−1 compared to
1.04 (95% CI 0.89-1.22) above. Mortality benefit was also higher in those with a confirmed
diagnosis of TB: RR 1.30 (95% CI 1.00-1.70) in those with confirmed TB compared to 1.13
(95% CI 0.90-1.43) without.
4.5 Discussion
I have presented, in this chapter, an analysis using a number of statistical techniques to
further explore the associations of mortality in this cohort, and to address the difficulties
encountered with the modelling strategies presented in Chapter 3. In addition I have
presented an explicit hypothesised causal structure of death to facilitate a causal inter-
pretation of the model parameters. In Chapter 3, maximum likelihood fitting of logistic
regression models was potentially biased because some predictors were perfectly associated
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Figure 4.6: Subgroup analysis of effect of TB therapy on mortality. A (Top) shows crude (unadjusted)
risk ratio for survival to 28 days; RR > 1 favours TB therapy, RR < 1 favours no TB therapy.
A significant effect is seen in the immunosupressed, anaemic, and to a lesser extent, those with a
confirmed diagnosis of TB. B (Bottom) shows the same analysis for the propensity-score matched
cohort, showing that the overall and subgroup effects are essentially unchanged, though uncertainty
in parameter values is greater.
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using Bayesian logistic regression with weakly informative priors. As expected, malaria
and meningitis were strongly associated with survival and death, respectively, but more
importantly inferences from the model were largely unchanged once these strong predictors
were included in the model. The strong association of TB therapy with survival persisted.
Unexpectedly, bloodstream infection showed a protective effect; given S. Typhi was the
commonest bloodstream infection isolate, which is associated with a low mortality in the
Blantyre context (2.5% since 2011[325]), this is certainly plausible.
To address the concern that a model with so many parameters might be overfit, I performed
dimensionality reduction with FAMD and refit the models using transformed predictor
variables. As might be expected in absolute terms the out of sample predictive accuracy
(as measured by ELPD) improved, but by an amount much less than the error in the
estimation of ELPD. This supports the inferences from the original model. In addition, the
composition of the transformed FAMD variables provides some insight into the presentation
of sepsis in Blantyre, and their effect on outcome. Though the situation is clearly complex,
the composition of the FAMD variables seems to suggest a number of different organ
dysfunction syndromes: shock with HIV immunosuppression (FAMD axis one); renal failure
with low oxygen saturations (FAMD axis two); low GCS with high white cell count (FAMD
axis three); and tachycardia and fever with young age (FAMD axis four). FAMD axes one
is strongly associated with death, and FAMD axes two and three more weakly associated.
This is in keeping with what is known about sepsis - that sepsis severity, quantified by
organ dysfunction, is a major determinant of outcome - but provides a hint that organ
dysfunction syndromes may cluster together and, in the case of FAMD 1, that the shock
syndrome clusters with HIV status. The dataset is too small for such inferences to be
robustly drawn, but this clinically plausible: the presentation of pneumonia is different
from meningitis, for example, in terms of organ dysfunction, and machine learning and
clustering techniques applied to large datasets are beginning to identify different sepsis
phenotypes[326]. The clinical utility of this remains to be seen.
As described in Chapter 3, time-to-antibacterials is thought to be one of the major modifiable
determinants of death in sepsis in high-income settings, but in a crude (unadjusted) analysis
there was no signal that this was the case in this cohort. I have expanded that analysis here,
and adjusted for putative confounders, but the findings are unchanged. Fitting a logistic
regression model and modelling time-to-antibacterials with a linear effect (and adjusting
for confounders) found an adjusted odds ratio of 1.01 for death per hour delay with a 95%
credible interval (95% CrI 0.98 - 1.04) that includes a clinically relevant effect size (i.e. the
aOR of 1.04 [1.02-1.05] from the large observational study of sepsis care in New York[7]).
There was a some suggestion from the raw data that a lengthy delay in antibacterials
could be associated with an increase in mortality, perhaps with a late nonlinear effect;
however the estimates from a nonlinear (second order polynomial) model had such high
uncertainty that it is not possible to draw any firm conclusions. The analysis I present
4.5. DISCUSSION 141
here, therefore, is consistent both with time-to-antibacterials having a similar effect on
outcome as in high-income settings, and with no effect. Larger studies would be needed to
distinguish these two scenarios. Similarly, uncertainties in estimates of effect of IV fluid
administration are such that the estimates could contain a clinically relevant effect, and
the analysis presented here does not advance the conclusions drawn in Chapter 3.
The protective effect of TB therapy remains significant and robust to correction for the
putative confounders included in the analyses presented here. Using two techniques - logistic
regression and propensity score matching - results in the same conclusions: that receipt
of TB therapy was associated with survival in this cohort. The effect size of receipt of
TB therapy (aOR 0.17 (0.03-0.74) is greater than the effect of antibacterial delay, even
in high income settings, highlighting the fact that determinants of mortality in sepsis are
likely to be different in sSA. Subgroup analysis found that the effect is perhaps driven by a
mortality benefit in the immunosuppressed and/or anaemic, and the effect size in these
subgroups was greater than in those with a diagnosis of TB, albeit with wide confidence
intervals. If true, this would suggest that there is a benefit to empiric TB therapy outside
those in whom a diagnosis of TB has been made in this study, and could contribute to the
equipoise needed to consider clinical trials of empiric TB therapy in sepsis in sSA. This
tentative suggestion (numbers are small and confidence intervals wide) is dependent on
the diagnostic accuracy of any tests used; the recently developed fujiLAM urinary LAM
test shows significantly higher sensitivity than the Alere LAM test used here[327], which
could negate the benefit of empiric TB therapy, but would in turn present a powerful point
of care triage tool that would permit targeted treatment of disseminated tuberculosis at
presentation.
4.5.1 Limitations
I have used a number of techniques to account for confounding, but this will only address
the included variables; it is very likely that there are unmeasured confounders, and these
could seriously bias the conclusions drawn. This is certainly possible, but any confounder
that acted to produce a spurious association between TB therapy and survival would have
to be associated with both TB therapy and survival. It seems likely that the clinicians
looking after the participants in this study would be more likely to treat sicker patients
with TB therapy, and produce bias in the opposite direction. Nevertheless, unmeasured
confounders are just that - unmeasured - and it is not possible to address this question
with the data here, though this is of course true of any similar study. Given that almost
all the participants who received TB therapy were HIV-infected, all conclusions regarding
this should be largely be applied to people living with HIV; it is not clear (and perhaps
unlikely) that the associations described here would also be present in the HIV-uninfected.
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I have made an attempt to put the modelling here in the framework of causal inference. If
the hypothesised causal framework presented above was right and I had truly adjusted for
all confounders, then the estimates of effect I present would be true causal effects. In fact
this is unlikely: both because of unmeasured confounders, and that the causal pathways
I have hypothesised are almost certainly a oversimplification. I have made choices about
inclusion of variables both in the logistic regression and propensity score analysis which
could also introduce bias.
4.6 Conclusions and further work
In conclusion, the findings from the modelling work in Chapter 3 are largely unchanged
when the models are expanded to address possible bias from excluding parameters due
to separation, missing data bias, and overfitting. I have identified major associations of
mortality in terms of causative pathogen, disease severity, and therapy delivered. Malaria
and meningitis are strongly associated with survival to and death by 28 days respectively;
BSI seems to be associated with survival to 28 days. Well-recognised markers of disease
severity are associated with death: shock, hypoxia, and inability to stand. The FAMD
analysis is suggestive that different types of organ dysfunction tend to cluster together. The
major association between treatments received and survival is the receipt of TB therapy,
in contrast to high income settings where time to antibacterials is the major determinant
of survival. The association is stronger in those who are anaemic and immunosuppressed.
This is a finding that deserves further exploration; the place of early TB therapy in the
treatment of HIV-infected participants with sepsis is unknown, but the data presented here
may contribute to the equipoise needed for clinical trials.
4.7 Appendix
Below I show bivariable associations of receipt of TB therapy and variable distributions of







Table 4.3: Bivariable associations of receipt of TB treatment in sepsis
Variable TB treatment No TB treatment Difference (95
Host Variables
Age (years) 37.7 (32.5-42.9) 35.6 (26.8-43.6) -2.2 (-5.3 to 2.5)
Male sex 30/53 (57%) 84/172 (49%) -8% (-24 to 9%)
HIV Infected* 46/52 (88%) 97/161 (60%) -28% (-41 to -15%)
Taking ART† 35/46 (76%) 82/97 (85%) 8% (-7 to 24%)
CD4 count† (µL-1) 60.0 (26.2-114.8) 123.0 (39.0-274.0) 63.0 (15.0 to 140.5)
Haemoglobin (x109 g dL-1) 9.7 (7.4-11.3) 11.1 (8.6-13.9) 1.4 (0.5 to 2.9)
Severity Variables
Temperature (°C) 38.5 (38.0-39.2) 38.4 (37.9-39.0) -0.1 (-0.4 to 0.2)
Heart rate (min-1)) 125.0 (110.0-134.0) 119.5 (99.8-132.0) -5.5 (-13.0 to -0.5)
Systolic BP (mmHg) 92.0 (81.0-107.0) 99.0 (86.0-120.0) 7.0 (-3.0 to 12.5)
Diastolic BP (mmHg) 67.0 (56.0-71.0) 65.0 (57.0-78.8) -2.0 (-5.0 to 4.0)
Mean arterial BP (mmHg) 76.0 (65.3-83.7) 77.2 (65.1-91.2) 1.2 (-5.0 to 8.3)
Respiratory rate (min-1)) 34.0 (30.0-38.0) 34.0 (32.0-37.0) 0.0 (-2.0 to 2.0)
Oxygen saturation (%) 96.0 (94.0-98.0) 96.0 (95.0-98.0) 0.0 (-1.0 to 1.0)
GCS 15.0 (15.0-15.0) 15.0 (15.0-15.0) 0.0 (0.0 to 0.0)
Unable to stand 13/53 (25%) 50/172 (29%) 5% (-10 to 19%)
Lactate (mmol L-1) 3.2 (2.4-4.9) 3.4 (2.2-5.3) 0.2 (-0.9 to 0.8)
White cell count (x109 L-1) 6.4 (4.6-9.1) 6.6 (4.3-11.7) 0.2 (-1.3 to 1.8)
Platelet count (x109 L-1) 225.5 (146.8-303.2) 215.0 (145.0-296.0) -10.5 (-65.0 to 21.0)
Bicarbonate (mmol L-1) 18.0 (16.0-21.0) 20.0 (17.0-22.5) 2.0 (0.0 to 3.0)
Urea (mmol L-1) 5.0 (3.8-8.7) 4.6 (3.3-7.7) -0.4 (-2.0 to 0.3)
Creatinine (mmol L-1) 76.0 (59.0-105.0) 75.5 (59.0-102.2) -0.5 (-14.0 to 11.0)
Diagnosis
BSI 4/53 (8%) 20/172 (12%) 4% (-6 to 14%)
TB 28/53 (53%) 48/172 (28%) -25% (-41 to -9%)
Malaria 6/53 (11%) 15/172 (9%) -3% (-13 to 8%)
Meningitis 1/53 (2%) 3/172 (2%) 0% (-4 to 4%)
No diagnosis 15/53 (28%) 96/172 (56%) 28% (12 to 43%)
Treatment Received
Antibacterials 47/53 (89%) 160/172 (93%) 4% (-6 to 15%)
Time to Antibacterials (hr) 5.1 (3.8-9.7) 5.4 (3.6-13.4) 0.3 (-2.1 to 1.4)
Antifungals 8/53 (15%) 18/172 (10%) -5% (-17 to 7%)




















Table 4.3: Bivariable associations of receipt of TB treatment in sepsis (continued)
Variable TB treatment No TB treatment Difference (95
Antimalarials 6/53 (11%) 6/172 (3%) -8% (-18 to 2%)
Time to Antimalarials (hr) 4.5 (3.0-11.7) 12.5 (3.3-21.7) NA
IV fluid (ml) 1.5 (1.0-2.0) 1.2 (0.5-2.0) -0.3 (-0.8 to 0.1)
Note:
BP = Blood pressure, GCS = Glasgow coma scale. Numeric variables are summarised as median
(IQR) and categorical variables as proportions. Variable values in the two groups (those who received
TB treatment versus not) are compared using difference of medians with 95
* Participants with HIV status unknown not included in this row
† Includes only HIV-infected participants
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No TB treatment TB treatment
TB Can't stand CO2 t0hr
HIV Malaria RR SpO2
BSI CD4 < 100 Meningitis Haemoglobin
0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 10 20 30 75 100 125 150 175
0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 0 20 40 60 60 70 80 90 100
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BSI CD4 < 100 Meningitis Haemoglobin
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Figure 4.7: Variable distributions following propensity score matching. A: original cohort. B: Propes-
nity score matched cohort. BSI = bloodstream infection, Sp02 = Capilliary oxygen saturation, TB
= tuberculosis, RR = Respiratory rate, CO2 = Serum bicarbonate, t0hr = Heart rate. Categrorical
variables (BSI, CD4 < 100, Meningitis, HIV, Malaria, TB, Can’t stand) are coded as 1 for present
and 0 for absent.
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Chapter 5
ESBL-E carriage in Malawian
adults in health and disease
5.1 Chapter Overview
This chapter presents the longitudinal ESBL-E colonisation status of sepsis survivors and
two comparator cohorts: antimicrobial-unexposed inpatients and community members.
In total, 425 participants were recruited: 225 participants with sepsis, and 100 each of
antimicrobial-unexposed inpatients and community members. Stool was sampled at 5
time points over six months. 1416 stool samples were collected and 51% (723/1417) of
samples grew 1032 bacteria, most commonly Escherichia coli (n = 686) and Klebsiella
pneumoniae (n = 245). Baseline ESBL-E carriage prevalence was 49% (95% CI 42-
56%) in participants with sepsis, 41% (95% CI 32-52%) and in antimicrobial-unexposed
inpatients (both on the day of admission) and 28% (95% CI 20-38%) in “healthy” community
members. In multivariable modelling, receipt of cotrimoxazole preventative therapy (CPT),
hospitalisation with the previous 4 weeks, use of unprotected water sources, household
crowding, and sample collection during the rainy season were all associated with ESBL-E
colonisation at enrolment. This suggests that in the community, within-household person
to person as well as environmental transmission may be important.
ESBL-E carriage prevalence rose rapidly after admission in antimicrobial-exposed par-
ticipants, to 78% (95% CI 71-84%) by the day 7 visit, a rise which was not seen in the
antimicrobial-unexposed arm of the study (51% at day 7 visit, 95% CI 38-64%), suggesting
that antimicrobial exposure and not hospitalisation per se is driving carriage. However, this
conclusion is open to confounding because antimicrobial-exposed participants differ from
antimicrobial-unexposed in a number of important ways, including a lower HIV prevalence
and shorter median length of hospital stay. Attempts to control for this confounding
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with logistic regression failed: collinearity and a small dataset resulted in very uncertain
parameter estimates. In addition, aggregate prevalences obscure a complex pattern of
shifting between colonised and non-colonised states at the individual level, and it is not
clear whether this represents intermittent ESBL-E shedding, imperfectly sensitive tests,
or true acquisition and loss events on a short time scale. I describe these difficulties, and
outline the methods that will be used to address them over the next three chapters.
5.2 Introduction and chapter aims
In the preceding two chapters I have described significant exposure to broad-spectrum
antimicrobials in a sepsis cohort. I now turn my attention to the consequences of this
antimicrobial exposure in terms of acquisition and carriage of ESBL-E and present a
description of longitudinal carriage of ESBL-E in sepsis survivors, plus two comparator
cohorts of antimicrobial unexposed inpatients and community members. I also attempt to
describe risk factors for carriage.
Data from sSA suggest that ESBL-E gut mucosal carriage is common (Chapter 1), but
routes of transmission are unknown. Antimicrobial exposure and hospitalisation have
been associated with ESBL-E carriage, but such longitudinal cohort data that do exist
are associated with short follow up time, often not following participants beyond hospital
discharge. The role of hospital acquisition of ESBL-E and carriage into the community
in driving drug-resistant infection versus community transmission is therefore unclear. In
addition, the mechanism of ESBL-E acquisition in hospitalised adults in sSA including the
relative effects of antimicrobials versus hospitalisation - exactly the understanding that
would be needed to design effective interventions - is unknown.
The aims of this chapter are therefore threefold:
1. To present the details of recruitment, follow up and ESBL-E colonisation status of
the participants recruited to the clinical study underpinning this thesis;
2. To explore associations of baseline ESBL-E colonisation to understand potential
community ESBL-E transmission routes;
3. To explore associations of ESBL-E acquisition by 28 days, particularly the relative
effects of hospitalisation and antimicrobial exposure.
5.3 Methods
The methods for recruitment and follow up of the clinical cohort along with the laboratory
methods of sample processing, stool culture, bacterial identification, ESBL confirmation
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and antimicrobial sensitivity testing are described in Chapter 2, Methods. Further methods
of the statistical analysis carried out in this chapter are detailed here.
Summary statistics across the three arms of the study are presented as proportions for
categorical data and medians and interquartile ranges for continuous data, with p-values
from Fisher’s exact test and the Kruskall-Wallace test, respectively, used to test for
differences between the arms. The magnitude of the time-varying exposures of interest -
hospitalisation and antimicrobial exposure - were expressed in three ways, to ensure that
the study procedures had generated three arms with good separation of exposures:
1. The proportion of participants in each arm who were exposed to a given exposure on
any given day was plotted;
2. Total person-days of exposure for each arm was calculated; the person-days at risk
were not equal across the three arms of the study because of varying numbers of
participants and drop-out rates, so the total person-days at risk were also calculated;
3. The number of participants who were exposed to a given exposure, along with the
median length of exposure were calculated.
ESBL-E colonisation was expressed as a simple proportion at each time point, and visualised
by plotting the proportion with binomial confidence intervals. For these plots, Arm 2 and 3
participants were censored at fist antimicrobial exposure (Arm 2 and 3) and hospitalisation
(Arm 3). Whilst time of measurement of ESBL-E status was ostensibly at day 0,7,28,90 or
180, in reality it was distributed around these points. To visualise these data accounting
for this, ESBL-E carriage status was plotted against time with ESBL-E colonisation coded
as 1 and not colonised a 0, and a non-parametric LOESS regression line (with first order
polynomial and smoothing parameter 0.75) fitted to them. This fits a local smoothed linear
regression using least squares and a proportion of the of the data points, to produce a
smoothed local best fit curve through the data points; in this case broadly equivalent to
binning observations in a large number of time category bins and calculating a prevalence
for each one, and can be interpreted as a ESBL-E rolling prevalence which accounts for the
varying measurement time.
This does not, however, account for the fact that the measurements are clustered within
individuals. In order to do this, a two-state model (with ESBL-E colonised and uncolonised
states) was fitted using the Aalen-Johansen estimate of state occupancy in the survival
package in R. This is a generalisation on the Kaplan-Meier curve and allows plotting of state
occupancy probability - an estimate of carriage prevalence at any time point - as a function
of time, rather than just the survival function as in a Kaplan-Meier curve. However, the
Aalen-Johansen estimate assumes that the time of state transition is known. In fact, the
data considered here are interval censored - that is, that transition is only known to have
happened within a particular time period between two study visits, and so to generate
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this estimate of state occupancy it is necessary to assume a transition time: I assumed
it happened halfway between measurements. A Markov model can account for all these
difficulties; the development and fitting of such a model is the subject of Chapter 8. ESBL-E
carriage was also visualised as a heat map, with each cell representing a sample, columns
representing individuals and rows the study visits.
To explore the associations of ESBL-E carriage, two logistic regression models were fit.
The first aimed to explore associations of baseline ESBL-E carriage. Variables that I
hypothesised a priori would be related to ESBL-E carriage were included in the model:
age, sex, HIV status, study arm, receipt of antiretroviral therapy (ART) or cotrimoxazole
preventative therapy (CPT), hospitalisation or receipt of antimicrobial therapy, household
crowding (number of adults and number of children in the household separately as linear
continuous variables), presence of animals at home, presence of a flushing toilet at home,
use of unprotected water sources (defined as surface water or unprotected springs or wells),
whether water was treated with chlorine, and sample collection during rainy season (defined
as date of sample collection between 1st November and 30th April). These variables were
fit individually (univariable model) and then in a full multivariable model. Odds ratios
with 95% confidence intervals and p-values are presented.
The second logistic regression model aimed to explore associations of ESBL-E acquisition
by the 28 day visit. This analysis included only participants who were a) ESBL-E un-
colonised at baseline and b) had an available sample at 28 days +/- 2 weeks. To explore
associations of ESBL-E acquisition, the exposures of interest (again specified a priori:
ceftriaxone, amoxicillin, ciprofloxacin and cotrimoxazole exposure and hospitalisation) were
first quantified as days of exposure between the baseline and follow up visit, and binned
into three groups: no exposure, five or fewer days of exposure, or more than five days of
exposure. Proportion of participants who had a detectable ESBL-E at follow up in each
group were plotted, stratified by these groups, to assess both for any association and for a
dose-response relationship. Multivariable analysis was carried out by dichotomising each
exposure as a binary variable (exposed/non-exposed) and including them all in a logistic
regression model. They were not used as a continuous linear predictor because a linear
relationship between antimicrobial exposure and ESBL-E acquisition seems unlikely, and
there were not enough data points to categorise the variables with more granularity.
5.4 Results
5.4.1 Study population
In total, 425 participants were recruited to the study between 19th February 2017 and 2nd
October 2018; 225 participants with sepsis (Arm 1), 100 inpatients without antimicrobial
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exposure at baseline (Arm 2) and 100 community members (Arm 3). Flow of participants
through the study is shown in Figure 5.1. It was often challenging to collect stool samples
from participants but 87% (1416/1631) eligible patient-visits resulted in the collection of a
stool sample. Drop out from the study and failure to collect stool samples were similar in
arm 1 and 2 and with no apparent systematic bias, but both drop out and missing samples
were less frequent in arm 3 (Figure 5.2A). There was significant variation in the timing
of stool sample collection, with a broad distribution around the ostensible collation day
(Figure 5.2B).
The baseline characteristics of the enrolled participants are shown in Table 5.1. There
were some important differences between the arms of the study: despite matching on age
and sex, antimicrobial-unexposed participants were older. They were also less likely to be
HIV-infected than participants with sepsis (13% [12/89] of those with known HIV status
were HIV-infected versus 67% [143/213] with sepsis), and less likely to have been treated for
TB. Sepsis participants were more likely to have received antimicrobials or been hospitalised
in the previous 4 weeks. In the community arm of the study, there were a high proportion of
participants (60% [60/100]) with an unknown HIV status, and there were some differences
in toilet facilities, water sources, cooking fuel and presence of animals at home across the
three groups.
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Excluded n = 122
Physiology criteria not met 64
Outside Blantyre 81































Screened n = 347




































Screened n = 122

















Screened n = 102
Figure 5.1: Study recruitment and follow up. At each time point eligible participants refers to
participants who are known to be alive and have not withdrawn from the study by that time point,
and samples collected refers to patients from whom a stool sample was sucessfully collected for that
visit.
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Arm 1 Arm 2 Arm 3
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Figure 5.2: A: Missing stool samples stratified by arm and visit. Bar height at a given visit represents
the number of eligible participants, coloured by successful sample collection (blue) or failure to
collect a sample (red). B: Distribution of actual day of sample collection for ostensible day 7, 28, 90

















Table 5.1: Participant characteristics
Variable Sepsis Inpatient Community p Total
Demographics
Age (yr) 35.9 (27.8-43.5) 40.4 (29.1-48.3) 32.5 (24.0-38.4) <0.001 35.6 (26.9-43.9)
Male sex 114/225 (51%) 51/100 (51%) 40/100 (40%) 0.533 205/425 (48%)
HIV/TB status
HIV Reactive 143/225 (64%) 12/100 (12%) 18/100 (18%) <0.001 173/425 (41%)
HIV Non Reactive 70/225 (31%) 77/100 (77%) 22/100 (22%) <0.001 169/425 (40%)
HIV Unknown 12/225 (5%) 11/100 (11%) 60/100 (60%) <0.001 83/425 (20%)
Ever treated for TB 37/225 (16%) 5/100 (5%) 4/100 (4%) 0.002 46/425 (11%)
Of those, current TB treatment 10/37 (27%) 0/5 (0%) 4/4 (100%) 0.098 14/46 (30%)
ART status*
Current ART* 117/143 (82%) 9/12 (75%) 18/18 (100%) 0.859 144/173 (83%)
Months on ART 28.7 (3.7-72.6) 35.1 (2.9-79.8) 31.5 (13.0-79.9) 0.693 29.5 (3.8-72.8)
ART regimen: EFV/3TC/TDF 110/117 (94%) 8/9 (89%) 17/18 (94%) 1.000 135/144 (94%)
ART status
Current CPT† 98/141 (70%) 5/12 (42%) 7/18 (39%) 0.328 110/171 (64%)
Healthcare exposure last 4wk
Antibiotics 60/225 (27%) 0/100 (0%) 0/100 (0%) <0.001 60/425 (14%)
Hospitalised 18/225 (8%) 1/100 (1%) 0/100 (0%) 0.001 19/425 (4%)
Tobacco/alcohol use
Never tobacco 196/225 (87%) 93/100 (93%) 90/100 (90%) 0.929 379/425 (89%)
Ex tobacco 17/225 (8%) 6/100 (6%) 2/100 (2%) 0.180 25/425 (6%)
Current tobacco 12/225 (5%) 1/100 (1%) 8/100 (8%) 0.070 21/425 (5%)
Current alcohol 51/225 (23%) 16/100 (16%) 18/100 (18%) 0.502 85/425 (20%)
Education
Primary incomplete or complete 97/225 (43%) 50/100 (50%) 42/100 (42%) 0.739 189/425 (44%)
Some secondary education 47/225 (21%) 18/100 (18%) 30/100 (30%) 0.238 95/425 (22%)
Secondary school complete 48/225 (21%) 16/100 (16%) 19/100 (19%) 0.677 83/425 (20%)
No formal schooling 16/225 (7%) 13/100 (13%) 4/100 (4%) 0.094 33/425 (8%)
College or higher 17/225 (8%) 3/100 (3%) 5/100 (5%) 0.346 25/425 (6%)
Employment
Unemployed 82/225 (36%) 34/100 (34%) 32/100 (32%) 0.866 148/425 (35%)
Self-employed 56/225 (25%) 32/100 (32%) 35/100 (35%) 0.325 123/425 (29%)
Currently employed 65/225 (29%) 26/100 (26%) 18/100 (18%) 0.269 109/425 (26%)







Retired 1/225 (0%) 2/100 (2%) 0/100 (0%) 0.280 3/425 (1%)
Toilet facilities
Pit latrine with slab +/- foot rest 104/225 (46%) 25/100 (25%) 35/100 (35%) 0.039 164/425 (39%)
Pit latrine with slab and cover +/- foot rest 45/225 (20%) 19/100 (19%) 55/100 (55%) <0.001 119/425 (28%)
Hanging toilet/latrine 59/225 (26%) 48/100 (48%) 9/100 (9%) <0.001 116/425 (27%)
Flush Toliet (any type) 14/225 (6%) 5/100 (5%) 1/100 (1%) 0.118 20/425 (5%)
No toilet 2/225 (1%) 2/100 (2%) 0/100 (0%) 0.533 4/425 (1%)
Composting toilet 1/225 (0%) 1/100 (1%) 0/100 (0%) 0.720 2/425 (0%)
Main water source
Public tap/standpipe 51/225 (23%) 8/100 (8%) 66/100 (66%) <0.001 125/425 (29%)
Piped outside dwelling 69/225 (31%) 37/100 (37%) 9/100 (9%) <0.001 115/425 (27%)
Tube well/borehole 64/225 (28%) 35/100 (35%) 15/100 (15%) 0.032 114/425 (27%)
Piped into dwelling 30/225 (13%) 11/100 (11%) 7/100 (7%) 0.353 48/425 (11%)
Unprotected well/spring 5/225 (2%) 6/100 (6%) 2/100 (2%) 0.181 13/425 (3%)
Surface water (including rainwater collection) 4/225 (2%) 2/100 (2%) 0/100 (0%) 0.556 6/425 (1%)
Tube well with powered pump 2/225 (1%) 1/100 (1%) 1/100 (1%) 1.000 4/425 (1%)
Treat water with chlorine 19/225 (8%) 5/100 (5%) 0/100 (0%) 0.004 24/425 (6%)
No. household members
Children 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 0.395 2.0 (1.0-3.0)
Adults 2.0 (2.0-3.0) 3.0 (2.0-4.0) 2.0 (2.0-4.0) 0.907 3.0 (2.0-4.0)
Electricty
Electricity available in house 119/225 (53%) 41/100 (41%) 58/100 (58%) 0.357 218/425 (51%)
Main cooking fuel
Charcoal 161/225 (72%) 63/100 (63%) 88/100 (88%) 0.291 312/425 (73%)
Wood 61/225 (27%) 35/100 (35%) 11/100 (11%) 0.004 107/425 (25%)
Electricity 3/225 (1%) 2/100 (2%) 1/100 (1%) 0.869 6/425 (1%)
Animals at home?
Any animal 71/225 (32%) 43/100 (43%) 15/100 (15%) 0.004 129/425 (30%)
Poultry 46/71 (65%) 34/43 (79%) 10/15 (67%) 0.800 90/129 (70%)
Dogs 18/71 (25%) 11/43 (26%) 9/15 (60%) 0.201 38/129 (29%)
Other 11/71 (15%) 9/43 (21%) 5/15 (33%) 0.413 25/129 (19%)
Goats 12/71 (17%) 7/43 (16%) 1/15 (7%) 0.830 20/129 (16%)


















ART = Antiretroviral therapy, CPT = Cotrimoxazole preventative therapy, EFV: Efavirenz, 3TC: Lamivudine, TDF: Tenofovir. Numeric
values are median (IQR)) unless otherwise stated. P-values are to assess for differences across the three groups: Fisher’s exact test across
the groups for categorical variable, and Kruskal-Wallace test for continuous variables.
* ART status includes HIV reactive only as denominator
† Missing CPT data for two participants.
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5.4.2 Exposures during the study period
Exposures to antimicrobials and hospitalisation of the cohort are shown in Figure 5.3 and
Table 5.2. Antimicrobial-unexposed inpatients (arm 2 participants) had a shorter length
of hospital stay than participants with sepsis (arm 1 participants): median (IQR) 2 (2-7)
versus 5 (2-10) days, p = 0.002 by Kruskal-Wallace test. Five of the 100 arm 2 participants
were taking CPT at baseline, 18 received further courses of antimicrobials during the study
period, and two were started on TB therapy. Some participants received combinations
of these therapies, so in total 23% (23/100) arm 2 participants received an antibacterial
during the study period, mostly within 30 days following enrolment (Figure 5.3)), and most
commonly ceftriaxone (Table 5.2). All of these participants were censored on first exposure.
Both antimicrobial exposure and hospitalisation were unusual in the community cohort; 7%
(7/100) community (arm 3) participants were taking CPT and one received a 5-day course
of amoxicillin meaning that 8% (8/100) Arm 3 participants received an antibacterial during
the study period. In addition one arm 3 participant was hospitalised for 1 day in the study
period. No arm 3 participant received any TB therapy, and no Arm 2 or 3 participants
received any antimalarial or antifungal therapy during the study period.
Because of the chronic nature of the therapy, the greatest antimicrobial exposure (in terms
of participant-days) in all arms were to cotrimoxazole and TB therapy, by an order of
magnitude (Table 5.2). Apart from these, the most commonly received antibacterial by arm
1 participants was ceftriaxone by some distance with 998 participant-days of exposure in 189
participants during the study period, and a median 5 (IQR 3-7) day course. Ciprofloxacin
and amoxicillin were also commonly received, with 61 participants receiving 398 participant-
days of exposure to ciprofloxacin with a median 7 (IQR 5-7) day course, and 39 participants
receiving 235 participant-days of exposure to amoxicillin with a median 5 (IQR 5-7) day
course.
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Arm 2: Inpatient
Arm 1: Sepsis










































Figure 5.3: Hospital and antibacterial exposure of participants expressed as (A) proportion of
arm 1 and arm 2 participant who are hospitalised and/or exposed to the most commonly received
antibacterials on any given day and (B) cumulative proportion of participants who have been







Table 5.2: Antimicrobial and hospital exposure stratified by arm
Number exposed Exposure (person-days) Median (IQR) exposure length (days)
Exposure Arm 1 Arm 2 Arm 3 Arm 1 Arm 2 Arm 3 Arm 1 Arm 2 Arm 3
Total At Risk 225 100 100 33797 14336 21983 - - -
Exposures
Hospitalised 225 100 1 1727 500 1 5 (2-10) 2 (2-7) 1 (1-1)
Cotrimoxazole 110 6 7 14447 549 1388 180 (27-190) 86 (6-177) 190 (183-206)
TB therapy 52 2 0 6843 291 0 178 (58-180) 146 (133-158) -
Ceftriaxone 183 7 0 997 26 0 5 (3-7) 3 (2-4) -
Ciprofloxacin 61 2 0 398 12 0 7 (5-7) 6 (6-6) -
Amoxicillin 38 3 1 235 21 5 7 (5-7) 5 (5-8) 5 (5-5)
Metronidazole 24 2 0 148 10 0 6 (2-7) 5 (5-5) -
Fluconazole 27 0 0 118 0 0 3 (2-5) - -
Aciclovir 2 0 0 47 0 0 24 (16-31) - -
Co-amoxiclav 10 2 0 40 12 0 5 (2-5) 6 (6-6) -
Erythromycin 5 0 0 38 0 0 7 (5-11) - -
Doxycycline 7 0 0 34 0 0 3 (2-6) - -
Artesunate 11 0 0 25 0 0 2 (2-3) - -
LA 7 0 0 19 0 0 3 (2-3) - -
Streptomycin 2 0 0 16 0 0 8 (7-9) - -
Gentamicin 4 0 0 15 0 0 4 (3-5) - -
Amphotericin 2 0 0 8 0 0 4 (4-4) - -
Azithromycin 2 2 0 7 12 0 4 (3-4) 6 (6-6) -
Penicillin 2 0 0 5 0 0 2 (2-3) - -
Flucloxacillin 2 0 0 5 0 0 2 (2-3) - -
Chloramphenicol 1 0 0 1 0 0 1 (1-1) - -
Quinine 1 0 0 1 0 0 1 (1-1) - -
Note:
TB = tuberculosis, LA =lumefantrine artemether. Median exposure length includes only those exposed. Total at
risk shows the total number of participants and participant-days of follow up included in the study.
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Table 5.3: ESBL carriage stratified by arm and visit
Arm 1 (Sepsis) Arm 2 (Inpatient) Arm 3 (Community)
Visit n Any ESBL n Any ESBL n Any ESBL
Day 0 222 109 (49%) 99 41 (41%) 99 28 (28%)
Day 7 162 127 (78%) 63 32 (51%) - -
Day 28 148 106 (72%) 71 37 (52%) 92 29 (32%)
Day 90 126 71 (56%) 60 29 (48%) - -
Day 180 127 61 (48%) 65 29 (45%) 83 24 (29%)
5.4.3 ESBL-E colonisation
ESBL-E colonisation prevalence as a function of time across the three arms of the study is
shown in Table 5.3 and Figure 5.4. Baseline colonisation prevalence was high in all groups,
and higher in arm 1 and 2 participants than community members: 49% (95% CI 42-56%) in
arm 1 participants, 41% (95% CI 32-52%) in arm 2 and 28% (95% 20-38%) in arm 3. Both
hospitalised groups showed a rise in colonisation prevalence following admission, though
this is much more marked in arm 1 participants: by the day 7 visit 78% (95% CI 71-84%)
of arm 1 participants were colonised compared to 51% (38-64%) of arm 2 participants. This
difference persisted through to day 28, when the crude prevalence in arm 1 was 72% (95%
CI 64-79%) versus 52% (95% CI 40-64%) in arm 2. By the end of the study period the
prevalence had fallen back to baseline levels in both groups. Within an individual, there
was often frequent flipping between the ESBL colonised to uncolonised state and back again
at different study visits and often on short time-scales (Figure 5.5).
In total, 723/1417 (51%) of samples grew at least one ESBL-E; 1032 organisms were
grown from the 723 samples, with a median 1 (IQR [1-2]) ESBL-E per sample. The most
commonly isolated organism as identified by the API system was E. coli (n = 686) followed
by Klebsiella pneumoniae (n = 245, Figure 5.6). Antimicrobial sensitivity testing was carried
out on the first 694/1032 (67%) organisms. Cotrimoxazole resistance was near universal
(675/694 [97%] of isolates), with intermediate proportions of gentamicin (367/694 [53%])
and ciprofloxacin (457/694 [65%]) resistance and less chloramphenicol resistance (232/694
[33%] of isolates). Meropenem and amikacin resistance was very unusual (14/694 [2%] and
15/694 [2%] of isolates respectively) but the fact that resistance to these antibacterials of
last resort was seen at all is troubling.
5.4.4 Associations of ESBL colonisation
I then used logistic regression to explore associations of ESBL-E colonisation at baseline
Of the 420 participants with an available enrolment stool culture result, 42% (178/420)
cultured at least one ESBL-E. Univariable and multivariable associations of colonisation
at enrolment are shown in 5.4. In univariable analysis HIV infection, ART and CPT are
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Figure 5.4: ESBL carriage prevalence as a function of time visualised in three different ways. In each
case participants from arm 2 are censored on first antimicrobial exposure and arm 3 are censored on
first antimicrobial exposure or hospitalisation. Top (A) prevalence at each visit plotted at ostensible
visit time; however, the visits are in fact distributed in time themselves so the middle plot (B) is an
attempt to show this by fitting a nonparametric smoothed LOESS regression line with a local linear
regression. However the confidence intervals in this method are too narrow because they assume
independence of the measurements, which are in fact clustered within patients. The bottom panel (C)
is an estimate of the proportion of ESBL-colonised participants from the Aalen-Johansen estimate,
which is a generalisation of the Kaplan-Meier curve. This takes into account the nonindependence
of the measurements, but does not take into account the interval-censored nature of the data, and
transitions to and from the ESBL colonised state are hence assumed to happen halfway between
measurements.
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Figure 5.5: Heatmap showing distribution of stool samples with detectable ESBL-E. Each column
represents a patient, and each cell a stool sample with valid result, coloured by presence or absence
of detectable ESBL-E, to demonstrate the complex patterns of apparent acquisition and loss in
many individuals over the study period.
associated with ESBL-E colonisation. This seems to be largely mediated by CPT as the
HIV and ART associations largely disappear on multivariable modelling but the effect of
CPT is still apparent (aOR 2.3 [95% CI 1.0 - 5.5]). Hospitalisation within the 4 weeks prior
to admission was strongly associated with ESBL-E colonisation on multivariable modelling,
though with wide confidence intervals (aOR 5.9 [95% CI 1.8-27.0]). Antimicrobial exposure
was not, but with confidence intervals that contained a clinically relevant effect size (aOR
1.3 [95% 0.7 - 2.6]). ESBL-E colonisation was more likely with more adults in the household
(aOR 1.2 [95% CI 1.0-1.4] per extra adult) , with use of an unprotected water source (aOR
3.0 [95% CI 1.1 - 8.8]) and in the rainy season (aOR 2.2 [95% CI 1.4-3.4]).
To explore associations of acquisition of ESBL-E by the day 28 visit, I analysed only those
participants who had no detectable ESBL-E at baseline, and an available follow up samples
at 28 days +/- 14 days. These numbered 150 participants: 64 Arm 1, 37 Arm 2 and
49 Arm 3 participants, and 49% (73/150) of them had a detectable ESBL-E at day 28.
Bivariable associations of ESBL-E acquisition with antimicrobial and hospital exposures
are shown in Figure 5.7A, stratified by the length of exposure; all antibacterials (including
TB therapy) showed an association with ESBL-E acquisition, with a suggestion of a dose-
response effect (in that longer exposures generally had a higher colonisation prevalence),
but confidence intervals were large in many cases. Antimalarials did not show this effect






























Figure 5.6: Species (A) and antimicrobial sensitivities (B) of cultured ESBL-E
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for antifungals. These relationships are very likely confounded, so should be regarded with
caution; however, due to a small dataset size and collinearity, logistic regression modelling
of ESBL-E acquisition (Figure 5.7B) produces such uncertain parameter estimates that
no conclusions can be drawn. A better modelling strategy using continuous time Markov
models is presented in Chapter 8.
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Table 5.4: Univariable and multivariable associations of ESBL colonisation at enrolment
Univariable Multivariable
Variable OR (95% CI) p-value aOR (95% CI) p-value
Demographics
Age (per year) 1.00 (0.99-1.02) 0.709 1.00 (0.98-1.02) 0.898
Male sex (vs female) 1.23 (0.84-1.82) 0.287 1.42 (0.93-2.19) 0.106
Study Arm
Arm 2 (vs 1) 0.73 (0.45-1.18) 0.203 1.57 (0.84-2.96) 0.157
Arm 3 (vs 1) 0.41 (0.24-0.68) 0.001 0.91 (0.45-1.84) 0.801
HIV status
HIV+ (vs HIV-) 1.68 (1.09-2.59) 0.018 1.16 (0.46-2.84) 0.750
HIV unknown (vs HIV-) 0.71 (0.40-1.24) 0.229 1.09 (0.55-2.18) 0.798
CPT (vs none) 2.46 (1.58-3.86) <0.001 2.29 (0.98-5.54) 0.060
ART (vs none) 1.99 (1.32-3.00) 0.001 1.06 (0.35-3.17) 0.918
Exposures last month
Hospitalisation 7.87 (2.57-34.22) 0.001 5.90 (1.78-26.94) 0.008
Antibiotics* 2.14 (1.27-3.67) 0.005 1.34 (0.71-2.57) 0.368
Household size
Children (per 1) 1.00 (0.87-1.14) 0.979 0.98 (0.84-1.14) 0.793
Adults (per 1) 1.14 (0.99-1.31) 0.064 1.19 (1.02-1.40) 0.026
Keep animals (vs not) 1.33 (0.88-2.03) 0.176 1.16 (0.73-1.85) 0.527
WaSH behaviour
Flushing toilet (vs not) 1.38 (0.55-3.44) 0.481 0.94 (0.34-2.55) 0.908
Unprotected water source 2.43 (0.96-6.64) 0.068 2.98 (1.08-8.78) 0.039
Treat water (vs not) 1.16 (0.50-2.66) 0.725 0.94 (0.37-2.34) 0.900
Season
Rainy season (vs. dry) 2.05 (1.38-3.06) <0.001 2.17 (1.38-3.44) 0.001
Note:
CPT = Cotrimoxazole preventative therapy, ART = antiretroviral therapy, WaSH =
Water, sanitation and hygiene. Entries in bold are those for which 95% confidence
intervals do not cross 1.
* Antibiotics includes TB therapy but excludes CPT.
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Figure 5.7: Univariable (A) and multivariable (B) associations of antimicrobial and hospital exposure
with acquisition of ESBL-E by 28 days. A: These plots show the proportion of participants who
have no detectable ESBL-E baseline but who do at 28 days, as a function of various exposures. All
antibacterials and hospitalisation show an association between exposure and ESBL-E acquisition,
with a suggestion of a dose-response relationship, though confidence intervals are wide in many
cases. Antimalarials show no apparent relationship though, as with fluconazole, the wide confidence
intervals make it difficult to draw any conclusions. The results from logistic regression to predict
ESBL-E acquisition are shown in (B); colinearity and small dataset size means that confidence
intervals are so large as to make the model useless.
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5.5 Discussion
In this chapter, I have presented the data which will be used to address the second aim
of this thesis - to describe, and identify determinants of, ESBL-E acquisition and carriage
in Malawian adults. It is possible to draw several conclusions from these data. First,
community ESBL-E carriage in Blantyre is common. The baseline community carriage
prevalence of 28% is considerably higher than the 4-7% seen in Europe[165–168] and
comparable to the sSA pooled community prevalence estimate presented in Chapter 1 of
18% (95% CI [11-27%]).
The associations of baseline ESBL-E carriage give insight into the routes of community
ESBL-E transmission in the urban Malawian setting. The high community prevalence
without apparent healthcare contact suggests that community transmission is common.
Household crowding and use of unprotected water sources are associated with ESBL-E
colonisation, suggesting both household person to person and environmental transmission
routes are of relevance. The number of adults in the household, rather than the number of
children, was associated with ESBL-E carriage in this study - which recruited only adults -
suggesting that within the household adult to adult transmission is a more important route
than child to adult transmission. This could be for a number of reasons - if the ESBL-E
prevalence were low in children, for example. Though children were not sampled in this
study and so the data here can not address that hypothesis, data from other studies suggest
this is unlikely: community prevalence in children ranged from 10-59% in four studies
in the Central African Republic[250], Senegal[270] and Tanzania[248,255], and is hence
comparable to the adult community prevalence seen in this study. Behavioural factors,
or a lower bacillary burden in children could also account for the associations seen here.
The seasonality of ESBL-E carriage prevalence is also consistent with an environmental
transmission route of ESBL-E - environmental faecal and hence ESBL-E contamination
would be likely higher in the rainy season - but behavioural factors (e.g. more indoor
crowding during the rains) or other causal pathways (e.g. more febrile illness and hence
hospitalisation and/or antimicrobial exposure) should also be considered as possibilities.
These data also offer insight into the role of HIV as a driver of ESBL-E colonisation. Prior
to this study, only two studies in sSA had assessed associations of HIV and community
ESBL-E carriage: one, in pregnant women, found no association[259], and one, in healthy
children under two, found a strong association[255]. HIV is known to have a profound effect
on gut function[328] and it is conceivable that a direct HIV effect on e.g. the microbiota
could result in reduced colonisation resistance to ESBL-E, or that increased antimicrobial
or healthcare exposure in the HIV infected could result in a higher colonisation prevalence.
However, in the Malawian adults considered here, there is a clear association between
HIV-infection and ESBL-E carriage which seems to be largely mediated by CPT. Given
that the adult HIV prevalence in Malawi is estimated to be 9.6%[329] and Malawian HIV
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guidelines mandate lifelong CPT for people living with HIV[330], CPT is potentially a
significant driver of ESBL-E colonisation in this setting.
It is also clear that there are significant associations between antimicrobial exposure, hospi-
talisation, and ESBL-E carriage prevalence, though the analysis presented here is unable
to provide an insight into the relevant importance of hospitalisation versus antimicrobial
exposure. Prior hospitalisation was strongly associated with baseline ESBL-E carriage
on multivariable logistic regression, but prior antimicrobial exposure (apart from CPT)
was not, though with confidence intervals that include a clinically relevant effect size. A
better estimate of the relative effects can come from the longitudinal sampling data. The
study was designed to explore the relative effects of hospital exposure and antimicrobial
exposure on ESBL-E colonisation, and so to produce groups with different levels of these
exposures. Despite some crossover of exposure, this was largely a success, with much
reduced antimicrobial exposure in Arm 2 compared to Arm 1, and virtually no antimicrobial
of hospital exposure in Arm 3. In an unadjusted analysis, Arm 1 participants show a
greater increase in ESBL-E carriage prevalence than Arm 2 participants, suggesting that
antimicrobial exposure, rather than hospitalisation, is driving apparent acquisition. The
prevalence of ESBL-E colonisation following antimicrobial exposure is striking, with 78% of
Arm 1 participants colonised by the day 7 visit. A return to pre-admission prevalence is
apparent over the 6-month study period.
However this conclusion - that antimicrobial exposure rather than hospitalisation is driving
apparent ESBL-E acquisition - is very open to bias from confounding, because antimicrobial-
unexposed participants are different from antimicrobial unexposed: younger, less likely to
be HIV-infected, less CPT exposure, and a shorter length of hospital stay. A multivariable
approach is necessary to provide unbiased estimates of the effects of antimicrobial use and
hospitalisation, but collinearity of exposures and a small dataset size means that a simple
modelling approach - logistic regression - produces such uncertain effect sizes as to be
useless. A different modelling approach, using continuous time Markov models, is presented
in Chapter 8.
The overall trend of ESBL-E carriage at any time point in the study obscures the complex
within-individual picture, with a pattern of multiple transitions between the detectable and
undetectable ESBL-E states over the study period for many individuals. There could be
several reasons for this: if a participant is truly continually colonised, then intermittent
shedding of ESBL-E or inadequate test sensitivity could explain apparent lack of ESBL-E
in culture. There are clearly some participants who are continually colonised except for at
one or two time points, which is suggestive of one or both of these scenarios. Alternatively,
these patterns could represent true acquisition or loss events.
The ESBL-E cultured from the participants in this study are, as expected, largely E. coli
and, to a lesser extent K. pneumoniae, as seen in other studies in sSA (see Chapter 1),
5.6. CONCLUSIONS AND FURTHER WORK 169
but also in high income settings such as Europe[177]. The prevalence of amikacin and
meropenem resistance was very low, although was present. Meropenem was introduced to
the Malawian national formulary in 2015[331], and is only sporadically available in QECH.
Previous studies of antimicrobial resistance in Blantyre have not found any genotypic or
phenotypic carbapenem resistance, though the MLW laboratories do not routinely test
for carbapenem sensitivity. To my knowledge the carbapenem resistant isolates found in
this study are the first to be described in Malawi, and the mechanisms of carbapenem
resistance are further explored in Chapter 6. Cotrimoxazole resistance was near universal,
which may be related to widespread CPT use. Interestingly, many of the isolated ESBL-E
were sensitive to chloramphenicol. This drug was, prior to the introduction of ceftriaxone,
first line treatment (along with penicillin) for sepsis in Malawi, but was replaced due to a
poor side effect profile and the ease of administration of once-daily ceftriaxone. Clearly
these isolates are carriage rather than invasive isolates and so may have different sensitivity
patterns to the bacteria that cause invasive infections, but this raises the prospect that
chloramphenicol might be reintroduced as a reserve antibiotic in the treatment of ESBL-E
in Malawi.
5.5.1 Limitations
There are limitations to this study and analysis. There was significant drop-out of Arm 1
and 2 participant through the study period. The proportion of participants truly lost to
follow up or voluntarily withdrawn from the study was low, however, and most withdrawals
were due to death or transfer out, which reflect the study populations of interest in urban
Blantyre. Logistic difficulties - participants being unable to travel to deliver a sample, or
being unavailable for a home visit - resulted in failure to collect 13% of eligible sample, and
again reflects the challenges inherent in the setting. Though the study protocol mandated
the timing of visits, the actual visit times have a broad temporal distribution. Nevertheless,
there does not seem to be any systematic bias in the missingness of participants or samples,
and if that is the case then the conclusions drawn should stand. HIV testing was not
carried out on community members, and so there is a high proportion of arm 3 participants
with an unknown HIV status, and the status that is recorded is self reported, which could
result in misclassification of HIV status and hence bias. Indeed, all baseline exposures were
self-reported and not verified, which could result in bias.
5.6 Conclusions and further work
ESBL-E colonisation in common in adults in Blantyre, and ongoing community transmission
with both person to person and environmental transmission routes seems likely. Rapid
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apparent acquisition of ESBL-E occurs in hospitalised participants exposed to antimicrobials
with a return to pre-admission ESBL-E colonisation prevalence by six months. The
aggregate data conceals a complex picture within individuals, however, with multiple
apparent transitions between the colonised and uncolonised state for many individuals over
the study period. The relative contribution of hospitalisation and antimicrobial exposure
in driving apparent acquisition events is not clear and logistic regression models failed to
provide any insight.
Several questions arise from this analysis and form the basis of further work in this thesis.
1. What is the mechanism underlying the frequent state transitions (from colonised to
uncolonised and back again) for many participants in this study?
2. Are these true acquisitions and losses, intermittent shedding, or a failure to detect
ESBL-E which are present?
3. What are the relative contributions of hospitalisation versus antimicrobial exposure in
driving the sharp increase in ESBL-E carriage prevalence following hospital admission
and antimicrobial exposure? Specifically, what is the biological mechanism of this
apparent increase? Is it associated primarily with hospitalisation - which could
represent a true ESBL-E acquisition from a contaminated hospital environment - or
primarily with antimicrobial exposure - which could be an enrichment of already-
carried ESBL-E which was undetected at baseline - or a synergistic combination of
the two?
I will spend the next three chapters attempting to address these questions, using whole
genome sequencing as a high resolution bacterial typing tool to track bacteria within
participants, and continuous-time Markov models to model state transitions between
colonised and uncolonised states over time.
Chapter 6
The genomic landscape of ESBL
producing E. coli in Blantyre,
Malawi
6.1 Chapter overview
In this chapter I present the results of whole-genome sequencing of 473 E. coli isolates,
cultured from 230 participants at a median of 2 (IQR 1-5) time points per participant.
These represent one colony pick from all stool samples which cultured E. coli up to the time
of shipping in October 2018. The isolates were largely phylogroup A (43% [204/473]), and
ST131 was the most common ST (14% [64/473]). A global collection of 800 E. coli genomes
was used to put the isolates from this study in a global context and a maximum likelihood
phylogenetic tree constructed. Isolates from this study were largely spread throughout the
tree, but there were exceptions: Malawian ST410 and ST167 were monophyletic suggesting
perhaps recent introduction to Malawi. These are recognised emerging high-risk clones.
These findings suggest that there no obvious restrictions in mixing of E. coli between
Blantyre and the rest of the world.
A diverse range on AMR genes were identified, with a median 16 (IQR 12-17) per isolate.
ESBL genes were largely of the blaCTXM family, and dominated by blaCTXM−15. The
abundance of genes seems to reflect local antibiotic pressures: genes conferring cotrimoxazole
and aminoglycoside resistance were almost ubiquitous, and quinolone, chloramphenicol
and tetracycline resistance genes also frequently seen. Carbapenem antibiotics are rarely
available, and carbapenem resistance genes rare. One carbapenemase, a blaNDM−5, was
identified, on an IncX plasmid very similar to one first identified in India around 2011.
To my knowledge the first carbapenemase described in Malawi. Its identification despite
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little antibiotic pressure along with the apparent ease international of spread of E. coli
suggested by this analysis suggest widespread resistance could rapidly emerge following
wider carbapenem roll out. Antibiotic stewardship interventions that can balance access to
and restriction of last line antibiotics in low resource settings are urgently needed.
6.2 Introduction and chapter aims
The previous chapter presented an overview of the longitudinal ESBL-E sampling that
was undertaken in this study. It is the overall aim of this thesis to use whole genome
sequencing (WGS) as a high-resolution typing method to longitudinally track bacteria
within participants. In this chapter, however, I present a descriptive analysis of the genomes
of 473 E. coli isolates sequenced for this study, before moving on to this specific aim in the
following chapter. The aims of the analysis presented in this chapter are, therefore:
1. Perform quality assurance and control of the sequenced genomes for downstream
analysis.
2. Place the isolates from this study in a global context using phylogenetics and a global
E. coli collection comprised of available genomes.
3. Provide a description of the AMR determinants in the sequenced E. coli isolates.
6.3 Methods
6.3.1 Bioinformatic pipeline
One E. coli colony from each patient sample was picked for DNA extraction and 150bp
paired-end short-read whole genome sequencing (WGS) using Illumina HiSeq X10 at the
Wellcome Sanger Institute (WSI). Read quality control was undertaken with Kraken v0.10.6
and Braken v1.0 to assign reads to species[332] and the WSI QC pipeline which maps
a random 100 Mbases from each sample to a reference and calculates depth of coverage,
number of heterogeneous SNPs, GC content and insert size. Samples that contained >
80% non E coli reads were discarded the remainder were de novo assembled with SPAdes
v3.11.0[333]. Assembly statistics (e.g. assembly length, N50) were calculated with QUAST
v4.6.0[334] and completeness and contamination of the assemblies assessed by checkM
v1.0.7[335], which uses presence or absence of lineage-associated collocated ubiquitous
single-copy genes to estimate these quantities. Contaminated assemblies (with checkM-
defined contamination of > 25%) or poor assemblies (with less than 1Mb assembled length)
were discarded. Annotation was carried out with prokka v1.5[336] with a genus specific
database from RefSeq and the Roary v1.007 pan-genome pipeline[337] was used to identify
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a core genome, considering genes contained in > 99% of isolates to be core. A core gene
multiple sequence alignment was generated using maaft v7.205[338], SNP-sites identified
using SNP-sites v2.4.1[339] and the resultant SNP alignment used to build a maximum
likelihood phylogenetic tree using IQ-TREE v1.6.3[340], using ascertainment bias correction
to correct for the fact that the input pseudosequence contained only variable sites, and
using the ModelFinder module used to find the best fitting nucleotide substitution model.
This calculates the likelihood of a number of different models and chooses the model with
the highest (best fitting) Bayesian Information Criterion, a statistic which penalises model
parameters. Reliability of inferred branch partitions was assessed with 1000 bootstrap
replicates. Trees were visualised in the ggtree v1.14.4 package[341] in R.
ARIBA v2.12.1[342] was used to identify AMR-associated genes using the SRST2
database[343], to identify plasmid replicons using the PlasmidFinder database[344]
and to perform in silico multi-locus sequence typing (MLST) using the database from
http://mlst.warwick.ac.uk/mlst/dbs/Ecoli accessed via www.pubmlst.org. The β-lactamase
genes ampC1, ampC2 and ampH were excluded from the analysis of AMR determinants
as they do not usually cause a resistant phenotype in E. coli. Because quinolone resistance
often results from SNPs in the chromosome in the quinolone resistance determining regions
(QRDRs) of the gyrA, gyrB, parE and parC genes - rather than acquisition of whole
AMR-determining genes, as is the case with the other genes sought by ARIBA - these
genes were downloaded from the comprehensive antimicrobial resistance database (CARD,
https://card.mcmaster.ca/) and ARIBA used to call SNPs in them, with default settings.
E. coli phylogrouping was performed with a quadruplex in silico PCR using the Clermont
scheme[345] and isPcr v33x2 (https://github.com/bowhan/kent/tree/master/src/isPcr)
6.3.2 Global E. coli collection
In order to place the isolates from this study in a global context, published E. coli assemblies
were downloaded from the WSI servers. These included 149 ESBL-producing E. coli from a
single centre study in Chachoengsao province, eastern Thailand[346]. In this study, human
clinical isolates from standard care in Bhuddhasothorn hospital were selected on the basis of
the ESBL phenotype, and environmental samples were collected as part of a cross sectional
study and selectively cultured for ESBL-E in 2014-2015. I also downloaded assemblies
of 362 enterotoxogenic E. coli (ETEC), selected for an ETEC genomic study from the
Gothenburg University ETEC collection to represent a broad collection of ETEC isolated
worldwide from 1980-2011[347]; 185 atypical enteropathogenic E. coli (aEPEC) sequenced
for a study of aEPEC and selected from samples from the Global Enteric Multicentre
Study (GEMS) in seven centres in Africa and Asia between 2007-2011[348]; and 94 E. coli
from QECH in Blantyre, Malawi, a combination of invasive (bloodstream and CSF) and
carriage isolates, selected for diversity in AMR phenotype from 1996-2014[279]. Details of
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the included samples are given in the appendix to this chapter.
Phylogroup and MLST were determined for these context genomes as described above. AMR
genes were identified with Ariba and the SRST2 database, as above, and context genomes
were classified as ESBL if they contained any Group 2be ESBL gene (see Bush-Jacoby
scheme in Chapter 1).
6.3.3 Statistical analysis
Association of AMR genes with phenotype was expressed as odds ratios and tests of
association used Fisher’s exact test. In order to explore clustering of AMR genes, the
Jaccard index was calculated for a given AMR-gene pair using the philentropy v0.3.0
package in R. The Jaccard index, a measure of the similarity of two sets of data, is defined
as intersection over union; in this context, for a given pair of AMR genes x and y, the
Jaccard index J(x, y) is the number of isolates that contain both gene x and y divided
by the total number that contain either x or y. By definition it lies between 0 (x and y
never co-occur) and 1 (x and y always co-occur). Co-occurrence matrices using the Jaccard
index were plotted using the pheatmap v1.0.12 package in R. The statistical significance of
co-occurrence of genes was assessed by generating 2x2 contingency tables for a given gene
pair and p values generated using a Fisher’s test with Bonferroni correction; a p value of less
that 0.05 was considered statistically significant. Co-occurrence networks of genes occurring
commonly together (defined as Jaccard index > 0.5) at a rate greater than expected by
chance (p < 0.05 following Bonferroni correction) were plotted using igraph v1.2.2[349] and
ggraph v1.0.2 in R.
6.4 Results
6.4.1 Samples and quality assurance and control
There is a detailed description of microbiological procedures in Chapter 2. In total, 519 E.
coli underwent DNA extraction and were shipped from Malawi to WSI; these represented
all sequential isolates at the time of final DNA extraction, which occurred in two batches
in February 2018 and October 2018. Kracken/Bracken read assignment of these samples is
shown in Figure 6.1. The majority of samples have > 90% or reads assigned to E. coli; a
minority have < 90% of reads assigned to E. coli but a very closely related species such
as Shigella, and as such are likely to be pure E. coli culture with read misclassification.
However, 12 samples have > 80% reads assigned to a non- E. coli species such as Klebsiella
pneumoniae. These samples were assumed to represent upstream species misidentification,
and were excluded. There also exists the possibility of within-participant transcription
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error. In the freezer archive, all samples from a single participant at a single time point
have the same sample ID, making an error possible; by definition (as only one E. coli was
sequenced at any time point in any individual) this would result in a species substitution.
Samples from different time points and different participants are clearly demarcated however,
making between-time point or between-participant errors very unlikely. Any such error
would therefore result in a sample being identified as non- E. coli and exclusion from the
analysis, reducing power but not introducing bias.
Of the remaining 507 samples, there were a median (IQR) of 2.3×106 (2.1−2.5×106) reads,
with a median (IQR) depth of coverage (obtained by mapping a random 100Mbases to a
reference E. coli genome, Escherichia coli strain K-12 substrain MG1655, NCBI reference
NC_000913.3) of 58 (51-66). One sample had an order of magnitude lower number of reads
(2.9× 105) with depth of coverage 0; this was assumed to represent sequencing failure and
it was excluded from further analysis.
The output from quast and checkM are shown in Figure 6.2, where N50 (the minimum
contig length upon which at least half assembled bases are contained) is plotted as a function
of total assembled length. The expected E. coli genome length is around 4.6Mb and most
samples cluster close to this at a total assembled length of ~ 5Mb. However it is clear that
some assemblies have failed, with low N50 and low assembled length. It is also apparent
that some samples seem to be contaminated, as indicated by low N50 and much longer than
expected total assembled length. Defining assembly failure as < 1Mb assembled length
(triangles in the plot, n = 9) and contamination as checkM-defined contamination of > 25%
(blue points in the plot, n = 24) and excluding both groups results in 33 further samples
being excluded from further analysis.
In total, therefore, 46/519 (9%) of samples which were submitted for sequencing were
excluded from downstream analysis. The remaining 473 samples represent 69% (474/686)
of the cultured E. coli in this study, and were recovered from 230 participants. 354 are
from patients with sepsis, 86 are from hospitalised inpatients and 33 are from community
members, with a median of 2 (range 1-5) samples per participant.
6.4.2 Phylogroup, MLST and core genome phylogeny of study isolates
The commonest E. coli phylogroup was phylogroup A, followed by phylogroup B2, F, B1
and C and D (Table 6.1). Two samples were Clade I or II (so called cryptic clades) and
six were unknown phylogroup using the Clermont PCR scheme. In the MLST analysis, 56
recognised sequence types (STs) were identified, and 12 samples were novel STs; however
over half (249/473 [53%]) of samples were represented by the top seven most frequent STs
(Figure 6.3). ST131 was the most commonly isolated ST (64/473 [14%] of isolates) followed
by ST410 (45/473 [10%] of isolates) and ST167 (38/473 [8%] of isolates).
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Figure 6.1: Species read assignment of all samples. Each horizontal bar is one sample. Most samples
have > 90% reads assigned to E. coli or related species (e.g. Shigella spp.) but twelve samples are
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Figure 6.2: N50 as a function of total assembled length. Failed assemblies with less than 1Mb
assembled shown as triangles. Contaminated assemblies with checkM-defined contamination above
25% shown in blue. Both of these groups of assemblies were exclduded from further analysis.









Clade I or II 2/473 (0%)
The Roary pan-genome pipeline identified a core genome in the study isolates of 2966 genes,
with a pan-genome of 26,840 genes. The resultant core gene pseudosequence of length
1,388,742 bases contained 99,693 variable sites, which were used to infer the maximum
likelihood phylogenetic tree. The IQTREE ModelFinder module determined that a general
time reversible (GTR) model with FreeRate site heterogeneity with 5 parameters provided
the best fit to the data. The inferred tree is shown in Figure 6.4 along with isolate
phylogroup and ST; in general, as expected, STs were largely monophyletic and phylogroups
tended to cluster together.
6.4.3 Study isolates in a global context
The global collection of E. coli comprised 1273 samples, including the 473 from this study.
753/1253 (60%) were from Africa, 335/1253 (27%) from Asia and 167 (13%) from South
America. The majority of samples, 1026/1253 (82%), were from stool, with 106/1253 (8%)
truly invasive samples from blood or CSF and 63/1253 (5%) possibly invasive samples












































































































Figure 6.3: E. coli multilocus sequence type distribution
from urine, pus, or sputum. 65/1253 (5%) samples were environmental, all from Thailand.
670/1253 (53%) of samples contained at least one ESBL-encoding gene. The majority of
isolates with an ESBL gene (622/670 [92%]) came from this study or the Thai ESBL study,
a potential source of bias. Phylogroup A was the commonest phylogroup in the global
collection (482/1273 [38%]), followed by B1 (333/1273 [26%]) and B2 (191/1273 [15%]);
phylogroup C was uncommon in the global collection (74/1273 [6%]) but the majority of
the phylogroup C samples came from this study (43/74 [58%]). All of these 43 phylogroup
C isolates belonged to a single ST, ST410; this ST was not seen at all in the previous
Malawian study of largely invasive isolates, despite being the second-commonest ST in this
study, and was unusual in the global collection (11/800 [1%] ST410 in global collection vs
43/473 [9%] in this study). Similarly, the third-commonest ST in this study, ST167, was
not seen at all in the global collection. However, ST131, the commonest ST in this study,
was again the commonest ST in the global collection.
The Roary pan-genome pipeline identified 2872 core genes in a pan genome of 44,840 genes;
this large pan-genome is consistent with the open E. coli pan genome that will continue
to increase in size as isolates are added. The core gene alignment contained 604,817 bases
with 77,194 variable sites, which were used to infer the maximum likelihood phylogenetic
tree, using the same nucleotide substitution model as previously.
The phylogeny is reconstructed in Figure 6.5. Isolates from this study are distributed
throughout the tree, and there is widespread mixing of isolates from diverse geographic
regions. Though invasive isolates are spread throughout the tree, there is a tendency for
them to cluster together, particularly in phylogroup B2, a phylogroup with has a recognised
association with ExPEC[350]. The Malawian ST410 and ST167 isolates clustered tightly
together, but by comparison, ST131 isolates from this study were distributed among ST131










































































Figure 6.4: Midpoint rooted maximum likelihood phylogenetic tree of included study E. coli isolates
showing phylogroups and sequence types. Bootstrap support of less than 90% is indicated by a
black circle at a given node. Scale bar indicates 0.01 SNPs/site.
















































Figure 6.5: Midpoint rooted maximum likelihood phylogenetic tree of included study E. coli placed
in the context of a global collection of genomes, showing phylogroups, source sample type and
continent of isolation (coloured bars). Dark grey bars indicate isolates from this study or isolates
with ESBL gene presence, as labelled (this study or ESBL, respectively). Three most frequently
isolated STs in the current study (131, 410 and 167) labelled. Bootstrap support of less than 90% is
















































































































































































































Malawi Thailand Guatemala Mexico Bolivia
Figure 6.6: Subtree of ST410 (A, left) and ST131 (B, right), and ST167 (C, bottom) showing
multiple introductions of ST131 into Malawi, in comparison to a single introduction of clonal ST410
and ST167 clades. Colour of tree tip label indicates isolation from this study (red) or other studies
(black), and coloured heatmap indicates country of isolation. Note that the scale bar in C is an
order of magnitude different from A and B.
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6.4.4 Antimicrobial resistance determinants
All identified AMR genes are shown in Figure 6.7A, alongside a summary of number of
isolates with resistance mutations to given antimicrobial classes (Figure 6.7B) and the
phenotypic resistance of the isolates for which phenotypic antimicrobial resistance testing
was carried out (449/473 [95%]). The isolates contained a median (IQR) of 16 (12-17)
resistance genes, and 100 different resistance alleles were identified in total. A description
of resistance gene by class is given below. In this section I consider and present data only
from the isolates from this study, rather than data from the context genomes presented
above.
6.4.4.1 β-lactam resistance
All isolates contained at least one gene that conferred resistance to third-generation
cephalosporins, either an ESBL gene (n= 472) or a carbapenemase (n=1). The ma-
jority of ESBL-gene containing isolates contained only one ESBL gene (459/472 [97%]);
fewer contained 2 (13/472 [3%]) and none contained more than 2. The blaCTX−M family
was most commonly represented in this collection, and 319/473 (67%) of isolates contained
blaCTXM−15. (26/473 [5%] of isolates) contained blaSHV genes. The β-lactamases blaTEM
and blaOXA were very common, most commonly the penicillinases blaOXA−1 and blaTEM−1
in 186/473 [39%] and 289/473 [61%] of isolates respectively. Plasmid-mediated blaampC
genes were identified in 45/473 (9%) of isolates, almost all (44/45) blaCMY−94, which was
lineage-restricted to the ST410 isolates. Presence of blaampC is unexpected as all of these
isolates were confirmed to be ESBL-producers by combination disc testing. This testing
uses cephalosporin-containing discs both with and without clavulanic acid, and confirms
EBSL production by a difference in zone size between these discs, as ESBL enzymes are
inactivated by clavulanic acid. However, the cephalosporins used in this test are likely to be
hydrolysed by ampC enzymes, and if these isolates were producing such enzymes it could
confer cephalosporin resistance regardless of the presence or absence of clavulanic acid. This
was not the case for any of these isolates; none of them hydrolysed the cephalosporins used
in the presence of clavulanic acid. It may be that the blaCMY genes were not expressed or
have been inactivated in the ST410 clade.
The single carbapenemase gene identified was s blaNDM−5; the isolate harbouring this gene
was recovered from the stool of a 67-year old man with no history of foreign travel nor
hospitalisation. He had been admitted to the hospital with fever seven days previously
and treated with seven days of intravenous ceftriaxone for sepsis, the source of which was
not clear. He made an uneventful recovery, and no carbapenemase-containing isolate was
recovered from his stool at any other time. The blaNDM−5 gene was carried on a partially
assembled IncX3 plasmid. BLAST of this assembly against the NCBI database showed
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that this contig had 99% sequence identity with a previously sequenced pNDM-MGR194
46.2 kbp blaNDM-5 containing Inc-X3 plasmid found in India between 2011-13[351]. We
fully assembled the plasmid by mapping reads back to pNDM-MGR194 with Burrows-
Wheeler alignment and found it to be extremely similar, with only 13 SNPs compared to
pNDM-MGR194.
6.4.4.2 Quinolone resistance
Quinolone resistance can be mediated by a number of different mechanisms and at least one
known determinant of quinolone resistance was present in 88% (418/473) isolates. 108/473
(23%) of isolates contained one of the the plasmid-mediated quinolone resistance (PMQR)
genes qnrS,qnrB or qepA; 172/473 (36%) carried the acetyltransferase aac(6’)-Ib-cr which
can hydrolyse fluoroquinolones with an amino nitrogen on the piperazinyl ring, such as
ciprofloxacin and norfloxacin[352]. Nonsynonymous mutations were identified in at least
one of the DNA gyrase subunits gyrA or gyrB or topoisomerase IV subunits parC or parE
in 349/449 (78%) of isolates. The majority of these mutations were well-described QRDR
mutations (codon 83 and 87 in gyrA, codon 80 and 84 in parC and codon 458 in parE[353],
Figure 6.8A), and they tended to cluster together (Figure 6.8B). Mutations in gyrB were
very unusual, with only 3 identified in the dataset.
The association between phenotypic and genotypic resistance is complex but some patterns
seem clear (Figure 6.8B). The well recognised constellation of mutations in gyrA at codon
83 and 87 and codon 80 of parC were strongly associated with phenotypic ciprofloxacin
resistance (OR 7.3 [95% CI 4.4-12.4], p < 0.001 by Fisher’s exact test), but gyrA codon
83 mutations alone seemed insufficient: of the 63 samples with this mutation alone and
available AST data only 30% (19/63) showed phenotypic resistance. Similarly, presence of
the qnrS plasmid-mediated gene seemed insufficient alone to confer phenotypic resistance:
of 57 samples in which this gene was present and AST data were available, only 25/57
(43%) had phenotypic ciprofloxacin resistance by disc diffusion testing.
6.4.4.3 Aminoglycoside resistance
The identified aminoglycoside resistance determinants are shown in Figure 6.9. Most
aminoglycoside resistance genes are classified into three families based on their ability
to acetylate, phosphorylate, or adenylate amino or hydroxyl groups found at various
positions around the aminoglycoside molecule, and are called acetyltransferases (AACs),
nucleotidyltranferases (ANTs), or phosphotransferases (APHs)[354]. They usually further
identified by the site of action in terms of the aminoglycoside carbon atom upon which
they act, subclass, and individual identifier. For example, the enzyme AAC(3)-Ib (gene
aac(3)-Ib) refers to an acetyltransferases acting at position 3 of subclass I and individual








































































































































































































































Figure 6.7: A: Frequency distribution of AMR genes identified in isolates. Class of antimicrobial
to which gene confers resistance is shown. B: Number of isolates with any mutation to a given
class. Any mutation that could possibly confer resistance to a given class is included, including any
mutation in the QRDR for quinolones. C: Phenotypic resistance patterns for subset of samples in
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Figure 6.8: A: Mutations in quinolone resistance-determining regions, showing that most mutations
are well-recognised (see text for details) B: Row and column clustered heatmap of commonest QRDR
mutations (gyrA83, gyrA87, parC80 or parE458 ), plamid-mediated quinolone resistance mutations
(qnr, qep or aac(6)̀-Ib-cr) and phenotypic resistance. The constellation of gyrA83, gyrA87 and
parC80 is strongly associated with phenotypic resistance, but gyrA83 or qnrS alone are insufficient to
confer resistance. Each row is one sample, red = presence, blue = absence. CIP R on AST indicates
those samples which are show phenotypic ciprofloxacin resistance on antimicrobial sensitivity testing
(AST). Those isolates without AST data are excluded from this heatmap.
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enzyme identifier b. All enzymes of a given class and subclass would be expected to confer
similar resistance. There is also a second nomenclature, where genes are referred to aac, aad
(instead of ANT) or aph, along with a letter to indicate side of modification; so aadA, for
example, is equivalent to ANT(3")-Ia[354]. There are some genes that confer aminoglycoside
resistance in different ways and are not included in this classification: the streptomycin
resistance genes strA and strB and the 16S rRNA methylase rmtB that confers resistance
to amikacin, gentamicin and gentamicin[355].
Aminoglycoside resistance genes were very common in the sequenced isolates, with 469/473
(99%) of isolates containing at least one aminoglycoside resistance gene, and most containing
multiple different genes: median number of aminoglycoside resistance genes per isolate was
4 (IQR 3-5). Despite streptomycin being absent from all Malawian treatment guidelines
save for retreatment of tuberculosis, the streptomycin resistance genes strA and strB were
near ubiquitous (Figure 6.9). Genes encoding the AAC and ANT enzyme families were
commonly seen: genes encoding ANT family enzymes were all aadA alleles (alternately
known as aad(3")-Ia) which would be expected to also confer streptomycin resistance.
Identified genes encoding AAC family enzymes were aac(3)-Ib and aac(3)-IIa, both of
which have been associated with gentamicin resistance, as has aac(6’)-Ib-cr which also
can confer resistance to quinolones. Genes encoding APH family enzymes were unusual.
Four were identified, and were all aph(3’)-Ia, which has been associated with amikacin and
kanamycin resistance. One rmtB gene was identified, which again has been associated with
amikacin resistance.
Genes of the aac family tended to co-occur (Figure 6.9B) and presence of any aac family
gene was strongly associated with gentamicin resistance (OR 9.3 [95% CI 6.0-14.8], p <
0.001). Of the five isolates that were resistant to amikacin on AST, two contained aac
family genes, five contained aad family genes and none contained rmtB or aph genes.
6.4.4.4 Chloramphenicol resistance
Presence of chloramphenicol resistance determinants was common; 248/473 (52%) of isolates
contained at least one chloramphenicol resistance gene (Figure 6.7), usually 1 (210/248
[85%]), less commonly 2 (37/248 [15%]) or 3 (1/248 [<1%]). The most commonly identified
gene was catB4, but presence of catB4 was not associated with phenotypic chloramphenicol
resistance (OR 0.9 [95% CI 0.6-1.4], p = 0.65). In comparison, presence of any other
chloramphenicol resistance gene was associated with phenotypic resistance (OR 2.5 [95%
CI 1.6-3.9], p < 0.001 for a composite variable of all other genes). The reason for this
is not clear, but in addition partially assembled catB4 genes were very common; of the
328 isolates in which there was no fully assembled catB4, 93% (306/323) were reported by




































































































Figure 6.9: A: Aminoglycoside mutations classified by expected resistance to gentamicin, amikacin
and kanamycin B: Row and column clustered heatmap showning phenotypic amikacin and gentamicin
resistance and identified aminoglycoside resistance genes. AadA indicates aadA genes, also referred to
as ANT(3")-Ia. Aac3_IIa and _IId refers to aac(3)-IIa and -IId genes respectively, and Aac6_Ib_cr
to aac(6’)-Ib-cr. Aph3 referrs to aph(3’)-Ia. GEN R on AST and AMK R on AST refer to samples
that were resistant to gentamicin or amikacin on antimicrobial sensitivity testing (AST). Each row
is one sample, red = presence, blue = absence. Samples lacking AST data were excluded from this
heatmap.
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seemed to be truncated by an IS26 insertion sequence (see Chapter 8).
6.4.4.5 Co-trimoxazole, tetracycline, macrolide and other resistance determi-
nants
Almost all isolates contained either a trimethoprim resistance (459/473 [97%]) or a
sulphonamide resistance gene (468/473 [99%]); only 3/473 isolates did not contain ei-
ther. Trimethoprim resistance genes were all of the dfrA family; sulII was the commonest
sulphonamide resistance determinant (Figures 6.7 and 6.10B). Phenotypic cotrimoxazole
resistance was also near-ubiquitous, in 96% (433/448) of those isolates in which antimicrobial
sensitivity testing was done.
Tetracycline and macrolide resistance genes were also very common: tetracycline resistance
determinants were identified in 411/473 (86%) of isolates, most commonly tetB (262/473
[55%] of isolates) and tetA (193/473 [41%] of isolates). Macrolide resistance determinants
were detected in 325/473 (69%); all isolates carried mphA most commonly alone but rarely
with ermB (9 isolates) or mefB (1 isolate). No antimicrobial sensitivity testing was carried
out for any agent of the tetracycline or macrolide class. Resistance determinants for
rifampicin (arr2 and arr3 ) were rarely identified, in 2 isolates and the sat2 gene, conferring
resistance to streptothricin (a nucleoside antibiotic with no clinical compounds in use) was
seen in 69/473 [15%] of isolates; the significance of this is unknown. Finally, the fosfomycin
resistance determinant fosA was seen in 28/473 [6%] of isolates, despite this antimicrobial
being unavailable in Malawi. It was not restricted to any one clade (Figure 6.13).
6.4.4.6 Clustering and lineage association of AMR determinants
Next, I explored associations of AMR determinants, both with each other in an attempt to
identify putative clusters that could represent mobile genetic elements (MGE) that could
be tracked within and between patients, and with lineages of the phylogeny. There was
clear clustering of AMR genes beyond what would be expected by chance (Figures 6.11 and
6.12), including clustering of the ESBL gene blaCTXM−15 with penicillinases blaOXA−1 and
blaTEM−1. Though some identified clusters correspond to known MGE (e.g. the sulII-strA-
strB cluster[356]), there was a clear lineage association of certain gene combinations on
mapping the presence or absence of AMR determinants back to the phylogeny (Figure 6.12),
meaning that these AMR-gene associations likely represent a combination of co-location on
MGE and confounding by association with lineage, and suggesting that using clusters of












































































Figure 6.10: Heatmap showning phenotypic chloramphenicol (A) and cotrimoxazole (B) resistance
and identified resistance genes that could be expected to confer resistance to these agents. Each row
is one sample, red = presence, blue = absence. Both heatmaps are row and column clustered.
6.4.5 Plasmid replicons
The frequency of isolation of different plasmid replicons is shown in Table 6.2 and presence
or absence of the identified plasmid replicons is shown mapped to the phylogeny in Figure
6.13. IncFIb was most commonly identified (399/473 [84%] of isolates), followed by IncFII
(383/473 [81%] of isolates) and IncF1a (324/373 [68%] of isolates). Col plasmids were also
frequently identified, in 308/473 [65%] of isolates. Once again, there seems to be some
lineage associations of presence or absence of replicons (Figure 6.13).
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In this chapter, I have presented the results of whole genome sequencing of 473 ESBL
E. coli recovered from serial sampling of 230 Malawian adults from a combination of
healthcare-associated and community settings. I have placed these Malawian isolates in the
context of the global diversity of E. coli using phylogroup, ST and phylogenetic modelling.
I have described the AMR determinants and plasmids present in the isolate of and explored
clustering of AMR genes.
6.5.1 Genomic landscape of ESBL E. coli in Malawi: global diversity
and high-risk clones
The E. coli recovered from stool of the study participants in this study are diverse,
encompassing the spectrum of diversity of the species with all major phylogroups and
56 STs represented. Phylogroup A was the commonest phylogroup seen, consistent with
the traditional view of this phylogroup as associated with commensal strains[350]. When
placed into the context of genomes from throughout the world, the Malawian isolates are
largely distributed throughout the phylogeny: in a global context, Malawi is sampling the
worldwide diversity of E. coli.
There were, however, several areas of the global phylogeny where the Malawian isolates
clustered tightly together, perhaps initially suggestive of Malawi-restricted clones; however
in considering the significance of this tree topology it is important to be cognisant of the
biases inherent in the global E. coli collection. ESBL-producing E. coli are unusual in the
ETEC[347] and GEMS[348] collections and all samples in these two studies were collected
before 2011. Both of these collections are exclusively recovered from stool. In contrast, the
clinical isolates from the Thai study[346] are all invasive, from a single centre, are selected
on the basis of being ESBL-producers, and were isolated in 2014 or 2015. The isolates
from the previous Malawian study were largely invasive[279], were selected for diversity
in AMR profile, and were all isolated before 2014. There was no study that selectively
cultured for ESBL producing E. coli in stool, as this study has done; in that, all of these















































































































































































































































































































































Figure 6.11: Row and column clustered heatmap of pairwise Jaccard index matrix, showing clustering
of AMR genes.


























Figure 6.12: Networks of associated (jaccard index > 0.5) AMR genes that occur more often than





































































































































































































































































































































































Figure 6.13: AMR genes (blue, chromasomal quinolone resistance and red, other AMR genes) and
plasmid replicons (purple) mapped back to tree showing that some AMR gene associations are also
associated with lineage.
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to apparent polyphyletic clustering of isolates from the current study in phylogroup A in
the global tree. It would be expected that ESBL producing phylogroup A E. coli would
be under-represented in the global collection compared to this study, as this phylogroup
is associated with commensal (and hence stool) associated strains, and the two studies
performing stool culture did not enrich for ESBL producers; the only study to do this
collected invasive isolates, which may be expected to lie in phylogroup B2 over A.
Nevertheless, two of the three commonest STs identified in this study, ST410 and ST167,
are unusual or absent in the global collection and could be considered to have a single
introduction into Malawi in the context of the topology of the inferred phylogenetic tree.
These could represent Malawi-restricted clades or, more likely given the diversity otherwise
seen in the tree, clades that are not represented in the global collection because of biases
in sample selection. ST410 is recognised as an emerging high-risk clone which has been
with isolated worldwide with some regularity since 2011 (including in Tanzania) and is
associated with blaCTXM−15 and blaNDM−5; coalescence analysis suggested a most recent
common ancestor of ST410 of the early 1800s (similar to ST131[189]), and acquisition
of blaCTXM−15 on a multireplicon IncFII-IncFIA-IncFIB plasmid in the late 1980s[357].
Similarly, ST167 has been recognised as commonly carrying ESBL genes and carbapenemases
in Chinese invasive isolates[358] - indeed, it was the commonest E. coli ST in one longitudinal
surveillance study of carbapenemases in 2012-16 in 25 Chinese provinces[359] - as well as
being very prevalent among meat-associated E. coli in Germany between 2011-2013 in one
study[360]. As such it, too, is also likely a successful global AMR-associated lineage. It
is therefore likely that these STs are not represented in the global tree because they have
recently emerged worldwide, and have also recently arrived in Malawi. If this is the case,
then ST410 and 167 have become rapidly established in Blantyre over the course of only
2-3 years (as they were not seen at all in the previous Malawian strain collection); in fact,
this is exactly what was seen in longitudinal nationwide genomic surveillance of E. coli in
the UK in 2003-04 when ST131 first arrived[361].
ST131 is a globally established high risk clone and the commonest ST in this study and
the global collection. Indeed this ST is thought to account for 40-80% of invasive ESBL E.
coli infection worldwide[188,362]. The topography of the global tree suggests no obvious
barriers to mixing between Malawian and global ST131. It may be that unbiased global
sampling would reveal the same pattern for ST167 and ST410. Though some progress
has been made in understanding the genomics of the emergence of ST131[189], the factors
that contribute to its apparent fitness are unknown: it is impossible to predict, at present,
from the genome of ST167 and ST410 whether they will repeat the course of ST131 to
become truly globally dominant as a cause of human disease. Such an understanding of the
determinants of fitness would be of great benefit in predicting and preventing global AMR
spread.
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6.5.2 Antimicrobial resistance determinants: domination of blaCTXM−15
and emergence of carbapenemases
The 473 isolates contained a diverse selection of antimicrobial resistance determinants, most
with genotypic multiclass resistance. Genotypic and phenotypic co-trimoxazole resistance
was near universal, as might be expected from a setting where lifelong co-trimoxazole
preventative therapy (CPT) is mandated by the Malawian HIV treatment guidelines for
HIV all infected adults[330], and mediated by dfrA and Sul alleles.
Determinants of aminoglycoside resistance were also present in almost every sample, most
commonly streptomycin resistance determinants, despite the lack of drug pressure. Well
recognised gentamicin-resistance determinants - aac(3) and aac(6") - were strongly associ-
ated with gentamicin resistance, but the aminoglycoside resistance genes present in isolates
displaying apparent amikacin resistance (aad5 and aac(3)) would not usually be expected
to confer amikacin resistance. Given the extreme rarity of phenotypic amikacin resistance,
re-testing these isolates with a more accurate AST method should be the first step (see
limitations, below).
Quinolone resistance determinants were also common. Quinolones are widely used in
Blantyre, and are the current treatment of choice for invasive Salmonella infections, one
of the commonest cause of bloodstream infection here[15]. The genotypic determinants of
quinolone resistance are complex, mediated by point mutations in the drug target regions,
acquisition of modifying enzymes or up regulation of multidrug resistance pumps, and
usually multiple genes or mutations are needed to bring about a resistant phenotype[363].
This is the pattern observed in this dataset where the proportion of isolates with identifiable
determinants of quinolone resistance was greater than those with phenotypic resistance.
Nevertheless, the genotype-phenotype associations seen in this data are largely those that
have been described in the literature: the gyrA83–parC80–gyrA87 mutation combination
has been shown to strongly predict combination quinolone resistance in a study of 10099 E.
coli genomes[364], and it is recognised that the presence of the qnrS gene alone is usually
not sufficient to bring about a resistant phenotype[365].
Presence of chloramphenicol resistance genes, particularly catB4, was more common than
phenotypic chloramphenicol resistance such that catB4 was not associated with phenotypic
resistance. This is unexpected, as presence of chloramphenicol resistance genes has been
shown to correlate well with phenotypic resistance[366], including in a study of 94 Malawian
invasive isolates[367], though in this Malawian collection (the same collection of isolates as
were included in the global collection in the current study), catB genes were rarely seen.
Interestingly, truncated catB4 elements (often in conjunction with an IS26 transposon)
were almost universal in the isolates in this study: of 323 isolates in which ARIBA
did not assemble a full catB4 sequence, 93% (306/323)) contained a truncated catB4
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element. This configuration (catB4 truncated by an IS26 element) has been described in
Enterobacteriaceae[368,369]. It could certainly be unrelated but its ubiquity in this study
raises at least the possibility of misassembly and false-positive identification of catB4 in
some cases. Laboratory errors resulting in erroneous AST should also be considered. It is
also possible that the catB4 gene in this collection is not expressed or downregulated in
some way; exploring these hypotheses is a possible direction for future work.
ESBL resistance in this collection is dominated by blaCTXM and blaCTXM−15 in particular;
this latter gene was carried by 319/473 [67%] of isolates. The only non-blaCTXM ESBL
gene identified in any significant prevalence was blaSHV−12; ESBL blaOXA and blaTEM
were very rare, though narrow-spectrum penicillinase alleles of this family were common.
The dominance of blaCTXM−15 is in keeping with the situation seen worldwide[155]. In
this collection, blaCTXM−15 was spread throughout the phylogeny rather than associated
with any particular clade, as would be expected from its global dominance. I identified
one carbapenemase, blaNDM−5, carried on a globally successful IncX3 plasmid. To my
knowledge, this is the first carbapenemase to be described in Malawi. Carbapenem
antimicrobials were introduced to the Malawian essential medicines list in 2015 but are
at best sporadically available, and only in tertiary centres, often for truncated courses.
The emergence of carbapenemases with such minimal carbapenem use and so soon after
introduction is troubling, and should prompt discussions regarding the best use of this
precious antimicrobial class; certainly, given the high prevalence of ESBL production among
invasive K. pneumoniae and E. coli[15], there is a case for expanded access but optimal
antimicrobial stewardship strategies in this context are unknown.
6.5.3 Study limitations
There are several limitations to the analysis carried out in this chapter. Only one E. coli pick
from each time point was sequenced which may have missed significant within-participant
diversity. This is seriously problematic for the analyses of the next chapter; here, diversity
may have been missed but the data presented here should at least reflect a random sample
from the E. coli carried by the participants in the study. Community isolates are under
represented, largely because of a lower ESBL-E prevalence in community members. The
sequenced E. coli isolates presented here do not represent all the samples in the study from
which ESBL producing E. coli were isolated, but only those up to the point at which the
samples were shipped for sequencing. I have focused on E. coli; in fact, these were often
isolated in conjunction with other bacteria, most notably Klebsiella pneumoniae, which
were not induced in this analysis. Given the propensity of K. pneumoniae to carry AMR
genes, the circulating AMR gene diversity in Enterobacteriaeciae carried by participants in
this study is likely greater than I describe here.
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For context genomes, I selected a global collection of E. coli based on what was available
but, as described above and in common with many analyses of this type, this is a biased
collection. This must be borne in mind when interpreting the global phylogeny. There are
inherent limitations in the short-read Illumina sequencing that was carried out: assembly
of areas with multiple nucleotide repeats (as found in plasmids and transposable elements
in particular) is difficult or impossible, making it impossible to fully characterise the MGE
in this dataset upon which the AMR genes are carried.
There are some discrepancies between phenotypic resistance and what would be expected
from identified genes. Partly phenotype may have been misclassified. The AST method
used was disc diffusion; certainly this is less accurate than an MIC determination method
such as E-tests or dilution methods, and a true comparison of genotypic to phenotypic
resistance - not the aim of this study - should use one of these methods. It is also possible
that there were technical problems with the AST procedure (e.g. an overly heavy inoculum)
though every attempt was made to avoid this, including with internal QC, and the work
was carried out in a laboratory which subscribes to the UK NEQAS QC procedure.
6.5.4 Conclusions and further work
In conclusion, I have shown that the E. coli population in this study is diverse, representing
global E. coli diversity, and suggesting significant mixing of E. coli between Blantyre
and the rest of the world. The AMR genes identified seem to reflect the local antibiotic
pressures: near universal cotrimoxazole resistance, moderate quinolone resistance and
very little carbapenem resistance. The presence of carbapenem resistance mediated by a
blaNDM−5 carbapenemase is to my knowledge the first carbapenemase described in Malawi.
Its presence along with apparently unrestricted mixing of E. coli from Malawi with the rest
of the world is a reminder that international spread of bacteria and AMR determinants,
even to low-resource settings like Malawi, can be rapid. Treatment options for invasive
Gram-negative infections in Malawi are often limited by ESBL resistance[15]. There is a
significant unmet need for carbapenem antibiotics, but antibiotic stewardship interventions
that can balance access to against restriction of these valuable last-line antimicrobials are
needed to prevent rapid emergence of resistance following wider-scale carbapenem roll-out
in Malawi.
Further work is planned:
• The discordance between chloramphenicol phenotype and genotype should be explored,
especially as this antibiotic - largely fallen from favour in Malawi since ceftriaxone
has been available - may have a role to play in treating some invasive ESBL-E
infections. Long-read sequencing of representative isolates will exclude the possibility
of missassembly and allow assessment of the genetic environment of the catB4 gene;
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it is possible that it has been downregulated or is not expressed, for example. More
accurate chloramphenicol AST using e.g. E-tests may also be helpful to confirm
phenotype, which should also be done with the apparent amikacin resistance isolates
presented here.
• The apparent recent arrival of the putative high-risk clones ST410 and ST167 deserves
further attention. The isolates here can be placed in a global context with other
publicly available ST410 and ST167 E. coli, but a question remains as to whether
these clones are causing invasive disease. This question can only be answered by
sequencing invasive isolates; this work is ongoing and will allow such a comparison to
be made.
• The remainder of the samples (post October 2018) will have one E. coli sent for
sequencing.
• All samples where K. pneumoniae were isolated will have one K. pneumoniae colony
pick sequenced allowing a comparative analysis of AMR determinants by K. pneumo-
niae and E. coli carried within a single participant.
• More broadly, I have presented a description of the isolates sequenced in this study,
but largely without reference to the available metadata. The motivation in sequencing
these isolates was to use WGS as a high-resolution typing scheme to track bacteria
within and between participants. This analysis is the focus of the next chapter.
6.6 Appendix
Table 6.3: Details of samples included in global phylogeny
Study Sample ID Accession No. Source Country
This study 26141_1_134 ERS2493389 Stool Malawi
This study 26141_1_135 ERS2493390 Stool Malawi
This study 26141_1_136 ERS2493391 Stool Malawi
This study 26141_1_137 ERS2493392 Stool Malawi
This study 26141_1_138 ERS2493393 Stool Malawi
This study 26141_1_139 ERS2493394 Stool Malawi
This study 26141_1_140 ERS2493395 Stool Malawi
This study 26141_1_141 ERS2493396 Stool Malawi
This study 26141_1_142 ERS2493397 Stool Malawi
This study 26141_1_143 ERS2493398 Stool Malawi
This study 26141_1_144 ERS2493399 Stool Malawi
This study 26141_1_145 ERS2493400 Stool Malawi
This study 26141_1_146 ERS2493401 Stool Malawi
This study 26141_1_147 ERS2493402 Stool Malawi
This study 26141_1_148 ERS2493403 Stool Malawi
This study 26141_1_149 ERS2493404 Stool Malawi
This study 26141_1_150 ERS2493405 Stool Malawi
This study 26141_1_151 ERS2493406 Stool Malawi
This study 26141_1_152 ERS2493407 Stool Malawi
This study 26141_1_153 ERS2493408 Stool Malawi
This study 26141_1_154 ERS2493409 Stool Malawi
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
This study 26141_1_155 ERS2493410 Stool Malawi
This study 26141_1_156 ERS2493411 Stool Malawi
This study 26141_1_157 ERS2493412 Stool Malawi
This study 26141_1_158 ERS2493413 Stool Malawi
This study 26141_1_159 ERS2493414 Stool Malawi
This study 26141_1_160 ERS2493415 Stool Malawi
This study 26141_1_161 ERS2493416 Stool Malawi
This study 26141_1_162 ERS2493417 Stool Malawi
This study 26141_1_164 ERS2493419 Stool Malawi
This study 26141_1_165 ERS2493420 Stool Malawi
This study 26141_1_166 ERS2493421 Stool Malawi
This study 26141_1_168 ERS2493423 Stool Malawi
This study 26141_1_169 ERS2493424 Stool Malawi
This study 26141_1_170 ERS2493425 Stool Malawi
This study 26141_1_171 ERS2493426 Stool Malawi
This study 26141_1_172 ERS2493427 Stool Malawi
This study 26141_1_173 ERS2493428 Stool Malawi
This study 26141_1_174 ERS2493429 Stool Malawi
This study 26141_1_175 ERS2493430 Stool Malawi
This study 26141_1_176 ERS2493431 Stool Malawi
This study 26141_1_177 ERS2493432 Stool Malawi
This study 26141_1_178 ERS2493433 Stool Malawi
This study 26141_1_179 ERS2493434 Stool Malawi
This study 26141_1_180 ERS2493435 Stool Malawi
This study 26141_1_181 ERS2493436 Stool Malawi
This study 26141_1_182 ERS2493437 Stool Malawi
This study 26141_1_183 ERS2493438 Stool Malawi
This study 26141_1_184 ERS2493439 Stool Malawi
This study 26141_1_186 ERS2493441 Stool Malawi
This study 26141_1_187 ERS2493442 Stool Malawi
This study 26141_1_189 ERS2493444 Stool Malawi
This study 26141_1_190 ERS2493445 Stool Malawi
This study 26141_1_191 ERS2493446 Stool Malawi
This study 26141_1_192 ERS2493447 Stool Malawi
This study 26141_1_193 ERS2493448 Stool Malawi
This study 26141_1_194 ERS2493449 Stool Malawi
This study 26141_1_195 ERS2493450 Stool Malawi
This study 26141_1_196 ERS2493451 Stool Malawi
This study 26141_1_197 ERS2493452 Stool Malawi
This study 26141_1_198 ERS2493453 Stool Malawi
This study 26141_1_199 ERS2493454 Stool Malawi
This study 26141_1_200 ERS2493456 Stool Malawi
This study 26141_1_201 ERS2493457 Stool Malawi
This study 26141_1_202 ERS2493458 Stool Malawi
This study 26141_1_203 ERS2493459 Stool Malawi
This study 26141_1_204 ERS2493460 Stool Malawi
This study 26141_1_205 ERS2493461 Stool Malawi
This study 26141_1_206 ERS2493463 Stool Malawi
This study 26141_1_207 ERS2493464 Stool Malawi
This study 26141_1_208 ERS2493465 Stool Malawi
This study 26141_1_209 ERS2493466 Stool Malawi
This study 26141_1_210 ERS2493468 Stool Malawi
This study 26141_1_211 ERS2493469 Stool Malawi
This study 26141_1_212 ERS2493470 Stool Malawi
This study 26141_1_213 ERS2493471 Stool Malawi
This study 26141_1_214 ERS2493472 Stool Malawi
This study 26141_1_215 ERS2493473 Stool Malawi
This study 26141_1_217 ERS2493475 Stool Malawi
This study 26141_1_218 ERS2493476 Stool Malawi
This study 26141_1_219 ERS2493477 Stool Malawi
This study 26141_1_220 ERS2493478 Stool Malawi
This study 26141_1_221 ERS2493479 Stool Malawi
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
This study 26141_1_222 ERS2493480 Stool Malawi
This study 26141_1_223 ERS2493481 Stool Malawi
This study 26141_1_224 ERS2493483 Stool Malawi
This study 26141_1_225 ERS2493484 Stool Malawi
This study 26141_1_226 ERS2493485 Stool Malawi
This study 26141_1_227 ERS2493486 Stool Malawi
This study 26141_1_228 ERS2493487 Stool Malawi
This study 26141_1_229 ERS2493488 Stool Malawi
This study 26141_1_230 ERS2493489 Stool Malawi
This study 26141_1_232 ERS2493491 Stool Malawi
This study 26141_1_236 ERS2493508 Stool Malawi
This study 26141_1_237 ERS2493509 Stool Malawi
This study 26141_1_239 ERS2493511 Stool Malawi
This study 26141_1_240 ERS2493512 Stool Malawi
This study 26141_1_241 ERS2493513 Stool Malawi
This study 26141_1_242 ERS2493515 Stool Malawi
This study 26141_1_243 ERS2493516 Stool Malawi
This study 26141_1_244 ERS2493517 Stool Malawi
This study 26141_1_246 ERS2493519 Stool Malawi
This study 26141_1_247 ERS2493520 Stool Malawi
This study 26141_1_248 ERS2493521 Stool Malawi
This study 26141_1_250 ERS2493495 Stool Malawi
This study 26141_1_251 ERS2493496 Stool Malawi
This study 26141_1_252 ERS2493497 Stool Malawi
This study 26141_1_253 ERS2493498 Stool Malawi
This study 26141_1_254 ERS2493499 Stool Malawi
This study 26141_1_255 ERS2493501 Stool Malawi
This study 26141_1_256 ERS2493502 Stool Malawi
This study 26141_1_257 ERS2493503 Stool Malawi
This study 26141_1_258 ERS2493504 Stool Malawi
This study 26141_1_259 ERS2493505 Stool Malawi
This study 26141_1_260 ERS2493506 Stool Malawi
This study 26141_1_261 ERS2493522 Stool Malawi
This study 26141_1_262 ERS2493523 Stool Malawi
This study 26141_1_263 ERS2493524 Stool Malawi
This study 26141_1_265 ERS2493526 Stool Malawi
This study 26141_1_266 ERS2493527 Stool Malawi
This study 26141_1_267 ERS2493528 Stool Malawi
This study 26141_1_268 ERS2493529 Stool Malawi
This study 26141_1_270 ERS2493531 Stool Malawi
This study 26141_1_271 ERS2493532 Stool Malawi
This study 26141_1_272 ERS2493533 Stool Malawi
This study 26141_1_273 ERS2493534 Stool Malawi
This study 26141_1_274 ERS2493537 Stool Malawi
This study 26141_1_275 ERS2493538 Stool Malawi
This study 26141_1_276 ERS2493539 Stool Malawi
This study 26141_1_277 ERS2493540 Stool Malawi
This study 26141_1_278 ERS2493541 Stool Malawi
This study 26141_1_279 ERS2493542 Stool Malawi
This study 26141_1_280 ERS2493543 Stool Malawi
This study 26141_1_282 ERS2493545 Stool Malawi
This study 26141_1_283 ERS2493546 Stool Malawi
This study 26141_1_284 ERR3168700 Stool Malawi
This study 26141_1_285 ERS2493548 Stool Malawi
This study 26141_1_286 ERS2493549 Stool Malawi
This study 26141_1_287 ERS2493550 Stool Malawi
This study 26141_1_288 ERS2493551 Stool Malawi
This study 26141_1_289 ERS2493552 Stool Malawi
This study 26141_1_290 ERS2493553 Stool Malawi
This study 26141_1_291 ERS2493554 Stool Malawi
This study 26141_1_292 ERS2493555 Stool Malawi
This study 26141_1_293 ERS2493556 Stool Malawi
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
This study 26141_1_295 ERS2493558 Stool Malawi
This study 26141_1_296 ERS2493560 Stool Malawi
This study 26141_1_297 ERS2493561 Stool Malawi
This study 26141_1_298 ERS2493563 Stool Malawi
This study 26141_1_299 ERS2493564 Stool Malawi
This study 28099_1_1 ERS2855095 Stool Malawi
This study 28099_1_10 ERS2855097 Stool Malawi
This study 28099_1_100 ERS2855215 Stool Malawi
This study 28099_1_102 ERS2855046 Stool Malawi
This study 28099_1_103 ERS2855121 Stool Malawi
This study 28099_1_104 ERS2855216 Stool Malawi
This study 28099_1_106 ERS2855047 Stool Malawi
This study 28099_1_107 ERS2855122 Stool Malawi
This study 28099_1_11 ERS2855194 Stool Malawi
This study 28099_1_110 ERS2855048 Stool Malawi
This study 28099_1_111 ERS2855123 Stool Malawi
This study 28099_1_112 ERS2855218 Stool Malawi
This study 28099_1_114 ERS2855049 Stool Malawi
This study 28099_1_115 ERS2855124 Stool Malawi
This study 28099_1_116 ERS2855219 Stool Malawi
This study 28099_1_118 ERS2855050 Stool Malawi
This study 28099_1_119 ERS2855125 Stool Malawi
This study 28099_1_120 ERS2855220 Stool Malawi
This study 28099_1_123 ERS2855126 Stool Malawi
This study 28099_1_125 ERS2855222 Stool Malawi
This study 28099_1_127 ERS2855019 Stool Malawi
This study 28099_1_128 ERS2855127 Stool Malawi
This study 28099_1_129 ERS2855223 Stool Malawi
This study 28099_1_131 ERS2855020 Stool Malawi
This study 28099_1_132 ERS2855128 Stool Malawi
This study 28099_1_133 ERS2855225 Stool Malawi
This study 28099_1_135 ERS2855021 Stool Malawi
This study 28099_1_136 ERS2855129 Stool Malawi
This study 28099_1_137 ERS2855226 Stool Malawi
This study 28099_1_139 ERS2855022 Stool Malawi
This study 28099_1_14 ERS2855098 Stool Malawi
This study 28099_1_141 ERS2855227 Stool Malawi
This study 28099_1_143 ERS2855023 Stool Malawi
This study 28099_1_144 ERS2855131 Stool Malawi
This study 28099_1_145 ERS2855228 Stool Malawi
This study 28099_1_148 ERS2855132 Stool Malawi
This study 28099_1_149 ERS2855229 Stool Malawi
This study 28099_1_151 ERS2855025 Stool Malawi
This study 28099_1_152 ERS2855133 Stool Malawi
This study 28099_1_153 ERS2855230 Stool Malawi
This study 28099_1_155 ERS2855026 Stool Malawi
This study 28099_1_156 ERS2855134 Stool Malawi
This study 28099_1_157 ERS2855231 Stool Malawi
This study 28099_1_159 ERS2855027 Stool Malawi
This study 28099_1_160 ERS2855135 Stool Malawi
This study 28099_1_161 ERS2855232 Stool Malawi
This study 28099_1_163 ERS2855028 Stool Malawi
This study 28099_1_165 ERS2855233 Stool Malawi
This study 28099_1_167 ERS2855029 Stool Malawi
This study 28099_1_168 ERS2855137 Stool Malawi
This study 28099_1_169 ERS2855234 Stool Malawi
This study 28099_1_171 ERS2855030 Stool Malawi
This study 28099_1_172 ERS2855138 Stool Malawi
This study 28099_1_173 ERS2855235 Stool Malawi
This study 28099_1_175 ERS2855031 Stool Malawi
This study 28099_1_176 ERS2855139 Stool Malawi
This study 28099_1_177 ERS2855236 Stool Malawi
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
This study 28099_1_179 ERS2855032 Stool Malawi
This study 28099_1_18 ERS2855099 Stool Malawi
This study 28099_1_180 ERS2855140 Stool Malawi
This study 28099_1_181 ERS2855237 Stool Malawi
This study 28099_1_185 ERS2855238 Stool Malawi
This study 28099_1_187 ERS2855034 Stool Malawi
This study 28099_1_188 ERS2855141 Stool Malawi
This study 28099_1_189 ERS2855239 Stool Malawi
This study 28099_1_19 ERS2855195 Stool Malawi
This study 28099_1_191 ERS2855035 Stool Malawi
This study 28099_1_192 ERS2855142 Stool Malawi
This study 28099_1_193 ERS2855240 Stool Malawi
This study 28099_1_195 ERS2855036 Stool Malawi
This study 28099_1_196 ERS2855143 Stool Malawi
This study 28099_1_199 ERS2855037 Stool Malawi
This study 28099_1_2 ERS2855192 Stool Malawi
This study 28099_1_200 ERS2855144 Stool Malawi
This study 28099_1_203 ERS2855038 Stool Malawi
This study 28099_1_204 ERS2855145 Stool Malawi
This study 28099_1_205 ERS2855243 Stool Malawi
This study 28099_1_207 ERS2855039 Stool Malawi
This study 28099_1_208 ERS2855146 Stool Malawi
This study 28099_1_209 ERS2855244 Stool Malawi
This study 28099_1_211 ERS2855051 Stool Malawi
This study 28099_1_212 ERS2855147 Stool Malawi
This study 28099_1_213 ERS2855148 Stool Malawi
This study 28099_1_214 ERS2855245 Stool Malawi
This study 28099_1_216 ERS2855052 Stool Malawi
This study 28099_1_217 ERS2855149 Stool Malawi
This study 28099_1_218 ERS2855246 Stool Malawi
This study 28099_1_22 ERS2855100 Stool Malawi
This study 28099_1_220 ERS2855053 Stool Malawi
This study 28099_1_221 ERS2855150 Stool Malawi
This study 28099_1_222 ERS2855247 Stool Malawi
This study 28099_1_224 ERS2855054 Stool Malawi
This study 28099_1_225 ERS2855151 Stool Malawi
This study 28099_1_226 ERS2855248 Stool Malawi
This study 28099_1_228 ERS2855055 Stool Malawi
This study 28099_1_229 ERS2855152 Stool Malawi
This study 28099_1_23 ERS2855196 Stool Malawi
This study 28099_1_230 ERS2855249 Stool Malawi
This study 28099_1_232 ERS2855056 Stool Malawi
This study 28099_1_233 ERS2855153 Stool Malawi
This study 28099_1_234 ERS2855250 Stool Malawi
This study 28099_1_236 ERS2855057 Stool Malawi
This study 28099_1_237 ERS2855154 Stool Malawi
This study 28099_1_238 ERS2855251 Stool Malawi
This study 28099_1_240 ERS2855058 Stool Malawi
This study 28099_1_241 ERS2855155 Stool Malawi
This study 28099_1_242 ERS2855252 Stool Malawi
This study 28099_1_244 ERS2855059 Stool Malawi
This study 28099_1_245 ERS2855156 Stool Malawi
This study 28099_1_246 ERS2855253 Stool Malawi
This study 28099_1_248 ERS2855060 Stool Malawi
This study 28099_1_249 ERS2855157 Stool Malawi
This study 28099_1_250 ERS2855254 Stool Malawi
This study 28099_1_252 ERS2855061 Stool Malawi
This study 28099_1_253 ERS2855158 Stool Malawi
This study 28099_1_254 ERS2855255 Stool Malawi
This study 28099_1_256 ERS2855062 Stool Malawi
This study 28099_1_257 ERS2855160 Stool Malawi
This study 28099_1_258 ERS2855256 Stool Malawi
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
This study 28099_1_26 ERS2855101 Stool Malawi
This study 28099_1_260 ERS2855063 Stool Malawi
This study 28099_1_261 ERS2855161 Stool Malawi
This study 28099_1_264 ERS2855064 Stool Malawi
This study 28099_1_266 ERS2855258 Stool Malawi
This study 28099_1_268 ERS2855065 Stool Malawi
This study 28099_1_269 ERS2855163 Stool Malawi
This study 28099_1_27 ERS2855197 Stool Malawi
This study 28099_1_270 ERS2855259 Stool Malawi
This study 28099_1_272 ERS2855066 Stool Malawi
This study 28099_1_273 ERS2855164 Stool Malawi
This study 28099_1_274 ERS2855260 Stool Malawi
This study 28099_1_277 ERS2855165 Stool Malawi
This study 28099_1_278 ERS2855269 Stool Malawi
This study 28099_1_280 ERS2855068 Stool Malawi
This study 28099_1_281 ERS2855166 Stool Malawi
This study 28099_1_282 ERS2855270 Stool Malawi
This study 28099_1_284 ERS2855069 Stool Malawi
This study 28099_1_285 ERS2855167 Stool Malawi
This study 28099_1_286 ERS2855271 Stool Malawi
This study 28099_1_288 ERS2855070 Stool Malawi
This study 28099_1_289 ERS2855168 Stool Malawi
This study 28099_1_293 ERS2855169 Stool Malawi
This study 28099_1_294 ERS2855273 Stool Malawi
This study 28099_1_297 ERS2855170 Stool Malawi
This study 28099_1_30 ERS2855102 Stool Malawi
This study 28099_1_300 ERS2855073 Stool Malawi
This study 28099_1_301 ERS2855074 Stool Malawi
This study 28099_1_302 ERS2855171 Stool Malawi
This study 28099_1_303 ERS2855275 Stool Malawi
This study 28099_1_305 ERS2855075 Stool Malawi
This study 28099_1_306 ERS2855172 Stool Malawi
This study 28099_1_307 ERS2855276 Stool Malawi
This study 28099_1_309 ERS2855076 Stool Malawi
This study 28099_1_31 ERS2855198 Stool Malawi
This study 28099_1_311 ERS2855277 Stool Malawi
This study 28099_1_313 ERS2855077 Stool Malawi
This study 28099_1_314 ERS2855174 Stool Malawi
This study 28099_1_315 ERS2855278 Stool Malawi
This study 28099_1_317 ERS2855078 Stool Malawi
This study 28099_1_318 ERS2855175 Stool Malawi
This study 28099_1_319 ERS2855279 Stool Malawi
This study 28099_1_321 ERS2855079 Stool Malawi
This study 28099_1_322 ERS2855176 Stool Malawi
This study 28099_1_323 ERS2855280 Stool Malawi
This study 28099_1_325 ERS2855080 Stool Malawi
This study 28099_1_326 ERS2855177 Stool Malawi
This study 28099_1_327 ERS2855281 Stool Malawi
This study 28099_1_329 ERS2855081 Stool Malawi
This study 28099_1_330 ERS2855178 Stool Malawi
This study 28099_1_331 ERS2855282 Stool Malawi
This study 28099_1_333 ERS2855082 Stool Malawi
This study 28099_1_334 ERS2855179 Stool Malawi
This study 28099_1_335 ERS2855283 Stool Malawi
This study 28099_1_337 ERS2855083 Stool Malawi
This study 28099_1_338 ERS2855180 Stool Malawi
This study 28099_1_339 ERS2855284 Stool Malawi
This study 28099_1_34 ERS2855103 Stool Malawi
This study 28099_1_341 ERS2855084 Stool Malawi
This study 28099_1_342 ERS2855181 Stool Malawi
This study 28099_1_343 ERS2855285 Stool Malawi
This study 28099_1_345 ERS2855085 Stool Malawi
6.6. APPENDIX 203
Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
This study 28099_1_346 ERS2855182 Stool Malawi
This study 28099_1_347 ERS2855286 Stool Malawi
This study 28099_1_349 ERS2855086 Stool Malawi
This study 28099_1_35 ERS2855199 Stool Malawi
This study 28099_1_350 ERS2855183 Stool Malawi
This study 28099_1_351 ERS2855287 Stool Malawi
This study 28099_1_353 ERS2855087 Stool Malawi
This study 28099_1_354 ERS2855184 Stool Malawi
This study 28099_1_355 ERS2855288 Stool Malawi
This study 28099_1_357 ERS2855088 Stool Malawi
This study 28099_1_358 ERS2855185 Stool Malawi
This study 28099_1_359 ERS2855289 Stool Malawi
This study 28099_1_361 ERS2855089 Stool Malawi
This study 28099_1_362 ERS2855186 Stool Malawi
This study 28099_1_363 ERS2855290 Stool Malawi
This study 28099_1_365 ERS2855090 Stool Malawi
This study 28099_1_366 ERS2855187 Stool Malawi
This study 28099_1_367 ERS2855291 Stool Malawi
This study 28099_1_370 ERS2855188 Stool Malawi
This study 28099_1_371 ERS2855292 Stool Malawi
This study 28099_1_373 ERS2855092 Stool Malawi
This study 28099_1_374 ERS2855189 Stool Malawi
This study 28099_1_375 ERS2855261 Stool Malawi
This study 28099_1_377 ERS2855093 Stool Malawi
This study 28099_1_378 ERS2855190 Stool Malawi
This study 28099_1_379 ERS2855262 Stool Malawi
This study 28099_1_38 ERS2855104 Stool Malawi
This study 28099_1_381 ERS2855094 Stool Malawi
This study 28099_1_382 ERS2855191 Stool Malawi
This study 28099_1_383 ERS2855263 Stool Malawi
This study 28099_1_39 ERS2855200 Stool Malawi
This study 28099_1_41 ERS2855009 Stool Malawi
This study 28099_1_42 ERS2855106 Stool Malawi
This study 28099_1_43 ERS2855201 Stool Malawi
This study 28099_1_46 ERS2855107 Stool Malawi
This study 28099_1_47 ERS2855202 Stool Malawi
This study 28099_1_49 ERS2855011 Stool Malawi
This study 28099_1_50 ERS2855108 Stool Malawi
This study 28099_1_51 ERS2855203 Stool Malawi
This study 28099_1_53 ERS2855012 Stool Malawi
This study 28099_1_54 ERS2855109 Stool Malawi
This study 28099_1_55 ERS2855204 Stool Malawi
This study 28099_1_57 ERS2855013 Stool Malawi
This study 28099_1_58 ERS2855110 Stool Malawi
This study 28099_1_59 ERS2855205 Stool Malawi
This study 28099_1_61 ERS2855014 Stool Malawi
This study 28099_1_62 ERS2855111 Stool Malawi
This study 28099_1_63 ERS2855206 Stool Malawi
This study 28099_1_65 ERS2855015 Stool Malawi
This study 28099_1_66 ERS2855112 Stool Malawi
This study 28099_1_69 ERS2855016 Stool Malawi
This study 28099_1_7 ERS2855193 Stool Malawi
This study 28099_1_70 ERS2855113 Stool Malawi
This study 28099_1_71 ERS2855208 Stool Malawi
This study 28099_1_73 ERS2855017 Stool Malawi
This study 28099_1_74 ERS2855114 Stool Malawi
This study 28099_1_75 ERS2855209 Stool Malawi
This study 28099_1_77 ERS2855040 Stool Malawi
This study 28099_1_78 ERS2855115 Stool Malawi
This study 28099_1_79 ERS2855210 Stool Malawi
This study 28099_1_81 ERS2855041 Stool Malawi
This study 28099_1_82 ERS2855116 Stool Malawi
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This study 28099_1_83 ERS2855211 Stool Malawi
This study 28099_1_85 ERS2855042 Stool Malawi
This study 28099_1_86 ERS2855117 Stool Malawi
This study 28099_1_87 ERS2855212 Stool Malawi
This study 28099_1_89 ERS2855043 Stool Malawi
This study 28099_1_90 ERS2855118 Stool Malawi
This study 28099_1_91 ERS2855213 Stool Malawi
This study 28099_1_93 ERS2855044 Stool Malawi
This study 28099_1_94 ERS2855119 Stool Malawi
This study 28099_1_95 ERS2855214 Stool Malawi
This study 28099_1_98 ERS2855045 Stool Malawi
This study 28099_1_99 ERS2855120 Stool Malawi
This study 28099_2_101 ERS2855313 Stool Malawi
This study 28099_2_105 ERS2855314 Stool Malawi
This study 28099_2_109 ERS2855315 Stool Malawi
This study 28099_2_113 ERS2855316 Stool Malawi
This study 28099_2_117 ERS2855317 Stool Malawi
This study 28099_2_12 ERS2855266 Stool Malawi
This study 28099_2_121 ERS2855318 Stool Malawi
This study 28099_2_126 ERS2855319 Stool Malawi
This study 28099_2_130 ERS2855320 Stool Malawi
This study 28099_2_138 ERS2855322 Stool Malawi
This study 28099_2_142 ERS2855323 Stool Malawi
This study 28099_2_146 ERS2855324 Stool Malawi
This study 28099_2_150 ERS2855325 Stool Malawi
This study 28099_2_154 ERS2855326 Stool Malawi
This study 28099_2_158 ERS2855327 Stool Malawi
This study 28099_2_16 ERS2855267 Stool Malawi
This study 28099_2_162 ERS2855328 Stool Malawi
This study 28099_2_166 ERS2855329 Stool Malawi
This study 28099_2_170 ERS2855330 Stool Malawi
This study 28099_2_174 ERS2855331 Stool Malawi
This study 28099_2_178 ERS2855332 Stool Malawi
This study 28099_2_182 ERS2855333 Stool Malawi
This study 28099_2_186 ERS2855334 Stool Malawi
This study 28099_2_190 ERS2855335 Stool Malawi
This study 28099_2_194 ERS2855336 Stool Malawi
This study 28099_2_198 ERS2855337 Stool Malawi
This study 28099_2_206 ERS2855339 Stool Malawi
This study 28099_2_210 ERS2855340 Stool Malawi
This study 28099_2_215 ERS2855341 Stool Malawi
This study 28099_2_219 ERS2855342 Stool Malawi
This study 28099_2_223 ERS2855343 Stool Malawi
This study 28099_2_227 ERS2855344 Stool Malawi
This study 28099_2_231 ERS2855345 Stool Malawi
This study 28099_2_235 ERS2855346 Stool Malawi
This study 28099_2_239 ERS2855347 Stool Malawi
This study 28099_2_24 ERS2855293 Stool Malawi
This study 28099_2_243 ERS2855349 Stool Malawi
This study 28099_2_247 ERS2855350 Stool Malawi
This study 28099_2_251 ERS2855351 Stool Malawi
This study 28099_2_255 ERS2855352 Stool Malawi
This study 28099_2_259 ERS2855353 Stool Malawi
This study 28099_2_263 ERS2855354 Stool Malawi
This study 28099_2_283 ERS2855359 Stool Malawi
This study 28099_2_287 ERS2855360 Stool Malawi
This study 28099_2_291 ERS2855361 Stool Malawi
This study 28099_2_295 ERS2855362 Stool Malawi
This study 28099_2_299 ERS2855363 Stool Malawi
This study 28099_2_3 ERS2855264 Stool Malawi
This study 28099_2_304 ERS2855364 Stool Malawi
This study 28099_2_308 ERS2855365 Stool Malawi
6.6. APPENDIX 205
Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
This study 28099_2_316 ERS2855224 Stool Malawi
This study 28099_2_32 ERS2855295 Stool Malawi
This study 28099_2_320 ERS2855348 Stool Malawi
This study 28099_2_36 ERS2855296 Stool Malawi
This study 28099_2_40 ERS2855297 Stool Malawi
This study 28099_2_44 ERS2855298 Stool Malawi
This study 28099_2_48 ERS2855299 Stool Malawi
This study 28099_2_56 ERS2855301 Stool Malawi
This study 28099_2_60 ERS2855302 Stool Malawi
This study 28099_2_64 ERS2855303 Stool Malawi
This study 28099_2_76 ERS2855306 Stool Malawi
This study 28099_2_8 ERS2855265 Stool Malawi
This study 28099_2_80 ERS2855307 Stool Malawi
This study 28099_2_84 ERS2855308 Stool Malawi
This study 28099_2_88 ERS2855309 Stool Malawi
This study 28099_2_92 ERS2855310 Stool Malawi
This study 28099_2_96 ERS2855311 Stool Malawi
This study 28099_2_97 ERS2855312 Stool Malawi
Ingle 2018 100269_aEPEC ERR134513 Stool Gambia
Ingle 2018 100383_aEPEC ERR137807 Stool Gambia
Ingle 2018 100446 ERR178176 Stool Gambia
Ingle 2018 100554_aEPEC ERR134514 Stool Gambia
Ingle 2018 100600_aEPEC ERR134515 Stool Gambia
Ingle 2018 102010_aEPEC ERR137808 Stool Gambia
Ingle 2018 102014_aEPEC ERR137809 Stool Gambia
Ingle 2018 102298_aEPEC ERR134516 Stool Gambia
Ingle 2018 102328_aEPEC ERR134517 Stool Gambia
Ingle 2018 102366_aEPEC ERR137810 Stool Gambia
Ingle 2018 102485_aEPEC ERR134518 Stool Gambia
Ingle 2018 103151 ERR178192 Stool Gambia
Ingle 2018 200135_aEPEC ERR134519 Stool Mali
Ingle 2018 200232 ERR178150 Stool Mali
Ingle 2018 200439_aEPEC ERR134520 Stool Mali
Ingle 2018 200456_aEPEC ERR137812 Stool Mali
Ingle 2018 200499 ERR178148 Stool Mali
Ingle 2018 200696 ERR178151 Stool Mali
Ingle 2018 200708_aEPEC ERR137782 Stool Mali
Ingle 2018 200758_aEPEC ERR137783 Stool Mali
Ingle 2018 200781_aEPEC ERR124658 Stool Mali
Ingle 2018 200959_aEPEC ERR137813 Stool Mali
Ingle 2018 201191_aEPEC ERR137814 Stool Mali
Ingle 2018 201214_aEPEC ERR134521 Stool Mali
Ingle 2018 201350 ERR178216 Stool Mali
Ingle 2018 201381_aEPEC ERR137784 Stool Mali
Ingle 2018 201488_aEPEC ERR137815 Stool Mali
Ingle 2018 201534_aEPEC ERR134522 Stool Mali
Ingle 2018 201589_aEPEC ERR137816 Stool Mali
Ingle 2018 202317_aEPEC ERR137817 Stool Mali
Ingle 2018 202374 ERR178152 Stool Mali
Ingle 2018 202387 ERR178149 Stool Mali
Ingle 2018 202423_aEPEC ERR134523 Stool Mali
Ingle 2018 202443_aEPEC ERR134524 Stool Mali
Ingle 2018 202453_aEPEC ERR134525 Stool Mali
Ingle 2018 202474 ERR178153 Stool Mali
Ingle 2018 202521_aEPEC ERR124659 Stool Mali
Ingle 2018 202621_aEPEC ERR137818 Stool Mali
Ingle 2018 202833_aEPEC ERR134526 Stool Mali
Ingle 2018 202973_aEPEC ERR134527 Stool Mali
Ingle 2018 203470_aEPEC ERR124660 Stool Mali
Ingle 2018 204263_aEPEC ERR124661 Stool Mali
Ingle 2018 204302_aEPEC ERR134528 Stool Mali
Ingle 2018 300073 ERR178193 Stool Mozambique
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Ingle 2018 300086_aEPEC ERR134529 Stool Mozambique
Ingle 2018 300711_aEPEC ERR134530 Stool Mozambique
Ingle 2018 300795_aEPEC ERR134531 Stool Mozambique
Ingle 2018 300812_aEPEC ERR137819 Stool Mozambique
Ingle 2018 300814_aEPEC ERR137820 Stool Mozambique
Ingle 2018 302082 ERR178198 Stool Mozambique
Ingle 2018 302302 ERR178154 Stool Mozambique
Ingle 2018 302613 ERR178210 Stool Mozambique
Ingle 2018 302619 ERR178211 Stool Mozambique
Ingle 2018 302700 ERR178217 Stool Mozambique
Ingle 2018 302701 ERR178212 Stool Mozambique
Ingle 2018 302710 ERR178218 Stool Mozambique
Ingle 2018 400549_aEPEC ERR137785 Stool Kenya
Ingle 2018 400654_aEPEC ERR137786 Stool Kenya
Ingle 2018 400714_aEPEC ERR137787 Stool Kenya
Ingle 2018 400896 ERR178177 Stool Kenya
Ingle 2018 400897_aEPEC ERR137821 Stool Kenya
Ingle 2018 400998_aEPEC ERR137789 Stool Kenya
Ingle 2018 401082 ERR178178 Stool Kenya
Ingle 2018 401117_aEPEC ERR137822 Stool Kenya
Ingle 2018 401174_aEPEC ERR137823 Stool Kenya
Ingle 2018 401250_aEPEC ERR137790 Stool Kenya
Ingle 2018 401352 ERR178199 Stool Kenya
Ingle 2018 401363 ERR178179 Stool Kenya
Ingle 2018 401480_aEPEC ERR124657 Stool Kenya
Ingle 2018 401553 ERR178155 Stool Kenya
Ingle 2018 401596_aEPEC ERR137791 Stool Kenya
Ingle 2018 401686 ERR178200 Stool Kenya
Ingle 2018 401709_aEPEC ERR137824 Stool Kenya
Ingle 2018 401886_aEPEC ERR137792 Stool Kenya
Ingle 2018 401907 ERR178201 Stool Kenya
Ingle 2018 401938_aEPEC ERR137793 Stool Kenya
Ingle 2018 402048_aEPEC ERR134532 Stool Kenya
Ingle 2018 402058_aEPEC ERR137825 Stool Kenya
Ingle 2018 402074_aEPEC ERR137794 Stool Kenya
Ingle 2018 402078 ERR178180 Stool Kenya
Ingle 2018 402097_aEPEC ERR137826 Stool Kenya
Ingle 2018 402099_aEPEC ERR134533 Stool Kenya
Ingle 2018 402138_aEPEC ERR124662 Stool Kenya
Ingle 2018 402227_aEPEC ERR137827 Stool Kenya
Ingle 2018 402248_aEPEC ERR134534 Stool Kenya
Ingle 2018 402403 ERR178181 Stool Kenya
Ingle 2018 402480_aEPEC ERR137795 Stool Kenya
Ingle 2018 402605 ERR178194 Stool Kenya
Ingle 2018 402617 ERR178156 Stool Kenya
Ingle 2018 402635 ERR178157 Stool Kenya
Ingle 2018 402654_aEPEC ERR134535 Stool Kenya
Ingle 2018 402696 ERR178202 Stool Kenya
Ingle 2018 402743_aEPEC ERR137796 Stool Kenya
Ingle 2018 402767 ERR178203 Stool Kenya
Ingle 2018 402770_aEPEC ERR134536 Stool Kenya
Ingle 2018 402780_aEPEC ERR137797 Stool Kenya
Ingle 2018 402794 ERR178204 Stool Kenya
Ingle 2018 402798 ERR178182 Stool Kenya
Ingle 2018 402837 ERR178183 Stool Kenya
Ingle 2018 402842 ERR178205 Stool Kenya
Ingle 2018 402898 ERR178184 Stool Kenya
Ingle 2018 402924 ERR178158 Stool Kenya
Ingle 2018 402977_aEPEC ERR137798 Stool Kenya
Ingle 2018 403066 ERR178159 Stool Kenya
Ingle 2018 403096_aEPEC ERR137799 Stool Kenya
Ingle 2018 403128_aEPEC ERR134537 Stool Kenya
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Ingle 2018 403308_aEPEC ERR134538 Stool Kenya
Ingle 2018 403523 ERR178206 Stool Kenya
Ingle 2018 403726_aEPEC ERR137800 Stool Kenya
Ingle 2018 403728 ERR178161 Stool Kenya
Ingle 2018 500094 ERR178207 Stool India
Ingle 2018 500095 ERR178208 Stool India
Ingle 2018 500193 ERR178213 Stool India
Ingle 2018 500197_aEPEC ERR137828 Stool India
Ingle 2018 500275_aEPEC ERR134539 Stool India
Ingle 2018 500618_aEPEC ERR134540 Stool India
Ingle 2018 500858_aEPEC ERR134541 Stool India
Ingle 2018 500864_aEPEC ERR134542 Stool India
Ingle 2018 500989 ERR178164 Stool India
Ingle 2018 501016 ERR178195 Stool India
Ingle 2018 501029_aEPEC ERR134543 Stool India
Ingle 2018 503023 ERR178196 Stool India
Ingle 2018 503028_aEPEC ERR134544 Stool India
Ingle 2018 503130_aEPEC ERR137829 Stool India
Ingle 2018 503225_aEPEC ERR134545 Stool India
Ingle 2018 503238_aEPEC ERR137801 Stool India
Ingle 2018 503256 ERR178197 Stool India
Ingle 2018 503311_aEPEC ERR124653 Stool India
Ingle 2018 503320 ERR178219 Stool India
Ingle 2018 503331 ERR178165 Stool India
Ingle 2018 503459_aEPEC ERR134546 Stool India
Ingle 2018 503537_aEPEC ERR124663 Stool India
Ingle 2018 503662_aEPEC ERR134547 Stool India
Ingle 2018 503891_aEPEC ERR137802 Stool India
Ingle 2018 503947_aEPEC ERR124654 Stool India
Ingle 2018 504005_aEPEC ERR137803 Stool India
Ingle 2018 504180 ERR178166 Stool India
Ingle 2018 504225_aEPEC ERR134548 Stool India
Ingle 2018 504300_aEPEC ERR134549 Stool India
Ingle 2018 504324 ERR178167 Stool India
Ingle 2018 504449_aEPEC ERR134550 Stool India
Ingle 2018 504528 ERR178168 Stool India
Ingle 2018 504647_aEPEC ERR134551 Stool India
Ingle 2018 504718 ERR178169 Stool India
Ingle 2018 504821_aEPEC ERR134552 Stool India
Ingle 2018 504888_aEPEC ERR134553 Stool India
Ingle 2018 504925_aEPEC ERR124664 Stool India
Ingle 2018 505148 ERR178170 Stool India
Ingle 2018 505393_aEPEC ERR124655 Stool India
Ingle 2018 505513_aEPEC ERR124656 Stool India
Ingle 2018 505545 ERR178171 Stool India
Ingle 2018 602206 ERR178172 Stool Bangladesh
Ingle 2018 602370_aEPEC ERR134554 Stool Bangladesh
Ingle 2018 700149 ERR178214 Stool Pakistan
Ingle 2018 700337_aEPEC ERR134555 Stool Pakistan
Ingle 2018 700495_aEPEC ERR134556 Stool Pakistan
Ingle 2018 700851 ERR178173 Stool Pakistan
Ingle 2018 700863 ERR178215 Stool Pakistan
Ingle 2018 702161_aEPEC ERR134558 Stool Pakistan
Ingle 2018 702328 ERR178174 Stool Pakistan
Ingle 2018 702566 ERR178175 Stool Pakistan
Ingle 2018 702745_aEPEC ERR137804 Stool Pakistan
Ingle 2018 702797 ERR178186 Stool Pakistan
Ingle 2018 702890_aEPEC ERR137805 Stool Pakistan
Ingle 2018 702898_aEPEC ERR137806 Stool Pakistan
Ingle 2018 702971 ERR178185 Stool Pakistan
Ingle 2018 703063 ERR178209 Stool Pakistan
Ingle 2018 703108 ERR178187 Stool Pakistan
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Ingle 2018 703128 ERR178188 Stool Pakistan
Ingle 2018 703258_aEPEC ERR134559 Stool Pakistan
Ingle 2018 703273 ERR178191 Stool Pakistan
Ingle 2018 703753 ERR178189 Stool Pakistan
Ingle 2018 703975_aEPEC ERR134560 Stool Pakistan
Ingle 2018 G100788-1A ERR175731 Stool Gambia
Ingle 2018 G302544 ERR178226 Stool Mozambique
Ingle 2018 G302551 ERR178225 Stool Mozambique
Ingle 2018 G303212 ERR175730 Stool Mozambique
Ingle 2018 G400792 ERR175725 Stool Kenya
Ingle 2018 G400871 ERR175724 Stool Kenya
Ingle 2018 G401436 ERR175727 Stool Kenya
Ingle 2018 G401529 ERR178227 Stool Kenya
Ingle 2018 G500007 ERR178223 Stool India
Ingle 2018 G500297-1 ERR175733 Stool India
Ingle 2018 G500407 ERR178221 Stool India
Ingle 2018 G500830 ERR175728 Stool India
Ingle 2018 G503854 ERR178224 Stool India
Ingle 2018 G504540 ERR178222 Stool India
Ingle 2018 G603423 ERR178228 Stool Bangladesh
Ingle 2018 G702074-1 ERR175734 Stool Pakistan
Ingle 2018 G702074-2 ERR175735 Stool Pakistan
Ingle 2018 R203092-3A ERR175736 Stool Mali
Ingle 2018 R203092-3B ERR175737 Stool Mali
Ingle 2018 R302583-2A ERR175738 Stool Mozambique
Ingle 2018 R302583-2B ERR175739 Stool Mozambique
Ingle 2018 R402077 ERR175726 Stool Kenya
Ingle 2018 R503696 ERR175729 Stool India
Mentzer 2014 E_1003 ERR054711 Stool Egypt
Mentzer 2014 E_1009 ERR054712 Stool Egypt
Mentzer 2014 E_1018 ERR084463 Stool Egypt
Mentzer 2014 E_1034 ERR052911 Stool Egypt
Mentzer 2014 E_1057CFn ERR119471 Stool Egypt
Mentzer 2014 E_106 ERR054666 Stool unknown
Mentzer 2014 E_1072CFn ERR119472 Stool Egypt
Mentzer 2014 E_1074 ERR052912 Stool Egypt
Mentzer 2014 E_1085 ERR052913 Stool Egypt
Mentzer 2014 E_1091 ERR052914 Stool Egypt
Mentzer 2014 E_110 ERR054678 Stool Bangladesh
Mentzer 2014 E_1101CFn ERR119473 Stool Egypt
Mentzer 2014 E_1102CFn ERR119474 Stool Egypt
Mentzer 2014 E_1111 ERR052915 Stool Egypt
Mentzer 2014 E_1167CFn ERR119475 Stool Egypt
Mentzer 2014 E_1169CFn ERR119476 Stool Egypt
Mentzer 2014 E_1189 ERR052916 Stool Egypt
Mentzer 2014 E_1193CFn ERR119477 Stool Egypt
Mentzer 2014 E_1242CFn ERR119478 Stool Egypt
Mentzer 2014 E_1245 ERR052917 Stool Egypt
Mentzer 2014 E_1248CFn ERR119479 Stool Egypt
Mentzer 2014 E_1258CFn ERR119480 Stool Egypt
Mentzer 2014 E_126 ERR054679 Stool unknown
Mentzer 2014 E_1264CFn ERR119481 Stool Egypt
Mentzer 2014 E_1281CFn ERR119482 Stool Egypt
Mentzer 2014 E_1282CFn ERR119483 Stool Egypt
Mentzer 2014 E_1285CFn ERR119484 Stool Egypt
Mentzer 2014 E_1287 ERR052918 Stool Egypt
Mentzer 2014 E_129 ERR054680 Stool Zaire
Mentzer 2014 E_1298 ERR052919 Stool Egypt
Mentzer 2014 E_1316 ERR161000 Stool Nepal
Mentzer 2014 E_133 ERR054681 Stool unknown
Mentzer 2014 E_1334 ERR084464 Stool China
Mentzer 2014 E_135 ERR054682 Stool unknown
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Mentzer 2014 E_1352CFn ERR119485 Stool Egypt
Mentzer 2014 E_1355CFn ERR119486 Stool Egypt
Mentzer 2014 E_1356CFn ERR119487 Stool Egypt
Mentzer 2014 E_1360_sec ERR178234 Stool Tunisia
Mentzer 2014 E_1362CFn ERR119489 Stool Egypt
Mentzer 2014 E_1363 ERR084466 Stool Egypt
Mentzer 2014 E_1365CFn ERR119490 Stool Egypt
Mentzer 2014 E_1373 ERR052920 Stool Indonesia
Mentzer 2014 E_1392 ERR052921 Stool Indonesia
Mentzer 2014 E_1398CFn ERR119491 Stool Indonesia
Mentzer 2014 E_1407CFn ERR119492 Stool Mexico
Mentzer 2014 E_141 ERR054683 Stool Burma
Mentzer 2014 E_1429tiny ERR217371 Stool Venezuela
Mentzer 2014 E_143 ERR054684 Stool Japan
Mentzer 2014 E_1432G ERR164830 Stool Venezuela
Mentzer 2014 E_1432w ERR164829 Stool Venezuela
Mentzer 2014 E_1433 ERR084468 Stool Morocco
Mentzer 2014 E_1460 ERR084469 Stool Indonesia
Mentzer 2014 E_151 ERR054685 Stool Japan
Mentzer 2014 E_1524 ERR084470 Stool Argentina
Mentzer 2014 E_1525CFn ERR119496 Stool Argentina
Mentzer 2014 E_1526CFn ERR119497 Stool Argentina
Mentzer 2014 E_1527 ERR084471 Stool Argentina
Mentzer 2014 E_1532CFn ERR119498 Stool Argentina
Mentzer 2014 E_1533CFn ERR119499 Stool Argentina
Mentzer 2014 E_1534CFn ERR119500 Stool Argentina
Mentzer 2014 E_1535 ERR084472 Stool Argentina
Mentzer 2014 E_1541 ERR052922 Stool Argentina
Mentzer 2014 E_1542CFn ERR119501 Stool Argentina
Mentzer 2014 E_1543CFn ERR119502 Stool Argentina
Mentzer 2014 E_1544CFn ERR119503 Stool Argentina
Mentzer 2014 E_1548 ERR052923 Stool Argentina
Mentzer 2014 E_1556CFn ERR119504 Stool Argentina
Mentzer 2014 E_1561CFn ERR119505 Stool Argentina
Mentzer 2014 E_1564CFn ERR119506 Stool Argentina
Mentzer 2014 E_1573CFn ERR119508 Stool Argentina
Mentzer 2014 E_1574CFn ERR119509 Stool Argentina
Mentzer 2014 E_1576CFn ERR119510 Stool Argentina
Mentzer 2014 E_157CFn ERR119507 Stool Japan
Mentzer 2014 E_1580CFn ERR119511 Stool Argentina
Mentzer 2014 E_1581CFn ERR119512 Stool Argentina
Mentzer 2014 E_1582CFn ERR119513 Stool Argentina
Mentzer 2014 E_1585CFn ERR119514 Stool Argentina
Mentzer 2014 E_1586CFn ERR119515 Stool Argentina
Mentzer 2014 E_1587CFn ERR119516 Stool Argentina
Mentzer 2014 E_1592CFn ERR119518 Stool Argentina
Mentzer 2014 E_1593 ERR084473 Stool Argentina
Mentzer 2014 E_1594CFn ERR119519 Stool Argentina
Mentzer 2014 E_1596CFn ERR119520 Stool Argentina
Mentzer 2014 E_1597CFn ERR119521 Stool Argentina
Mentzer 2014 E_1599CFn ERR119522 Stool Argentina
Mentzer 2014 E_159CFn ERR119517 Stool Japan
Mentzer 2014 E_1600CFn ERR119524 Stool Argentina
Mentzer 2014 E_1604CFn ERR119525 Stool Argentina
Mentzer 2014 E_1607CFn ERR119526 Stool Argentina
Mentzer 2014 E_1609CFn ERR119527 Stool Argentina
Mentzer 2014 E_1611CFn ERR119528 Stool Argentina
Mentzer 2014 E_1615CFn ERR119529 Stool Argentina
Mentzer 2014 E_1616CFn ERR119530 Stool Argentina
Mentzer 2014 E_1617CFn ERR119531 Stool Argentina
Mentzer 2014 E_1620 ERR084474 Stool Argentina
Mentzer 2014 E_1623CFn ERR119532 Stool Indonesia
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
Mentzer 2014 E_1624 ERR052924 Stool Indonesia
Mentzer 2014 E_1625CFn ERR119533 Stool Indonesia
Mentzer 2014 E_1628CFn ERR119534 Stool Indonesia
Mentzer 2014 E_1634CFn ERR119535 Stool Indonesia
Mentzer 2014 E_1635 ERR084475 Stool Indonesia
Mentzer 2014 E_1637CFn ERR119536 Stool Indonesia
Mentzer 2014 E_1638CFn ERR119537 Stool Indonesia
Mentzer 2014 E_1640CFn ERR119538 Stool Indonesia
Mentzer 2014 E_1641CFn ERR119539 Stool Indonesia
Mentzer 2014 E_1642CFn ERR119540 Stool Indonesia
Mentzer 2014 E_1646 ERR052925 Stool Indonesia
Mentzer 2014 E_1647CFn ERR119541 Stool Indonesia
Mentzer 2014 E_1648CFn ERR119542 Stool Indonesia
Mentzer 2014 E_1649 ERR084476 Stool Indonesia
Mentzer 2014 E_1650CFn ERR119543 Stool Indonesia
Mentzer 2014 E_1654 ERR054665 Stool Indonesia
Mentzer 2014 E_1657 ERR084477 Stool Indonesia
Mentzer 2014 E_1659CFn ERR119544 Stool Indonesia
Mentzer 2014 E_1661CFn ERR119545 Stool Indonesia
Mentzer 2014 E_1666CFn ERR119546 Stool Indonesia
Mentzer 2014 E_1667 ERR084478 Stool Indonesia
Mentzer 2014 E_1673CFn ERR119548 Stool Indonesia
Mentzer 2014 E_1674CFn ERR119549 Stool Indonesia
Mentzer 2014 E_1679sec ERR217373 Stool Indonesia
Mentzer 2014 E_167CFn ERR119547 Stool Japan
Mentzer 2014 E_1682CFn ERR119551 Stool Indonesia
Mentzer 2014 E_1684CFn ERR119552 Stool Indonesia
Mentzer 2014 E_1690CFn ERR119553 Stool Indonesia
Mentzer 2014 E_1712CFn ERR119554 Stool Bangladesh
Mentzer 2014 E_1716 ERR052926 Stool Bangladesh
Mentzer 2014 E_1724 ERR084479 Stool Bangladesh
Mentzer 2014 E_1735CFn ERR119555 Stool Bangladesh
Mentzer 2014 E_1736CFn ERR119556 Stool Bangladesh
Mentzer 2014 E_1739CFn ERR119557 Stool Bangladesh
Mentzer 2014 E_1741 ERR084480 Stool Bangladesh
Mentzer 2014 E_1744CFn ERR119558 Stool Bangladesh
Mentzer 2014 E_1750 ERR084481 Stool Bangladesh
Mentzer 2014 E_1752CFn ERR119559 Stool Bangladesh
Mentzer 2014 E_1760 ERR084482 Stool Bangladesh
Mentzer 2014 E_1779 ERR052927 Stool Bangladesh
Mentzer 2014 E_1784 ERR052928 Stool Bangladesh
Mentzer 2014 E_1795 ERR084483 Stool Bangladesh
Mentzer 2014 E_1797 ERR084484 Stool Bangladesh
Mentzer 2014 E_1841 ERR084485 Stool Bangladesh
Mentzer 2014 E_1871CFn ERR119560 Stool Bangladesh
Mentzer 2014 E_1883 ERR084486 Stool Bangladesh
Mentzer 2014 E_1918 ERR084487 Stool Bangladesh
Mentzer 2014 E_1939 ERR084488 Stool Bangladesh
Mentzer 2014 E_1947 ERR084489 Stool Bangladesh
Mentzer 2014 E_1961CFn ERR119561 Stool Bangladesh
Mentzer 2014 E_1994 ERR084490 Stool Bangladesh
Mentzer 2014 E_2088 ERR084491 Stool Bangladesh
Mentzer 2014 E_2092 ERR089723 Stool Bangladesh
Mentzer 2014 E_21 ERR054667 Stool Bangladesh
Mentzer 2014 E_2108CFn ERR119562 Stool Bangladesh
Mentzer 2014 E_2110CFn ERR119563 Stool Bangladesh
Mentzer 2014 E_2118 ERR089724 Stool Bangladesh
Mentzer 2014 E_2121CFn ERR119564 Stool Bangladesh
Mentzer 2014 E_2131 ERR089725 Stool Bangladesh
Mentzer 2014 E_2185 ERR089726 Stool Bolivia
Mentzer 2014 E_220 ERR054686 Stool Japan
Mentzer 2014 E_2219 ERR089727 Stool Bolivia
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
Mentzer 2014 E_222CFn ERR119380 Stool Japan
Mentzer 2014 E_223CFn ERR119381 Stool Japan
Mentzer 2014 E_224 ERR054687 Stool Japan
Mentzer 2014 E_2256 ERR089728 Stool Thailand
Mentzer 2014 E_2339 ERR089729 Stool Bolivia
Mentzer 2014 E_2347 ERR089730 Stool Bolivia
Mentzer 2014 E_2348 ERR089731 Stool Bolivia
Mentzer 2014 E_2362_sec ERR178236 Stool Bolivia
Mentzer 2014 E_237 ERR054688 Stool Japan
Mentzer 2014 E_2370sec ERR217375 Stool Japan
Mentzer 2014 E_2386 ERR089732 Stool Bolivia
Mentzer 2014 E_2397 ERR089733 Stool Bolivia
Mentzer 2014 E_239CFn ERR119382 Stool Japan
Mentzer 2014 E_2439 ERR164832 Stool Bolivia
Mentzer 2014 E_251 ERR054689 Stool Japan
Mentzer 2014 E_263CFn ERR119383 Stool Japan
Mentzer 2014 E_272 ERR054690 Stool Japan
Mentzer 2014 E_28 ERR054668 Stool Bangladesh
Mentzer 2014 E_2980 ERR089734 Stool Bangladesh
Mentzer 2014 E_2981_sec ERR178239 Stool Bangladesh
Mentzer 2014 E_329CFn ERR119384 Stool Mexico
Mentzer 2014 E_330CFn ERR119385 Stool Mexico
Mentzer 2014 E_333 ERR049162 Stool Mexico
Mentzer 2014 E_335CFn ERR119386 Stool Mexico
Mentzer 2014 E_336CFn ERR119387 Stool Mexico
Mentzer 2014 E_340CFn ERR119388 Stool Mexico
Mentzer 2014 E_343CFn ERR119389 Stool Mexico
Mentzer 2014 E_344 ERR049163 Stool Mexico
Mentzer 2014 E_351CFn ERR119390 Stool Mexico
Mentzer 2014 E_354CFn ERR119391 Stool Mexico
Mentzer 2014 E_356CFn ERR119392 Stool Mexico
Mentzer 2014 E_36 ERR054669 Stool Bangladesh
Mentzer 2014 E_360CFn ERR119393 Stool Mexico
Mentzer 2014 E_361CFn ERR119394 Stool Mexico
Mentzer 2014 E_370 ERR049164 Stool Guatemala
Mentzer 2014 E_390CFn ERR119395 Stool Guatemala
Mentzer 2014 E_391CFn ERR119396 Stool Guatemala
Mentzer 2014 E_399CFn ERR119397 Stool Guatemala
Mentzer 2014 E_405CFn ERR119398 Stool Guatemala
Mentzer 2014 E_415CFn ERR119399 Stool Guatemala
Mentzer 2014 E_416 ERR049165 Stool Guatemala
Mentzer 2014 E_425CFn ERR119400 Stool Guatemala
Mentzer 2014 E_445CFn ERR119401 Stool Guatemala
Mentzer 2014 E_45 ERR054670 Stool Bangladesh
Mentzer 2014 E_451CFn ERR119402 Stool Guatemala
Mentzer 2014 E_471 ERR049166 Stool Guatemala
Mentzer 2014 E_5089 ERR164833 Stool Bangladesh
Mentzer 2014 E_509 ERR178229 Stool Mexico
Mentzer 2014 E_513CFn ERR119404 Stool Mexico
Mentzer 2014 E_517 ERR049167 Stool Mexico
Mentzer 2014 E_519CFn ERR119405 Stool Mexico
Mentzer 2014 E_520CFn ERR119406 Stool Mexico
Mentzer 2014 E_523CFn ERR119407 Stool Mexico
Mentzer 2014 E_527CFn ERR119408 Stool Mexico
Mentzer 2014 E_528CFn ERR119409 Stool Mexico
Mentzer 2014 E_529CFn ERR119410 Stool Mexico
Mentzer 2014 E_54 ERR049158 Stool Bangladesh
Mentzer 2014 E_554 ERR049168 Stool Mexico
Mentzer 2014 E_562 ERR049169 Stool Mexico
Mentzer 2014 E_563 ERR049170 Stool Mexico
Mentzer 2014 E_604CFn ERR119411 Stool Guatemala
Mentzer 2014 E_616CFn ERR119412 Stool Guatemala
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
Mentzer 2014 E_618CFn ERR119413 Stool Guatemala
Mentzer 2014 E_620CFn ERR119414 Stool Guatemala
Mentzer 2014 E_621 ERR178230 Stool Guatemala
Mentzer 2014 E_622CFn ERR119416 Stool Guatemala
Mentzer 2014 E_626CFn ERR119417 Stool Guatemala
Mentzer 2014 E_628CFn ERR119418 Stool Guatemala
Mentzer 2014 E_632 ERR049171 Stool Guatemala
Mentzer 2014 E_636 ERR049172 Stool Guatemala
Mentzer 2014 E_645CFn ERR119419 Stool Guatemala
Mentzer 2014 E_655 ERR049173 Stool Guatemala
Mentzer 2014 E_658CFn ERR119420 Stool Guatemala
Mentzer 2014 E_659CFn ERR119421 Stool Guatemala
Mentzer 2014 E_66 ERR054671 Stool Bangladesh
Mentzer 2014 E_662CFn ERR119422 Stool Guatemala
Mentzer 2014 E_70 ERR049159 Stool Bangladesh
Mentzer 2014 E_703CFn ERR119423 Stool Guatemala
Mentzer 2014 E_704CFn ERR119424 Stool Guatemala
Mentzer 2014 E_705CFn ERR119425 Stool Guatemala
Mentzer 2014 E_71 ERR049160 Stool Bangladesh
Mentzer 2014 E_710 ERR178231 Stool Guatemala
Mentzer 2014 E_74 ERR054672 Stool Bangladesh
Mentzer 2014 E_79 ERR054673 Stool Bangladesh
Mentzer 2014 E_8 ERR049156 Stool Bangladesh
Mentzer 2014 E_806 ERR054691 Stool Guatemala
Mentzer 2014 E_810 ERR054692 Stool Guatemala
Mentzer 2014 E_811 ERR178232 Stool Guatemala
Mentzer 2014 E_812 ERR054693 Stool Guatemala
Mentzer 2014 E_816 ERR054694 Stool Guatemala
Mentzer 2014 E_818CFn ERR119428 Stool Guatemala
Mentzer 2014 E_819CFn ERR119429 Stool Guatemala
Mentzer 2014 E_821CFn ERR119430 Stool Guatemala
Mentzer 2014 E_822 ERR054695 Stool Guatemala
Mentzer 2014 E_828CFn ERR119431 Stool Guatemala
Mentzer 2014 E_833CFn ERR119432 Stool Guatemala
Mentzer 2014 E_841CFn ERR119433 Stool Guatemala
Mentzer 2014 E_842 ERR054696 Stool Guatemala
Mentzer 2014 E_85 ERR054674 Stool Bangladesh
Mentzer 2014 E_855CFn ERR119434 Stool Guatemala
Mentzer 2014 E_856 ERR054697 Stool Guatemala
Mentzer 2014 E_858 ERR054698 Stool Guatemala
Mentzer 2014 E_860CFn ERR119435 Stool Guatemala
Mentzer 2014 E_863 ERR049174 Stool Guatemala
Mentzer 2014 E_865CFn ERR119436 Stool Guatemala
Mentzer 2014 E_867 ERR054699 Stool Guatemala
Mentzer 2014 E_87 ERR054675 Stool Bangladesh
Mentzer 2014 E_871 ERR054700 Stool Guatemala
Mentzer 2014 E_873CFn ERR119437 Stool Guatemala
Mentzer 2014 E_876CFn ERR119438 Stool Guatemala
Mentzer 2014 E_877 ERR049175 Stool Guatemala
Mentzer 2014 E_879 ERR049176 Stool Guatemala
Mentzer 2014 E_88 ERR049161 Stool Bangladesh
Mentzer 2014 E_881CFn ERR119439 Stool Guatemala
Mentzer 2014 E_882 ERR054701 Stool Guatemala
Mentzer 2014 E_883 ERR054702 Stool Guatemala
Mentzer 2014 E_884CFn ERR119441 Stool Guatemala
Mentzer 2014 E_885CFn ERR119442 Stool Guatemala
Mentzer 2014 E_887CFn ERR119443 Stool Guatemala
Mentzer 2014 E_888CFn ERR119444 Stool Guatemala
Mentzer 2014 E_890CFn ERR119445 Stool Guatemala
Mentzer 2014 E_891CFn ERR119446 Stool Guatemala
Mentzer 2014 E_892CFn ERR119447 Stool Guatemala
Mentzer 2014 E_893CFn ERR119448 Stool Guatemala
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Study Sample ID Accession No. Source Country
Mentzer 2014 E_895 ERR054703 Stool Guatemala
Mentzer 2014 E_897 ERR049177 Stool Guatemala
Mentzer 2014 E_898CFn ERR119449 Stool Guatemala
Mentzer 2014 E_899CFn ERR119450 Stool Guatemala
Mentzer 2014 E_900 ERR054704 Stool Guatemala
Mentzer 2014 E_901 ERR054705 Stool Guatemala
Mentzer 2014 E_903 ERR054706 Stool Guatemala
Mentzer 2014 E_907 ERR054707 Stool Guatemala
Mentzer 2014 E_908CFn ERR119452 Stool Guatemala
Mentzer 2014 E_916 ERR049178 Stool Guatemala
Mentzer 2014 E_917 ERR049179 Stool Guatemala
Mentzer 2014 E_920 ERR054708 Stool Guatemala
Mentzer 2014 E_924CFn ERR119453 Stool Guatemala
Mentzer 2014 E_925 ERR052905 Stool Guatemala
Mentzer 2014 E_927 ERR052906 Stool Egypt
Mentzer 2014 E_928 ERR054709 Stool Egypt
Mentzer 2014 E_934CFn ERR119455 Stool Egypt
Mentzer 2014 E_935CFn ERR119456 Stool Egypt
Mentzer 2014 E_936CFn ERR119457 Stool Egypt
Mentzer 2014 E_938 ERR052907 Stool Egypt
Mentzer 2014 E_939CFn ERR119458 Stool Egypt
Mentzer 2014 E_940 ERR052908 Stool Egypt
Mentzer 2014 E_941CFn ERR119459 Stool Egypt
Mentzer 2014 E_943 ERR054710 Stool Egypt
Mentzer 2014 E_944CFn ERR119460 Stool Egypt
Mentzer 2014 E_945CFn ERR119461 Stool Egypt
Mentzer 2014 E_947CFn ERR119462 Stool Egypt
Mentzer 2014 E_949CFn ERR119463 Stool Egypt
Mentzer 2014 E_952CFn ERR119464 Stool Egypt
Mentzer 2014 E_953 ERR052909 Stool Egypt
Mentzer 2014 E_955CFn ERR119465 Stool Egypt
Mentzer 2014 E_956CFn ERR119466 Stool Egypt
Mentzer 2014 E_957 ERR164828 Stool Egypt
Mentzer 2014 E_97 ERR054676 Stool Bangladesh
Mentzer 2014 E_978CFn ERR119468 Stool Egypt
Mentzer 2014 E_986 ERR052910 Stool Egypt
Mentzer 2014 E_99 ERR054677 Stool Bangladesh
Mentzer 2014 E_995 ERR160999 Stool Egypt
Mentzer 2014 E_996CFn ERR119469 Stool Egypt
Mentzer 2014 E_998CFn ERR119470 Stool Egypt
Mentzer 2014 E160CFn ERR119523 Stool Japan
Mentzer 2014 E2367CFn ERR119566 Stool Bolivia
Mentzer 2014 E2371CFn ERR119568 Stool Bolivia
Mentzer 2014 E2377CFn ERR119569 Stool Bolivia
Mentzer 2014 E2388CFn ERR119570 Stool Bolivia
Mentzer 2014 E2392CFn ERR119571 Stool Bolivia
Mentzer 2014 E2393CFn ERR119572 Stool Bolivia
Mentzer 2014 E2395CFn ERR119573 Stool Bolivia
Mentzer 2014 E2404CFn ERR119574 Stool Bolivia
Mentzer 2014 E2405CFn ERR119575 Stool Bolivia
Mentzer 2014 E3015CFn ERR119577 Stool Egypt
Mentzer 2014 E4134CFn ERR119578 Stool Israel
Mentzer 2014 E5049 ERR089738 Stool India
Mentzer 2014 E5051 ERR089739 Stool India
Mentzer 2014 E5052 ERR089740 Stool India
Mentzer 2014 E5080 ERR089741 Stool Bangladesh
Mentzer 2014 E5081 ERR089742 Stool Bangladesh
Mentzer 2014 E5082 ERR089743 Stool Bangladesh
Mentzer 2014 E5084 ERR089744 Stool Bangladesh
Mentzer 2014 E5085 ERR089745 Stool Bangladesh
Mentzer 2014 E5086 ERR089746 Stool Bangladesh
Mentzer 2014 E5087 ERR089747 Stool Bangladesh
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
Mentzer 2014 E5088 ERR089748 Stool Bangladesh
Mentzer 2014 ILBEcoli5442571 ERR279354 Stool Kenya
Mentzer 2014 ILBEcoli5442572 ERR279355 Stool Kenya
Mentzer 2014 ILBEcoli5442573 ERR279356 Stool Kenya
Mentzer 2014 ILBEcoli5442574 ERR279357 Stool Kenya
Mentzer 2014 ILBEcoli5442575 ERR279358 Stool Kenya
Mentzer 2014 ILBEcoli5442576 ERR279359 Stool Kenya
Mentzer 2014 ILBEcoli5442577 ERR279360 Stool Kenya
Mentzer 2014 ILBEcoli5442578 ERR279361 Stool Kenya
Mentzer 2014 ILBEcoli5442579 ERR279362 Stool Kenya
Mentzer 2014 ILBEcoli5442580 ERR279363 Stool Kenya
Mentzer 2014 ILBEcoli5442581 ERR279364 Stool Kenya
Mentzer 2014 ILBEcoli5442582 ERR279365 Stool Kenya
Mentzer 2014 ILBEcoli5442583 ERR279366 Stool Kenya
Mentzer 2014 ILBEcoli5442587 ERR279370 Stool Guinea Bissau
Mentzer 2014 ILBEcoli5442588 ERR279371 Stool Guinea Bissau
Mentzer 2014 ILBEcoli5442589 ERR279372 Stool Guinea Bissau
Mentzer 2014 ILBEcoli5442590 ERR279373 Stool Guinea Bissau
Musicha 2017 3487STDY6036382 ERR926351 Blood Malawi
Musicha 2017 3487STDY6036383 ERR926352 Blood Malawi
Musicha 2017 3487STDY6036384 ERR926353 Blood Malawi
Musicha 2017 3487STDY6036385 ERR926354 CSF Malawi
Musicha 2017 3487STDY6036386 ERR926355 Blood Malawi
Musicha 2017 3487STDY6036387 ERR926356 Blood Malawi
Musicha 2017 3487STDY6036388 ERR926357 Blood Malawi
Musicha 2017 3487STDY6036389 ERR926358 Blood Malawi
Musicha 2017 3487STDY6036390 ERR926359 CSF Malawi
Musicha 2017 3487STDY6036391 ERR926360 Blood Malawi
Musicha 2017 3487STDY6036392 ERR926361 Blood Malawi
Musicha 2017 3487STDY6036393 ERR926362 Blood Malawi
Musicha 2017 3487STDY6036394 ERR926363 Blood Malawi
Musicha 2017 3487STDY6036395 ERR926364 Blood Malawi
Musicha 2017 3487STDY6036396 ERR926365 CSF Malawi
Musicha 2017 3487STDY6036397 ERR926366 Blood Malawi
Musicha 2017 3487STDY6036398 ERR926367 Blood Malawi
Musicha 2017 3487STDY6036399 ERR926368 Blood Malawi
Musicha 2017 3487STDY6036400 ERR926369 CSF Malawi
Musicha 2017 3487STDY6036403 ERR926372 CSF Malawi
Musicha 2017 3487STDY6036404 ERR926373 Blood Malawi
Musicha 2017 3487STDY6036405 ERR926374 CSF Malawi
Musicha 2017 3487STDY6036406 ERR926375 Blood Malawi
Musicha 2017 3487STDY6036407 ERR926376 CSF Malawi
Musicha 2017 3487STDY6036408 ERR926377 Blood Malawi
Musicha 2017 3487STDY6036409 ERR926378 Blood Malawi
Musicha 2017 3487STDY6036410 ERR926379 Blood Malawi
Musicha 2017 3487STDY6036411 ERR926380 Blood Malawi
Musicha 2017 3487STDY6036412 ERR926381 Blood Malawi
Musicha 2017 3487STDY6036413 ERR971988 CSF Malawi
Musicha 2017 3487STDY6036414 ERR926382 Blood Malawi
Musicha 2017 3487STDY6036415 ERR926383 CSF Malawi
Musicha 2017 3487STDY6036416 ERR926384 CSF Malawi
Musicha 2017 3487STDY6036417 ERR926385 CSF Malawi
Musicha 2017 3487STDY6036418 ERR926386 CSF Malawi
Musicha 2017 3487STDY6036420 ERR926388 CSF Malawi
Musicha 2017 3487STDY6036421 ERR926389 Blood Malawi
Musicha 2017 3487STDY6036422 ERR926390 CSF Malawi
Musicha 2017 3487STDY6036423 ERR926391 CSF Malawi
Musicha 2017 3487STDY6036424 ERR926392 Blood Malawi
Musicha 2017 3487STDY6036425 ERR926393 Blood Malawi
Musicha 2017 3487STDY6036426 ERR926394 Blood Malawi
Musicha 2017 3487STDY6036427 ERR926395 Blood Malawi
Musicha 2017 3487STDY6036428 ERR926396 Blood Malawi
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Study Sample ID Accession No. Source Country
Musicha 2017 3487STDY6036429 ERR926397 Blood Malawi
Musicha 2017 3487STDY6036430 ERR926398 Blood Malawi
Musicha 2017 3487STDY6036431 ERR926399 Blood Malawi
Musicha 2017 3487STDY6036432 ERR926400 Blood Malawi
Musicha 2017 3487STDY6036433 ERR926401 CSF Malawi
Musicha 2017 3487STDY6036434 ERR926402 CSF Malawi
Musicha 2017 3487STDY6036435 ERR926403 CSF Malawi
Musicha 2017 3487STDY6036436 ERR926404 Blood Malawi
Musicha 2017 3487STDY6036437 ERR926405 Blood Malawi
Musicha 2017 3487STDY6036438 ERR926406 Blood Malawi
Musicha 2017 3487STDY6036440 ERR926408 CSF Malawi
Musicha 2017 3487STDY6036441 ERR926409 Blood Malawi
Musicha 2017 3487STDY6036443 ERR926411 Blood Malawi
Musicha 2017 3487STDY6036444 ERR926412 Blood Malawi
Musicha 2017 3487STDY6036445 ERR926413 RS Malawi
Musicha 2017 3487STDY6036446 ERR971989 Blood Malawi
Musicha 2017 3487STDY6036447 ERR926414 CSF Malawi
Musicha 2017 3487STDY6036448 ERR926415 Blood Malawi
Musicha 2017 3487STDY6036449 ERR926416 Blood Malawi
Musicha 2017 3487STDY6036450 ERR926417 RS Malawi
Musicha 2017 3487STDY6036451 ERR926418 CSF Malawi
Musicha 2017 3487STDY6036452 ERR926419 Blood Malawi
Musicha 2017 3487STDY6036453 ERR926420 Blood Malawi
Musicha 2017 3487STDY6036454 ERR971990 Blood Malawi
Musicha 2017 3487STDY6036455 ERR926421 CSF Malawi
Musicha 2017 3487STDY6036456 ERR971991 Blood Malawi
Musicha 2017 3487STDY6036457 ERR926422 RS Malawi
Musicha 2017 3487STDY6036458 ERR926423 Blood Malawi
Musicha 2017 3487STDY6036460 ERR926425 CSF Malawi
Musicha 2017 3487STDY6036461 ERR926426 Blood Malawi
Musicha 2017 3487STDY6036462 ERR971992 Blood Malawi
Musicha 2017 3487STDY6036463 ERR926427 CSF Malawi
Musicha 2017 3487STDY6036464 ERR926428 Blood Malawi
Musicha 2017 3487STDY6036465 ERR926429 Blood Malawi
Musicha 2017 3487STDY6036466 ERR926430 RS Malawi
Musicha 2017 3487STDY6036467 ERR926431 RS Malawi
Musicha 2017 3487STDY6036468 ERR926432 Blood Malawi
Musicha 2017 3487STDY6036470 ERR926434 Blood Malawi
Musicha 2017 3487STDY6036471 ERR926435 RS Malawi
Musicha 2017 3487STDY6036473 ERR971994 RS Malawi
Musicha 2017 3487STDY6036486 ERR926444 Blood Malawi
Musicha 2017 3487STDY6036506 ERR971962 Blood Malawi
Musicha 2017 3487STDY6036508 ERR971963 Blood Malawi
Musicha 2017 3487STDY6036519 ERR972008 Blood Malawi
Musicha 2017 3487STDY6036520 ERR971966 Blood Malawi
Musicha 2017 3487STDY6036526 ERR971968 Blood Malawi
Musicha 2017 3487STDY6036533 ERR971970 Blood Malawi
Musicha 2017 3487STDY6036547 ERR971979 Blood Malawi
Musicha 2017 3487STDY6036565 ERR971987 RS Malawi
Runchaeron 2017 3898STDY6199571 ERR1218581 Urine Thailand
Runchaeron 2017 3898STDY6199572 ERR1218582 Urine Thailand
Runchaeron 2017 3898STDY6199573 ERR1218583 Urine Thailand
Runchaeron 2017 3898STDY6199574 ERR1218584 Sputum Thailand
Runchaeron 2017 3898STDY6199575 ERR1218585 Urine Thailand
Runchaeron 2017 3898STDY6199576 ERR1218534 Blood Thailand
Runchaeron 2017 3898STDY6199577 ERR1218586 Pus Thailand
Runchaeron 2017 3898STDY6199578 ERR1218587 Blood Thailand
Runchaeron 2017 3898STDY6199579 ERR1218588 Urine Thailand
Runchaeron 2017 3898STDY6199580 ERR1218589 Urine Thailand
Runchaeron 2017 3898STDY6199581 ERR1218590 Pus Thailand
Runchaeron 2017 3898STDY6199582 ERR1218591 Pus Thailand
Runchaeron 2017 3898STDY6199583 ERR1218592 Urine Thailand
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
Runchaeron 2017 3898STDY6199584 ERR1218593 Urine Thailand
Runchaeron 2017 3898STDY6199585 ERR1218594 Urine Thailand
Runchaeron 2017 3898STDY6199586 ERR1218595 Blood Thailand
Runchaeron 2017 3898STDY6199587 ERR1218596 Pus Thailand
Runchaeron 2017 3898STDY6199588 ERR1218597 Urine Thailand
Runchaeron 2017 3898STDY6199589 ERR1218535 Blood Thailand
Runchaeron 2017 3898STDY6199590 ERR1218598 Urine Thailand
Runchaeron 2017 3898STDY6199591 ERR1218599 Pus Thailand
Runchaeron 2017 3898STDY6199592 ERR1218600 Urine Thailand
Runchaeron 2017 3898STDY6199593 ERR1218536 Blood Thailand
Runchaeron 2017 3898STDY6199594 ERR1218601 Urine Thailand
Runchaeron 2017 3898STDY6199595 ERR1218602 Blood Thailand
Runchaeron 2017 3898STDY6199596 ERR1218537 Pus Thailand
Runchaeron 2017 3898STDY6199597 ERR1218538 Pus Thailand
Runchaeron 2017 3898STDY6199598 ERR1218603 Pus Thailand
Runchaeron 2017 3898STDY6199599 ERR1218539 Urine Thailand
Runchaeron 2017 3898STDY6199600 ERR1218604 Pus Thailand
Runchaeron 2017 3898STDY6199601 ERR1218540 Pus Thailand
Runchaeron 2017 3898STDY6199602 ERR1218605 Urine Thailand
Runchaeron 2017 3898STDY6199603 ERR1218606 Urine Thailand
Runchaeron 2017 3898STDY6199604 ERR1218607 Urine Thailand
Runchaeron 2017 3898STDY6199605 ERR1218608 Blood Thailand
Runchaeron 2017 3898STDY6199606 ERR1218609 Pus Thailand
Runchaeron 2017 3898STDY6199607 ERR1218610 Pus Thailand
Runchaeron 2017 3898STDY6199608 ERR1218541 Urine Thailand
Runchaeron 2017 3898STDY6199609 ERR1218611 Blood Thailand
Runchaeron 2017 3898STDY6199610 ERR1218542 Pus Thailand
Runchaeron 2017 3898STDY6199611 ERR1218612 Urine Thailand
Runchaeron 2017 3898STDY6199612 ERR1218613 Pus Thailand
Runchaeron 2017 3898STDY6199613 ERR1218614 Blood Thailand
Runchaeron 2017 3898STDY6199614 ERR1218543 Urine Thailand
Runchaeron 2017 3898STDY6199615 ERR1218615 Blood Thailand
Runchaeron 2017 3898STDY6199616 ERR1218616 Urine Thailand
Runchaeron 2017 3898STDY6199617 ERR1218617 Blood Thailand
Runchaeron 2017 3898STDY6199618 ERR1218618 Blood Thailand
Runchaeron 2017 3898STDY6199619 ERR1218619 Urine Thailand
Runchaeron 2017 3898STDY6199620 ERR1218620 Urine Thailand
Runchaeron 2017 3898STDY6199621 ERR1218621 Blood Thailand
Runchaeron 2017 3898STDY6199622 ERR1218544 Urine Thailand
Runchaeron 2017 3898STDY6199623 ERR1218622 Urine Thailand
Runchaeron 2017 3898STDY6199624 ERR1218545 Blood Thailand
Runchaeron 2017 3898STDY6199625 ERR1218623 Urine Thailand
Runchaeron 2017 3898STDY6199626 ERR1218624 Urine Thailand
Runchaeron 2017 3898STDY6199627 ERR1218625 Urine Thailand
Runchaeron 2017 3898STDY6199628 ERR1218626 Urine Thailand
Runchaeron 2017 3898STDY6199629 ERR1218627 Urine Thailand
Runchaeron 2017 3898STDY6199630 ERR1218628 Blood Thailand
Runchaeron 2017 3898STDY6199631 ERR1218629 Blood Thailand
Runchaeron 2017 3898STDY6199632 ERR1218630 Pus Thailand
Runchaeron 2017 3898STDY6199633 ERR1218631 Pus Thailand
Runchaeron 2017 3898STDY6199634 ERR1218632 Urine Thailand
Runchaeron 2017 3898STDY6199635 ERR1218633 Blood Thailand
Runchaeron 2017 3898STDY6199636 ERR1218634 Pus Thailand
Runchaeron 2017 3898STDY6199637 ERR1218635 Urine Thailand
Runchaeron 2017 3898STDY6199638 ERR1218546 Urine Thailand
Runchaeron 2017 3898STDY6199639 ERR1218636 Pus Thailand
Runchaeron 2017 3898STDY6199640 ERR1218637 Urine Thailand
Runchaeron 2017 3898STDY6199642 ERR1218639 Blood Thailand
Runchaeron 2017 3898STDY6199643 ERR1218640 Pus Thailand
Runchaeron 2017 3898STDY6199644 ERR1218641 Blood Thailand
Runchaeron 2017 3898STDY6199645 ERR1218642 Canal Thailand
Runchaeron 2017 3898STDY6199648 ERR1218643 Canal Thailand
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
Runchaeron 2017 3898STDY6199649 ERR1218644 Canal Thailand
Runchaeron 2017 3898STDY6199651 ERR1218549 Canal Thailand
Runchaeron 2017 3898STDY6199653 ERR1218551 Canal Thailand
Runchaeron 2017 3898STDY6199654 ERR1218646 Canal Thailand
Runchaeron 2017 3898STDY6199656 ERR1218552 Canal Thailand
Runchaeron 2017 3898STDY6199657 ERR1218648 Canal Thailand
Runchaeron 2017 3898STDY6199658 ERR1218553 Canal Thailand
Runchaeron 2017 3898STDY6199659 ERR1218649 Canal Thailand
Runchaeron 2017 3898STDY6199660 ERR1218650 Canal Thailand
Runchaeron 2017 3898STDY6199661 ERR1218651 Canal Thailand
Runchaeron 2017 3898STDY6199662 ERR1218652 Canal Thailand
Runchaeron 2017 3898STDY6199664 ERR1218654 Canal Thailand
Runchaeron 2017 3898STDY6199665 ERR1218655 Canal Thailand
Runchaeron 2017 3898STDY6199667 ERR1218656 Canal Thailand
Runchaeron 2017 3898STDY6199669 ERR1218658 Canal Thailand
Runchaeron 2017 3898STDY6199670 ERR1218659 Canal Thailand
Runchaeron 2017 3898STDY6199671 ERR1218660 Canal Thailand
Runchaeron 2017 3898STDY6199672 ERR1218661 Canal Thailand
Runchaeron 2017 3898STDY6199673 ERR1218662 Canal Thailand
Runchaeron 2017 3898STDY6199674 ERR1218663 Canal Thailand
Runchaeron 2017 3898STDY6199675 ERR1218664 Canal Thailand
Runchaeron 2017 3898STDY6199677 ERR1218666 Canal Thailand
Runchaeron 2017 3898STDY6199680 ERR1218669 Canal Thailand
Runchaeron 2017 3898STDY6199682 ERR1218671 Canal Thailand
Runchaeron 2017 3898STDY6199685 ERR1218674 Canal Thailand
Runchaeron 2017 3898STDY6199686 ERR1218675 Canal Thailand
Runchaeron 2017 3898STDY6199687 ERR1218676 Canal Thailand
Runchaeron 2017 3898STDY6199689 ERR1218678 Canal Thailand
Runchaeron 2017 3898STDY6199692 ERR1218681 Canal Thailand
Runchaeron 2017 3898STDY6199693 ERR1218682 Canal Thailand
Runchaeron 2017 3898STDY6199694 ERR1218683 Canal Thailand
Runchaeron 2017 3898STDY6199695 ERR1218684 Canal Thailand
Runchaeron 2017 3898STDY6199696 ERR1218685 Canal Thailand
Runchaeron 2017 3898STDY6199697 ERR1218686 Canal Thailand
Runchaeron 2017 3898STDY6199698 ERR1218554 Canal Thailand
Runchaeron 2017 3898STDY6199700 ERR1218688 Canal Thailand
Runchaeron 2017 3898STDY6199701 ERR1218689 Canal Thailand
Runchaeron 2017 3898STDY6199702 ERR1218690 Untreated hospital sewage Thailand
Runchaeron 2017 3898STDY6199704 ERR1218692 Untreated hospital sewage Thailand
Runchaeron 2017 3898STDY6199705 ERR1218693 Untreated hospital sewage Thailand
Runchaeron 2017 3898STDY6199706 ERR1218694 Canal Thailand
Runchaeron 2017 3898STDY6199707 ERR1218695 Canal Thailand
Runchaeron 2017 3898STDY6199708 ERR1218696 Canal Thailand
Runchaeron 2017 3898STDY6199709 ERR1218697 Farm Thailand
Runchaeron 2017 3898STDY6199710 ERR1218698 Farm Thailand
Runchaeron 2017 3898STDY6199713 ERR1218701 Farm Thailand
Runchaeron 2017 3898STDY6199714 ERR1218702 Farm Thailand
Runchaeron 2017 3898STDY6199715 ERR1218703 Farm Thailand
Runchaeron 2017 3898STDY6199764 ERR1218705 Urine Thailand
Runchaeron 2017 3898STDY6199766 ERR1218556 Pus Thailand
Runchaeron 2017 3898STDY6199768 ERR1218706 Urine Thailand
Runchaeron 2017 3898STDY6199769 ERR1218707 Urine Thailand
Runchaeron 2017 3898STDY6199772 ERR1218708 Pus Thailand
Runchaeron 2017 3898STDY6199773 ERR1218557 Pus Thailand
Runchaeron 2017 3898STDY6199778 ERR1218709 Canal Thailand
Runchaeron 2017 3898STDY6199780 ERR1218710 Canal Thailand
Runchaeron 2017 3898STDY6199781 ERR1218558 Canal Thailand
Runchaeron 2017 3898STDY6199784 ERR1218711 Canal Thailand
Runchaeron 2017 3898STDY6199790 ERR1218559 Urine Thailand
Runchaeron 2017 3898STDY6199792 ERR1218712 Blood Thailand
Runchaeron 2017 3898STDY6199793 ERR1218713 Urine Thailand
Runchaeron 2017 3898STDY6199796 ERR1218560 Pus Thailand
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Table 6.3: Details of samples included in global phylogeny (continued)
Study Sample ID Accession No. Source Country
Runchaeron 2017 3898STDY6199798 ERR1218714 Blood Thailand
Runchaeron 2017 3898STDY6199799 ERR1218715 Canal Thailand
Runchaeron 2017 3898STDY6199802 ERR1218716 Canal Thailand
Runchaeron 2017 3898STDY6199804 ERR1218561 Canal Thailand
Runchaeron 2017 3898STDY6199805 ERR1218717 Canal Thailand
Runchaeron 2017 3898STDY6199806 ERR1218718 Canal Thailand
Runchaeron 2017 3898STDY6199807 ERR1218719 Canal Thailand
Runchaeron 2017 3898STDY6199808 ERR1218562 Canal Thailand
Runchaeron 2017 3898STDY6199809 ERR1218720 Canal Thailand
Runchaeron 2017 3898STDY6199815 ERR1218564 Farm Thailand
Runchaeron 2017 3898STDY6199816 ERR1218723 Canal Thailand
Runchaeron 2017 3898STDY6199923 ERR1218774 Canal Thailand
Note:
Accession numbers for this study starting ERS are not yet published on GenBank.
RS = Rectal swab
Chapter 7
Whole genome sequencing to track
longitudinal ESBL-E colonisation
7.1 Chapter overview
In this chapter, I present an attempt to use short read whole genome sequence (WGS)
data as a high resolution typing tool to track bacteria and mobile genetic elements (MGE)
within the participants of the study. I use the hierarchical BAPS (Bayesian analysis of
population structure) algorithm to classify the core gene alignment of 473 E. coli into
48 sequence clusters, which mapped well to the phylogeny. I used the cd-hit algorithm
to cluster 488 ESBL-gene containing contigs into 99 clusters, which showed some lineage
association on mapping them back to the phylogeny. Largely, hospital associated isolates
were independent of sequence cluster assignment with the exception of sequence cluster 23
which was associated with hospital acquisition (p = 6.3× 10−4), and corresponded to the
putative recently arrived high-risk clone ST410 described in Chapter 6.
The combination of hierBAPS sequence cluster and ESBL-contig cluster together were
conserved within participants on longitudinal sampling compared to between-participants
(p = 1.1× 10−12) whereas either alone was not (p = 0.4 and p = 1.0). However beyond 35
days apart any two samples from a single a participant were only as likely to contain the
same sequence cluster-ESBL cluster combination as any two samples randomly selected
from the dataset. This suggests that, firstly, the unit of transmission in this system is
likely to be the bacterium rather than the MGE. Secondly, the within-participant ESBL
contig cluster bacterial sequence cluster association suggests that a given bacterium-MGE
combination is reasonably stable on the timescale of the study. Finally, these data suggest
there is turnover of ESBL E. coli on a time scale of around 35 days suggestive of either
frequent re-exposure or some other endogenous turnover in the microbiota.
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7.2 Introduction and chapter aims
In Chapter 5, I described the epidemiology of ESBL-E carriage in study participants as they
were exposed to antimicrobials and hospitalisation, showing a dramatic increase in carriage
prevalence following hospitalisation and, particularly, hospitalisation and antibacterial
exposure. In Chapter 6, I presented details of the whole genome sequencing of a sample of
473 E. coli isolates recovered from the stool of these study participants, placed them in a
global context, and described the antimicrobial resistance (AMR) determinants that the
isolates carried. In this chapter, I present an analysis whereby I combine the WGS data
with the metadata from Chapter 5 in an attempt to use WGS as a high-resolution typing
tool to track carriage of ESBL E. coli within participants in this study. Specifically, the
aims of this chapter are:
1. To use clustering algorithms to classify clusters of bacteria and MGE that can be used
in further analyses to track bacteria and MGE within participants and associations
between bacteria and MGE and metadata.
2. To explore whether apparent hospital acquisitions of ESBL E. coli can be distinguished
on a genomic level from community associated E. coli.
3. To use bacteria and MGE clusters to determine a), which, if any, element is conserved
within participants over time and b) the time scale over which bacteria and MGE
change over time within-host.
7.3 Methods
The collection, culture, whole genome sequencing and bioinformatic analysis of the isolates
analysed in this chapter are described in Chapter 2, Methods, and Chapter 7. The methods
of the further analyses covered in this chapter are described here.
The rhierBAPS v1.1.0 package in R[370] was used to cluster the core genome pseudosequence
into sequence clusters (SCs). Two levels were used and these level 2 clusters used to test
associations (see statistical analysis, below). To track putative mobile genetic elements
ESBL-gene containing contigs were identified using BLASTn v2.7.0[371] of all contigs
against the SRST2 database[343] of AMR genes (the same database used with ARIBA in
the previous chapter). Contigs containing any given ESBL gene were grouped by the ESBL
gene they contained (for example, all blaCTXM−15 gene-containing clusters were grouped
together). Each group was then clustered using cd-hit v4.6[372] to produce mutually
exclusive ESBL-gene-containing contig clusters for each identified ESBL gene. Henceforth,
these clusters will be referred to as ESBL-clusters, for brevity.
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In order to attempt to determine the biological significance of the identified ESBL-clusters
(i.e. what kind of MGE element they are likely to represent), basic statistics were plotted:
number of samples contained within each cluster, length of longest contig in cluster in
kbases, length distribution of all contigs in cluster relative to longest contig and distribution
of sequence identity compared to the longest contig in the cluster. Presence of insertion
sequences (i.e compound transposons), AMR determinants and plasmid replicons were
identified for ESBL-cluster representative sequence (as determined by cd-hit i.e one, the
longest, for each ESBL-cluster) using BLAST. BLAST default settings were used against
the insertion sequence finder (ISfinder) database[373] and the SRST2 database, filtering
such that sequence identity was greater or equal to 95%, taking the top hit (as determined
by bitscore) for any given location if there were two overlapping hits, and visualising the
results in ggenes v0.3.2 package in R. To assess lineage association, the ESBL-clusters were
mapped back to the core gene phylogeny.
To explore hospital or community associations of isolated E. coli, the location of isolation
was first mapped onto the phylogenetic tree; location of isolation was classified as hospital,
community, or recent hospital discharge (defined as a date of isolation within 2 weeks of
hospital discharge). This latter category was used because it is possible that a patient
could acquire an ESBL-E clone in hospital but only be sampled once leaving hospital; using
only hospital isolated and community isolated categories could therefore introduce bias.
Hospital or community association of each sequence cluster was assessed using a Fisher’s
exact test of proportion of hospital associated samples (defined as sum of hospital isolated
and recent hospital discharge) for the given sequence cluster as compared to proportion of
hospital associated samples in the remainder of the samples, with a Bonferroni correction
for multiple comparisons. p < 0.05 was again considered statistically significant.
To compare within-patient to between-patient conservation of bacteria (as represented by
sequence cluster) and ESBL-containing MGE (as represented by the ESBL-clusters) several
approaches were taken. Firstly, I assessed whether either sequence cluster or ESBL-cluster
were conserved within an individual at all. I hypothesised that within-patient correlation
is a function of time: samples closer together in time are more likely to be similar. To
assess if this was the case for bacteria, pairwise core genome pseudosequence SNP distance
was was calculated using snp-dists v0.4 (https://github.com/tseemann/snp-dists) for all
samples and plotted against the time difference (in days) between samples, within and
between patients, and with a smoothed curve fitted using a general additive model (GAM)
with cubic splines. Because of significant overplotting, this was also plotted as a 2D density
plot. Based on these plots, the within and between patient SNP distances were compared
in two post-hoc defined groups binned by time distance between the samples (50 days or
less vs. more than 50 days, cutoffs that were determined from inspection of the pairwise
SNP distance vs time plots), and distributions compared with Kruskal-Wallace tests.
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I then compared the within patient temporal clustering of ESBL-clusters and sequence
clusters, by estimating the proportion of within-patient samples that contain the same ESBL-
cluster or sequence cluster, as a function of time; essentially a temporal auto-correlation
function. To estimate this, I considered pairwise comparison of all within-patient samples.
For any given time (t) between samples I defined a window of +/-5 days and estimated the
probabilities as the number of all within-patient sample pairs in the window [t− 5, t+ 5]
that contained the same sequence cluster or ESBL-cluster divided by the total number
of all within-patient sample pairs within that time window. Exact binomial confidence
intervals for these proportions were generated and probabilities plotted as a function of
time. In order to estimate the probability of two samples containing the same sequence
cluster or contig-cluster purely by chance, 1000 sample pairs were randomly drawn from all
samples with replacement and the proportion of these samples that contained the same
sequence cluster or ESBL-cluster calculated.
Finally, to inform the question as to what the likely unit of transmission in this system is, I
assessed what was most conserved within patients, in pairwise sample comparison: bacteria
(as represented by core gene sequence cluster), ESBL-containing MGE (as represented
by ESBL-cluster), or both. Simple proportions in all-against-all pairwise comparison -
stratified by whether between-patient or within-patient - were calculated: the proportion of
samples that contain the same core gene sequence cluster only, the proportion of samples
that contain the same ESBL-cluster only, and the proportion that contain both sequence
cluster and ESBL-cluster. Proportions were compared between within and between-patient
strata in these three groups using Fisher’s exact test, with p < 0.05 considered statistically
significant.
7.4 Results
As described above, in order to test metadata associations of bacterial lineages or MGE,
I used several techniques: considering core gene SNP distance between isolates to infer
continuous carriage and/or transmission events, and clustering core gene pseudosequences
and ESBL-containing contigs into mutually exclusive groups which can then be used to
test associations. Below, I first describe the outcomes of the clustering algorithms used,
before describing tests of association of the results with metadata.
7.4.1 Hierarchical BAPS clustering of core gene pseudosequences
The hierarchical BAPS algorithm clustered the core gene alignments into 15 level one (top
level) clusters, denoted sequence clusters A-O, and a total of 48 level two (lower level)
clusters, denoted sequence clusters 1-48 that were almost exclusively monophyletic and
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often corresponded closely to the multilocus sequence types (STs, Figure 7.1A). Intracluster
pairwise SNP distance varied (Figure 7.1B) but the clusters were often reasonably clonal:
SC6, SC8 and SC23, for example (the three largest clusters) had median (IQR) intragroup
pairwise SNP distance of 62 (34-97), 326 (18-378) and 18 (11-24) respectively.
7.4.2 ESBL-clusters
The 473 samples contained 486 ESBL genes (Figure 7.2A); 5 genes only occurred once in
the collection and so no attempt was made to cluster them. Of the remaining 481 genes,
BLAST failed to identify the ESBL-gene containing contig in 2 samples (one in which
ARIBA had identified blaCTXM−15 one blaCTXM−27), but identified the remaining 479
ESBL genes on 478 contigs, with perfect agreement with ARIBA as to which AMR gene
was present in which sample. Only one contig carried two ESBL genes: blaCTXM−3 and
blaCTXM−15; the remaining 477 contigs contained one. The cd-hit algorithm grouped the
477 unique contigs into 99 clusters (Figure 7.2B). In total, over 90% of the ESBL-genes
(432/479 [90%]) were contained in the 52 largest contig clusters.
The cd-hit algorithm selects one member of a cluster (the longest) as the representative.
The structure of these representative contigs was explored in an attempt to understand the
type of MGE they were likely to represent. The length of the representative clusters was
very variable, ranging from 1.8kbp to 905.8kbp, with median (IQR) 46.1kbp (11.1-215.5kbp).
The other cluster members were usually fragments of these representative contigs with
varying sizes - a median (IQR) 60% (36-100%) of the representative contig length - but had
high sequence identity, median (IQR) 100.0% (99.7-100.0%) (Figure 7.6 in the appendix to
this chapter).
I then explored the insertion sequence (IS), AMR gene and plasmid replicon content of
the representative contig for each cluster using BLAST against the SRST2, ISfinder and
Plasmidfinder databases (Figures 7.8 and 7.9 in the appendix to this chapter). Every
ESBL gene was closely associated with at least one IS, commonly ISEcp1, IS26 and
IS903B. IS26 was frequently associated with an apparent 108bp fragment of a catB4
chloramphenicol resistance determinant. Some ESBL-genes were associated with particular
IS; blaCTXM−15, blaCTXM−9 and blaCTXM−1, for example were very commonly associated
with ISEcp1, whereas blaSHV−12 was associated with IS26. ESBL genes were not infrequently
associated with other resistance determinants, including commonly blaCTXM−15 with
blaTEM−1. Plasmid replicons were occasionally identified, including an IncFIB plasmid
carrying blaCTXM−15 and an IncQ1 plasmid carrying blaCTXM−27. It is clear that the
same configuration of AMR genes and IS are seen across different contigs, despite a varying
backbone, implying historical transposition events. Finally, to assess lineage associations of
the identified ESBL-clusters, I mapped the clusters back to the tree, and found that there
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Figure 7.1: A: Core gene hierarchical BAPS clusters mapped back to phylogeny. Heatmap shows
level 2 (lower level) with colour denoting level 1 (top level) cluster membership. B: Intracluster
pairwise SNP distance for level 2 sequence clusters. Axis restricted to 0-1500 SNPs and as result
SC17 (median 6881 SNPs), SC29 (median 2970 SNPs), SC31 (median 2970 SNPs) and SC44 (median
12322 SNPs) boxes are not shown. Boxplots show median and IQR, whiskers show 1.5 times IQR,
and outliers are points falling beyond whiskers.
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was often a strong lineage association (Figure 7.2C).
7.4.3 Assessing for healthcare-associated lineages
Having clustered bacteria and MGE using rhierBAPS and cd-hit respectively, I then mapped
the location of sample collection back to the phylogeny and used the hierBAPS SCs to
assess for healthcare associated lineages (Figure 7.3). In general, healthcare-associated
isolates were distributed throughout the tree and across all SCs, rather than there being a
clear hospital-associated lineage. The exception to this was SC23, corresponding to MLST
410, which was more likely to be healthcare associated. When comparing the proportion
of healthcare associated samples within each SC to the remained of samples, only SC23
had a statistically significantly increased proportion of healthcare associated samples on
Fisher’s exact test (p = 6.3× 10−4, threshold of significance following Bonferroni correction
1.0 × 10−3), though it was by no means health-facility restricted: 50% (21/42) of SC23
samples were isolated in the community.
7.4.4 Assessing for within-patient conservation of lineage or MGE
To answer the question as to what elements (bacteria or MGE) are conserved within
individuals across time I first compared all-against-all pairwise SNP distance between and
within patients; first as a scatter plot, and then, because of significant overplotting, as a
density plot (Figure 7.4). This suggested that there are a cluster of points close to the
origin in the within-patient plot that are not seen in the between-patient plot: before
approximately 50 days, there are more similar within-patient isolates than seen in the
between-patent isolates. Dichotomising time at 50 days (based on inspection of the density
plots) and performing a Kruskal-Wallace test enabled me to identify a statistically significant
difference between the before 50 day and after 50 day pairwise SNP distance distribution in
the within patient stratum (p = 0.008) but not in the between-patient stratum (p = 0.07).
After 50 days, the distribution of between- and within- patent SNP distances are similar
(p = 0.45). However it is clear from the plots that even at small t and within-participant,
there is significant diversity is the SNP distances, and that some isolates close together in
time, within the same participant, are only distantly related.
Having confirmed that there is a signal for within-participant temporal conservation of
ESBL-E, I then sought to determine if the sequence clusters and ESBL-clusters were
similarly conserved over time, and if so, which was the more conserved. The proportion of
within-patient sample pairs that contained the same ESBL-cluster and sequence cluster
were significantly greater than would be expected by chance when the time between the
samples is less than 35 days for sequence cluster and 32 days for ESBL-cluster (Figure 7.5A).
After this time, the lower confidence interval of the sequence cluster and ESBL-cluster
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Figure 7.2: A: Frequency distribution of ESBL genes in included samples. B: Frequency distribution
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Figure 7.3: A: Location of sample isolation mapped back to phylogeny B: Distribution of location
of sample isolation stratified by hierBAPS cluster. In each case, community isolates include those
cultured from samples collected on the first day of hospital admissison, in-hospital isolates are from
patients who have been hospitalised > 24 hrs and recent discharge isolates are from patients who
have been discharged from hospital within the last 2 weeks. Sequence cluster 23, highlighted in red,
showed a statistically sigificant association with hospitalisation (see text).
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Figure 7.4: Within and between participant pairwise SNP distances. A: Scatterplot of pairwise SNP
distances as a function of time with GAM model fitted curve. B: Pairwise SNP distance as function
of time as a 2D density plot, showing cluster of isolates close to origin that are close together in
time and SNP-distance. C: Pairwsise SNP distance distribution before and after 50 days, within
and between patients, showing statistically significant decrease in pairwise SNP distance within
patients before 50 days. After 50 days, between- and within- patient distributuions are similar.
curve crossed the proportion of samples that would be expected to be the same by chance,
suggesting that, after 35 or 32 days, the chance of any two within-patient samples having
the same sequence cluster or ESBL-cluster (respectively) is the same as if the two samples
were randomly picked from the data set without regard to patient. The two curves have a
very similar appearance; to address the question of which element is most conserved within
an individual - sequence cluster, ESBL-cluster, or both - I performed an all-against-all
pairwise comparison of which elements were conserved (Figure 7.5C), and found that only
ESBL-cluster and sequence cluster together are conserved within patients at a significantly
greater proportion than between patients (p = 1.1× 10−12).
7.5 Discussion
In this chapter, I have used clustering algorithms on WGS data to group bacteria and
putative MGE. I have then assessed associations of these groups with metadata to attempt
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Figure 7.5: Probability of any two samples from within a given participant containing the same
ESBL-cluster (A, left panel) or being a member of the same hierBAPS cluster (A, right panel). Time
is windowed at +/- 5 days around the time indicated on the x axis. Dotted line is the probability
that two samples would belong the the same group by chance, constructed by randomly sampling
1000 sample pairs. B: proportion of samples that contain the same herBAPS cluster alone, or
ESBL-cluster alone, or both, demonstrating that the ESBL cluster-hierBAPS cluster pairing is the
most conserved of the three.
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First, I looked for healthcare associated E. coli sequence clusters. Healthcare associated
bacteria were not associated with a particular sequence cluster, and were spread throughout
the phylogeny rather than apparent hospital acquisitions being restricted to a single clade
or clone. The exception to this was SC23, which corresponds to ST410, and was more
likely to be healthcare associated. This could be consistent with the hypothesis that it is a
recently arrived high-risk clone, which may be, at least initially, hospital-associated. Even
so, it is clearly not hospital restricted, with half of the ST410 isolates being isolated from
the community.
I showed in Chapter 5 that there was an increase in colonisation prevalence of ESBL-E in
study participants following admission to hospital, particularly in the antibiotic-exposed.
Despite this it seems as though the genomic diversity of ESBL E. coli apparently acquired
in hospital is largely the same as E. coli isolated in the stool of community members.
This result could be explained by two hypotheses: first, that these are true transmission
events that are occurring within the hospital, and that the diversity of ESBL E. coli within
the hospital is the same as the community; or, second, that these “hospital acquisitions”
are actually minority variant E. coli present in the microbiota (and therefore acquired in
the community) at a low abundance and hence not detected by culture, and enriched for
with antimicrobial exposure in hospital. Distinguishing between these two hypotheses is
important as they would each require a different intervention: hospital infection control in
the former case, or strategies to protect the microbiota from the deleterious effect of broad
spectrum antimicrobials (such as pre- or probiotics, or oral β-lactamases) in the latter.
It is of course possible that both hypotheses are true; they are not mutually exclusive.
The genomic data are consistent with both, perhaps with a suggestion from the hospital
association of ST410 that there is at least some true hospital acquisition. The longitudinal
models I present in the next chapter can help to shed more light on the mechanism of
increase of ESBL-E prevalence following admission, by quantifying the relative effects of
hospital admission versus antimicrobial exposure.
By forming sequence clusters and ESBL-clusters, I was able to demonstrate that bacteria
and MGE are conserved together, within-patient, over time, whereas bacteria and MGE
alone are not. Some previous longitudinal studies of ESBL-E found that E. coli STs tended
to vary over time but that in many cases ESBL gene and plasmid replicons remained the
same, which could be due to a conserved MGE transferring between bacteria[177]. Given
my findings, this is unlikely to be the case. Though not directly addressed in this study it
is possible to speculate therefore that the unit of transmission of ESBL between patients
is likely to be the bacterium rather than, for example, horizontal gene transfer of ESBL
genes on plasmids or transposons. The within-participant association of sequence cluster
with ESBL-cluster suggests that MGE are reasonably conserved within bacteria, at least
on the timescale of the study. Mapping the ESBL-clusters back to the E. coli phylogeny
also shows some lineage association, which is consistent with this. The within-patient
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correlation of SC and ESBL-cluster lasts only for 32-35 days; two samples from a single
patient more than 35 days apart are as likely to contain the same SC/ESBL cluster as two
samples from two different patients. This implies either an exogenous re-exposure or some
other endogenous mechanism whereby the dominant ESBL strain is replaced by a minority
variant from within the microbiota. Again, the longitudinal models in the next chapter will
investigate this further.
This analysis also is suggestive that there is significant within-participant diversity of
ESBL E. coli. At a maximum (i.e. with samples that are days apart), only around 20% of
within-patient samples contain the same SC/ESBL-cluster. This is many times more than
would be expected by chance, but still implies that at any time point there is significant
diversity of ESBL E. coli strains, that have been missed by only taking forward one colony
pick for sequencing. Without multiple picks from one time point, however, it is not possible
to fully define within-host diversity. Limited data are available to define this diversity;
one study that examined this question found that it varied between individuals, and that
some individuals harboured widespread diversity of STs and ESBL genes whereas some did
not[374].
7.5.1 Limitations
Only one colony pick from the ESBL selective media was taken forward for sequencing.
In effect, we have randomly sampled one strain from all available strains at any give time
point. This is likely to result in an underestimation of the extent to which strains persist
within the individual over time, as strains that are present (but not sampled) are classed as
absent in the above analysis.
Community members are under represented in this dataset; I have classified isolates as
community or hospital associated, but there may have been healthcare contacts (especially
in arm 1 and 2 of the study) which have not been recorded which would mean that isolates
that were actually healthcare associated were classed as community associated. Healthcare
contact is probably less likely in the true community arm of the study (arm 3).
I have attempted to overcome the difficulty of reconstructing MGE by defining ESBL-
clusters as a proxy for MGE, but this approach has limitations. Some of the assembled
contigs are short and likely represent transposons; the same transposons have likely inserted
into multiple plasmids in the past and as such, these short contigs may cluster with other
sequences that would be seen to be very different, were a full assembly available. In addition,
the biological significance of these ESBL-clusters is not clear. It is not possible to say with
certainty what they represent (e.g. plasmids) as they are only fragments. Nevertheless, the
fact that I have seen within-patient associations of the ESBL-clusters lends some support
to their use, as erroneous clustering would be expected to bias any associations towards to
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null.
7.6 Conclusions and further work
In this chapter, I have shown that apparent hospital acquired ESBL E. coli are largely as
diverse as community isolates. This suggests either widespread mixing of strains between
the hospital and community and/or an enrichment effect as study participants are admitted
to hospital and exposed to antimicrobials and carried but undetected ESBL E. coli become
detectable by culture. By clustering bacteria and putative MGE I find that the bacteria-
MGE combination is the element that is most conserved within-participant over time,
but not after 32-35 days, suggestive of a constant re-exposure or some other replacement
mechanism. Many questions remain unanswered and further work is planned:
• Shotgun metagenomic sequencing of stool would allow testing of the competing acqui-
sition and unmasking hypotheses of rapid increase in ESBL-E prevalence by defining
the microbiota and total AMR gene content pre-, during and post- antimicrobial
exposure. This would also provide an opportunity to explore the role of the micro-
biota to colonisation resistance to ESBL-E, and help to define the within-host ESBL
diversity at any time point.
• Long read sequencing would allow a proper characterisation of the MGE that carry
ESBL genes in the Malawian context, giving the resolution necessary to truly track
MGE within and between patients and strains.
• Short-read sequencing of the Klebsiella pneumoniae isolates from this study (as
discussed in the previous chapter) would allow a comparison between the mechanisms
of AMR and MGE prevalent in this species as compared to E. coli, and assess the
extent to which horizontal gene transfer between the two is driving ESBL spread in
Blantyre.
• Sequencing one E coli from each sample in which E coli was identified but has not yet
had a representative sequenced (i.e. samples collected after October 2018) will give
more power to detect metadata associations - in particular by expanding the number
of isolates from true community members (arm 3) of the study, under represented in
this dataset.
• Finally, incorporating the resolution afforded by sequencing into a longitudinal mod-
elling approach may provide new insights in to the dynamics of ESBL-E carriage.
This is taken up in the next chapter.











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 7.6: Summary statistics for 99 ESBL-containing contig clusters as deterined by cd-hit. A:
Number of contigs per cluster. B: Length (kbp) of longest sample in each cluster. This is defined
as the cluster representative sample by cd-hit to which all other samples are compared for the
purposes of length and sequence identity. C: Distribution of contig lengths by cluster expressed
as a proportion of longest contig length. D: Distribution of sequence identity of cluster members
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AMR gene Insertion sequence (IS) Plasmid replicon
Figure 7.7: AMR genes, insertion sequences (IS) and plasmid replicons identified in the representative contig of each contig cluster, for blaCTXM15
containing contigs, ordered by number of samples of cluster from most (top) to least (bottom). IS26 is very frequently associated with a 108bp fragment
of catB4 chloramphenicol resistance gene, shown as a red fragment within the green IS26 element. Plots show furthest IS/AMR gene or plasmid
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Figure 7.8: AMR genes, insertion sequences (IS) and plasmid replicons identified in the representative contig of each contig cluster for blaCTXM27 (A)
and blaSHV12 (B). Ordered by number of samples of cluster from top (largest) to bottom (smallest) for each ESBL gene. IS26 is very frequently
associated with a 108bp fragment of catB4 chloramphenicol resistance gene, shown as a red fragnemt within the green IS26 element. Plots show
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Figure 7.9: AMR genes, insertion sequences (IS) and plasmid replicons identified in the representative contig of each contig cluster for blaCTXM14 (A)
and blaCTXM9 (B), ordered by number of samples in cluster from most (top) to least (bottom). IS26 is very frequently associated with a 108bp
fragment of catB4 chloramphenicol resistance gene, shown as a red fragnemt within the green IS26 element. Plots show furthest IS/AMR gene or
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Figure 7.10: AMR genes, insertion sequences (IS) and plasmid replicons identified in the representative contig of each contig cluster for blaCTXM3
(A) and blaCTXM16 (B) and blaCTXM1 (C) , ordered by number of samples in cluster from most (top) to least (bottom). IS26 is very frequently
associated with a 108bp fragment of catB4 chloramphenicol resistance gene, shown as a red fragnemt within the green IS26 element. Plots show
furthest IS/AMR gene or plasmid replicon up to +/- 10,000bp from the ESBL gene of interest.
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Chapter 8
Longitudinal Markov models of
ESBL-E carriage
8.1 Chapter Overview
In this chapter, I develop time-inhomogeneous Markov models of ESBL-E carriage by
individuals and fit them using the Bayesian probabilistic programming language Stan. I
demonstrate that fitting these models is feasible with modest computational requirements,
and that they are very flexible. I find that hospitalisation acts to increase both rate of
ESBL-E acquisition and loss, with a net effect of rapidly increasing ESBL-E carriage
prevalence; further, I find that antibacterial exposure acts to prolong ESBL-E carriage by
reducing the rate of ESBL-E loss. It is, however, the synergistic effect of hospitalisation and
antibacterial exposure that drives the rapid increase in ESBL-E carriage prevalence observed
in antibacterial-exposed inpatients. I also find that co-trimoxazole preventative therapy
(CPT) likely plays an important role as a determinant of long-term ESBL-E carriage. The
models I have developed also support a post-exposure effect of antibacterials, such that
they continue to have an effect long after they have been excreted from the body. I present
hypotheses about the mechanism of such an effect along with the implications of my findings
for antimicrobial stewardship interventions, and planned further work.
8.2 Introduction and chapter aims
In Chapter 5, I presented the longitudinal ESBL-E carriage data for the three arms of the
clinical study that underpin this thesis. Antibacterial-exposed, hospitalised participants
(arm 1) showed a rapid increase in ESBL-E carriage prevalence, whilst antibacterial-
unexposed hospitalised participants (arm 2) showed a much more modest increase. This
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suggests that antimicrobial exposure is the most significant determinant of acquisition
of carriage; however, this unadjusted analysis is open to confounding. The participants
recruited to the two arms of the study differed in important ways: antimicrobial unexposed
participants were younger, less likely to be HIV-infected, with less cotrimoxazole preventative
therapy (CPT) exposure, and crucially, a shorter length of hospital stay. An attempt to
adjust for potential confounders using simple logistic regression models failed; therefore
in this chapter I develop longitudinal models to quantify the relative roles of antibacterial
exposure and hospitalisation in driving ESBL-E carriage.
There have been few prior attempts to model longitudinal ESBL-E carriage, and none
where the focus was on he role of antimicrobials, including:
1. Fitting a Weibull distribution to community sample data[182]
2. Fitting a beta-distribution of admission and discharge carriage probability to data
from trials of contact precautions in Dutch hospitals[375]
3. Modelling household ESBL-E acquisition as a Markov process[376].
None of these studies included the effect of antibacterial exposure as a covariate. The
Markov model approach is an attractive method to model multi-state interval-censored
data[377], has been used with a variety of clinical datasets[378–380] and is implemented
in the msm package in R[381] where a maximum likelihood method is used to fit the
models. However, msm allows only stepwise-constant covariate effects, largely for reasons
of computational tractability in the maximum-likelihood framework, but there is no reason
to assume that the effect of antibacterial exposure, for example, will act in this fashion.
The aims of this chapter, therefore, are:
1. To generalise msm-type models to allow true time-varying covariates;
2. To demonstrate the feasibility of fitting such models;
3. To use the fitted models to infer an unbiased estimate of the relative roles of an-
tibacterial exposure and hospitalisation in driving ESBL-E carriage by both fitted
parameter estimates and simulating different levels of exposure;
4. To compare models with and without a post-exposure effect of antibacterials to assess
the support in this data for such an effect;
5. To combine the models with ESBL-E species data and with the WGS isolate typing
presented in Chapter 7 to explore carriage at the level of species, E. coli sequence
cluster and ESBL-containing mobile genetic element.
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8.3 Methods
8.3.1 Developing the models used in this chapter
In the broadest sense when constructing a model, our aim is to estimate the most likely
values of the parameters of the model, θ, given the data we have, x. The starting point
for estimating likely parameter values, given a choice of model, is usually the likelihood:
this is the probability of the data, given a set of parameter values. In standard probability
notation, this is written as P (x|θ). In fact, this is not the quantity we are interested in; we
would like to know P (θ|x): the probability of the parameter values, given the data. Both
frequentist and Bayesian modelling approaches provide methods to estimate this quantity,
but the starting point for both is the likelihood, P (x|θ), because it is usually much more
straightforward to derive an expression for P (x|θ) rather than P (θ|x). I will here derive
a general likelihood for a two state intermittently observed process; in order to use this
likelihood, it is necessary to make some assumptions about the data generating process. I
have chosen to use a Markov model, and I will then derive the likelihood for this model,
describe how covariates will be incorporated, describe how the model was fit - the process
taking us from the likelihood to the most likely parameter values - and finally how goodness
of was fit assessed.
8.3.2 General form of likelihood
First, I derive a general expression for the likelihood of a two-state intermittently observed
process without making any assumptions about the model structure or functional form.
Assume we have N participants with any given participant n in a state Sn(t) at time t:
either ESBL-E colonised (Sn(t) = 1) or uncolonised (Sn(t) = 0). For each participant n
we have a number of measurements of Sn(t) at a number of time points. The number of
measurements varies for each participant, and can be denoted by jn, making the time of
measurements tnjn for participant n; and so for each participant we know the jn values
Sn(tnjn).
To arrive at the likelihood for these observations, consider first the simplest situation that
we have: the measurements of ESBL status at two time points, tA and tB for a single
participant, n. The likelihood we wish to calculate, in words, is the probability of the
participant being in the second observed state at time tB, given they were in the first state
at tA and given the parameters of the model, θ. Or, mathematically:
P (Sn(tB)|Sn(tA), θ) (8.1)
Assuming all the observations are independent, the probability of all of the states we have
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observed for this participant is the product of all the probabilities of the individual states:
jn∏
k=2
P (Sn(tnk)|Sn(tnk−1), θ) (8.2)
And the probability of observing the data we have is then simply the product of the





P (Sn(tnk)|Sn(tnk−1), θ) (8.3)
This is the quantity that we wish to calculate: the likelihood for the observed data, P (x|θ).
Note that the sum over states for an individual in equation (8.3) starts from 2; if a
participant has only one available sample then this does not provide any information about
transition probabilities, and must be excluded from the analysis.
8.3.3 Markov model likelihood
In order to calculate the likelihood, we need to make some assumptions about the data
generating process. In this case, I have chosen to use a Markov model. Markov models
are defined by instantaneous transition probabilities, analogous to the hazard of death in
a survival model, which is a simple two-state Markov system. Unlike a survival model
(where it is not possible to move from the death state to alive), a general Markov model is
defined by a transition hazard from each state to each other state in the system. These
are traditionally expressed as a Q matrix of instantaneous transition intensities[377,381]







Where qij represents the instantaneous transition intensity from state i to state j. The
rows of the Q-matrix must sum to 1 (every participant has to be in one state or another),
so if we define the hazard of ESBL-E acquisition to be λ and the hazard of ESBL-E loss to







However, we are not interested in the Q-matrix per se but rather the probability pij of
starting in state i at time 0 and being in state j at time t; this can be written in matrix





Where Q(t).P(t) is the matrix product of Q(t) and P(t). In order to evaluate P(t),
therefore we need to solve this system of differential equations. However, there are limited
situations in which these equations have analytic solutions. If the system has time constant
or piecewise constant Q matrix the matrix exponential is a solution:
P(t) = eQ (8.7)
However, there is no reason to suspect particularly that the effect of covariates on ESBL-E
carriage (e.g. antimicrobials) would be stepwise constant and so a more flexible model is
needed. For general time-varying transition intensities, there is no analytic solution to the
above equations. However, all is not lost: we can express the likelihood in terms of the
differential equations defined by the equations above and solve them numerically in order
to calculate the likelihood. The matrix notation above can be simplified, assuming that the
system starts in state 1 or 0:
dP0(t)
dt
= −λ(t)P0(t) + µ(t)P1(t) (8.8)
dP1(t)
dt
= λ(t)P0(t)− µ(t)P1(t) (8.9)
Where Pi(t) is the probability of being in state i at time t. Numerical ordinary differen-
tial equation (ODE) solvers can quickly solve these equations to calculate, for example,
P (Sn(tB)|Sn(tA), θ) from the simplest example above: the probability that a participant n
at time tB is in a given state, given that they were in state Sn(tA) at time tA, and given
the parameters θ. This calculation can be completed for all measurements and participants,
resulting in the likelihood of the system, P (x|θ).
In order to use this model for inference, two questions must be addressed: first, how to
incorporate time-varying covariates; and second, how to practically fit the model. I address
each of these questions below.
8.3.4 Incorporating covariates: a proportional hazard model
I have chosen to incorporate covariates using a proportional-hazards model, following both
Marshall and Jones[382] and the msm package in R[381]. In this model the transmission
intensities become:
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Figure 8.1: Two state ESBL-E model showing instanteneous hazard of ESBL-E acquisition (λ) or
loss (µ).
λ(t) = λ0 exp (β0x0(t) + β1x1(t) + ...βmxm(t)) (8.10)
µ(t) = µ0 exp (α0x0(t) + α1x1(t) + ...αmxm(t)) (8.11)
Where the xk, k = 1, 2...m are them time-varying covariates in the model and the coefficients
αk and βk are the coefficients of these covariates; these have a straightforward interpretation
in that the exponential, eαk oreβk can be interpreted as a hazard ratio, as per a simple
survival model.
An assumption then needs to be made about the functional form of xm. In a stepwise-
constant covariate model in which an exposure occurs between tA and tB, x(t) would take
the value 1 for all tA ≤ t ≤ tBt and 0 at other times, meaning that the effect of the exposure
does not persist once it ceases. Though this may be plausible for some exposures, it seems
possible that antimicrobial exposure (for example) might have a longer lasting effect or
post-exposure effect; in order to explore this possibility, it is necessary to decide on a
flexible, plausible, functional form that such an effect might take. I have decided to use an
exponential function, such that:
xk(t) =

0 if t < tA
1 if tA ≤ t ≤ tB
exp −(t− tB)
γk
if t > tB
(8.12)
Where the parameter γk is a model parameter for each of the covariates, to be estimated
from the data, and is related to the half life, tk1
2
of the decay of the effect of the exposure by:
tk1
2
= γk ln(2) ≈ 0.69γk (8.13)
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This parametrisation has the advantage that the data can fit the size of the parameters γk;
if the data are more in keeping with a stepwise effect of the covariates, then a small ( 1) γ
would approximate a step function and this could be fit by the model. Alternatively a larger
γ would result in the effect of the covariate persisting after exposure, but decaying over
time. This allows us to test the hypothesis that antimicrobial exposure (for example) has
an effect that persists once exposure finishes, by both the magnitude of the fitted γk, and
comparing stepwise-constant covariate models to models incorporating the γk parameters.
The parameters of the model all have the advantage of having a reasonably intuitive meaning:
exp(α) and exp(β) are the hazard ratio for ESBL-E loss and acquisition, respectively; the
reciprocals of λ and µ are the mean time in days spent in the uncolonised or colonised
states, respectively, with covariate values set to 0; and ln(2)γ ≈ 0.69γ, as stated above, is
the half life of the post-exposure effect.
8.3.5 Building and fitting models
The Bayesian probabilistic programming language Stan incorporates an ordinary differential
equation solver, and will allow the fitting of the model in a Bayesian framework[320]. In
this framework, Bayes’ rule allows us to estimate our probability distribution of interest,
P (θ|x), called the posterior in the Bayesian framework, a long as we provide a prior,
encoding our prior beliefs about the values of the parameters as a probability distribution
for each parameter[316]. Stan then uses the No-U-Turn Sampler (NUTS) implementation
of Markov-chain Monte-Carlo (MCMC) sampling[383] to sample from the posterior to
provide P (θ|x). It can be shown that, given infinite chain length, MCMC estimates are
guaranteed to be unbiased samples from the posterior; when this occurs the chains have
said to converged. Unfortunately there is no diagnostic test that guarantees convergence,
rather tests that are necessary but not sufficient to ensure convergence: running multiple
chains from different starting points with examination of traceplots to show within and
between mixing of chains, and the R̂ statistic, which measures mixing of the two halves of
an MCMC chain. At convergence, R̂ should be close to 1[316]. In addition, divergences
- failure in the NUTS sampler - can be indicative of difficult topography in the posterior
at the area where the divergences occur, and suggest that parameter estimates may be
biased[384], and are flagged by Stan. All of these tests were used to diagnose convergence.
Two decisions must be made in order to fit the model: covariates must be chosen to include,
and priors specified. Models were built sequentially to predict ESBL-E status, starting
from the simplest possible, then adding complexity:
• Model 1: Composite antibacterial variable (includes all antibacterials) and hospitali-
sation variable as explanatory variables, both included with stepwise constant effect
and no post exposure effect.
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• Model 2: As per model 1 except antibacterial exposure modelled with decaying
post-exposure effect.
• Model 3: Hospitalisation, TB therapy and co-trimoxazole exposure all modelled as
stepwise constant covariates. All other antibacterials included in a composite variable
with decaying post-exposure effect.
• Model 4: Hospitalisation, TB therapy and co-trimoxazole exposure all modelled
as stepwise constant covariates; ceftriaxone, ciprofloxacin and amoxicillin exposure
included in a composite variable with decaying post-exposure effect, with γ allowed
to vary for each agent.
Weakly informative priors were used. A normally distributed prior centred at 0 with
standard deviation 2 was used for all the α and β parameters. A parameter value of 2
corresponds to a hazard ratio of 7.4; it would be surprising if any effect is greater than this so
this could be argued to be a weakly informative prior. Normally distributed priors centred
at 0 with standard deviation 0.2 were used for the µ and λ parameters; in a model with no
covariates, the inverse of these parameters are the mean times that an individual would
remain in the colonised or uncolonised states, respectively, so a value of 0.2 corresponds to
a mean state occupancy time of 50 days. A normally distributed prior centred at 0 and
with standard deviation 50 days was used for all γ parameters.
The Stan code for the models is given in the appendix to this chapter. Four chains were
run in each case, with a warmup of 500 iterations and run for 1000 iterations in total.
Convergence was assessed using the diagnostics described above. Stan v2.19 was used to
sample from the posterior, accessed via Rstan v2.19.2, and run on the Wellcome Sanger
Institute computing cluster under Linux Red Hat v7.6, running R v3.5.3, and gcc v6.3.0
C++ compiler. Four cores (one per MCMC chain) and 3GB of memory per model fit were
used. Posterior samples were brought to my local machine (MacBook Pro running mac OS
Mojave 10.14.5) and further analyses undertaken with R3.6.0.
8.3.6 Assessing goodness of fit
Model goodness of fit was assessed in two ways; first, by graphical posterior predictive
checks: comparing predicted total number of ESBL-E positive samples to the actual number
across the three arms. This was done by using the posterior parameter estimates for each
MCMC draw (after discarding warmup samples) to generate a predicted probability of the
ESBL-E positive state for each data point, then sampling from a Bernoulli distribution to
convert to predicted state occupancy. Each data point therefore had 2000 predictions for
state occupancy, one for each posterior draw. These were plotted as kernel density plots
against actual state occupancy, stratified by arm, to visualise the goodness of fit of the
model, and to compare between models.
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Second, models were compared using leave-one-out cross validation, as implemented in the
loo v2.1.0 package in R[322]. This estimates the out-of sample predictive ability of the model
by estimating a quantity called the expected log predictive density (ELPD) essentially
the log of the likelihood for a new, unseen dataset conditional on the current data. This
quantity is estimated using leave-one-out cross validation to produce and estimate of the
ELPD, hereafter referred to as ELPDloo. The standard error of ELPDloo for a model is
also calculated and so two models can be compared by comparing the ELPDloo difference
and standard error; if the difference is greater than twice the standard error (i.e. a 95%
confidence interval, assuming normality) we can be confident that one model would be
expected to have greater out-of-sample predictive ability than the other[322]. Because this
technique estimates out-of-sample predictive ability it naturally incorporates a penalty for
including multiple parameters and hence overfitting, as an overfit model would be expected
to have worse out of sample predictive ability and hence lower ELPDloo.
8.3.7 Exploring differences in carriage dynamics by bacterial species and
E. coli genotype
The models fit as described above predict whether a participant will be colonised with any
ESBL producing organism at a given time point, but this classification obscures a lot of
complexity. A participant can be colonised with different ESBL- producing species (largely
Eschericha coli or Klebsiella pneumoniae), and different clones of those species containing
different ESBL genes on different mobile genetic elements (MGEs). It may be that there is
heterogeneity in carriage dynamics across these different levels of the system. To address
this hypothesis, the best fitting model identified from the four described above was refit but
the “colonised” state modified to either consider the species level or to use the whole genome
sequence data presented in Chapters 6 and 7. The analysis in Chapter 7 suggests that the
element most conserved within participants is the bacterial clone-ESBL contig combination,
where the bacterial clone clusters were defined with the hierarchical BAPS algorithm and
the ESBL-contig clusters defined with the cd-hit algorithm, as described in Chapter 7. The
hierBAPS cluster-contig cluster pairs are coded as follows in this chapter: a.ESBLgene.b
where a is the ID number of the level 2 hierBAPS cluster, and ESBLgene.b is the number
of the contig cluster for a given ESBL gene, and for the rest of the chapter for brevity each
unique hierBAPS cluster-contig cluster will be referred to as an E. coli genotype. All E. coli
genotypes which were identified in more than 15 samples - 6 in total - were included and so
the models were refit defining the colonised state as the presence of, respectively, ESBL
E.coli , K. pneumoniae or one of the six included hierBAPS cluster-contig cluster pairs.
The parameters for these models were compared with each other and with the original
ESBL model.
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8.3.8 Simulations from the posterior
Finally, in order to better understand the relative role of antimicrobial exposure and
hospitalisation in driving ESBL-E carriage, I conducted simulations with these exposures
set at varying levels. The probability of ESBL colonisation as a function of time was
calculated by solving the equations (8.8) and (8.9) using the R package deSolve v1.2.4[385],
for each of the 2000 posterior parameter estimates from the posterior and assuming a 50%
initial probability of ESBL colonisation. This yielded a distribution of carriage probability
at each time point which was summarised using the median and 95% confidence intervals
and plotted against time for varying covariate values: days of hospitalisation was varied
from zero to twenty in steps of five, as was antimicrobial exposure, and each simulation
repeated both with and without CPT.
8.4 Results
8.4.1 The effect of antibacterials and hospitalisation on ESBL-E carriage
First, I fit the four models with three specific aims:
1. To identify the model that provides the best trade off between predictive ability and
the computational cost to fit;
2. To explore the relative effects of hospitalisation versus antimicrobial exposure on
ESBL-E carriage by assessing the posterior parameter values of these models;
3. To assess support in the data for a post-antibacterial effect on ESBL-E carriage that
persists once antibacterial therapy is stopped.
For these models, the colonised state was defined as at least one ESBL producing organism
of any species identified in a sample, and uncolonised as no ESBL producer identified.
After excluding participants with only one sample, there were 993 pairs of samples in 363
participants remaining that contributed data to the analysis. All four models converged
within the 1000 iterations; R̂ was less than 1.1 for all parameters and all traceplots showed
good mixing of chains. There were no divergences of the NUTS MCMC sampler in any of
the models. There was a computational cost to increasing the number of parameters, as
would be expected from the increase in dimensionality of the posterior: model one took 3.5
hours to fit, model two 13.7 hours, model three 17.1 hours and model four 33.4 hours.
The parameter estimates for the models are shown in Figure 8.2. There were significant
correlations between some posterior parameters (see Figure 8.6 in the chapter appendix
for pairwise plots for model 2 as an example): particularly λ and µ, and the α and β
parameters. This is not necessarily problematic in that it is not necessarily a source of
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bias, but can make it difficult for some MCMC algorithms (e.g. Metropolis-Hastings) to
adequately sample from the posterior[316]. Nevertheless, the diagnostics suggest that the
Stan NUTS sampler had no problems.
The effect of hospitalisation is consistent across all models; in most models, the 95% credible
intervals for both α and β for hospitalisation do not cross zero and are positive, suggesting
that the hazard ratio of hospitalisation on both the rate of acquisition and loss of ESBL-E
is very likely to be greater than one, and the effect of hospitalisation is to increase both the
rate of acquisition and loss of ESBL-E. The estimated effect sizes are consistent across the
models though, as expected, uncertainty in the estimate increases as more parameters are
added to the model.
The effect of antibacterial exposure is also reasonably consistent across the models; the
parameter α is negative in all cases, and often the 95% credible intervals do not cross zero,
suggesting that the hazard ratio of antimicrobial exposure is likely to be less than zero.
The effect sizes are similar in all cases, for all agents (including TB therapy), whether
antibacterial exposure is considered as an aggregate variable or as individual agents; though
in the extreme case where agents are all considered individually (Model 4, Figure 8.2D) the
uncertainty in the estimates makes it difficult to draw any firm conclusions. This suggests
that all the considered antibacterial agents act, with broadly similar effect size, to prolong
ESBL-E carriage by reducing the rate of loss. No β parameter (the log hazard ratio of
ESBL-E acquisition) has 95% credible intervals that do not cross zero, consistent with
antibacterial exposure having no or limited effect on ESBL-E acquisition.
The relative predictive ability of the four models were assessed in two ways: first, the
predicted proportion of ESBL-E positive samples were plotted by sampling from the
posterior (Figure 8.3); second, the pairwise ELPDloo differences (and standard errors in
the differences) between all models calculated (Table 8.1). All models predicted ESBL-E
carriage reasonably poorly for arm two and three participants, but better for arm one
(Figure 8.3). The addition of a post-antibiotic effect improved model fit (seen by comparing
model 1 to model 2 graphically in Figure 8.3 and by an ELPDloo difference of more than
two standard errors in Table 8.1) but models two, three and four, had similar fit despite
the increase in number of parameters from seven in model two to seventeen parameters
in model four. Model two therefore provides a good balance between computational
tractability, interpretation and predictive ability; the parameter estimates for this model,
expressed as hazard ratios for α and β, the mean time in state for λ and µ and half life of
post-antibacterial effect for γ are shown in Table 8.2. The significant ELPDloo difference
between model 1 and 2 provides strong support for a post-antibiotic effect of antimicrobial
exposure.
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Figure 8.2: Parameter estimates from increasingly complex Markov models to predict ESBL carriage.
Black lines are 95% and red lines 80% credible intervals. A: Model 1 includes stepwise constant
covariates only, animicrobial exposure (abx) and hospitalisation (hosp). λ is the baseline hazard
and β the log hazard ratio of ESBL-E acquisition, µ the baseline hazard and α the log hazard ratio
of ESBL-E loss. B: Model 2 adds a post-exposure effect of antimicrobial exposure, parameterised by
γ as described in the text. C: Model 3 adds stepwise constant covariates for TB therapy (tb) and
cotrimoxazole (cotr) with all other antimicrobial exposure captured in the abx variable, which has a
post exposure effect as before. D: Model 4 seperates the effect of antimicrobial exposure into the
component agents, with post exposure effects for all except cotrimoxazole and TB therapy. In most
models 95% credible intervals of α[hosp] and β[hosp] do not cross zero and are positive, suggesting
that hospitaliation acts to both increase rate of ESBL-E acquisition and loss; for antimicrobial
exposure, on the other hand, only the 95% for antimicrobial α values consistently do not cross
zero, and are negative, suggesting that the effect of antimicrobial exposure is to reduce the rate of
ESBL-E loss. It is also clear that adding parameters to the model increases the uncertainty in the
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Figure 8.3: Posterior predictive checks: kernal density estimate, D, of predicted proprtion of ESBL-E
positive samples, stratified by arm for Model 1 (A), Model 2 (B), Model 3 (C) and Model 4 (D),
generated by sampling from a Bernoulli distribution using the predicted probability for each sample
(n=993) for each draw from the posterior, excluding warmup draws (n = 2000). True proportion of
ESBL-E positive samples are shown for each arm by dotted vertical line. In all cases, predictions are
poor for arm 2 and 3 samples, but the addition of a post-antibacterial effect improves fit, especially
in arm 1 participants: compare Model 1 (A) with stepwise constant covariates to Model 2 (B) with
post-antibacterial effect. Models 2-3 (B-D) have similar predictions despite more parameters.
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Table 8.1: Estimates (and standard error) of pairwise expected log predictive density (ELPD)
differences for all models
Model 1 Model 2 Model 3 Model 4
Model 1 0.0 (0.0) 10.5 (4.2) 10.0 (6.4) 15.0 (7.0)
Model 2 - 0.0 (0.0) -0.5 (5.2) 4.4 (6.0)
Model 3 - - 0.0 (0.0) 4.9 (3.7)
Model 4 - - - 0.0 (0.0)
Note:
Cells in table compare row model to column model. A
positive number favours the model in the column. The
standard error of the ELPD difference is given in brackets;
if twice the standard error is less than the estimated ELPD
difference then we can be confident that the column model
has better out-of-sample predictive fit than the row model.
All models have better fit than model 1 but models 2-4 all
have similar fit.
8.4.2 Exploring bacterial species and genotype differences in carriage
dynamics
Next, I explored the differences in carriage dynamics between ESBL-E species and E. coli
genotype, by refitting model 2 but considering the colonised/uncolonised states to be, in
turn, presence or absence of E. coli, K. pneumoniae or any of the top six most prevalent
E. coli genotypes (as defined by the combination of ESBL containing contig cluster and
E. coli hierBAPS cluster [Chapter 7]), and refitting the model for each one. All 993
within-participant sample-pair comparisons were used to fit the E. coli and K. pneumoniae
models, but because sample collection continued after the sequenced E. coli included here
were shipped, all samples collected after this time were excluded from the genotype models.
585 samples from 251 participants were therefore included in the genotype models.
The parameter estimates for these eight models (alongside the original ESBL-E pres-
ence/absence model) are shown in Figure 8.4. In general, there was more uncertainty
in the parameter estimates for the new models, as might be expected as there are fewer
carriage events, and fewer samples in the case of the genotype models. The only significant
parameter difference between the models was in the λ parameter, the baseline hazard of
state acquisition. The magnitude of the difference was large; for example the median (95%
CI) λESBL estimate of 0.10 (0.07-0.15) is almost three orders of magnitude larger than the
estimate of λ6.CTXM.27, 0.002 (0.001- 0.003). These values would correspond to a mean
(95% CI) time in the uncolonised state of 10 (6-14) days for the ESBL model versus 500
(333-1000) days for the genotype model, assuming all other covariates were zero. The
hazard rate of state loss, µ was similar, however, meaning that the time in the colonised
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Figure 8.4: Parameter estimates from two state models predicting species and E. coli genotype
carriage, compared to original model, which predicted carriage of any ESBL-E. A: All parameters,
showing that the only significant difference between the models is the parameter λ (the hazard of
acquisition), with an order of magnitude difference between the hazard of ESBL acquisition versus
the acqusition of a particular genotype. B: λ parameter only for genotype models, showing that the
estimates are similar for each genotype.
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Table 8.2: Parameter estimates (and 95% confidence intervals) from model 2
Variable Value
Effect of Antibacterials
Hazard ratio for ESBL-E loss 0.16 (0.05-0.58)
Hazard ratio for ESBL-E acquisition 0.57 (0.16-2.25)
Effect of Hospitalisation
Hazard ratio for ESBL-E loss 10.01 (1.24-52.34)
Hazard ratio for ESBL-E acquisition 27.82 (3.60-143.18)
Post Antibacterial Effect
Half life (days) 43.67 (15.42-97.66)
Mean time in state
Uncolonised (days) 9.65 (4.22-25.07)
Colonised (days) 5.76 (2.54-14.30)
Note:
Hazard ratios are the exponential of the parameters α and β in
the model; half life is equal to log(2) multiplied by γ; mean time
in state assumes all other covariates are equal to zero and is then
the reciprocal of λ or µ.
8.4.3 Simulation of different antibacterial and hospitalisation scenarios
Finally, to better understand the relative roles of antimicrobial exposure and hospitalisation
in driving ESBL-E carriage, I simulated the probability of ESBL-E colonisation as antibac-
terial and hospital exposure changed from 0 to 20 days, assuming a 50% baseline probability
of ESBL-E colonisation (Figure 8.5) and both with and without cotrimoxazole preventative
therapy. Model 2 was used for these simulations. Hospitalisation seems to rapidly increase
carriage probability and antimicrobial exposure produces a slower rise. Most striking,
however, is that the effect of both exposures simultaneously causes a rapid increase in
ESBL-E colonisation probability as well as prolonged decay to baseline probability: by
the end of the 100 day simulation period in those simulations with both hospital and
antibacterial exposure, most probabilities have not yet returned to baseline levels. Shorter
course lengths of antibacterials seemed to have similar effects to longer courses. In the
model used for the simulations (model two), the effect of all antibacterials (including CPT)
is equal and so CPT seems to be the primary driver of an increased long-term carriage
probability. TB therapy is also included in the composite “antibacterial” variable, so these
conclusions would be equally valid for TB therapy.
8.5 Discussion
In this chapter, I have extended the continuous-time Markov models available in the msm
package in R to incorporate true time-varying covariates (rather than stepwise constant). I
have fitted them to the data presented in Chapter 5 using a Bayesian framework and a
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Figure 8.5: Simulations of different antibacterial and hospitalisation scenarios. CPT = Cotrimoxazole
preventative therapy. Plots show estimated probability of being in the ESBL+ state for given
covariate values as a function of time, assuming a baseline 50% probability of ESBL-E colonisation.
Antimicrobial exposure ranges across columns from 0 to 20 days, and hospitalisation across rows from
0 to 20 days. Hospitaliation causes a more rapid increase in probability than antimicrobial exposure,
wheras antimicrobial exposure in the form of CPT is the primary deteriminent of increased long-
term carriage probability. However, there is a synergistic effect of hospitalisation and antimicrobial
exposure that results in rapid rise in colonisation probability and prolonged decay.
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differential equation solver in the probabilistic programming language Stan. From these
fitted models, it is possible to draw several conclusions.
First, the class of models that I present are feasible to fit in a reasonable amount of time
with modest computational requirements, and are very flexible. The models were largely fit
overnight on the WSI cluster with four cores and 3GB RAM. These are not particularly
onerous requirements, and the times to fit would be expected to be similar on a desktop
machine. The parametrisation of the model is extremely flexible; I chose an exponential
form of a post-antibacterial effect but any functional form could be used, simply by replacing
the function that generates the covariate values, x(t) in Stan model. If a function can be
written down, it can be fitted in this framework with minimal effort. This provides, for
example, the opportunity to explore in silico different hypotheses as to the ways in which
antimicrobial exposure drives ESBL-E carriage, by exploring the functional form of the
antimicrobial exposure covariate that best fits the data.
Second, the values of the parameter estimates and the simulations from the ESBL models
allow an insight into the drivers of ESBL-E colonisation in Malawian adults, and suggests
areas to target for interventions. Hospitalisation acts to increase both ESBL-E acquisition
and loss, the net result of which is a rapid increase in the probability of ESBL-E colonisation
following admission. Antimicrobial exposure acts to reduce the rate of ESBL-E loss and
thus prolong carriage, but it simultaneous hospitalisation and antimicrobial exposure have
a synergistic effect to produce the observed rapid increase in ESBL-E carriage prevalence
seen in antibacterial exposed inpatients. The crude unadjusted analysis suggested that
antimicrobial exposure alone was driving ESBL carriage; in fact, these models show that
both hospitalisation and antimicrobial exposure act in synergy.
Whether these associations represent causal relationships and the mechanisms of any rela-
tionships are not addressed by the models, but causal associations are certainly biologically
plausible. The hospital environment at QECH is such that cleaning is difficult, hand
washing facilities for staff, participants and guardians are lacking, wards are crowded with
participants close together, and one toilet is shared between around 60 patients, all of which
potentially facilitate the acquisition of ESBL-E. The level of granularity of the models is
such that the relative contributions of person-to-person transmission or transmission from
the hospital environment or toilet facilities is not clear, and as it stands hospitalisation is
used as an aggregate proxy for all of these putative transmission routes.
The genomics data (Chapter 6) perhaps provides additional insight. There is no one
hospital clone and in terms of E. coli diversity at least, the hospital is largely an extension
of the community. Given the number of adult admissions to QECH per year - around
15,000[386], this is perhaps not surprising: if each adult admission is cared for by two
guardians then ~5% of the population of Blantyre - 800,000 at the 2018 census - is passing
through QECH yearly. Given this, there is likely a frequent influx of ESBL-E clones from
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the community, which could, given the genomic data, suggest simple patient-to-patient
transmission is the main route of ESBL-E acquisition; however, the hospital association
of E. coli ST410 implies a hospital reservoir of some sort. Further studies are needed to
clearly understand transmission dynamics of AMR-bacteria within the hospital setting in
Malawi, which could inform infection prevention and control (IPC) interventions. Evidence
based IPC interventions which can be deployed in low-resource settings are urgently needed
and, given the rates of hospital exposure in Blantyre, could potentially have a significant
impact on the prevalence of ESBL-E there.
Strategies to mitigate against the effect of antimicrobials on ESBL-E carriage are also needed.
The data presented here support a post-exposure effect of antibacterials on prolonging
ESBL-E carriage duration, such that short courses of antimicrobials seem to have a similar
effect to longer courses in hospitalised participants. This finding may be contingent on
the parametrisation of the post-antibiotic effect, and requires further exploration, but
could have significant implications for antimicrobial stewardship. In this model framework,
two days of antibacterial therapy to ten inpatients would results in more participant-days
carriage of ESBL-E than twenty days of antibacterial therapy to one patient - as seen from
the simulations presented in Figure 8.5 - despite the same number of defined daily doses
being used in total. This would suggest that antimicrobial stewardship interventions to
avoid unnecessary antibacterials altogether would be more effective than those limiting
antibacterial course lengths by e.g. review of blood culture results at 48 hours. The post-
antibacterial effect has a lengthy half life of 44 days (95% credible interval 15-98 days),
much longer than the time by which most antimicrobials will have been excreted from
the body. Such a prolonged effect is biologically plausible, however even short courses of
antimicrobials are known to profoundly alter the composition of the gut microbiota[387,388],
which could certainly alter ESBL-E carriage dynamics[389]. Further studies of the role of
the microbiota in colonisation resistance to ESBL-E could shed light on the mechanisms of
the post-antibacterial effect I demonstrate here, and pave the way for microbiota-modulating
therapies to mitigate against it.
The role of CPT in driving long-term ESBL-E carriage is likely significant, and it appears
to be a major determinant of long-term ESBL-E colonisation. Again, this is perhaps not
surprising given that cotrimoxazole exposure dwarfs exposure to all other antimicrobials
combined in the cohort, and that cotrimoxazole resistance genes are near-ubiquitous in the
sequenced ESBL E. coli isolates. It is not possible to say from the short read sequence
data but cotrimoxaole resistance determinants could be collocated with ESBL resistance
determinants, which would explain an apparent selection pressure for ESBL-E carriage
from CPT. CPT has been shown to have significant mortality benefits in people living
with HIV[390], and lifelong CPT is mandated by WHO guidelines for all people living with
HIV in areas with high malaria or bacterial infection prevalence, including Malawi[330,390].
Given an estimated adult Malawian HIV prevalence of 9.6%[284], CPT is likely therefore a
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major driver of ESBL-E carriage in Malawi. The risk of driving AMR with CPT needs to
be balanced against its benefits, and may be possible that in the era of high ART coverage,
reducing malaria incidence and growing Gram-negative resistance that these risks begin to
outweigh the benefits. The exact mechanism by which CPT confers a reduced mortality risk
- whether it acts primarily to prevent opportunistic infections, bacterial infections or malaria
- remains controversial. A recent RCT in Uganda carried out in 2012[391] showed that a
strategy of stopping CPT once the CD4 cell count is persistently above 250 cells µL−1
is associated with more CPT-preventable infections, including malaria and pneumonia,
but no difference in mortality (1.7% vs 1.8% over 12 months). Results are awaited of the
TSCQ trial (ClinicalTrials.gov identifier NCT01650558), which has assessed the effect of
mortality of CPT versus chloroquine malaria prophylaxis in Malawian HIV-infected adults,
based on the hypothesis that in malaria-endemic areas the mortality benefit of CPT is
primarily driven by its antimalarial properties. Given the findings here, a chloroquine based
prophylaxis strategy could significantly impact ESBL-E carriage prevalence (and hence,
possibly, infections) in Malawi and would be very attractive from this perspective if non
inferior to CPT in mortality endpoints.
Finally, using WGS as a high resolution typing tool allows very granular insight into ESBL-E
carriage at the genotype level. Within the limitations of reasonably uncertain parameter
estimates due to small numbers, all parameters for genotype carriage models were the same
as the general ESBL carriage model, with the exception of λ. This indicates that the rate
of acquisition of a given E. coli genotype is two to three orders of magnitude lower then
the overall rate of ESBL acquisition, in turn suggesting that apparent continual ESBL-E
carriage in fact represents a much more frequent apparent acquisition of different ESBL-E
genotypes. This could represent true acquisition or some other dynamic shift in the relative
abundance of ESBL producing E. coli in the microbiota over time. This analysis is, however,
hampered by the fact that only one colony pick at each time point was sequenced and
hence the true distribution of E. coli genotypes at a given time point is unknown.
8.5.1 Limitations
There are several limitations to the analysis presented here. First, despite a reasonable
number of data points, the parameter estimates from these models have moderate uncer-
tainty. Some of this may be consequent on the model structure: with strongly correlated
parameters, the data may be consistent with a wide range of paired parameter values. Even
those parameter values whose 95% credible intervals cross zero (e.g. the hazard ratio of
antibacterial exposure on ESBL-E acquisition in model 2) largely incorporate a clinically
meaningful effect size, and so care must be taken not to interpret a lack of certainty of
a significant effect as a lack of effect. Uncertainty in parameter estimates increases as
more parameters are added, meaning that understanding the relative effects of different
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antibacterial agents on ESBL-E carriage is not possible, and in most models antibacterials
are considered as an aggregate variable. A priori, different antibacterial agents would
not be expected to have the same effect on ESBL-E carriage dynamics, but here they are
considered together. There is some support for this strategy from the fact that the estimated
effect sizes of ceftriaxone, ciprofloxacin and amoxicillin (the most commonly administered
antibacterials apart from CPT and TB therapy) are similar when considered individually
and in aggregate, but uncertainty in these estimates warrants caution. The apparent effect
of TB therapy is particularly surprising, given that the first-line combination of rifampicin,
pyrizinamide, ethambutol and isoniazid would be expected to have a limited selection
pressure for ESBL-E, and warrants further study. This could represent Gram-negative
activity of rifampicin or confounding by CPT, given that the majority of participants
receiving TB therapy also receive CPT.
In addition, despite fitting well to participants from arm 1 of the study (those with
sepsis), the models fit poorly to arm 2 (antimicrobial unexposed participants) and arm 3
(community members). The reasons for this are not clear, but it strongly suggests that
there are covariates that are not included in the model that differentiate the arms of the
study in some way. If these covariates are also associated with the exposures of interest
(hospitalisation and antibacterial exposure) then this is a potential source of bias from
confounding.
These models assume perfect test characteristics, such that the measurement of ESBL-E
status (or species or genotype, depending on the model) perfectly represents the true state.
This is unlikely to be the case in practice, and there is also likely to be differential test
characteristics between the different stool testing methods (stool or rectal swab culture) used.
This may have introduced bias to the parameter estimates and simulations. Expanding
the model to incorporate imperfect tests - a hidden Markov model - could address this
limitation, as well as provide estimates of test sensitivity and specificity. Conceptually
this is straightforward; the underlying “true” state is modelled, the likelihood for a given
participant (Equation (8.3)) becomes the sum over all possible underlying paths through the
system and parameters are added for the sensitivity and specificity of the tests used. This
will, however, increase computational costs: if a participant has ESBL-E status measured
at n time points then calculating the likelihood required summing over all 2n possible
combinations of states, rather than just one as in the models presented here.
Generalising the model to allow states to be hidden or censored would also address a serious
limitation of the genotype models. In these models, the absence of a particular genotype
from a sample is interpreted as true absence, but the true situation is more complex. If no
ESBL at all is cultured then we can be confident that a given genotype is absent, within
the confines of the test sensitivity. However, if E. coli were cultured at any time point, then
only one colony pick was taken forward for sequencing, meaning that it is possible that any
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number of other genotypes were present in the sample but not picked and sequenced and
therefore identified. Data on within-participant gut mucosal ESBL-E diversity are sparse,
but those data that are available suggest that it may be considerable[374], and so these
models should be considered as merely exploratory. Expanding the model to allow states to
be censored (i.e. for the true underlying state to remain unknown for a given measurement)
is equivalent to the changes that would be necessary to incorporate hidden Markov models,
and would address these problems.
8.6 Conclusion and further work
In conclusion, I have developed and fit time-inhomogeneous Markov models to the clinical
longitudinal ESBL-E carriage data. The models are computationally tractable, extremely
flexible, and provide insight into the drivers of ESBL-E carriage in Blantyre. Though both
hospitalisation and antibacterial exposure significantly affect the probability of ESBL-E
carriage independently, they appear to act synergistically together to drive colonisation.
Antibacterial exposure seems to have an effect that persists long after most antibacterials
would be expected to be excreted from the body; the models provide no data on the
mechanism of this but one hypothesis would be that it is mediated by changed in the
microbiota. Short courses of antibacterials seem to produce a similar effect to longer courses,
which may have implications for antibacterial stewardship interventions. Co-trimoxazole
preventative therapy may be one of the major drivers of long-term ESBL-E carriage in
Malawian adults and this should be considered in developing international and national
guidelines on its use.
These conclusions suggest a direction for future work. The models must be expanded to
incorporate censored states to allow the fitting of hidden Markov models and to account for
the single colony pick sampling method which was used. This, in conjunction with whole
genome sequencing of the remainder of the isolates from the study will allow unbiased
models to be fitted to understand carriage at the level of the genotype. Finally, shotgun
metagenomic sequencing of stored extracted stool DNA from the participants in this study
will a) define the total diversity of ESBL genes within each sample and b) will allow
an analysis to identify microbiota associations of ESBL-E colonisation and the effect of
antibacterial exposure. This will allow testing of the hypothesis that the post-antibacterial
effect I have identified is mediated via the microbiota.
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8.7 Appendix
The Stan code for the fitted models is below; the stepwise-constant covariate model is
presented first, and all other models were fitted with the second model. Pairwise posterior
parameter estimates for model two (to demonstrate strong parameter correlations) are also
shown below; see text for details.
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Figure 8.6: ESBL-E carriage model pairwise posterior parameter estimates, showing correlations
between alpha and beta for a given covariate, and lambda and mu. These results are for model 2 to
predict ESBL-E probability - see text for details. Alpha[1] and beta[1] are the coefficients for the
composite antibacterial exposure variable, alpha[2] and beta[2] for hospitalisation, lambda the rate
of ESBL-E loss, mu the rate of ESBL-E acquisition, and gamma the scaled (by log(2)) half life of
the post-antibacterial effect.
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// Stan final model incorporating varying numbers of covariates
// Optional gamma decay
// Uses rk45 ODE solver
// Joe Lewis July 2019
// to call this model from Rstan, pass it the following data
// N: integer = number of rows of data, each row consisting of two ESBL
// observations for one patient
// n_covs: integer vector of length 3 = [number of
// nontimevarying covariates,
// number of stepwise constant covariates,
// number of exp decay covariates ]
// covs_type: integer vector of length(number of covariates) =
// each position encodes the type of variable
// in the order they are presented in covs_mat:
// 3 = time varying with exponential decay of effect
// 2 = time varying with piecewise constant
// 1 = nontimevarying
// All the exp decay variables must always go first
// cov_mat: real matrix of start and stop times of
// covariates 3*(with number of covariate) cols
// Each covariate needs three columns, in this order
// start_time: time that covariate started
// stop time: time that covariate stopped.
// If there is no covariate exposure in this row, code as -999
// prev_stop time: if covariate has exp. decay, this is
// the previous stop time (before current row e.g. -10)
// If no previous exposure, code as 999
// If non time varying exposure, code as 999 = present, -999 absent
// start state: real vector of length2 = start state in
// format (ESBL-, ESBL+) ie esbl positive coded as
// [0,1] and ESBL negative coded as [1,0]
// end state: integer length 1, final state.
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// this will also generate and save log-likelihoods to do model comparison with loo.
functions {
// Time varying covariate value calculation
// Needs to be passed a 1d array of covariates
// each 3 entries are (cov_start_time, cov_end_time, prev_cov_end_time)
// prev_cov_end_time is coded as
// t of prev cov end time if has been exposure, pos no if not
// Needs to return a matrix with n_cov rows and 1 column
// to act on the alphas and betas of the model
// n_covs is an array with integer for each cov
// 1 = not tme varying and coded with prev time- present if > 0
// and absent of < 0
// 2 = time varying but no decay; prev time is ignored
// 3 = time varying with decay. If there is no











for (n in 1:size(n_covs_passed)) {
s = 1 + ((n-1)*3);
f = s + 1;
p = f + 1;
// for each row in cov matrix (ie each covariate)
if (n_covs_passed[n] == 3) {
// gamma decay
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if (cov_mat_passed[f] > 0) { //if there is exposure this block
if (t1 <= cov_mat_passed[f] && t1 >= cov_mat_passed[s]) {
// if exposure is happening now
// set value to 1
out_vars[n] = 1;
} else if (t1 > cov_mat_passed[f]) {
// otherwise if there is exposure in this block
// and this covariate is set to have a decaying effect
// and time is after it has stopped
// set value to decay from stop time
out_vars[n] = exp((t1-cov_mat_passed[f])/(-1*gamma_passed[n]));
} else if (t1 < cov_mat_passed[s] && cov_mat_passed[p] < 0) {
// otherwise, if time is before start time
// and there is previous exposure
// set value to decay from previous time
out_vars[n] = exp((t1-cov_mat_passed[p])/(-1*gamma_passed[n]));
} else {
// otherwise set to 0
out_vars[n] = 0;
}
} else { // if there is no exposure in this block






} else if (n_covs_passed[n] == 2) {
if (t1 <= cov_mat_passed[f] && t1 >= cov_mat_passed[s]) {
// if exposure is happening now





} else if (n_covs_passed[n] == 1) {
if (cov_mat_passed[p] > 0) {






} // end of for loop
return out_vars;
} // end of fn
// function to return lambda(t) and mu(t)
// this should take a vector of length n_cov of time
// varying values of the covariates of the betas
// (from the time varying coef fn)
// and two vectors of length n_cov of parameters
//the alphas (that act on mu)
// and the betas (that act on lambda)
// and return a vect or of length two for the




// differential state equation
real[] twostateODE2_flat(real t, // time
real[] y, // state
real[] theta, // parameters
real[] x_r, //data
int[] x_i) { // data
// y is state as [p0,p1]
// theta defined as
// [ lambda, mu, gamma0, ... gamman,
// alpha0, alpha1, ... alphan,
// beta0 ... betan ]
// where n is number of covariatese
// data x_r is 1d array of covariates, 3 for each covariate
// x_i is array of covariate type as
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// [number of non-timedep var,
//number of timedep nongamma var,
//number of gamma var,
// then an integer for each cov:
//1 (non timedep),2(nongamm) or 3(gamma)]
real dydt[2];
real coefs[size(x_i[])-3]; //vector of coefs
real alphaz[size(x_i[])-3]; // vector of alphas








gammaz = theta[3:(2+ x_i[3])];
alphaz = theta[(3+ x_i[3]):(3+x_i[3] + x_i[1] + x_i[2] + x_i[3] -1)] ;
betaz = theta[(3+x_i[3] + x_i[1] + x_i[2] +
x_i[3]):(2+x_i[3] + 2*(x_i[1] + x_i[2] + x_i[3]))];
coefs = return_time_varying_coefs_exp_flat(x_r, t, x_i[4:size(x_i)], gammaz);
lambda_pr = lambda0*exp(dot_product(coefs, betaz));
mu_pr = mu0*exp(dot_product(coefs, alphaz));
dydt[1] = -y[1]*lambda_pr + y[2]*mu_pr;
dydt[2] = y[1]*lambda_pr - y[2]*mu_pr;
return dydt;
} // end of function
} // end of block
data {
int < lower = 1 > N; // Number of rows of data
int <lower = 0> n_covs[3]; //[nontimevary, timevarynogamma, timevarygamma]
int covs_type[sum(n_covs)]; // integer for each cov to define type
real t[N]; // end time
real cov_mat[N,sum(n_covs[])*3]; // array of covariates, 3 rows for each
real start_state[N,2]; // start state (at t=0) in form [p0,p1]
int end_state[N]; // end state (at t) as integer
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}
transformed data {
int x_i_pass[3 + sum(n_covs)];
x_i_pass[] = append_array(n_covs[], covs_type[]);
}
parameters {
real < lower = 0 > lambda;
real < lower = 0 > mu;





real theta[2 + 2*(sum(n_covs)) + n_covs[3]];
theta[1] = lambda;
theta[2] = mu;
theta[3:(2+ n_covs[3])] = gammas[];
theta[(3+ n_covs[3]):(3+n_covs[3] + sum(n_covs) -1)] = alphas[];

























// needed for loo
vector[N] log_lik;
real temp[1,2];
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// Stan model for msm style interval censored model, stepwise constant covariates
functions {
// Differential state equations for solving
real[] twostateODE(real t, // time
real[] y, // state
real[] theta, // parameters
real[] x_r, // data (real)


















// first coef, abx, start x_r[1] and end time x_r[2]
if (x_r[1] == 999) {
// dont do anything, there is nothing for this covariate
} else if (t <= x_r[2] && t >= x_r[1]) {
lambda_beta_sum = lambda_beta_sum + ab_beta0;
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mu_alpha_sum = mu_alpha_sum + ab_alpha0;
}
// second coef coef, abx, start x_r[3] and end time x_r[4]
if (x_r[3] == 999) {
// don't do anything, there is nothing for this covariate
} else if (t <= x_r[4] && t >= x_r[3]) {
lambda_beta_sum = lambda_beta_sum + hosp_beta1;
mu_alpha_sum = mu_alpha_sum + hosp_alpha1;
}
dydt[1] = -y[1]*lambda*exp(lambda_beta_sum) + y[2]*mu*exp(mu_alpha_sum);





int < lower = 1 > N; // Sample size
real t[N]; // end time
real start_state[N,2]; // start state (at t_start) in form [p0,p1]
int end_state[N]; // end state (at t) as integer
real covariates[N,4]; // covariate start and end times







real < lower = 0 > lambda;
real < lower = 0 > mu;




























































// The posterior predictive distribution
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Chapter 9
Conclusions and further work
9.1 Introduction
In this thesis, I have presented the findings from a clinical study with two broad aims:
first, to describe the presentation, aetiology, outcomes and determinants of outcomes in
adults in Blantyre, Malawi; and second, to describe colonisation with ESBL-E as sepsis
survivors pass from the hospital to the community, and an analysis to identify determinants
of carriage. In Chapter one, I presented a hypothesis that it is possible to improve outcomes
for patients with sepsis whilst reducing over-reliance on broad spectrum antibacterials such
as ceftriaxone, and hence minimise pressure for the development of antimicrobial resistance,
by rapidly initiating antimicrobial therapy to cover all pathogens likely to cause sepsis in
Blantyre. In this chapter I review the findings of this thesis in the context of this hypothesis,
and suggest directions for future work.
9.2 Summary of findings
The clinical study of sepsis presented in Chapters 3 and 4 confirm that sepsis is Malawi
is very different from sepsis in high-income low-HIV and low-TB prevalence settings from
where most studies of sepsis arise. Malawian patients presenting with sepsis, as elsewhere in
sSA, are young, and predominantly HIV-infected. They have been sick for a longer period
of time (median 7 days) with clinical syndromes/pathogens not typically associated with
fulminant disease in high income settings i.e. typhoid fever, disseminated tuberculosis, and
malaria. The easily modifiable determinants of sepsis outcome that have received so much
attention in high-income settings - rapid administration of antibacterials and fluids - were
not associated with survival in this cohort. This could be due to a true lack of effect, or to
underpowering, but it highlights the need for data from sSA to guide the development of
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sepsis protocols relevant to sSA.
TB was the commonest cause of sepsis identified in the cohort - 34% of participants had at
least one positive diagnostic test for TB, rising to 50% in HIV-infected participants - and
administration of antituberculous chemotherapy showed an association with survival (RR
1.22 for survival [95% CI 1.03-1.46] in propensity-score analysis). Confidence intervals are
large, but the effect size for benefit in the anaemic (for example) is larger than that in those
with confirmed TB, suggesting that there may be a role for empiric TB therapy in sepsis,
but the role of TB therapy in the treatment of the critically unwell is unknown, and must
be the focus of further work (see below). The 28-day mortality of sepsis in Blantyre was
lower than expected at 18% (95% CI 13-23%), and lower than historical mortality estimates
from across the continent described in Chapter 1. The reasons for this are speculative, but
ART coverage was high compared to historical cohorts. Despite this, it seems likely that the
presentation of sepsis in a number of participants in this study was a manifestation of ART
failure. Few participants were switched to second-line therapy, and longer-term mortality
(beyond 28 days) was significant in the HIV-infected with a near doubling of mortality from
19% (95% CI 13-26%) at 28 days to 36% (95% CI 28-45%) at 180 days. Together, these
data suggest that a HIV test at admission may have a role in triage of initial antimicrobial
therapy in sepsis in sSA and that urgent HIV viral load measurement in those with sepsis
and suspicion of ART failure could help to facilitate rapid switch on to second line therapy.
In Chapter 5, I presented details of gut mucosal colonisation with ESBL-E in sepsis
participants but also antibiotic-unexposed hospital inpatients and community members.
Community carriage is common, with a baseline community carriage prevalence of 28%
(95% CI 20-38%) and factors associated with baseline carriage (household crowding, un-
protected water source and sample collection during rainy season) strongly suggest that
within-household and environmental transmission routes are important. Co-trimoxazole
preventative therapy (CPT) was also associated with ESBL-E carriage at baseline, as
was recent hospitalisation. In antibacterial-exposed inpatients there is a dramatic rise in
ESBL-E colonisation prevalence, which is not seen in the antibacterial-unexposed. As
expected, broad spectrum antibacterial exposure, largely ceftriaxone, was near-universal
in the sepsis cohort with a median 5 days (IQR 3-7) of exposure, but this is dwarfed
in person-days of exposure by co-trimoxazole. This is perhaps unsurprising given that
co-trimoxazole is mandated lifelong for all people living with HIV in Malawi, but the
magnitude of the difference is more than an order of magnitude: 14,447 person days of
exposure of co-trimoxazole versus 997 for ceftriaxone.
Genomic analyses using whole genome sequencing of a subset of cultured isolates reveals
no obvious restrictions of mixing of E. coli, whether internationally or between hospital
and community settings. The exception to this is a putative recently arrived high-risk
clone, ST410, which shows some healthcare association. The genomic landscape of ESBL
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in Blantyre is dominated by blaCTX−M , reflecting the global situation, and, worryingly,
I describe (to my knowledge) the first carbapenemase identified in Enterobacteriaceae
in Malawi, a blaNDM−5 carried on a globally successful IncX plasmid. Other identified
AMR genes reflect the local antibiotic pressures: in particular, co-trimoxazole resistance
determinants are near-ubiquitous. Using WGS as a high-resolution typing tool by clustering
bacteria core genes and ESBL-containing contigs I show that it is the ESBL contig-bacteria
combination that is conserved within patients, suggesting that the unit of transmission in
this system is the bacteria, rather than transfer of MGE. I also demonstrate significant
turnover of ESBL-E: beyond 35 days, two samples from within a patient are no more likely
to contain the same ESBL contig-bacteria combination than due to chance alone.
Finally, I develop and fit two-state continuous-time Markov models in a Bayesian framework
to understand the drivers of ESBL-E carriage in this cohort. I find that hospitalisation
increases both ESBL-E acquisition and loss with a net effect of rapid ESBL-E acquisition
following hospitalisation. Antibacterial exposure acts to prolong carriage by reducing the
rate of loss, and I find support in the data for a prolonged post-antibiotic effect with a long
half-life of 43 days (95% CI 15-98 days) that acts to prolong carriage long after antibacterial
exposure has finished. Simulations show that there is synergy between hospitalisation and
antibacterial exposure which produces the sharp rises in ESBL-E colonisation prevalence,
but also that the post-antibiotic effect results in significantly prolonged carriage. In
addition, the post-antibiotic effect means that short courses of antibacterials have, in terms
of ESBL-E carriage, similar effects to prolonged courses, with significant implications for
antimicrobial stewardship. Co-trimoxazole preventative therapy seems to be a significant
driver of long-term carriage.
9.3 Conclusions and future research priorities
In light of these findings, is it possible to provide suggestions for antibiotic strategies for
sepsis in Blantyre that will improve outcomes whilst minimising acquisition of ESBL-E?
I suggest not for severely unwell patients that urgently need antimicrobials: the post-
antibiotic effect from the longitudinal models means that a short course of antibacterials
(e.g. 2 days) has a similar effect to a longer one (e.g more than 7 days), at least in terms
of ESBL-E acquisition, and that all the considered antibacterials seem to have a similar
effect of ESBL-E carriage. The models imply therefore that the antimicrobial stewardship
intervention to best minimise ESBL-E carriage is to avoid antibacterials altogether. This is
not feasible in these very unwell patients, in whom initial empiric antimicrobial therapy is
certainly appropriate. However health systems interventions that support the safe restriction
of antimicrobials in patients that do not require them such as patients with viral respiratory
tract infections (e.g. improved point of care diagnostics) may achieve this effect. The data
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I present therefore highlight several areas of further research priority.
1. Identification of TB and initiation of antituberculous chemotherapy at pre-
sentation
There is a strong suggestion that antituberculous chemotherapy may improve outcomes
in sepsis in Blantyre, but the best ways to deploy this therapy in the critically unwell are
unknown. Whether empiric therapy is warranted depends on the diagnostic ability of the
available tests for TB and, since performing the testing for urinary lipoarabinomannan
(uLAM) that I have presented here, a more sensitive uLAM assay has become available.
To truly make recommendation for the use of TB therapy in sepsis, it is necessary to
understand the impact of this improved diagnostic on the analysis I have presented. To
that end the stored urines from this study will be tested with the new, more sensitive
fujiLAM assay. To understand the reasons for the unexpectedly low prevalence of TB
bloodstream infection, these will be tested alongside Xpert Ultra testing of stored blood
samples. These results will allow clear recommendations for the use of TB therapy in sepsis,
which can be taken forward for testing in clinical trials. The pharmacokinetics of standard
quadruple antituberculous therapy in the critically unwell are not, however, well described
and pharmacokinetic studies in this population, perhaps as part of clinical trials of TB
therapy in sepsis, should be undertaken. More broadly, interventions for disseminated TB
have generally focussed on rapid diagnosis of TB, following the standard diagnostic and
treatment paradigms for outpatient TB. I suggest that the data I present here provide
support for a clinical trial of presumptive TB therapy in critically unwell inpatients.
2. Investigation of post 28-day mortality in HIV-infected participants
The cause of the significant post-28 day mortality in HIV-infected participants warrants
further scrutiny. This requires more in depth clinical follow up than was possible in this
study, but a starting point is to clearly define whether the participants in this study
who seem to be failing ART had true HIV virological failure. This can be achieved with
retrospective testing of stored blood samples. The global success of ART roll out means
that failure of first line therapy is likely to be increasingly common, and strategies to
rapidly identify ART failure and switch people to second line may be needed. It may be
that hospital admissions with severe infection provide such an opportunity. Demonstrating
virologic failure is a necessary first step.
3. Understand the biology of post-antibiotic selection pressure for ESBL-E
colonisation
The key finding from the longitudinal modelling of ESBL-E carriage is that there is a
prolonged post-antibiotic effect. It is this that leads me to state that the overall hypothesis
of this thesis - that we can improve sepsis outcomes whilst minimising ESBL-E acquisition
- cannot be supported with the available data, because a shorter course of antibacterials in
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hospitalised patients is predicted to have a similar effect to a longer one. However, this also
makes the post antibiotic effect an attractive target for intervention. I have demonstrated
an association, but there is a need to understand the biology. How is it mediated? I suggest
that a likely candidate, and a good starting point, is the composition of the gut microbiota.
The effect of even short courses of antimicrobials on the microbiota can be profound, and
antibacterial-mediated destruction of microbiota colonisation resistance to ESBL-E could
certainly cause the effects I have described. Total stool DNA has been extracted in real
time from the participants in the study, and shotgun metagenomic sequencing of these
samples can be used to start to assess the role of the microbiota in mediating the post
antibiotic effect: changes in the microbiota predictive of ESBL-E colonisation (or ESBL-E
abundance) and identification of taxa associated with non-colonisation with ESBL-E at
baseline could provide an understanding of mechanism, Ultimately, this could suggest
microbiota-modulating therapies to promote colonisation resistance to ESBL-E.
Metagenomics can also address one of the limitations of the genomic analysis: that only
one colony pick from each participant at each time point was sequenced, so the total within-
host ESBL-E diversity is unknown. Metagenomics can not tell the whole story, however,
as it can not place AMR genes within bacteria, but must be supplemented by further
colony picks for whole genome sequencing. Stored plate sweeps from all the participants
in the study can facilitate this. In addition, the work is already under way to sequence
E. coli from all remaining samples and one K. pneumoniae from all samples in which this
species was identified, using short-read sequencing. This will allow comparison of the AMR
determinants carried within these two species within one host, over time, and allow an
understanding of the extent to which horizontal gene transfer is occurring. To truly define
the MGE upon which ESBL genes are carried requires long-read sequencing. This work is
also under way on a number of representative isolates. This will also allow an analysis of
the genomic environment of the apparently inactive catB4 genes that were frequently seen
in this analysis.
4. Re-evaluate co-trimoxazole preventative therapy protocols in an era of rising
Gram-negative resistance
Finally, my analysis of determinants of ESBL-E carriage suggests that co-trimoxazole
preventative therapy (CPT) may be a major driver of AMR carriage. The exact mechanism
of mortality benefit of CPT is unknown and it may be that its benefit is driven by
e.g. antimalarial activity; studies to address this hypothesis are under way (e.g. TSCQ trial
ClinicalTrials.gov identifier NCT01650558). The fact that co-trimoxazole resistance is near
ubiquitous in the ESBL E. coli in this study along with the modelling findings suggests
that CPT may be having strong unintended selection pressure for ESBL-E. In an era of
rising Gram-negative resistance I suggest that in some cases the benefits of this therapy
may be outweighed by its risks and that perhaps a more nuanced approach to CPT usage
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than lifelong treatment for all people living with HIV is required, which is still sufficiently
pragmatic to be useful in sSA. This would require clinical studies examining the outcomes
of strategies such as stopping CPT once well established on ART, and my data suggest
that AMR endpoints (such as ESBL-E carriage) should be included in such trials.
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